<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients - Karpe, KM - 2017 | Cochrane Library</title> <meta content="Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients - Karpe, KM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006750.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients - Karpe, KM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006750.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006750.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients" name="citation_title"/> <meta content="Krishna M Karpe" name="citation_author"/> <meta content="krishna.karpe@act.gov.au" name="citation_author_email"/> <meta content="Girish S Talaulikar" name="citation_author"/> <meta content="Giles D Walters" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD006750.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006750.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006750.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006750.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Graft Survival; *Kidney Transplantation [mortality]; *Withholding Treatment; Acute Disease; Calcineurin Inhibitors [*administration &amp; dosage, *adverse effects]; Cytomegalovirus Infections [epidemiology, prevention &amp; control]; Drug Substitution; Graft Rejection [epidemiology, *etiology, prevention &amp; control]; Hypertension [epidemiology]; Immunosuppression Therapy [methods]; Immunosuppressive Agents [therapeutic use]; Intention to Treat Analysis; Kidney; Neoplasms [epidemiology]; Randomized Controlled Trials as Topic; TOR Serine‐Threonine Kinases [*antagonists &amp; inhibitors]; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006750.pub2&amp;doi=10.1002/14651858.CD006750.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006750\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006750\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006750.pub2",title:"Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients",firstPublishedDate:"Jul 21, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006750.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006750.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006750.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006750.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006750.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006750.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006750.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006750.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006750.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006750.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2491 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006750.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/appendices#CD006750-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/table_n/CD006750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/table_n/CD006750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#CD006750-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Krishna M Karpe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#CD006750-cr-0003">Girish S Talaulikar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information#CD006750-cr-0004">Giles D Walters</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information/en#CD006750-sec-0118">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006750.pub2">https://doi.org/10.1002/14651858.CD006750.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006750-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006750-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006750-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006750-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006750-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006750-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006750-abs-0001" lang="en"> <section id="CD006750-sec-0001"> <h3 class="title" id="CD006750-sec-0001">Background</h3> <p>Calcineurin inhibitors (CNI) can reduce acute transplant rejection and immediate graft loss but are associated with significant adverse effects such as hypertension and nephrotoxicity which may contribute to chronic rejection. CNI toxicity has led to numerous studies investigating CNI withdrawal and tapering strategies. Despite this, uncertainty remains about minimisation or withdrawal of CNI. </p> </section> <section id="CD006750-sec-0002"> <h3 class="title" id="CD006750-sec-0002">Objectives</h3> <p>This review aimed to look at the benefits and harms of CNI tapering or withdrawal in terms of graft function and loss, incidence of acute rejection episodes, treatment‐related side effects (hypertension, hyperlipidaemia) and death. </p> </section> <section id="CD006750-sec-0003"> <h3 class="title" id="CD006750-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Specialised Register to 11 October 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD006750-sec-0004"> <h3 class="title" id="CD006750-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) where drug regimens containing CNI were compared to alternative drug regimens (CNI withdrawal, tapering or low dose) in the post‐transplant period were included, without age or dosage restriction. </p> </section> <section id="CD006750-sec-0005"> <h3 class="title" id="CD006750-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed studies for eligibility, risk of bias, and extracted data. Results were expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI). </p> </section> <section id="CD006750-sec-0006"> <h3 class="title" id="CD006750-sec-0006">Main results</h3> <p>We included 83 studies that involved 16,156 participants. Most were open‐label studies; less than 30% of studies reported randomisation method and allocation concealment. Studies were analysed as intent‐to‐treat in 60% and all pre‐specified outcomes were reported in 54 studies. The attrition and reporting bias were unclear in the remainder of the studies as factors used to judge bias were reported inconsistently. We also noted that 50% (47 studies) of studies were funded by the pharmaceutical industry. </p> <p>We classified studies into four groups: CNI withdrawal or avoidance with or without substitution with mammalian target of rapamycin inhibitors (mTOR‐I); and low dose CNI with or without mTOR‐I. The withdrawal groups were further stratified as avoidance and withdrawal subgroups for major outcomes. </p> <p>CNI withdrawal may lead to rejection (RR 2.54, 95% CI 1.56 to 4.12; moderate certainty evidence), may make little or no difference to death (RR 1.09, 95% CI 0.96 to 1.24; moderate certainty), and probably slightly reduces graft loss (RR 0.85, 95% CI 0.74 to 0.98; low quality evidence). Hypertension was probably reduced in the CNI withdrawal group (RR 0.82, 95% CI 0.71 to 0.95; low certainty), while CNI withdrawal may make little or no difference to malignancy (RR 1.10, 95% CI 0.93 to 1.30; low certainty), and probably makes little or no difference to cytomegalovirus (CMV) (RR 0.87, 95% CI 0.52 to 1.45; low certainty) </p> <p>CNI avoidance may result in increased acute rejection (RR 2.16, 95% CI 0.85 to 5.49; low certainty) but little or no difference in graft loss (RR 0.96, 95% CI 0.79 to 1.16; low certainty). Late CNI withdrawal increased acute rejection (RR 3.21, 95% CI 1.59 to 6.48; moderate certainty) but probably reduced graft loss (RR 0.84, 95% CI 0.72 to 0.97, low certainty). </p> <p>Results were similar when CNI avoidance or withdrawal was combined with the introduction of mTOR‐I; acute rejection was probably increased (RR 1.43; 95% CI 1.15 to 1.78; moderate certainty) and there was probably little or no difference in death (RR 0.96; 95% CI 0.69 to 1.36, moderate certainty). mTOR‐I substitution may make little or no difference to graft loss (RR 0.94, 95% CI 0.75 to 1.19; low certainty), probably makes little of no difference to hypertension (RR 0.86, 95% CI 0.64 to 1.15; moderate), and probably reduced the risk of cytomegalovirus (CMV) (RR 0.60, 95% CI 0.44 to 0.82; moderate certainty) and malignancy (RR 0.69, 95% CI 0.47 to 1.00; low certainty). Lymphoceles were increased with mTOR‐I substitution (RR 1.45, 95% CI 0.95 to 2.21; low certainty). </p> <p>Low dose CNI combined with mTOR‐I probably increased glomerular filtration rate (GFR) (MD 6.24 mL/min, 95% CI 3.28 to 9.119; moderate certainty), reduced graft loss (RR 0.75, 95% CI 0.55 to 1.02; moderate certainty), and made little or no difference to acute rejection (RR 1.13 ; 95% CI 0.91 to 1.40; moderate certainty). Hypertension was decreased (RR 0.98, 95% CI 0.80 to 1.20; low certainty) as was CMV (RR 0.41, 95% CI 0.16 to 1.06; low certainty). Low dose CNI plus mTOR‐I makes probably makes little of no difference to malignancy (RR 1.22, 95% CI 0.42 to 3.53; low certainty) and may make little of no difference to death (RR 1.16, 95% CI 0.71 to 1.90; moderate certainty). </p> </section> <section id="CD006750-sec-0007"> <h3 class="title" id="CD006750-sec-0007">Authors' conclusions</h3> <p>CNI avoidance increased acute rejection and CNI withdrawal increases acute rejection but reduced graft loss at least over the short‐term. Low dose CNI with induction regimens reduced acute rejection and graft loss with no major adverse events, also in the short‐term. The use of mTOR‐I reduced CMV infections but increased the risk of acute rejection. These conclusions must be tempered by the lack of long‐term data in most of the studies, particularly with regards to chronic antibody‐mediated rejection, and the suboptimal methodological quality of the included studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006750-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006750-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006750-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006750-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006750-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006750-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006750-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006750-abs-0003" lang="en"> <h3>Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients</h3> <p><b>What is the issue?</b> </p> <p>Calcineurin inhibitors (CNI, cyclosporin and tacrolimus) are an important part of treatment to suppress the immune system to prevent rejection of transplanted kidneys. However, CNI can cause high blood pressure and kidney scarring which contribute to worsening of risk factors for heart attack, stroke, and loss of the transplanted organ over time. </p> <p>There are conflicting data on the results of withdrawing these drugs from kidney transplant recipients; some studies suggest improved kidney function but others report a moderate risk of developing rejection. Because of this uncertainty, we assessed the benefits and harms of CNI withdrawal or tapering in kidney transplant recipients to identify which approach was more beneficial. </p> <p><b>What did we do?</b> <br/> We included 83 studies that involved more than 16,000 people in our review. Studies which compared standard dose CNI regimens with withdrawal, tapering or low dose CNI in the post‐transplant period were analysed. </p> <p><b>What did we find?</b> <br/> Although withdrawing CNI treatment resulted in more rejections in the short term, there was no clear change in transplanted organ failure, death, development of cancer, or infections. Replacing CNI with another group of drugs ‐ the mTOR inhibitors ‐ did not significantly change outcomes, except for fewer cytomegalovirus (CMV) infections. Lower CNI dose was associated with fewer episodes of kidney transplant rejection and loss, but only in the first year to up to five years after the transplant. </p> <p><b>Conclusions</b> <br/> We found that the long‐term outcomes for stopping or gradually reducing CNI therapy were not clear, and that mTOR inhibitors can reduce CMV infections with a higher risk of acute rejection. There were insufficient studies with long term follow‐up to clearly determine which treatment is better for people who receive kidney transplants. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006750-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006750-sec-0108"></div> <h3 class="title" id="CD006750-sec-0109">Implications for practice</h3> <section id="CD006750-sec-0109"> <p>CNI avoidance increased acute rejection and CNI withdrawal increases acute rejection but reduced graft loss at least over the short‐term. Low dose CNI with induction regimens reduced acute rejection and graft loss with no major adverse events, also in the short‐term. The use of mTOR‐I reduced CMV infections but increased the risk of acute rejection. These conclusions must be tempered by the lack of long‐term data in most of the studies, particularly with regards to chronic antibody‐mediated rejection, and the suboptimal methodological quality of the included studies. </p> </section> <h3 class="title" id="CD006750-sec-0110">Implications for research</h3> <section id="CD006750-sec-0110"> <p>Despite a large number of randomised multicentre studies, significant issues remain unanswered. Most study data highlighted short‐term outcomes due to the short follow‐up. Longer follow‐up will highlight hard end points such as cardiovascular outcomes, long‐term graft survival and effects on malignancy. Cost benefit analysis and quality of life surveys to assess the effect of lower immunosuppression may also be of significant benefit. Carefully structured longer term studies into immunosuppression of kidney transplant patients need to delineate patient death, malignancy risk in protocols with or without CNI, immunological risk will need to include acute rejection, donor‐specific antibodies and antibody‐mediated rejection. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006750-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006750-sec-0029"></div> <div class="table" id="CD006750-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CNI withdrawal versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI withdrawal<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 9 months to 20 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.96 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 (14 )</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1,000<br/> (216 to 279) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 9 months to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.54<br/> (1.56 to 4.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1666 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4 5 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1,000<br/> (214 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 3.56 mL/min more (1.13 less to 8.25</p> <p>more) than the control group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>910 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 9 months to 20 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.74 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2090 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 9 10 11 12</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1,000<br/> (175 to 231) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.71 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>950 (5 )</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1,000<br/> (394 to 527) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 9 months to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.52 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>608 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1,000<br/> (51 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/> (0.93 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1079 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 4 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1,000<br/> (239 to 334) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> despite different follow up times, heterogeneity not noted on analysis </p> <p><sup>2</sup> Most studies were ITT analysis, some small studies did not specify randomisation and allocation concealment </p> <p><sup>3</sup> Larger studies closer to pooled estimate on funnel plot </p> <p><sup>4</sup> Some studies were small with large confidence intervals, CI fails to exclude benefit or harm </p> <p><sup>5</sup> Heterogeneity low when biopsy‐proven rejections were analysed in subgroup </p> <p><sup>6</sup> Smaller studies not distributed around point estimate </p> <p><sup>7</sup> Significant heterogeneity noted despite separating time periods of reporting GFR </p> <p><sup>8</sup> Only few studies reported GFR with possible attrition bias </p> <p><sup>9</sup> 2 large studies had more than 2 comparison groups </p> <p><sup>10</sup> Very few studies reported the outcome </p> <p><sup>11</sup> Symmetric distribution studies around estimate of effect </p> <p><sup>12</sup> 2 studies with high event rates skew the effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006750-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose calcineurin inhibitors (CNI) versus to standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low dose CNI versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> low dose CNI<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose CNI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/> (0.50 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3462 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000<br/> (12 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3757 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1,000<br/> (139 to 183) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 4.1 mL/min more (2.07 more to 6.12 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2623 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.55 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3286 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sensitivity analysis after excluding 1 study which also involved steroid withdrawal; significant reduction in graft loss in the low dose regimen </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1,000<br/> (32 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.70 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1877 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 7 8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1,000<br/> (153 to 218) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.94 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1948 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 8 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000<br/> (95 to 163) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.41 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1637 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000<br/> (6 to 30) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most studies with ITT analysis, randomisation procedure and allocation concealment not clear from most publications </p> <p><sup>2</sup> Minimal heterogeneity noted on analysis </p> <p><sup>3</sup> Several small studies with wide confidence intervals </p> <p><sup>4</sup> Despite studies with or without induction, sensitivity analysis made no difference to outcome </p> <p><sup>5</sup> Heterogeneity noted only between subgroups </p> <p><sup>6</sup> Only 2/15 studies had more than 2 comparison groups </p> <p><sup>7</sup> Industry sponsored </p> <p><sup>8</sup> 1/6 studies did not report some outcomes due to high dropout </p> <p><sup>9</sup> Only 5 studies reported the outcome and had wide CI </p> <p><sup>10</sup> Few studies reported the outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006750-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CNI withdrawal + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI withdrawal + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI withdrawal + mTOR</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.69 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5427 (23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (18 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (1.15 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5903 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1,000<br/> (154 to 238) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 1 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.75 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5446 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1,000<br/> (40 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.64 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2207 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1,000<br/> (139 to 250) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV Infection<br/> follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.44 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2503 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>9 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1,000<br/> (66 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.47 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000<br/> (26 to 54) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: lymphocele<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.95 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1926 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 8 11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1,000<br/> (95 to 220) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Randomisation method and allocation concealment performed in most studies </p> <p><sup>2</sup> No significant heterogeneity noted in analysis </p> <p><sup>3</sup> Only 2 studies had more than 2 comparison arms </p> <p><sup>4</sup> Many studies with small events and wide CI </p> <p><sup>5</sup> Significant heterogeneity in studies in biopsy‐proven acute rejection </p> <p><sup>6</sup> Funnel plot skewed </p> <p><sup>7</sup> Significant heterogeneity noted </p> <p><sup>8</sup> Few studies reported this outcome </p> <p><sup>9</sup> Moderate heterogeneity but follow‐up times are variable </p> <p><sup>10</sup> Not all studies reported the outcome </p> <p><sup>11</sup> Heterogeneity is not significant when 1 long‐term study was excluded </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006750-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low dose CNI + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> low dose CNI + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose CNI + mTORi</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.71 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2750 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (16 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.91 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3300 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1,000<br/> (120 to 185) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 6.24 mL/min more (3.28 more to 9.19 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1749 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.45 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3304 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/> (17 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.80 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1421 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1,000<br/> (162 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 1 to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.16 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1250 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 7 9</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1,000<br/> (17 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 1 to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (0.42 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1074 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000<br/> (5 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Randomisation and allocation process not clear in some studies </p> <p><sup>2</sup> No significant heterogeneity </p> <p><sup>3</sup> Only 2 of the studies had more than 2 comparisons </p> <p><sup>4</sup> Some small studies with wide CI </p> <p><sup>5</sup> Substantial heterogeneity noted due to recording at different time periods </p> <p><sup>6</sup> Small number of events and some small studies with wide CI </p> <p><sup>7</sup> Only few studies reported this outcome </p> <p><sup>8</sup> 95% CI fails to exclude benefit or harm </p> <p><sup>9</sup> Heterogeneity present but when abstract only studies are removed, heterogeneity is zero </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006750-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal versus standard dose CNI</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subgroup analysis: CNI avoidance and late withdrawal versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI avoidance and late withdrawal<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI avoidance and withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: avoidance<br/> Follow‐up: range 1 to 12 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.16<br/> (0.85 to 5.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>744 per 1,000<br/> (293 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.21<br/> (1.59 to 6.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1428 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1,000<br/> (162 to 661) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for avoidance studies in the intervention group was 2.22 mL/min lower (14.84 less to 10.4 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for late withdrawal studies in the intervention group was 5.54 mL/min more (1.66 more to 9.43 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>668 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.79 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>566 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1,000<br/> (281 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.72 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1831 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3 9 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1,000<br/> (187 to 252) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> 3 small studies with one study including a non‐randomised arm </p> <p><sup>2</sup> Significant heterogeneity </p> <p><sup>3</sup> Several small studies with wide confidence intervals </p> <p><sup>4</sup> Small numbers to make a judgement of difference </p> <p><sup>5</sup> Skewed funnel plot </p> <p><sup>6</sup> Substantial heterogeneity </p> <p><sup>7</sup> 2/4 are small studies with wide CI </p> <p><sup>8</sup> 4 studies included with one study with high event rate </p> <p><sup>9</sup> No heterogeneity identified on analysis </p> <p><sup>10</sup> Larger studies are not industry sponsored </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006750-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subgroup analysis: CNI avoidance and late withdrawal + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI avoidance and late withdrawal + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI avoidance and withdrawal + mTORi</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: avoidance<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.98 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1844 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1,000<br/> (229 to 386) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: late withdrawal<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.90<br/> (1.44 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3636 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000<br/> (94 to 163) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: avoidance<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for avoidance studies in the intervention group was 6.45 mL/min higher (1.33 higher to 11.58 higher) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1748 (9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: late withdrawal<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for late withdrawal studies in the intervention group was MD 4.55 higher<br/> (0.26 higher to 8.85 higher) than for control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2679 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.72 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1420 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000<br/> (53 to 110) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.65 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4026 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/> (30 to 59) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Several smaller studies with wide CI </p> <p><sup>2</sup> Significant heterogeneity </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006750-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006750-sec-0030"></div> <section id="CD006750-sec-0031"> <h3 class="title" id="CD006750-sec-0031">Description of the condition</h3> <p>Standard immunosuppressive protocols to prevent acute graft rejection in kidney transplantation involve three major groups of drugs ‐ calcineurin inhibitor(s) (CNI), antimetabolites and steroids. CNI have been an important part of primary immunosuppression therapy together with adjunctive agents such as mycophenolate mofetil (MMF), azathioprine (AZA) and steroids in kidney transplant recipients (<a href="./references#CD006750-bbs2-0164" title="HariharanS , JohnsonCP , BresnahanBA , TarantoSE , McIntoshMJ , StableinD . Improved graft survival after renal transplantation in the United States, 1988 to 1996. New England Journal of Medicine2000;342(9):605‐12. [MEDLINE: 10699159] ">Hariharan 2000</a>). </p> <p>CNI inhibit the calcium‐dependent enzyme serine phosphatase calcineurin. This process prevents the dephosphorylation of nuclear factors of activated T lymphocytes (NFAT), which is essential for translocation into the nucleus leading to reduced activation of cytokine genes for interleukin‐2 (IL2) production. Cyclosporin (CsA) and tacrolimus (TAC) are CNI used for kidney transplant recipients (<a href="./references#CD006750-bbs2-0170" title="MelkA , HalloranP . Immunosuppressive agents used in transplantation. In: JohnsonRJ , FeehallyJ editor(s). Comprehensive Clinical Nephrology. 2nd Edition. Mosby, 2003:1062‐4. ">Melk 2003</a>). </p> </section> <section id="CD006750-sec-0032"> <h3 class="title" id="CD006750-sec-0032">Description of the intervention</h3> <p>CNI have dramatically reduced the incidence of acute transplant rejection and decreased early graft loss (<a href="./references#CD006750-bbs2-0160" title="AhsanN , JohnsonC , GonwaT , HalloranP , StegallM , HardyM , et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation2001;72(2):245‐50. [MEDLINE: 11477347] ">Ahsan 2001</a>). However, CNI have been associated with significant adverse effects such as nephrotoxicity (<a href="./references#CD006750-bbs2-0161" title="BennettWM , DeMattosA , MeyerMM , AndohT , BarryJM . Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney International1996;50(4):1089‐100. [MEDLINE: 8887265] ">Bennett 1996</a>) causing decreased glomerular filtration rate (GFR), hypertension, hyperlipidaemia and a significant contribution to chronic allograft nephropathy. These effects could lead to subsequent graft loss and contribute directly or indirectly to patient morbidity and mortality by affecting the cardiovascular risk factors (<a href="./references#CD006750-bbs2-0167" title="KasiskeBL , GuijarroC , MassyZA , WiederkehrMR , MaJZ . Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology1996;7(1):158‐65. [MEDLINE: 8808124] ">Kasiske 1996</a>). The immunological causes of graft loss have to be however considered. The potential risks of CNI use should be balanced against the risks of acute rejection and chronic antibody‐mediated rejection, especially in patients with a high immunological risk. </p> </section> <section id="CD006750-sec-0033"> <h3 class="title" id="CD006750-sec-0033">How the intervention might work</h3> <p>The significant toxicity profile of CNI have prompted many studies investigating CNI withdrawal and tapering strategies. However, some highlighted an increase in acute rejection following withdrawal (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>) and others showed no effect on graft survival and a short term improvement in creatinine values (<a href="./references#CD006750-bbs2-0162" title="GonwaTA , HricikDE , BrinkerK , GrinyoJM , SchenaFP , Sirolimus Renal Function Study Group. Improved renal function in sirolimus‐treated renal transplant patients after early cyclosporine elimination. Transplantation2002;74(11):1560‐7. [MEDLINE: 12490789] ">Gonwa 2002</a>). </p> </section> <section id="CD006750-sec-0034"> <h3 class="title" id="CD006750-sec-0034">Why it is important to do this review</h3> <p>Despite the large number of studies conducted, uncertainty remains about tapering or withdrawing CNI. These strategies must be balanced with the significant benefits conferred by CNI in preventing early graft rejection. In the absence of a clear clinical consensus, this review aimed to assess the benefits and harms of CNI withdrawal or tapering for kidney transplant recipients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006750-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006750-sec-0035"></div> <p>This review aimed to look at the benefits and harms of CNI tapering or withdrawal in terms of graft function and loss, incidence of acute rejection episodes, treatment‐related side effects (hypertension, hyperlipidaemia) and death. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006750-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006750-sec-0036"></div> <section id="CD006750-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006750-sec-0038"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) where standard dose CNI regimens were compared with CNI withdrawal or tapering for kidney transplant recipients were included. The first period of randomised cross‐over studies were also included. </p> </section> <section id="CD006750-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD006750-sec-0040"> <h5 class="title">Inclusion criteria</h5> <p>Patients with end‐stage kidney disease (ESKD), irrespective of age or gender, who received a first or subsequent cadaveric or living donor kidney transplant and received CNI (CsA or TAC) as the primary immunosuppression, were included. </p> </section> <section id="CD006750-sec-0041"> <h5 class="title">Exclusion criteria</h5> <p>Recipients who received another solid organ in addition to a kidney transplant (e.g. pancreas) were excluded. </p> </section> </section> <section id="CD006750-sec-0042"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD006750-list-0001"> <li> <p>Transplant recipients who received CNI (CsA or TAC) as the primary immunosuppression which was subsequently tapered or withdrawn completely were included. </p> </li> <li> <p>All studies where tapering or withdrawal was compared with controls were included irrespective of the duration of treatment prior to the intervention. In cases of significant heterogeneity, subgroup analysis was performed. </p> </li> <li> <p>All definitions of tapering mentioned in the studies were included irrespective of the duration of tapering; sensitivity analysis was used to differentiate between the tapering groups. </p> </li> <li> <p>Studies that defined low dose either by exposure to CsA and TAC calculated using 12‐hour post‐dose nadir (trough; C0) blood levels, or studies which employed fixed doses (mg/kg) were included. </p> </li> </ul> </p> <p>Specific comparisons were made between:</p> <p> <ul id="CD006750-list-0002"> <li> <p>Standard dose CNI versus CNI withdrawal</p> </li> <li> <p>Low dose CNI versus standard dose CNI</p> </li> <li> <p>CNI withdrawal with conversion to mammalian target of rapamycin inhibitor (mTOR‐I) versus standard dose CNI </p> </li> <li> <p>Low dose CNI with conversion to mTOR‐I versus normal dose CNI.</p> </li> </ul> </p> <p>In case of significant heterogeneity among interventions, subgroup analysis was carried out in: </p> <p> <ul id="CD006750-list-0003"> <li> <p>Duration of tapering or withdrawal</p> </li> <li> <p>AZA and MMF groups.</p> </li> </ul> </p> </section> <section id="CD006750-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p> <ul id="CD006750-list-0004"> <li> <p>Graft loss (censored and not censored for death)</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Acute rejection episodes: both clinical and biopsy‐proven acute rejection (BPAR) were included </p> </li> <li> <p>Graft kidney function at six months and at one, two and five years measured by serum creatinine (SCr), calculated GFR or creatinine clearance (CrCl) </p> </li> <li> <p>Treatment‐related side effects (e.g. hyperlipidaemia, hypertension)</p> </li> <li> <p>Rates of malignancy</p> </li> <li> <p>Incidence of infections.</p> </li> </ul> </p> </section> </section> <section id="CD006750-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006750-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> to 11 October 2016 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD006750-list-0005"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD006750-sec-0114">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD006750-sec-0046"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD006750-list-0006"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD006750-sec-0047"> <h3 class="title" id="CD006750-sec-0047">Data collection and analysis</h3> <section id="CD006750-sec-0048"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that were relevant to the review. Titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews that included relevant data or information on trials were retained initially. The same two authors independently assessed retrieved abstracts, and if necessary, the full text of studies which satisfied the inclusion criteria. Studies reported in non‐English language journals were translated before assessment. Discrepancies were resolved by discussion with a third author. </p> </section> <section id="CD006750-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by the same authors using standard data extraction forms. Where more than one publication of one study existed, reports were grouped together and the most recent or most complete data set were used. Any discrepancies between published versions were highlighted. </p> </section> <section id="CD006750-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD006750-bbs2-0166" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD006750-sec-0115">Appendix 2</a>). </p> <p> <ul id="CD006750-list-0007"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD006750-list-0008"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD006750-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Results for dichotomous outcomes (e.g. incidence of acute rejections, graft loss, death) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. blood pressure, SCr, GFR), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used. </p> </section> <section id="CD006750-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>Further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. </p> </section> <section id="CD006750-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Cochran Q test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD006750-bbs2-0165" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). In case of significant heterogeneity, subgroup analysis was considered. </p> </section> <section id="CD006750-sec-0054"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD006750-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity (e.g. interventions and study quality). Heterogeneity among participants could be related to age and renal pathology. Heterogeneity in treatments could be related to prior agent(s) used, the agent (CsA/TAC) and duration of therapy prior to withdrawal or tapering. Adverse effects are tabulated and assessed with descriptive techniques, as they are likely to be different for the various agents used. </p> </section> <section id="CD006750-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was used to differentiate between tapering groups.</p> <section id="CD006750-sec-0057"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD006750-bbs2-0172" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD006750-bbs2-0163" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD006750-bbs2-0173" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD006750-list-0009"> <li> <p>Death</p> </li> <li> <p>Graft loss</p> </li> <li> <p>Acute rejection</p> </li> <li> <p>GFR</p> </li> <li> <p>Adverse events (e.g. hypertension, CMV infection, malignancy).</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006750-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006750-sec-0058"></div> <section id="CD006750-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD006750-sec-0060"> <h4 class="title">Results of the search</h4> <p>Our search identified 2398 records. After title and abstract review we excluded 1605 records. The remaining 793 records were for 159 studies. We included only studies that compared standard dose CNI with tapering or withdrawal with or without mTOR‐I substitution which resulted in 83 studies (583 reports) being included in the analyses. We excluded 72 studies (202 records). Four studies (8 records) are ongoing (<a href="./references#CD006750-bbs2-0156" title="David‐NetoE , GalanteN , AltonaM , PaulaF , TriboniA , RamosF , et al. A randomized, prospective study comparing everolimus/low tacrolimus with regular tacrolimus/MPS for the elderly renal transplant recipients [abstract]. Transplantation2014;98(Suppl 1):549. [EMBASE: 71545379] ">David‐Neto 2014</a>; <a href="./references#CD006750-bbs2-0157" title="Sanchez‐FructuosoA , RuizJC , HernandezD , Sanchez‐PlumedJ , FernandezA , Pastor RodriguezA , et al. Early everolimus introduction and calcineurin inhibitor withdrawal in renal transplant patients: a multicenter, randomized, open‐label study (the ERIC study) [abstract no: 1647]. American Journal of Transplantation2010;10(Suppl 4):506. [EMBASE: 70465022] ">ERIC Study 2010</a>; <a href="./references#CD006750-bbs2-0158" title="NicholsonM . A prospective randomised trial of the use of cellcept to allow early tacrolimus withdrawal in live donor kidney transplantation. www.isrctn.com/ISRCTN63298320 (accessed 6 February 2017). ">ISRCTN63298320</a>; <a href="./references#CD006750-bbs2-0159" title="ChadbanS , HughesP , CampbellS , IrishA , LimW , O'ConnellP , et al. TRANSFORM trial design: a randomized, multicentre, open‐label study of everolimus with reduced calcineurin inhibitors in over 20000 de novo renal transplant recipients [abstract no:48]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 32nd Annual Scientific Meeting; 2014 Jun 11‐13; Canberra (ACT). 2014:61. LegendreC , SrinivasT , PascualJ , ChadbanS , CitterioF , HenryM , et al. The TRANSFORM trial design: a large randomized, multicenter, open‐label study of everolimus with reduced calcineurin inhibitors in de novo renal transplantation [abstract no: P16]. Transplant International2013;26(Suppl 3):23‐4. [EMBASE: 71356170] PascualJ , ChadbanS , CitterioF , HenryM , LegendreC , OppenheimerF , et al. TRANSFORM trial design: effect of everolimus on long‐term outcomes after kidney transplantation [abstract no: P308]. Transplant International2013;26(Suppl 2):247. [EMBASE: 71359928] PascualJ , SrinivasTR , ChadbanS , CitterioF , HenryM , LegendreC , et al. Balancing efficacy and renal function preservation after kidney transplantation with everolimus and reduced calcineurin inhibitors for better graft outcomes: design of the TRANSFORM study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii535. [EMBASE: 71493013] PascualJ , SrinivasTR , ChadbanS , CitterioF , OppenheimerF , TedescoH , et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long‐term outcomes after kidney transplantation. Open Access Journal of Clinical Trials2013;6:45‐54. [EMBASE: 605631666] ">TRANSFORM Study 2013</a>) and will be assessed in a future update of this review. See <a href="#CD006750-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD006750-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart showing number of studies identified" data-id="CD006750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart showing number of studies identified</p> </div> </div> </div> </section> <section id="CD006750-sec-0061"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD006750-sec-0121" title="">Characteristics of included studies</a>. </p> <p>The 83 studies included 16,156 randomised participants. Of these, 13 studies were available only in abstract form (2345 participants) (<a href="./references#CD006750-bbs2-0002" title="AlsinaJ , GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , et al. Low dose cyclosporine (CsA), ALG and steroids in first cadaveric renal transplants [abstract]. 10th International Congress of Nephrology; 1987 Jul 26‐31; London, UK. 1987:606. [CENTRAL: CN‐00583779] GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , AndresE , et al. Low dose cyclosporine (CyA), ALG and steroids in first cadaveric renal transplants [abstract]. Kidney International1988;34(2):301. [CENTRAL: CN‐00644138] GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , AndresE , et al. Low‐dose cyclosporin (CsA), ALG and steroids in first cadaveric renal transplants [abstract]. Nephrology Dialysis Transplantation1988;3(1):99‐100. ">Alsina 1987</a>; <a href="./references#CD006750-bbs2-0011" title="BertoniE , BecherelliP , SalvadoriM . Triple therapy with neoral, steroids and enteric‐coated mycophenolate acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: F‐PO614]. Journal of the American Society of Nephrology2007;18(Abstracts):234A. [CENTRAL: CN‐00716078] RosatiA , BertoniE , RossoG , LartiA , MehmetajA , SalvadoriM . Triple therapy with Neoral, steroids and enteric coated mycophenolic acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: SaP477]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi396. [CENTRAL: CN‐00725011] ">Bertoni 2007</a>; <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a>; <a href="./references#CD006750-bbs2-0031" title="El‐AgroudyA , AlarrayedS , GhareebS , FaridE , AlhellowH , AbdullaS . Long‐term outcome of a prospective randomized trial of conversion from tacrolimus to sirolimus treatment after renal transplantation [abstract no: B964]. Transplantation2014;98(Suppl 1):539. [EMBASE: 71545346] ">El‐Agroudy 2014</a>; <a href="./references#CD006750-bbs2-0040" title="HeeringP , WesthoffA , IvensK K , GrabenseeB . Comparison between the effects of CSA and azathioprine on functional renal parameters in randomized study after renal transplantation [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):940. [CENTRAL: CN‐00484304] HeeringP , WesthoffA , IvensK , HelmchenU , GrabenseeB . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine: a randomized controlled study [abstract]. 12th International Congress of Nephrology; 1993 Jun 13‐18; Jerusalem, Israel. 1993:194. HeeringP , WesthoffK , IvensB , KutkuhnB , GrabenseeH . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine [abstract]. Nephrology Dialysis Transplantation1993;8(9):1041. [CENTRAL: CN‐00260889] IvensK , HeeringP , WitholdW , KochM , ReinauerH , GrabenseeB . Withdrawal of cyclosporine improves the cardio‐vascular risk profile in renal graft recipients [abstract]. Journal of the American Society of Nephrology1994;5(3):1013. ">Heering 1993</a>; <a href="./references#CD006750-bbs2-0041" title="ArnsW , BuddeK , SommererC , WitzkeO , GubaM , JacobiJ , et al. Month 48 follow‐up results of HERAKLES trial on three different treatment regimen and switching off behaviour in de novo renal transplant patients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953873] ArnsW , NeumayerH , LehnerF , WitzkeO , SommererC , KliemV , et al. HERAKLES at month 24: follow‐up results on efficacy and safety of three different treatment regimens in de novo renal transplant patients demonstrate options for individualized immunosuppression [abstract no: BO148]. Transplant International2013;26(Suppl 2):21. [EMBASE: 71356261] ArnsW , SommererC , WitzkeO , LehnerF , ZeierM , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES trial [abstract no: 1722]. Transplantation2012;94(10):995. [EMBASE: 71251769] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/ mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: 716]. Transplantation2014;98(Suppl 1):81. [EMBASE: 71543792] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 24 [abstract no: B932]. American Journal of Transplantation2013;13(Suppl 5):310‐1. [EMBASE: 71057508] BuddeK , SommererC , WeithoferP , WitzkeO , GubaM , JacobiJ , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 48 [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954274] BuddeK , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES Study [abstract no: 50]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745997] GubaM , BuddeK , SommererC , NeumayerHH , LehnerF , ReinkeP , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: V62]. Transplant International2014;27(Suppl 3):22. [EMBASE: 71664029] GubaM , WitzkeO , LehnerF , ArnsW , SommererC , NeumayerH , et al. The HERAKLES study at 24 month: Superior renal function in an everolimus‐based CNI free regimen [abstract no: O219]. Transplant International2013;26(Suppl 2):110. [EMBASE: 71359365] HauserIA , WitzkeO , ArnsW , ReinkeP , SommererC , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novorenal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: P132]. Transplant International2014;27(Suppl 3):51. [EMBASE: 71664135] HoerningA , KohlerS , JunC , LuJ , FuJ , TebbeB , et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clinical &amp; Experimental Immunology2012;168(2):251‐9. [MEDLINE: 22471287] LehnerF , GubaM , ArnsW , SommererC , NeumayerHH , JacobiJ , et al. Follow‐up data from HERAKLES study at month 24: maintained superior renal function in patients on an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus [abstract no: P04]. Transplant International2013;26(Suppl 1):28. [EMBASE: 71356287] LehnerF , SommererC , WitzkeO , ArnsW , KliemV , NeumayerHH , et al. HERAKLES at month 24: efficacy and safety of 3 different regimens in de novo renal transplant patients [abstract no: BO148]. Transplant International2013;26(Suppl 2):82. [EMBASE: 71359263] SommererC , BuddeK , KliemV , WitzkeO , GubaM , JacobiJ , et al. Efficacy and safety of three different treatment regimen in de novo renal transplant patients: month 48 follow‐up results of the HERAKLES trial [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953341] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post HOC analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: 2921]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] SommererC , LehnerF , BuddeK , ArnsW , HauserIA , SuwelackB , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: P127]. Transplant International2014;27(Suppl 3):50. [EMBASE: 71664131] SommererC , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES Trial [abstract no: 51]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745998] WitzkeO , BuddeK , LehnerF , ZeierM , NeumayerHH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES study [abstract no: 1675]. Transplantation2012;94(Suppl):993. [EMBASE: 71251766] ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: follow‐up results of the HERAKLES trial at month 24 [abstract no: 495]. American Journal of Transplantation2013;13(Suppl S5):183. ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: 718]. Transplantation2014;98(Suppl 1):81‐2. [EMBASE: 71543794] ">HERAKLES Study 2012</a>; <a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0046" title="KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Daclizumab and mycophenolate mofetil in renal transplant recipients: 2‐year outcome after early reduction of cyclosporine [abstract no: 1266]. American Journal of Transplantation2003;3(Suppl 5):476. [CENTRAL: CN‐00446199] KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Lowering cyclosporine dose is not associated with an increased risk of gastro‐intestinal adverse events nor the need for dosage decrease of mycophenolate mofetil [abstract no: P743]. Transplantation2004;78(2 Suppl):462. [CENTRAL: CN‐00509292] ">Kreis 2003</a>; <a href="./references#CD006750-bbs2-0050" title="David‐NetoE , LemosF , AntonopoulosI , SouzaP , PiovesanA , VenturaC , KanashiroH , et al. Five‐year follow‐up of the MoDIFY study (modification of doses to improve function through the years) shows benefit of low tacrolimus and regular MMF doses [abstract]. Journal of Urology2011;185(4 Suppl 1):e828. [EMBASE: 70378695] David‐NetoE , LemosFC , deSouzaPS , VenturaCG , deCastroMCR\ , AgenaF , et al. Five‐year follow‐up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]. American Journal of Transplantation2010;10(Suppl 4):508. [EMBASE: 70465030] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Interim analysis of the MODIFY study in renal transplantation [abstract]. Transplantation2004;78(2 Suppl):278‐9. [CENTRAL: CN‐00509408] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. Transplantation2004;78(2 Suppl):278. David‐NetoE , PereiraLM , deCastroCR , MattosRM , SumitaNM , MendesME , et al. Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract]. American Journal of Transplantation2004;4(Suppl 8):234‐5. [CENTRAL: CN‐00509150] David‐NetoE , PereiraLM , deCastroMC , MattosRM , VenturaCG , SumitaNM , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):255. [CENTRAL: CN‐00509409] David‐NetoE , SouzaPS , PanajotopoulosN , RodriguesH , VenturaCG , DavidDS , et al. The impact of pretransplant donor‐specific antibodies on graft outcome in renal transplantation: a six‐year follow‐up study. Clinics2012;67(4):355‐61. [MEDLINE: 22522761] PereiraLM , deCastroMC , VenturaCG , ReisFS , SumitaNM , SaitoMI , et al. The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract]. American Journal of Transplantation2005;5(Suppl 11):466. PereiraLM , deCastroMC , VenturaCG , SoaresPS , FerreiraGF , SaldanhaLB , et al. A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1‐year result of the MODIFY study [abstract no: 53]. American Journal of Transplantation2006;6(Suppl 2):84. [CENTRAL: CN‐00671794] ">MODIFY Study 2012</a>; <a href="./references#CD006750-bbs2-0057" title="Pacheco‐SilvaA , TonatoE , DuraoMJr , Requiao‐MouraL , ArrudaE , ChinenR , et al. A randomized clinical trial of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation [abstract no: P460]. Transplant International2013;26(Suppl 2):277‐8. [EMBASE: 71360073] ">Pacheco‐Silva 2013</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0067" title="RossiniM , LoverreA , StalloneG , InfanteB , SchenaA , MaioranoA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 1149]. American Journal of Transplantation2007;7(Suppl 2):442. [CENTRAL: CN‐00725010] RossiniM , StalloneG , InfanteB , CapobiancoC , LoverreA , SchenaA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 548]. Transplant International2007;20(Suppl 2):226. ">Rossini 2007</a>; <a href="./references#CD006750-bbs2-0069" title="SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]. Transplant International2007;20(Suppl 2):20. SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]. Transplantation2008;86(2 Suppl):39. [CENTRAL: CN‐00679020] ">Salvadori 2007</a>). </p> <section id="CD006750-sec-0062"> <h5 class="title">CNI withdrawal or avoidance versus standard dose CNI regimens</h5> <p>We found 17 studies (81 reports, 1939 participants) that compared CNI withdrawal or avoidance with standard dose CNI regimens; four studies compared avoidance with standard dose CNI regimens (<a href="./references#CD006750-bbs2-0005" title="AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR‐matched de novo kidney transplant recipients. Transplantation2006;82(1):62‐8. [MEDLINE: 16861943] AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor‐avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients [abstract no: SP737]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv264. AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clinical Transplantation2009;23(4):511‐8. [MEDLINE: 19210527] AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation [abstract no: 529]. American Journal of Transplantation2008;8(Suppl 2):319. ">Asberg 2006</a>; <a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a>; <a href="./references#CD006750-bbs2-0036" title="GrimbertP , BaronC , FruchaudG , HemeryF , DesvauxD , BuissonC , et al. Long‐term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low‐risk renal transplant recipients. Transplant International2002;15(11):550‐5. [MEDLINE: 12461659] ">Grimbert 2002</a>; <a href="./references#CD006750-bbs2-0045" title="HausbergM , LangD , LeversA , SuwelackB , KistersK , TokmakF , et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. Journal of Hypertension2006;24(5):957‐64. [MEDLINE: 16612259] HausbergM , SuwelackB , KoschM , BarenbrockM , GerhardtU , HohageH , et al. Effects of calcineurin‐inhibitor withdrawal on sympathetic nerve activity and blood pressure in renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift2001;126:S193. [CENTRAL: CN‐00383083] KoschM , HausbergM , SuwelackB . Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation2003;76(10):1516‐9. [MEDLINE: 14657697] KoschM , SuwelackB , BarenbrockM , KobeltV , HohageH , RahnKH , et al. Studies on effects of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Deutsche Medizinische Wochenschrift2001;126:S185. [CENTRAL: CN‐00383367] ">Kosch 2003a</a>), and one study with three arms and compared avoidance and withdrawal with standard dose CNI (<a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>). The remainder compared CNI withdrawal with standard dose CNI regimen. </p> <p><a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a> and <a href="./references#CD006750-bbs2-0027" title="FormicaR , NickersonP , PoggioE , TinckamK , RushD , GibsonI , et al. Immune monitoring and tacrolimus (TAC) withdrawal in low risk recipients of kidney transplants‐results of CTOT09 [abstract]. Transplantation2014;98(Suppl 1):225. [EMBASE: 71544207] HricikDE , FormicaRN , NickersonP , RushD , FairchildRL , PoggioED , et al. Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients. Journal of the American Society of Nephrology2015;26(12):3114‐22. [MEDLINE: 25925687] NickersonP , WiebeC , FormicaR , TinckamK , PoggioE , BunnapradistS , et al. Epitope mismatch predicts de novo DSA after CNI withdrawal in low‐risk kidney transplant recipients [abstract]. Transplantation2014;98(Suppl 1):137. [EMBASE: 71543963] ">CTOT‐09 Study 2015</a> investigated TAC; two studies involved patients on either CsA or TAC (<a href="./references#CD006750-bbs2-0060" title="PascualJ , BloomD , TorrealbaJ , BrahmbhattR , ChangZ , SollingerHW , et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T‐regulatory cells. American Journal of Transplantation2008;8(7):1529‐36. [MEDLINE: 18510645] ">Pascual 2008</a>; <a href="./references#CD006750-bbs2-0077" title="HillebrandU , SuwelackB , GerhardtU , KobeltV , KraemerJ , HohageH . Impact of calcineurin inhibitor withdrawal and mycophenolate mofetil substitution on hematologic toxicity [abstract no: 0014]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415864] SuwelackB , DietKH , KobeltV , HohageH , GerhardtU . Impact of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in chronic allograft nephropathy [abstract no: 1048]. American Journal of Transplantation2002;2(Suppl 3):402. [CENTRAL: CN‐00416722] SuwelackB , GerhardtU , HohageH . Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. American Journal of Transplantation2004;4(4):655‐62. [MEDLINE: 15023160] SuwelackB , GerhardtU , KobeltV , HillebrandU , MatzkiesF , HohageH . Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels. Transplantation Proceedings2002;34(5):1803‐5. [MEDLINE: 12176583] SuwelackB , HausbergM , HillebrandU , RahnKH , HohageH . Study on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients [abstract no: 0637]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416723] SuwelackB , KobeltV , GerhardtU , VolmerS , HohageH . Course of intima thickness in long term renal transplant recipients treated with or without calcineurin‐inhibitors [abstract no: P04.21]. Kidney &amp; Blood Pressure Research2004;27(5‐6):335. [CENTRAL: CN‐00615862] SuwelackB , KobeltV , HillebrandU , GerhardtU , MatzkiesF , HohageH . Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. Transplantation Proceedings2002;34(5):1808‐9. [MEDLINE: 12176585] SuwelackB , KobeltV , HohageH , GerhardtU . Studies on effects of calcineurin‐inhibitor withdrawal on arterial wall structure and intima media thickness in longterm transplant recipients [abstract no: P290]. Transplantation2004;78(2 Suppl):295. [CENTRAL: CN‐00509495] SuwelackB , MalyarV , WaldschmidtG , HohageH . 5 year follow‐up of a randomized study on calcineurin‐inhibitor‐withdrawal with addition of MMF in chronic allograft nephropathy [abstract no: F‐PO600]. Journal of the American Society of Nephrology2007;18(Abstracts):231A. SuwelackBM , GerhardtUW , HohageH . Influence of calcineurin‐inhibitor free immunosuppression on carotid intima media thickness in chronic allograft nephropathy [abstract no: 659]. American Journal of Transplantation2003;3(Suppl 5):320. [CENTRAL: CN‐00447914] ">Suwelack 2002</a>), and the remainder were CsA‐based studies (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>; <a href="./references#CD006750-bbs2-0005" title="AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR‐matched de novo kidney transplant recipients. Transplantation2006;82(1):62‐8. [MEDLINE: 16861943] AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor‐avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients [abstract no: SP737]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv264. AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clinical Transplantation2009;23(4):511‐8. [MEDLINE: 19210527] AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation [abstract no: 529]. American Journal of Transplantation2008;8(Suppl 2):319. ">Asberg 2006</a>; <a href="./references#CD006750-bbs2-0030" title="DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , MarshallS , et al. MMF substitution for CSA in chronic allograft dysfunction: 2 year follow‐up of a multi‐center randomized controlled study [abstract no: 1513]. American Journal of Transplantation2005;5(Suppl 11):541. DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , SutterC , et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the &quot;creeping creatinine&quot; study. Transplantation2005;79(4):466‐75. [MEDLINE: 15729174] DudleyCR , MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi‐center randomized controlled study [abstract no: 41]. American Journal of Transplantation2002;2(Suppl 3):148. Tedesco de SilvaH . MMF replacing CSA reverses the &quot;creeping creatinine&quot; of renal transplant recipients of a multi‐center randomized controlled study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416751] ">Dudley 2005</a>; <a href="./references#CD006750-bbs2-0036" title="GrimbertP , BaronC , FruchaudG , HemeryF , DesvauxD , BuissonC , et al. Long‐term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low‐risk renal transplant recipients. Transplant International2002;15(11):550‐5. [MEDLINE: 12461659] ">Grimbert 2002</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0039" title="HazzanM , BuobD , LabaletteM , ProvotF , GlowackiF , HoffmannM , et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation2006;82(5):657‐62. [MEDLINE: 16969289] HazzanM , CopinMC , LabaletteM , GlowackiF , ProvotF , RoumilhacD , et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients receiving mycophenolate mofetil: results from a prospective, randomized trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00445673] HazzanM , HertigA , BuobD , NoelC , CopinM , RondeauE , et al. Cyclosporin induces epithelial to mesenchymal transition in renal grafts [abstract no: 131]. American Journal of Transplantation2008;8(Suppl 2):214. HazzanM , LabaletteM , CopinMC , GlowackiF , ProvotF , PruvFR , et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Journal of the American Society of Nephrology2005;16(8):2509‐16. [MEDLINE: 15987748] ">Hazzan 2005</a>; <a href="./references#CD006750-bbs2-0040" title="HeeringP , WesthoffA , IvensK K , GrabenseeB . Comparison between the effects of CSA and azathioprine on functional renal parameters in randomized study after renal transplantation [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):940. [CENTRAL: CN‐00484304] HeeringP , WesthoffA , IvensK , HelmchenU , GrabenseeB . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine: a randomized controlled study [abstract]. 12th International Congress of Nephrology; 1993 Jun 13‐18; Jerusalem, Israel. 1993:194. HeeringP , WesthoffK , IvensB , KutkuhnB , GrabenseeH . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine [abstract]. Nephrology Dialysis Transplantation1993;8(9):1041. [CENTRAL: CN‐00260889] IvensK , HeeringP , WitholdW , KochM , ReinauerH , GrabenseeB . Withdrawal of cyclosporine improves the cardio‐vascular risk profile in renal graft recipients [abstract]. Journal of the American Society of Nephrology1994;5(3):1013. ">Heering 1993</a>; <a href="./references#CD006750-bbs2-0042" title="BakkerRC , HollanderAA , MallatMJ , BruijnJA , PaulLC , deFijterJW . Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney International2003;64(3):1027‐34. [MEDLINE: 12911553] HollanderAA , vanSaaseJL , KootteAM , vanDorpWT , vanBockelHJ , vanEsLA , et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet1995;345(8950):610‐4. [MEDLINE: 7898178] ">Hollander 1995</a>; <a href="./references#CD006750-bbs2-0044" title="IsoniemiH . Renal allograft immunosuppression V: glucose intolerance occurring in different immunosuppressive treatments. Clinical Transplantation1991;5(3):268‐72. [EMBASE: 21188067] IsoniemiH . Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transplant International1991;4(1):31‐7. [MEDLINE: 2059298] IsoniemiH , AhonenJ , EklundB , HockerstedtK , SalmelaK , vonWillebrandE , et al. Renal allograft immunosuppression. II. A randomized trial of withdrawal of one drug in triple drug immunosuppression. Transplant International1990;3(3):121‐7. [MEDLINE: 2271083] IsoniemiH , AhonenJ , KrogerusL , EklundB , HockerstedtK , SalmelaK , et al. Chronic rejection of renal allografts with four immunosuppressive regimens. Transplantation Proceedings1992;24(6):2716‐7. [MEDLINE: 1465912] IsoniemiH , EklundB , HockerstedtK , KorsbackC , SalmelaK , vonWillebrandE , et al. Discontinuation of one drug in triple drug treatment of renal allograft patients: 1‐year results. Transplantation Proceedings1990;22(4):1365‐6. [MEDLINE: 2202111] IsoniemiH , KrogerusL , vonWillebrandE , TaskinenE , Gronhagen‐RiskaC , AhonenJ , et al. Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts. Transplant International1991;4(3):151‐6. [MEDLINE: 1958279] IsoniemiH , TikkanenM , HayryP , EklundB , HockerstedtK , SalmelaK , et al. Lipid profiles with triple drug immunosuppressive therapy and with double drug combinations after renal transplantation and stable graft function. Transplantation Proceedings1991;23(1 (Pt 2)):1029‐31. [MEDLINE: 1989148] IsoniemiH , TikkanenMJ , AhonenJ , HayryP . Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transplant International1991;4(3):130‐5. [MEDLINE: 1958276] IsoniemiH , vonWillebrandE , AhonenJ , EklundB , HockerstedtK , KrogerusL , et al. Late histopathological findings in renal allografts with four immunosuppressive regimens. Transplant International1992;5 Suppl 1:S6‐7. [MEDLINE: 14621718] IsoniemiHM , AhonenJ , TikkanenMJ , vonWillebrandEO , KrogerusL , EklundBH , et al. Long‐term consequences of different immunosuppressive regimens for renal allografts.[Erratum appears in Transplantation 1998 Sep 15;66(5):678]. Transplantation1993;55(3):494‐9. [MEDLINE: 8456467] IsoniemiHM , KrogerusL , vonWillebrandE , TaskinenE , AhonenJ , HayryP . Histopathological findings in well‐functioning, long‐term renal allografts. Kidney International1992;41(1):155‐60. [MEDLINE: 1593852] ">Isoniemi 1990</a>; <a href="./references#CD006750-bbs2-0045" title="HausbergM , LangD , LeversA , SuwelackB , KistersK , TokmakF , et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. Journal of Hypertension2006;24(5):957‐64. [MEDLINE: 16612259] HausbergM , SuwelackB , KoschM , BarenbrockM , GerhardtU , HohageH , et al. Effects of calcineurin‐inhibitor withdrawal on sympathetic nerve activity and blood pressure in renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift2001;126:S193. [CENTRAL: CN‐00383083] KoschM , HausbergM , SuwelackB . Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation2003;76(10):1516‐9. [MEDLINE: 14657697] KoschM , SuwelackB , BarenbrockM , KobeltV , HohageH , RahnKH , et al. Studies on effects of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Deutsche Medizinische Wochenschrift2001;126:S185. [CENTRAL: CN‐00383367] ">Kosch 2003a</a>; <a href="./references#CD006750-bbs2-0047" title="JossN . Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. Scottish Medical Journal2005;50(2):82. [CENTRAL: CN‐00653805] JossN , Glasgow Transplant Group. Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:197. [CENTRAL: CN‐00636135] JossN , RodgerRS , McMillanMA , JunorBJ . Randomized study comparing cyclosporine with azathioprine one year after renal transplantation‐15‐year outcome data. Transplantation2007;83(5):582‐7. [MEDLINE: 17353778] MacPheeIA , BradleyJA , BriggsJD , JunorBJ , MacphersonSG , McMillanMA , et al. Long‐term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation1998;66(9):1186‐92. [MEDLINE: 9825816] MacPheeIA , BriggsJD , JunorBJ , McMillanMA , RodgerRS , WatsonMA . A prospective randomised controlled trial of long‐term outcome for renal transplant recipients converted from cyclosporin to azathioprine treatment one year after transplantation [abstract]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00602085] ">MacPhee 1998</a>; <a href="./references#CD006750-bbs2-0061" title="JensenJD , HansenHE , PedersenEB . Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron1994;67(3):297‐301. [MEDLINE: 7936019] PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation. A prospective, randomized study from 1 to 6 years after transplantation. Nephrology Dialysis Transplantation1993;8(3):250‐4. [MEDLINE: 8385294] PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation: a prospective randomized study from 1 to 6 years after transplantation [abstract]. Nephrology Dialysis Transplantation1993;8(9):1047. PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporine to azathioprine one year after renal transplantation. A prospective, randomized study from one to six years after transplantation [abstract]. 12th International Congress of Nephrology; 1993 June 13‐18; Jerusalem, Israel. 1993:194. [CENTRAL: CN‐00644352] PedersenEB , HansenHE , OlsenS . The effect of cyclosporine and azathioprine on GFR and renal histopathology 12 to 24 months after renal transplantation. Transplantation Proceedings1992;24(1):309‐10. [MEDLINE: 1539289] PedersenEB , HansenHE , OlsenS , DanielsenH , EiskjaerAW , JespersenB , et al. Comparison between the effect of cyclosporin and azathioprine on functional and morphological renal parameters in a randomised study from one to two years after renal transplantation [abstract]. Nephrology Dialysis Transplantation1991;6(10):832‐3. PedersenEB , HansenHE , OlsenS , DanielsenH , EiskjaerH , JespersenB , et al. Comparison between the effects of cyclosporine and azathioprine on functional and morphologic renal parameters in a randomized study from 12 to 24 months after renal transplantation. Clinical Transplantation1991;5(6 I):456‐66. [EMBASE: 22024462] ">Pedersen 1991</a>; <a href="./references#CD006750-bbs2-0071" title="RoodnatJ , HilbrandsLB , HeneRJ , deSevauxRG , GregoorPJ , Kal‐van GestelJA , et al. 15 year follow‐up of a multicentre, randomised, calcineurin inhibitor (CNI) withdrawal study in kidney transplantation [abstract no: BO156]. Transplant International2013;26(Suppl 2):83‐4. [EMBASE: 71359271] RoodnatJI , HilbrandsLB , HeneRJ , deSevauxRG , Smak GregoorPJ , Kal‐van GestelJA , et al. 15‐year follow‐up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation2014;98(1):47‐53. [MEDLINE: 24521775] Smak GregoorPJ , deSevauxRG , HeneRJ , HesseCJ , HilbrandsLB , VosP , et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation1999;68(10):1603‐6. [MEDLINE: 10589962] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow‐up data [abstract no: 441]. American Journal of Transplantation2001;1(Suppl 1):246. [CENTRAL: CN‐00763745] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Journal of the American Society of Nephrology2002;13(5):1365‐73. [MEDLINE: 11961025] Smak GregoorPJ , vanGelderT , IJzermansJN , WeimarW . Long‐term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00447777] VanGelderT , deSevauxR , HeneR , WeimarW , HoitsmaA , LigtenbergG , et al. Discontinuation of cyclosporine or prednisone 6 months after kidney transplantation: a randomized trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):920A. [CENTRAL: CN‐00583812] deSevauxRG , GregoorP , SmakJH , HeneRJ , WeimarW , HoitsmaAJ , et al. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomized study [abstract no: 935]. Transplantation1999;67(7):S240. [CENTRAL: CN‐00767038] ">Smak Gregoor 1999</a>). </p> </section> <section id="CD006750-sec-0063"> <h5 class="title">Standard versus low dose CNI</h5> <p>We included 18 studies (89 reports, 2904 participants) that compared standard dose CNI with low dose CNI. Of these, 15 were CsA‐based studies (<a href="./references#CD006750-bbs2-0002" title="AlsinaJ , GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , et al. Low dose cyclosporine (CsA), ALG and steroids in first cadaveric renal transplants [abstract]. 10th International Congress of Nephrology; 1987 Jul 26‐31; London, UK. 1987:606. [CENTRAL: CN‐00583779] GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , AndresE , et al. Low dose cyclosporine (CyA), ALG and steroids in first cadaveric renal transplants [abstract]. Kidney International1988;34(2):301. [CENTRAL: CN‐00644138] GrinoJM , CastelaoAM , SabateI , MestreM , Gil‐VernetS , AndresE , et al. Low‐dose cyclosporin (CsA), ALG and steroids in first cadaveric renal transplants [abstract]. Nephrology Dialysis Transplantation1988;3(1):99‐100. ">Alsina 1987</a>; <a href="./references#CD006750-bbs2-0003" title="AndresA , MarcenR , SanchezJ , ValdesF , ErrastiP , SolaR , et al. Comparative study of three different patterns of immunosuppression based on induction with basiliximab and low initial doses or delayed initiation of neoral in kidney transplant recipients at high risk of delayed graft function [abstract no: 1629]. American Journal of Transplantation2005;5(Suppl 11):570. [CENTRAL: CN‐00644164] AndresA , MarcenR , ValdesF , PlumedJS , SolaR , ErrastiP , et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clinical Transplantation2009;23(1):23‐32. [MEDLINE: 18798851] MarcenR , AndresA , Sanchez‐PlumedJ , ValdesF , ErrastiP , SolaR , et al. A randomized study to compare immunosuppression based on basiliximab induction and low initial doses or delayed neoral in kidney transplant recipients at high risk for delayed graft function [abstract no: PO‐266]. Transplant International2005;18(Suppl 1):114. ">Andres 2009</a>; <a href="./references#CD006750-bbs2-0007" title="BaczkowskaT , DurlikM , PerkowskaA , SadowskaA , CieciuraT , Nowacka‐CieciuraE , et al. Cytokines and growth factors serum level and renal allograft function (preliminary report) [Cytokiny i czynniki wzrostu w surowicy u biorcow nerki allogenicznej a losy przeszczepu (doniesienie wstepne)]. Polski Merkuriusz Lekarski2003;15(88):356‐8. [MEDLINE: 14974365] BaczkowskaT , PerkowskaA , CieciuraT , WierzbickiP , KlosowkaD , MatloszB , et al. Daclizumab allows for a protocol with low‐dose cyclosporine in low rejection‐risk kidney recipients ‐ preliminary data [abstract no: T435]. Nephrology Dialysis Transplantation2002;17(Suppl 1):309. [CENTRAL: CN‐00400168] BaczkowskaT , Perkowska‐FranckaA , DurlikM , CieciuraT , Nowacka‐CieciuraE , PazikJ , et al. The role of the protocol biopsies in renal allograft recipients. Transplantation Proceedings2003;35(6):2179‐81. [MEDLINE: 14529881] BaczkowskaT , Perkowska‐PtasinskaA , CieciuraT , PazikJ , Nowacka‐CieciuraE , LewandowskiZ , et al. Untreated subclinical, borderline rejection in 12 and 36‐month protocol biopsies is not associated with progressive loss of GFR at 5‐year's follow‐up [abstract no: 1755]. Transplantation2008;86(2 Suppl):581. [CENTRAL: CN‐00671803] BaczkowskaT , Perkowska‐PtasinskaA , LewandowskiZ , Nowacka‐CieciuraE , CieciuraT , PazikJ , et al. Serum TGF‐b1 correlates with chronic histopathological lesions in protocol biopsies in kidney allograft recipients [abstract no: P354]. Transplantation2004;78(2 Suppl):319. [CENTRAL: CN‐00583398] BaczkowskaT , Perkowska‐PtasinskaA , LewandowskiZ , Nowacka‐CieciuraE , PazikJ , CieciuraT , et al. Increased renal TFG‐b protein expression in human allograft specimens correlates with renal allograft function and chronic histopathological changes [abstract no: SaP437]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi382. BaczkowskaT , Perkowska‐PtasinskaA , PazikJ , CieciuraT , Nowacka‐CieciuraE , LewandowskiZ , et al. The role of the protocol biopsies in renal allograft recipients: five‐years' follow‐up [abstract no: P093]. Transplant International2007;20(Suppl 2):118. BaczkowskaT , Perkowska‐PtasinskaA , PazikJ , LewandowskiZ , Nowacka‐CieciuraE , CieciuraT , et al. The role of the protocol biopsies in renal allograft recipients: three‐years' follow‐up [abstract no: SP736]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv263. [CENTRAL: CN‐00602089] BaczkowskaT , Perkowska‐PtasinskaA , SadowskaA , LewandowskiZ , Nowacka‐CieciuraE , CieciuraT , et al. Serum TGF‐beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. Transplantation Proceedings2005;37(2):773‐5. [MEDLINE: 15848527] BaczkowskaT , SadowskaA , Perkowska‐PtasinskaA , LewandowskiZ , CieciuraT , PazikJ , et al. Optimal mycophenolic acid and mycophenolic acid glucuronide levels at the early period after kidney transplantation are the key contributors to improving long‐term outcomes. Transplantation Proceedings2009;41(8):3019‐23. [MEDLINE: 19857666] BaczkowskaT , WierzbickiP , Perkowska‐PtasinskaA , KlosowskaD , NowaczykM , KowalskaGK , et al. Pharmacodynamic monitoring in kidney allograft recipients with and without calcineurin inhibitors [abstract no: P‐593]. Transplant International2009;22(Suppl 2):242. ">Baczkowska 2003</a>; <a href="./references#CD006750-bbs2-0013" title="BuddeK , BosmansJ , ZeierM , SennesaelJ , HoptU , FischerWH , et al. Safety and efficacy of reduced or full dose of cyclosporine (neoral®) in combination with mycophenolate sodium (Myfortic®), basiliximab (Simulect®), and steroids in de novo kidney transplant recipients [abstract]. Transplantation2004;78(2 Suppl):83. [CENTRAL: CN‐00527096] BuddeK , BosmansJL , SennesaelJ , ZeierM , HoptU , FischerW , et al. Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric‐coated mycophenolate‐sodium, and steroids [abstract no: 1195]. American Journal of Transplantation2005;5(Suppl 11):461. [CENTRAL: CN‐00644165] BuddeK , BosmansJL , SennesaelJ , ZeierM , PisarskiP , SchutzM , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab. Clinical Nephrology2007;67(3):164‐75. [MEDLINE: 17390741] BuddeK , ZeierM , BosmansJL , SennesaelJ , GlanderP , FischerW , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab [abstract no: F‐PO1088]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00644166] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Budde 2007</a>; <a href="./references#CD006750-bbs2-0015" title="CaiL , ZengF , LiuB , WeiL , ChenZ , JiangJ . A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients. International Journal of Clinical Practice. Supplement2014;68(181):23‐30. [MEDLINE: 24673716] ">Cai 2014</a>; <a href="./references#CD006750-bbs2-0019" title="ChadbanS , CampbellS , RussG , WalkerR , ChapmanJ , PussellB , et al. A one‐year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric‐coated mycophenolate sodium (EC‐MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA‐ME), basiliximab and steroids in de novo kidney transplantation [abstract no: 32]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:51. [CENTRAL: CN‐00583470] ChadbanS , ErisJ , RussG , CampbellS , ChapmanJ , PussellB , et al. Enteric‐coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology2013;18(1):63‐70. [MEDLINE: 23110508] ">Chadban 2013</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0028" title="Smak GregoorPJ , deSevauxRG , HeneRJ , HilbrandsLB , vanGelderT , HoitsmaAJ , et al. The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):699A. [CENTRAL: CN‐00447776] deSevauxRG , GregoorPJ , HeneRJ , HoitsmaAJ , VosP , WeimarW , et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. Journal of the American Society of Nephrology2001;12(8):1750‐7. [MEDLINE: 11461949] deSevauxRG , Smak GregoorPJ , HeneRJ , HoitsmaAJ , VosP , et al. Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00583239] deSévauxRG , Smak GregoorPJ , HenéRJ , WeimarW , HoitsmaAJ , VanGelderT , et al. A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]. Transplantation1998;65(12):S107. [CENTRAL: CN‐00583548] ">de Sevaux 2001</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>, <a href="./references#CD006750-bbs2-0032" title="FangmannJ , ArnsW , MartiH , BuddeK , BeckurtsT , HaussJ . Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation ‐ impact on renal function and rejection episodes [abstract no: 113]. American Journal of Transplantation2005;5(Suppl 11):185. [CENTRAL: CN‐00644197] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]. American Journal of Transplantation2004;4(Suppl 8):353. [CENTRAL: CN‐00509182] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]. Transplantation2004;78(2 Suppl):280. FangmannJ , ArnsW , MartiHP , HaussJ , KettelerM , BeckurtsT , et al. Impact of daclizumab, low‐dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology Dialysis Transplantation2010;25(1):283‐92. [MEDLINE: 19773417] ">Fangmann 2010</a>; <a href="./references#CD006750-bbs2-0033" title="FergusonR , MulgaonkarS , Tedesco SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced‐exposure (R‐E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra (ACT). 2003:63. [CENTRAL: CN‐00445317] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorU , et al. FTY720 with reduced‐exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415638] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , RussG , et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12‐month preliminary results [abstract no: 624]. American Journal of Transplantation2003;3(Suppl 5):311. [CENTRAL: CN‐00445316] MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorfU , RussG , et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1‐year dose‐finding study.[Erratum appears in Am J Transplant. 2006 Dec;6(12):3044]. American Journal of Transplantation2006;6(8):1848‐57. [MEDLINE: 16771816] RussG , FergusonRM , MulgaonkarS , Tedesco‐SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced dose Neoral (RDN) may offer a safety/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]. American Journal of Transplantation2004;4(Suppl 8):432. [CENTRAL: CN‐00509451] ">Ferguson 2006</a>; <a href="./references#CD006750-bbs2-0046" title="KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Daclizumab and mycophenolate mofetil in renal transplant recipients: 2‐year outcome after early reduction of cyclosporine [abstract no: 1266]. American Journal of Transplantation2003;3(Suppl 5):476. [CENTRAL: CN‐00446199] KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Lowering cyclosporine dose is not associated with an increased risk of gastro‐intestinal adverse events nor the need for dosage decrease of mycophenolate mofetil [abstract no: P743]. Transplantation2004;78(2 Suppl):462. [CENTRAL: CN‐00509292] ">Kreis 2003</a>; <a href="./references#CD006750-bbs2-0059" title="PascualM , CurtisJ , DelmonicoFL , FarrellML , WilliamsWW , KalilR , et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation2003;75(9):1501‐5. [MEDLINE: 12792504] WongW , Tolkoff‐RubinN , DelmonicoFL , CardarelliF , SaidmanSL , FarrellML , et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplantation2004;18(4):341‐8. [MEDLINE: 15233807] WongW , Tolkoff‐RubinN , DelmonicoFL , FarellML , ShihV , WilliamsW , et al. Analysis of the cardiovascular risk profile in stable renal transplant recipients after 50% cyclosporine reduction [abstract]. American Journal of Transplantation2003;3(Suppl 5):213. [CENTRAL: CN‐00448411] WongW , Tolkoff‐RubinN , DelmonicoFL , FarrellML , ShihV , CosimiAB , et al. A randomized clinical trial to analyze the effect of 50% cyclosporine reduction on the cardiovascular risk profile in stable kidney transplant recipients [abstract]. Journal of the American Society of Nephrology2003;14(Nov):186A. [CENTRAL: CN‐00550675] ">Pascual 2003</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>; <a href="./references#CD006750-bbs2-0069" title="SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]. Transplant International2007;20(Suppl 2):20. SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]. Transplantation2008;86(2 Suppl):39. [CENTRAL: CN‐00679020] ">Salvadori 2007</a>); two investigated TAC (<a href="./references#CD006750-bbs2-0021" title="AsderakisA , ChanL . Renal function with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month study in de novo renal transplant recipients [abstract no: O111]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ChanL , AndresA , BunnapradistS , GugliuzzaK , ParasuramanR , PeddiVR , et al. Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC‐MPS. Journal of Transplantation2012;2012:941640. [MEDLINE: 23227307] ChanL , HartM , AndresA , GugliuzzaK , BunnapradistS , ParasumaranR . Renal function and incidence of NODM with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month comparative study in de novo renal transplant recipients [abstract no: 718]. Transplantation2008;86(2S):251. NicholsonML , ChanL . Incidence of new onset diabetes mellitus in de novo renal transplant recipients treated with enteric‐coated mycophenolate sodium in combination with reduced or standard tacrolimus target levels: results of a 6‐month randomized study [abstract no: P266]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ">Chan 2012</a>; <a href="./references#CD006750-bbs2-0050" title="David‐NetoE , LemosF , AntonopoulosI , SouzaP , PiovesanA , VenturaC , KanashiroH , et al. Five‐year follow‐up of the MoDIFY study (modification of doses to improve function through the years) shows benefit of low tacrolimus and regular MMF doses [abstract]. Journal of Urology2011;185(4 Suppl 1):e828. [EMBASE: 70378695] David‐NetoE , LemosFC , deSouzaPS , VenturaCG , deCastroMCR\ , AgenaF , et al. Five‐year follow‐up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]. American Journal of Transplantation2010;10(Suppl 4):508. [EMBASE: 70465030] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Interim analysis of the MODIFY study in renal transplantation [abstract]. Transplantation2004;78(2 Suppl):278‐9. [CENTRAL: CN‐00509408] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. Transplantation2004;78(2 Suppl):278. David‐NetoE , PereiraLM , deCastroCR , MattosRM , SumitaNM , MendesME , et al. Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract]. American Journal of Transplantation2004;4(Suppl 8):234‐5. [CENTRAL: CN‐00509150] David‐NetoE , PereiraLM , deCastroMC , MattosRM , VenturaCG , SumitaNM , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):255. [CENTRAL: CN‐00509409] David‐NetoE , SouzaPS , PanajotopoulosN , RodriguesH , VenturaCG , DavidDS , et al. The impact of pretransplant donor‐specific antibodies on graft outcome in renal transplantation: a six‐year follow‐up study. Clinics2012;67(4):355‐61. [MEDLINE: 22522761] PereiraLM , deCastroMC , VenturaCG , ReisFS , SumitaNM , SaitoMI , et al. The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract]. American Journal of Transplantation2005;5(Suppl 11):466. PereiraLM , deCastroMC , VenturaCG , SoaresPS , FerreiraGF , SaldanhaLB , et al. A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1‐year result of the MODIFY study [abstract no: 53]. American Journal of Transplantation2006;6(Suppl 2):84. [CENTRAL: CN‐00671794] ">MODIFY Study 2012</a>); and <a href="./references#CD006750-bbs2-0055" title="BloomR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]. Transplantation2008;86(2 Suppl):301. [CENTRAL: CN‐00740509] GastonR , BloomR , ShahT , CibrikD , AngelisM , MulgaonkarS , et al. 6‐month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH‐PO565]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00602020] GastonR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00653708] GastonRS , KaplanB , ShahT , CibrikD , ShawLM , AngelisM , et al. Fixed‐ or controlled‐dose mycophenolate mofetil with standard‐ or reduced‐dose calcineurin inhibitors: the OPTICEPT trial. American Journal of Transplantation2009;9(7):1607‐19. [MEDLINE: 19459794] KaplanB , GastonR , Meier‐KriescheH , BloomR , PatelD , ShawL . Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]. American Journal of Transplantation2009;9(Suppl 2):419. [CENTRAL: CN‐00794654] KaplanB , GastonRS , Meier‐KriescheHU , BloomRD , ShawLM . Mycophenolic acid exposure in high‐ and low‐weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Therapeutic Drug Monitoring2010;32(2):224‐7. [MEDLINE: 20216117] ShawL , KaplanB , AngelisM , BloomR , GastonR , Meier‐KriescheH , et al. Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU‐FC128]. Journal of the American Society of Nephrology2007;18(Abstracts):96A‐7A. [CENTRAL: CN‐00724911] ">OPTICEPT Study 2009</a> included either TAC or CsA. Of these, 12 studies involved introduction of low dose CNI regimen early in the post‐transplant period and six introduced low dose CNI later in the post‐transplant period (<a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0046" title="KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Daclizumab and mycophenolate mofetil in renal transplant recipients: 2‐year outcome after early reduction of cyclosporine [abstract no: 1266]. American Journal of Transplantation2003;3(Suppl 5):476. [CENTRAL: CN‐00446199] KreisH , MiloradovichT , MouradG , CointaultO , BerthouxF , DelahousseM , et al. Lowering cyclosporine dose is not associated with an increased risk of gastro‐intestinal adverse events nor the need for dosage decrease of mycophenolate mofetil [abstract no: P743]. Transplantation2004;78(2 Suppl):462. [CENTRAL: CN‐00509292] ">Kreis 2003</a>; <a href="./references#CD006750-bbs2-0050" title="David‐NetoE , LemosF , AntonopoulosI , SouzaP , PiovesanA , VenturaC , KanashiroH , et al. Five‐year follow‐up of the MoDIFY study (modification of doses to improve function through the years) shows benefit of low tacrolimus and regular MMF doses [abstract]. Journal of Urology2011;185(4 Suppl 1):e828. [EMBASE: 70378695] David‐NetoE , LemosFC , deSouzaPS , VenturaCG , deCastroMCR\ , AgenaF , et al. Five‐year follow‐up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]. American Journal of Transplantation2010;10(Suppl 4):508. [EMBASE: 70465030] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Interim analysis of the MODIFY study in renal transplantation [abstract]. Transplantation2004;78(2 Suppl):278‐9. [CENTRAL: CN‐00509408] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. Transplantation2004;78(2 Suppl):278. David‐NetoE , PereiraLM , deCastroCR , MattosRM , SumitaNM , MendesME , et al. Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract]. American Journal of Transplantation2004;4(Suppl 8):234‐5. [CENTRAL: CN‐00509150] David‐NetoE , PereiraLM , deCastroMC , MattosRM , VenturaCG , SumitaNM , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):255. [CENTRAL: CN‐00509409] David‐NetoE , SouzaPS , PanajotopoulosN , RodriguesH , VenturaCG , DavidDS , et al. The impact of pretransplant donor‐specific antibodies on graft outcome in renal transplantation: a six‐year follow‐up study. Clinics2012;67(4):355‐61. [MEDLINE: 22522761] PereiraLM , deCastroMC , VenturaCG , ReisFS , SumitaNM , SaitoMI , et al. The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract]. American Journal of Transplantation2005;5(Suppl 11):466. PereiraLM , deCastroMC , VenturaCG , SoaresPS , FerreiraGF , SaldanhaLB , et al. A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1‐year result of the MODIFY study [abstract no: 53]. American Journal of Transplantation2006;6(Suppl 2):84. [CENTRAL: CN‐00671794] ">MODIFY Study 2012</a>; <a href="./references#CD006750-bbs2-0059" title="PascualM , CurtisJ , DelmonicoFL , FarrellML , WilliamsWW , KalilR , et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation2003;75(9):1501‐5. [MEDLINE: 12792504] WongW , Tolkoff‐RubinN , DelmonicoFL , CardarelliF , SaidmanSL , FarrellML , et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplantation2004;18(4):341‐8. [MEDLINE: 15233807] WongW , Tolkoff‐RubinN , DelmonicoFL , FarellML , ShihV , WilliamsW , et al. Analysis of the cardiovascular risk profile in stable renal transplant recipients after 50% cyclosporine reduction [abstract]. American Journal of Transplantation2003;3(Suppl 5):213. [CENTRAL: CN‐00448411] WongW , Tolkoff‐RubinN , DelmonicoFL , FarrellML , ShihV , CosimiAB , et al. A randomized clinical trial to analyze the effect of 50% cyclosporine reduction on the cardiovascular risk profile in stable kidney transplant recipients [abstract]. Journal of the American Society of Nephrology2003;14(Nov):186A. [CENTRAL: CN‐00550675] ">Pascual 2003</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>). </p> </section> <section id="CD006750-sec-0064"> <h5 class="title">Standard dose CNI versus CNI withdrawal or avoidance with mTOR‐I substitution</h5> <p>There were 29 studies (252 reports, 5012 participants) that compared standard dose CNI with CNI withdrawal or avoidance combined with mTOR‐I substitution (<a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0016" title="FranzS , RegeniterA , HopferH , MihatschM , DickenmannM . Tubular toxicity in sirolimus‐ and cyclosporine‐based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. American Journal of Kidney Diseases2010;55(2):335‐43. [MEDLINE: 19926370] GianniniO , DickenmannM , KimMJ , FranzS , MayrM , MihatschMJ , et al. The CALFREE Study ‐ an open, prospective, randomized single center study to investigate calcineurin free immunosuppression in 100 de novo, normal risk renal transplant recipients: preliminary results [abstract no: P04.02]. Kidney &amp; Blood Pressure Research2004;27(5‐6):329. [CENTRAL: CN‐00615861] ">CALFREE Study 2010</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0018" title="HertigA , KamarN , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract]. Transplantation2014;98:81. [EMBASE: 71543793] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , Hurault De LignyB , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: O5]. Transplant International2013;26(Suppl 3):2. [EMBASE: 71356080] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , LignyBH , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: P081]. Transplant International2013;26(Suppl 2):201. [EMBASE: 71359712] RostaingL , HertigA , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Fibrosis progression according to epithelial‐mesenchymal transition profile: a randomized trial of everolimus versus CsA. American Journal of Transplantation2015;15(5):1303‐12. [MEDLINE: 25808994] ">CERTITEM Study 2015</a>; <a href="./references#CD006750-bbs2-0022" title="AlvaradoA , ChhabraD , WangE , NajafianN , FriedewaldJ , HoB , et al. Prospective randomized study to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone‐free immunosuppressive regimen [abstract no: 53]. American Journal of Transplantation2012;12(Suppl S3):42. [EMBASE: 70746000] AlvaradoA , ShettyA , TraitanonO , LeventhalJ , MasV , ChhabraD , et al. Calcineurin‐inhibitor conversion to mTOR inhibitor in renal transplant recipients leads to worse long term clinical outcomes [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953109] ChhabraD , AlvaradoA , DalalP , LeventhalJ , WangC , Sustento‐ReodicaN , et al. Impact of calcineurin‐inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone‐free regimen. American Journal of Transplantation2013;13(11):2902‐11. [MEDLINE: 24007570] GallonL , TraitanonO , Sustento‐ReodicaN , LeventhalJ , AnsariMJ , GehrauRC , et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International2014;87(4):828‐38. [MEDLINE: 25354238] ShahG , XuL , DalalP , ChhabranD , FriedewaldJ , HoB , et al. Conversion from CNI to SRL in a pred‐free immunosuppressive regimen: interim report of a prospective randomized study [abstract no: 1641]. American Journal of Transplantation2010;10(Suppl 4):504. ">Chhabra 2013</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0031" title="El‐AgroudyA , AlarrayedS , GhareebS , FaridE , AlhellowH , AbdullaS . Long‐term outcome of a prospective randomized trial of conversion from tacrolimus to sirolimus treatment after renal transplantation [abstract no: B964]. Transplantation2014;98(Suppl 1):539. [EMBASE: 71545346] ">El‐Agroudy 2014</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0048" title="Martinez‐MierG , Mendez‐LopezMT , Budar‐FernandezLF , Estrada‐OrosJ , Franco‐AbaroaR , George‐MicelliE , et al. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation2006;82(11):1533‐6. [MEDLINE: 17164728] ">Martinez‐Mier 2006</a>; <a href="./references#CD006750-bbs2-0052" title="NafarM , AlipourB , AhmadpoorP , Pour‐Reza‐GholiF , SamadianF , SamavatS , et al. Sirolimus versus calcineurin inhibitor‐based immunosuppressive therapy in kidney transplantation: a 4‐year follow‐up. Iranian Journal of Kidney Diseases2012;6(4):300‐6. [MEDLINE: 22797101] ">Nafar 2012</a>; <a href="./references#CD006750-bbs2-0056" title="FlechnerS , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)+ mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year safety results from the Orion Trial [abstract no: 444]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no: 1141]. American Journal of Transplantation2007;7(Suppl 2):440. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no: 52]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653711] FlechnerS , GlydaM , SteinbergS , HarlerMB , ORION Trial Investigators. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from The ORION Study [abstract no: P477]. Transplant International2007;20(Suppl 2):209. FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year efficacy results from the ORION trial [abstract no: 287]. American Journal of Transplantation2008;8(Suppl 2):254. [CENTRAL: CN‐00653710] FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. Preliminary two‐year efficacy results from a randomized, open‐label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + mycophenolate regimen (MMF) in de novo renal allograft recipients [abstract no: 531]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740478] FlechnerSM , GlydaM , CockfieldS , GrinyoJ , LegendreC , RussG , et al. The ORION Study: comparison of two sirolimus‐based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.[Erratum appears in Am J Transplant. 2012 Jan;12(1):268]. American Journal of Transplantation2011;11(8):1633‐44. [MEDLINE: 21668635] FlechnerSM , GlydaM , See TaiS , ORION Trial Investigators. Delayed graft function (DGF) in two sirolimus (SRL)‐based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients [abstract no: 299]. American Journal of Transplantation2009;9(Suppl 2):277. [CENTRAL: CN‐00774294] FlechnerSM , GlydaM , SteinbergS , CopleyJB , ORION Trial Investigators. The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: interim results from the Orion Study [abstract no: SU‐FC124]. Journal of the American Society of Nephrology2007;18(Abstracts):95A. [CENTRAL: CN‐00716077] RussG , FlechnerSM , CockfieldS , GrinyoJ , WissingKM , LegendreC , et al. Cardiovascular risk profile of renal transplant recipients enrolled in an open‐label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC)+ mycophenolate regimen (MMF): preliminary results from the Orion Trial [abstract no: 445]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] ">ORION Study 2011</a>; <a href="./references#CD006750-bbs2-0057" title="Pacheco‐SilvaA , TonatoE , DuraoMJr , Requiao‐MouraL , ArrudaE , ChinenR , et al. A randomized clinical trial of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation [abstract no: P460]. Transplant International2013;26(Suppl 2):277‐8. [EMBASE: 71360073] ">Pacheco‐Silva 2013</a>; <a href="./references#CD006750-bbs2-0062" title="PontrelliP , RossiniM , InfanteB , StalloneG , SchenaA , LoverreA , et al. Rapamycin inhibits PAI‐1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation2008;85(1):125‐34. [MEDLINE: 18192922] RossiniM , PontrelliP , StalloneG , InfanteB , SchenaA , LoverreA , et al. Regression of glomerulosclerosis in chronic allograft nephropathy (CAN) following calcineurin inhibitors (CNI) withdrawal and conversion to sirolimus (SRL) [abstract no: TH‐PO554]. Journal of the American Society of Nephrology2006;17(Abstracts):225A. [CENTRAL: CN‐00725009] StalloneG , PontrelliP , InfanteB , SchenaA , UrsiM , RanieriE , et al. Rapamycin (RAPA) inhibits PAI‐1 expression and reduce interstitial fibrosis in chronic allograft nephropathy (CAN) [abstract no: SO04]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v4. [CENTRAL: CN‐00716118] ">Pontrelli 2008</a>; <a href="./references#CD006750-bbs2-0065" title="RivelliRF , GoncalvesRT , LeiteMJr , SantosMA , DelgadoAG , CardosoLR , et al. Early withdrawal of calcineurin inhibitor from a sirolimus‐based immunosuppression stabilizes fibrosis and the transforming growth factor‐beta signalling pathway in kidney transplant. Nephrology2015;20(3):168‐76. [MEDLINE: 25404086] ">Rivelli 2015</a>; <a href="./references#CD006750-bbs2-0066" title="BalshawR , MarraC , NashanB , HagenmeyerEG , KeownP . First year cost‐implications of early cyclosporine withdrawal in renal transplantation [abstract no: 2378]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415221] CampistolJM , ErisJ , OberbauerR , FriendP , HutchisonB , MoralesJM , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology2006;17(2):581‐9. [MEDLINE: 16434506] CampistolJM , KreisH , OberbauerR , MotaA , RiadH , ChapmanJ , et al. Sirolimus‐based therapy following early cyclosporin withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract]. American Journal of Transplantation2004;4(Suppl 8):344. [CENTRAL: CN‐00509115] CampistolJM , LegendreC , FriendP , RiadH , CastagnetoM . Evaluating cardiovascular risk factors associated with long‐term sirolimus (Rapamune®) immunotherapy used with or without cyclosporine [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):311. [CENTRAL: CN‐00550754] CampistolJM , OberbauerR , HartmannA , KreisH , MotaA , AriasM , et al. Long‐term graft survival is significantly better in patients receiving sirolimus‐based therapy after early cyclosporine withdrawal [abstract no: W736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):784. [CENTRAL: CN‐00444661] CampistolJM , OberbauerR , KreisH , BraultY , BurkeJT , Rapamune Maintenance Regimen Study Group. Predicting 10‐year graft survival with sirolimus used either as base therapy or in association with cyclosporine [abstract no: 1458]. American Journal of Transplantation2003;3(Suppl 5):474. [CENTRAL: CN‐00444662] CampistolJM , OberbauerR , KreisH , LawenJ , MoralesJM , ChapmanJ , et al. Elimination of cyclosporine with sirolimus‐based immunotherapy: 2‐year results confirm improved renal function [abstract no: SA‐P0489]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00444663] ChapmanJ , JohnsonRW , KreisH , OberbauerR , VanrenterghemY , ClaessonK , et al. Improved renal function using sirolimus (Rapamune®) maintenance therapy and cyclosporine elimination in renal allograft recipients: 12‐month results of the tri‐continental trial [abstract no: A4615]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):882A. [CENTRAL: CN‐00550709] ChapmanJ , OberbauerR , CampistolJM , GrinyoJM , MoralesJM , MotaA , et al. Renal transplant patients receiving sirolimus‐based therapy after early cyclosporine withdrawal demonstrate superior renal allograft survival and improved renal function at 48 months after transplantation [abstract no: SU‐FC103]. Journal of the American Society of Nephrology2004;15(Oct):66A. [CENTRAL: CN‐00583160] ErisJ , GrinyoJM , BraultY , HutchisonB . Sirolimus therapy after early cyclosporine withdrawal in renal transplantation significantly reduces the rate of skin cancer compared with continuous combined therapy with cyclosporine [abstract no: OR‐040]. Transplant International2005;18(Suppl):10. ErisJ , RussG , HutchinsonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation [abstract no: 105]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644323] ErisJ , RussG , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Conversion to sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation [abstract no: 1581]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00644325] FriendP , MotaA , KreisH , SegoloniG , LegendreC , PratsD , et al. Cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy is beneficial to patients regardless of baseline renal function [abstract no: 0553]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415680] FriendP , RussG , OberbauerR , MurgiaMG , TufvesonG , ChapmanJ , et al. Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function. Transplant International2007;20(9):754‐60. [MEDLINE: 17565578] GrinyoJM , VanrentergheimY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. Sirolimus (Rapamune) in patients receiving kidney from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 534]. American Journal of Transplantation2002;2(Suppl 3):272. [CENTRAL: CN‐00415776] GrinyoJM , VanrenterghemY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. The effects of sirolimus (Rapamune) in patients receiving kidneys from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 0435]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00420830] HartmannA , ColonJ , PenaJ , MartinezJ , WalkerR , ArnsW , et al. Favourable cardiovascular risk profile in renal transplant patients receiving sirolimus maintenance therapy following cyclosporine withdrawal: 3 year results of the Rapamune Maintenance Regimen trial [abstract no: W756]. Nephrology Dialysis Transplantation2003;18(Suppl 4):791‐2. [CENTRAL: CN‐00445657] HartmannA , MotaA , LegendreC , SegoloniG , GrinyoJM , HutchisonB , et al. Patients receiving sirolimus maintenance therapy have better renal function after early cyclosporine withdrawal irrespective of baseline renal function: intent‐to‐treat results at 3 years [abstract no: W743]. Nephrology Dialysis Transplantation2003;18(Suppl 4):787. [CENTRAL: CN‐00445658] HartmannA , OberbauerR , KreisH , JohnsonRW , MotaA , SchenaFP , et al. Long‐term results of cyclosporine elimination with sirolimus‐based therapy show improved renal function [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):19. [CENTRAL: CN‐00550651] HutchisonB , ClaessonK , MotaA , ErisJM , KreisH , OberbauerR , et al. Quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination: 2‐year results [abstract no: 499]. American Journal of Transplantation2002;2(Suppl 3):263. [CENTRAL: CN‐00415909] JohnsonR , OberbauerR , KreisH , BrattstromB , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation [abstract no: 0429]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00445947] JohnsonRW , KreisH , OberbauerR , BrattstromC , ClaessonK , ErisJ . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation2001;72(5):777‐86. [MEDLINE: 11571437] KeownP , ChenJ , KreisH , OberbauerR , ClaessonK , MotaA , et al. Improved quality of life after cyclosporine elimination in sirolimus‐treated renal transplant patients [abstract no: A4711]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):901A. [CENTRAL: CN‐00550607] KreisH , JohnsonR , MayerG , BrattstromC , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine‐free immunosuppression in renal transplantation resulting in lower blood pressure and improved renal function [abstract no: A3662]. Journal of the American Society of Nephrology2000;11(Sept):696A‐7A. [CENTRAL: CN‐00550424] KreisH , OberbauerR , CampistolJM , MathewT , DalozeP , SchenaFP , et al. Long‐term benefits with sirolimus‐based therapy after early cyclosporine withdrawal. Journal of the American Society of Nephrology2004;15(3):809‐17. [MEDLINE: 14978184] KreisH , OberbauerR , ClaessonK , MotaA , AriasM , DurandD , et al. Quality‐of‐life assessments in sirolimus‐treated renal transplant patients after cyclosporine elimination [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00446200] KreisH , OberbauerR , MotaA , ClaessonK , RiadH , CampistolJM , et al. Sirolimus‐based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a continuous combination of sirolimus and cyclosporine [abstract]. American Journal of Transplantation2003;3(Suppl 5):460. [CENTRAL: CN‐00446201] LegendreC , BraultY , MoralesJM , OberbauerR , AltieriP , RiadH , et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years. Clinical Transplantation2007;21(3):330‐6. [MEDLINE: 17488381] LegendreC , DalozeP , ColonJ , ChapmanJ , PenaJ , MartinezJ , et al. Sirolimus (Rapamune) used with or without cyclosporine for long term therapy: a comparison of cardiovascular risk factors. [abstract no: 1015]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00416111] LegendreC , MotaA , FriendP , SegoloniG , GrinyoJM , HutchisonB , et al. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 3 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):466. [CENTRAL: CN‐00446313] MathewT , KreisH , DoyenK . Malignancy in renal transplant recipients receiving sirolimus (rapamune) maintenance therapy: 2‐year follow up from 5 multicenter studies [abstract no: 58]. American Journal of Transplantation2002;2(Suppl 3):152. [CENTRAL: CN‐00416243] MathewT , KreisH , DoyenK . Two‐year incidence of malignancy in sirolimus (Rapamune)‐treated renal transplant recipients: follow‐up results from 5 multicenter studies [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416244] MathewT , KreisH , FriendP . Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation2004;18(4):446‐9. [MEDLINE: 15233824] MoralesJM , HartmannA , WalkerR , ArnsW , SenatorskiG , GrinyoJM , et al. Similar lipid profile but improved long‐term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplantation Proceedings2009;41(6):2339‐44. [MEDLINE: 19715914] MoralesJM , KreisH , OberbauerR , CampistolJM , MotaA , HenriquesAC , et al. 48‐month results of sirolimus‐based therapy following early cyclosporine withdrawal demonstrate superior renal allograft survival [abstract no: MO05]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:214. [CENTRAL: CN‐00509360] MoralesJM , OberbauerR , LegendreC , RuizJC , MotaA , ChapmanJ , et al. Analysis of risk factors for reduced renal function in renal transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal: 5‐year results from the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC156]. Journal of the American Society of Nephrology2005;16:72A. [CENTRAL: CN‐00644316] MotaA , AriasM , TaskinenEI , PaavonenT , BraultY , LegendreC , et al. Sirolimus‐based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. American Journal of Transplantation2004;4(6):953‐61. [MEDLINE: 15147430] MotaA , AriasM , TaskinenEI , PaavonenT , LegendreC , ClaessonK , et al. Sirolimus‐based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years following kidney transplantation [abstract no: 1486]. American Journal of Transplantation2004;4(Suppl 8):566. [CENTRAL: CN‐00509364] MotaA , SegoloniG , LegendreC , PratsD , HutchisonB , MoralesJM , et al. Patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy irrespective of baseline renal function [abstract no: 395]. American Journal of Transplantation2002;2(Suppl 3):237. [CENTRAL: CN‐00420843] OberbauerR , AriasM , ClaessonK , MotaA , ErisJM , HutchisonB , et al. Two‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 0257]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416378] OberbauerR , HutchisonB , ErisJ , AriasM , ClaessonK , MotaA , et al. Health‐related quality‐of‐life outcomes of sirolimus‐treated kidney transplant patients after elimination of cyclosporine A: results of a 2‐year randomized clinical trial. Transplantation2003;75(8):1277‐85. [MEDLINE: 12717216] OberbauerR , HutchisonB , ErisJ , AriasM , MotaA , the Rapamune Maintenance Regimen Study Group. Health‐related quality‐of‐life assessment in kidney transplant patients receiving sirolimus maintenance therapy with early elimination of cyclosporine: 3‐year results [abstract no: W758]. Nephrology Dialysis Transplantation2003;18(Suppl 4):243. [CENTRAL: CN‐00446999] OberbauerR , HutchisonB , ErisJ , RiadH , ClaessonK , LawenJ , et al. Three‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 249]. American Journal of Transplantation2003;3(Suppl 5):215. [CENTRAL: CN‐00447000] OberbauerR , KreisH , CampistolJM , MotaA , DalozeP , RuizJC , et al. Renal function improves significantly after early cyclosporine withdrawal in sirolimus‐treated renal transplant recipients: 3‐year results of the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC041]. Journal of the American Society of Nephrology2003;14(Nov):10A. [CENTRAL: CN‐00550606] OberbauerR , KreisH , JohnsonRW , MotaA , ClaessonK , RuizJC , et al. Long‐term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2‐year results of the Rapamune Maintenance Regimen Study. Transplantation2003;76(2):364‐70. [MEDLINE: 12883194] OberbauerR , KreisH , JohnsonRWG , MotaA , ClaessonK , AriasM , et al. Long‐term improvement in renal function is shown in patients treated with sirolimus (Rapamune) and cyclosporine withdrawal: 2‐year results of the Rapamune Maintenance Regimen trial [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416379] OberbauerR , MotaA , PratsD , MathewT , MoralesJM , DalozeP , et al. Renal transplant patients with risk factors for reduced renal function benefit from cyclosporine withdrawal and sirolimus maintenance therapy [abstract no: W742]. Nephrology Dialysis Transplantation2003;18(Suppl 4):786‐7. [CENTRAL: CN‐00447001] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation [abstract no: O80]. Transplantation2004;78(2 Suppl):30. [CENTRAL: CN‐00653813] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation.[erratum appears in Transpl Int. 2005 Mar;18(3):369]. Transplant International2005;18(1):22‐8. [MEDLINE: 15612979] PaczekL , MotaA , SchenaFP , JohnsonRW , PratsD , MathewT , et al. Renal function benefit from sirolimus maintenance therapy after early cyclosporine withdrawal in the presence of risk factors [abstract no: 180]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00447075] RuizJC , CampistolJM , GrinyoJM , MotaA , PratsD , GutierrezJA , et al. Early cyclosporine a withdrawal in kidney‐transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation2004;78(9):1312‐8. [MEDLINE: 15548969] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions [abstract no: SU‐FC0235]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):48A. [CENTRAL: CN‐00447509] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Proceedings2003;35(5):1669‐70. [MEDLINE: 12962750] RuizJC , CampistolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplantation Proceedings2007;39(7):2151‐2. [MEDLINE: 17889121] RuizJC , CampstolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. The early use of sirolimus with CsA elimination is not associated with progressive proteinuria [abstract no: P113]. Transplant International2007;20(Suppl 2):122. [CENTRAL: CN‐00740556] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Anaemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function [abstract no: 2504]. Nephrology2006;11(Suppl 2):A37. [CENTRAL: CN‐00644362] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus (SRL) maintenance therapy after early cyclosporine (CsA) withdrawal benefits renal transplant recipients with risk factors for reduced renal function: 5‐year results [abstract no: 103]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:90. [CENTRAL: CN‐00644320] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus‐based therapy following early cyclosporine withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract no: P150]. Nephrology2004;9(Suppl 1):A38. [CENTRAL: CN‐00509449] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 159]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN‐00644317] RussG , JamiesonN , OberbauerR , AriasM , MurgiaMG , BlanchoG , et al. Three‐year health‐related quality‐of‐life outcomes for sirolimus‐treated kidney transplant patients after elimination of cyclosporine. Transplant International2007;20(10):875‐83. [MEDLINE: 17854445] RussG , OberbauerR , FriendP , CampistolJM , BurkeJT . The impact of renal function on the incidence of anemia in sirolimus‐treated renal transplant recipients [abstract no: TH‐PO563]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. [CENTRAL: CN‐00615898] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Long‐term impact of baseline renal function in kidney transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal [abstract no: FC‐50004]. Nephrology2005;10(Suppl 1):A2. [CENTRAL: CN‐00644319] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 1009]. American Journal of Transplantation2005;5(Suppl 11):413. RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation2005;80(9):1204‐11. [MEDLINE: 16314787] SchenaFP , JamiesonN , ColonJ , ShokerA , PenaJ , MartinezM , et al. Favorable cardiovascular risk profile when sirolimus is used without cyclosporine compared to combination therapy: 3‐year results of the Rapamune Maintenance Regimen trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):479. [CENTRAL: CN‐00447616] VanrenterghemY , KreisH , OberbauerR , MotaA , JohnsonWG , Sirolimus Tri‐contienental Renal Transplant Study Group. Improved renal function in renal allograft recipients with sirolimus (Rapamune) maintenance therapy and early cyclosporine withdrawal: 12‐month results [abstract]. Nephrology Dialysis Transplantation2001;16(6):A209. [CENTRAL: CN‐00448163] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] WalkerR , RussG , ErisJ , HutchinsonB , ChapmanJ , PussellB , et al. Treatment of hyperlipidemia in sirolimus (SRL)‐treated renal transplant recipients: long‐term findings from the Rapamune Maintenance Regimen (RMR) Trial [abstract no 27]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:49. [CENTRAL: CN‐00644318] ">RMR Study 2001</a>; <a href="./references#CD006750-bbs2-0067" title="RossiniM , LoverreA , StalloneG , InfanteB , SchenaA , MaioranoA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 1149]. American Journal of Transplantation2007;7(Suppl 2):442. [CENTRAL: CN‐00725010] RossiniM , StalloneG , InfanteB , CapobiancoC , LoverreA , SchenaA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 548]. Transplant International2007;20(Suppl 2):226. ">Rossini 2007</a>; <a href="./references#CD006750-bbs2-0070" title="SchaeferHM , KizilisikAT , FeurerI , NylanderWA , LangoneAJ , HeldermanJH , et al. Short‐term results under three different immunosuppressive regimens at one center. Transplantation Proceedings2006;38(10):3466‐7. [MEDLINE: 17175305] ">Schaefer 2006</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0074" title="StalloneG , DiPaolaS , SchenaA , InfanteB , GrandalianoG , BattagliaM , et al. Early withdrawal of cyclosporine A improves 1‐year kidney graft structure and function in sirolimus‐treated patients. Transplantation2003;75(7):998‐1003. [MEDLINE: 12698087] StalloneG , SchenaA , InfanteB , GrandalianoG , GesualdoL , SchenaPF , et al. Early withdrawal of cyclosporine (CSA) ameliorates 1‐year kidney graft function and structure in sirolimus (SRL)‐treated patients. [abstract no: 1014]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00527169] ">Stallone 2003</a>; <a href="./references#CD006750-bbs2-0075" title="StalloneG , DiPaoloS , SchenaA , InfanteB , BattagliaM , DitonnoP , et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1‐year graft function. Journal of the American Society of Nephrology2004;15(1):228‐33. [MEDLINE: 14694177] StalloneG , InfanteB , SchenaA , DiPaoloS , GesualdoL , DitonnoP , et al. Sirolimus prolongs delayed graft function in recipients of sub‐optimal cadaveric kidney donors [abstract]. American Journal of Transplantation2003;3(Suppl 5):563. [CENTRAL: CN‐00447829] ">Stallone 2004</a>; <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). Of these, nine compared CNI avoidance with mTOR‐I substitution versus conventional CNI regimen (<a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0052" title="NafarM , AlipourB , AhmadpoorP , Pour‐Reza‐GholiF , SamadianF , SamavatS , et al. Sirolimus versus calcineurin inhibitor‐based immunosuppressive therapy in kidney transplantation: a 4‐year follow‐up. Iranian Journal of Kidney Diseases2012;6(4):300‐6. [MEDLINE: 22797101] ">Nafar 2012</a>; <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>; <a href="./references#CD006750-bbs2-0070" title="SchaeferHM , KizilisikAT , FeurerI , NylanderWA , LangoneAJ , HeldermanJH , et al. Short‐term results under three different immunosuppressive regimens at one center. Transplantation Proceedings2006;38(10):3466‐7. [MEDLINE: 17175305] ">Schaefer 2006</a>; <a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0016" title="FranzS , RegeniterA , HopferH , MihatschM , DickenmannM . Tubular toxicity in sirolimus‐ and cyclosporine‐based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. American Journal of Kidney Diseases2010;55(2):335‐43. [MEDLINE: 19926370] GianniniO , DickenmannM , KimMJ , FranzS , MayrM , MihatschMJ , et al. The CALFREE Study ‐ an open, prospective, randomized single center study to investigate calcineurin free immunosuppression in 100 de novo, normal risk renal transplant recipients: preliminary results [abstract no: P04.02]. Kidney &amp; Blood Pressure Research2004;27(5‐6):329. [CENTRAL: CN‐00615861] ">CALFREE Study 2010</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0048" title="Martinez‐MierG , Mendez‐LopezMT , Budar‐FernandezLF , Estrada‐OrosJ , Franco‐AbaroaR , George‐MicelliE , et al. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation2006;82(11):1533‐6. [MEDLINE: 17164728] ">Martinez‐Mier 2006,</a><a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>). The rest looked at delayed CNI withdrawal with mTOR‐I substitution. </p> <p>We included only five studies that investigated everolimus (<a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0018" title="HertigA , KamarN , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract]. Transplantation2014;98:81. [EMBASE: 71543793] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , Hurault De LignyB , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: O5]. Transplant International2013;26(Suppl 3):2. [EMBASE: 71356080] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , LignyBH , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: P081]. Transplant International2013;26(Suppl 2):201. [EMBASE: 71359712] RostaingL , HertigA , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Fibrosis progression according to epithelial‐mesenchymal transition profile: a randomized trial of everolimus versus CsA. American Journal of Transplantation2015;15(5):1303‐12. [MEDLINE: 25808994] ">CERTITEM Study 2015</a>; <a href="./references#CD006750-bbs2-0057" title="Pacheco‐SilvaA , TonatoE , DuraoMJr , Requiao‐MouraL , ArrudaE , ChinenR , et al. A randomized clinical trial of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation [abstract no: P460]. Transplant International2013;26(Suppl 2):277‐8. [EMBASE: 71360073] ">Pacheco‐Silva 2013</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>); the remainder investigated sirolimus. The CNI studied were: </p> <p> <ul id="CD006750-list-0010"> <li> <p>TAC (eight studies: <a href="./references#CD006750-bbs2-0022" title="AlvaradoA , ChhabraD , WangE , NajafianN , FriedewaldJ , HoB , et al. Prospective randomized study to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone‐free immunosuppressive regimen [abstract no: 53]. American Journal of Transplantation2012;12(Suppl S3):42. [EMBASE: 70746000] AlvaradoA , ShettyA , TraitanonO , LeventhalJ , MasV , ChhabraD , et al. Calcineurin‐inhibitor conversion to mTOR inhibitor in renal transplant recipients leads to worse long term clinical outcomes [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953109] ChhabraD , AlvaradoA , DalalP , LeventhalJ , WangC , Sustento‐ReodicaN , et al. Impact of calcineurin‐inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone‐free regimen. American Journal of Transplantation2013;13(11):2902‐11. [MEDLINE: 24007570] GallonL , TraitanonO , Sustento‐ReodicaN , LeventhalJ , AnsariMJ , GehrauRC , et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International2014;87(4):828‐38. [MEDLINE: 25354238] ShahG , XuL , DalalP , ChhabranD , FriedewaldJ , HoB , et al. Conversion from CNI to SRL in a pred‐free immunosuppressive regimen: interim report of a prospective randomized study [abstract no: 1641]. American Journal of Transplantation2010;10(Suppl 4):504. ">Chhabra 2013</a>; <a href="./references#CD006750-bbs2-0031" title="El‐AgroudyA , AlarrayedS , GhareebS , FaridE , AlhellowH , AbdullaS . Long‐term outcome of a prospective randomized trial of conversion from tacrolimus to sirolimus treatment after renal transplantation [abstract no: B964]. Transplantation2014;98(Suppl 1):539. [EMBASE: 71545346] ">El‐Agroudy 2014</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0056" title="FlechnerS , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)+ mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year safety results from the Orion Trial [abstract no: 444]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no: 1141]. American Journal of Transplantation2007;7(Suppl 2):440. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no: 52]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653711] FlechnerS , GlydaM , SteinbergS , HarlerMB , ORION Trial Investigators. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from The ORION Study [abstract no: P477]. Transplant International2007;20(Suppl 2):209. FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year efficacy results from the ORION trial [abstract no: 287]. American Journal of Transplantation2008;8(Suppl 2):254. [CENTRAL: CN‐00653710] FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. Preliminary two‐year efficacy results from a randomized, open‐label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + mycophenolate regimen (MMF) in de novo renal allograft recipients [abstract no: 531]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740478] FlechnerSM , GlydaM , CockfieldS , GrinyoJ , LegendreC , RussG , et al. The ORION Study: comparison of two sirolimus‐based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.[Erratum appears in Am J Transplant. 2012 Jan;12(1):268]. American Journal of Transplantation2011;11(8):1633‐44. [MEDLINE: 21668635] FlechnerSM , GlydaM , See TaiS , ORION Trial Investigators. Delayed graft function (DGF) in two sirolimus (SRL)‐based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients [abstract no: 299]. American Journal of Transplantation2009;9(Suppl 2):277. [CENTRAL: CN‐00774294] FlechnerSM , GlydaM , SteinbergS , CopleyJB , ORION Trial Investigators. The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: interim results from the Orion Study [abstract no: SU‐FC124]. Journal of the American Society of Nephrology2007;18(Abstracts):95A. [CENTRAL: CN‐00716077] RussG , FlechnerSM , CockfieldS , GrinyoJ , WissingKM , LegendreC , et al. Cardiovascular risk profile of renal transplant recipients enrolled in an open‐label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC)+ mycophenolate regimen (MMF): preliminary results from the Orion Trial [abstract no: 445]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] ">ORION Study 2011</a>; <a href="./references#CD006750-bbs2-0057" title="Pacheco‐SilvaA , TonatoE , DuraoMJr , Requiao‐MouraL , ArrudaE , ChinenR , et al. A randomized clinical trial of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation [abstract no: P460]. Transplant International2013;26(Suppl 2):277‐8. [EMBASE: 71360073] ">Pacheco‐Silva 2013</a>; <a href="./references#CD006750-bbs2-0065" title="RivelliRF , GoncalvesRT , LeiteMJr , SantosMA , DelgadoAG , CardosoLR , et al. Early withdrawal of calcineurin inhibitor from a sirolimus‐based immunosuppression stabilizes fibrosis and the transforming growth factor‐beta signalling pathway in kidney transplant. Nephrology2015;20(3):168‐76. [MEDLINE: 25404086] ">Rivelli 2015</a>; <a href="./references#CD006750-bbs2-0070" title="SchaeferHM , KizilisikAT , FeurerI , NylanderWA , LangoneAJ , HeldermanJH , et al. Short‐term results under three different immunosuppressive regimens at one center. Transplantation Proceedings2006;38(10):3466‐7. [MEDLINE: 17175305] ">Schaefer 2006</a>; <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>) </p> </li> <li> <p>CsA (13 studies: <a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0016" title="FranzS , RegeniterA , HopferH , MihatschM , DickenmannM . Tubular toxicity in sirolimus‐ and cyclosporine‐based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. American Journal of Kidney Diseases2010;55(2):335‐43. [MEDLINE: 19926370] GianniniO , DickenmannM , KimMJ , FranzS , MayrM , MihatschMJ , et al. The CALFREE Study ‐ an open, prospective, randomized single center study to investigate calcineurin free immunosuppression in 100 de novo, normal risk renal transplant recipients: preliminary results [abstract no: P04.02]. Kidney &amp; Blood Pressure Research2004;27(5‐6):329. [CENTRAL: CN‐00615861] ">CALFREE Study 2010</a>; <a href="./references#CD006750-bbs2-0018" title="HertigA , KamarN , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract]. Transplantation2014;98:81. [EMBASE: 71543793] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , Hurault De LignyB , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: O5]. Transplant International2013;26(Suppl 3):2. [EMBASE: 71356080] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , LignyBH , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: P081]. Transplant International2013;26(Suppl 2):201. [EMBASE: 71359712] RostaingL , HertigA , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Fibrosis progression according to epithelial‐mesenchymal transition profile: a randomized trial of everolimus versus CsA. American Journal of Transplantation2015;15(5):1303‐12. [MEDLINE: 25808994] ">CERTITEM Study 2015</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0048" title="Martinez‐MierG , Mendez‐LopezMT , Budar‐FernandezLF , Estrada‐OrosJ , Franco‐AbaroaR , George‐MicelliE , et al. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation2006;82(11):1533‐6. [MEDLINE: 17164728] ">Martinez‐Mier 2006</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0052" title="NafarM , AlipourB , AhmadpoorP , Pour‐Reza‐GholiF , SamadianF , SamavatS , et al. Sirolimus versus calcineurin inhibitor‐based immunosuppressive therapy in kidney transplantation: a 4‐year follow‐up. Iranian Journal of Kidney Diseases2012;6(4):300‐6. [MEDLINE: 22797101] ">Nafar 2012</a>; <a href="./references#CD006750-bbs2-0066" title="BalshawR , MarraC , NashanB , HagenmeyerEG , KeownP . First year cost‐implications of early cyclosporine withdrawal in renal transplantation [abstract no: 2378]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415221] CampistolJM , ErisJ , OberbauerR , FriendP , HutchisonB , MoralesJM , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology2006;17(2):581‐9. [MEDLINE: 16434506] CampistolJM , KreisH , OberbauerR , MotaA , RiadH , ChapmanJ , et al. Sirolimus‐based therapy following early cyclosporin withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract]. American Journal of Transplantation2004;4(Suppl 8):344. [CENTRAL: CN‐00509115] CampistolJM , LegendreC , FriendP , RiadH , CastagnetoM . Evaluating cardiovascular risk factors associated with long‐term sirolimus (Rapamune®) immunotherapy used with or without cyclosporine [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):311. [CENTRAL: CN‐00550754] CampistolJM , OberbauerR , HartmannA , KreisH , MotaA , AriasM , et al. Long‐term graft survival is significantly better in patients receiving sirolimus‐based therapy after early cyclosporine withdrawal [abstract no: W736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):784. [CENTRAL: CN‐00444661] CampistolJM , OberbauerR , KreisH , BraultY , BurkeJT , Rapamune Maintenance Regimen Study Group. Predicting 10‐year graft survival with sirolimus used either as base therapy or in association with cyclosporine [abstract no: 1458]. American Journal of Transplantation2003;3(Suppl 5):474. [CENTRAL: CN‐00444662] CampistolJM , OberbauerR , KreisH , LawenJ , MoralesJM , ChapmanJ , et al. Elimination of cyclosporine with sirolimus‐based immunotherapy: 2‐year results confirm improved renal function [abstract no: SA‐P0489]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00444663] ChapmanJ , JohnsonRW , KreisH , OberbauerR , VanrenterghemY , ClaessonK , et al. Improved renal function using sirolimus (Rapamune®) maintenance therapy and cyclosporine elimination in renal allograft recipients: 12‐month results of the tri‐continental trial [abstract no: A4615]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):882A. [CENTRAL: CN‐00550709] ChapmanJ , OberbauerR , CampistolJM , GrinyoJM , MoralesJM , MotaA , et al. Renal transplant patients receiving sirolimus‐based therapy after early cyclosporine withdrawal demonstrate superior renal allograft survival and improved renal function at 48 months after transplantation [abstract no: SU‐FC103]. Journal of the American Society of Nephrology2004;15(Oct):66A. [CENTRAL: CN‐00583160] ErisJ , GrinyoJM , BraultY , HutchisonB . Sirolimus therapy after early cyclosporine withdrawal in renal transplantation significantly reduces the rate of skin cancer compared with continuous combined therapy with cyclosporine [abstract no: OR‐040]. Transplant International2005;18(Suppl):10. ErisJ , RussG , HutchinsonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation [abstract no: 105]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644323] ErisJ , RussG , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Conversion to sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation [abstract no: 1581]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00644325] FriendP , MotaA , KreisH , SegoloniG , LegendreC , PratsD , et al. Cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy is beneficial to patients regardless of baseline renal function [abstract no: 0553]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415680] FriendP , RussG , OberbauerR , MurgiaMG , TufvesonG , ChapmanJ , et al. Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function. Transplant International2007;20(9):754‐60. [MEDLINE: 17565578] GrinyoJM , VanrentergheimY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. Sirolimus (Rapamune) in patients receiving kidney from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 534]. American Journal of Transplantation2002;2(Suppl 3):272. [CENTRAL: CN‐00415776] GrinyoJM , VanrenterghemY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. The effects of sirolimus (Rapamune) in patients receiving kidneys from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 0435]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00420830] HartmannA , ColonJ , PenaJ , MartinezJ , WalkerR , ArnsW , et al. Favourable cardiovascular risk profile in renal transplant patients receiving sirolimus maintenance therapy following cyclosporine withdrawal: 3 year results of the Rapamune Maintenance Regimen trial [abstract no: W756]. Nephrology Dialysis Transplantation2003;18(Suppl 4):791‐2. [CENTRAL: CN‐00445657] HartmannA , MotaA , LegendreC , SegoloniG , GrinyoJM , HutchisonB , et al. Patients receiving sirolimus maintenance therapy have better renal function after early cyclosporine withdrawal irrespective of baseline renal function: intent‐to‐treat results at 3 years [abstract no: W743]. Nephrology Dialysis Transplantation2003;18(Suppl 4):787. [CENTRAL: CN‐00445658] HartmannA , OberbauerR , KreisH , JohnsonRW , MotaA , SchenaFP , et al. Long‐term results of cyclosporine elimination with sirolimus‐based therapy show improved renal function [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):19. [CENTRAL: CN‐00550651] HutchisonB , ClaessonK , MotaA , ErisJM , KreisH , OberbauerR , et al. Quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination: 2‐year results [abstract no: 499]. American Journal of Transplantation2002;2(Suppl 3):263. [CENTRAL: CN‐00415909] JohnsonR , OberbauerR , KreisH , BrattstromB , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation [abstract no: 0429]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00445947] JohnsonRW , KreisH , OberbauerR , BrattstromC , ClaessonK , ErisJ . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation2001;72(5):777‐86. [MEDLINE: 11571437] KeownP , ChenJ , KreisH , OberbauerR , ClaessonK , MotaA , et al. Improved quality of life after cyclosporine elimination in sirolimus‐treated renal transplant patients [abstract no: A4711]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):901A. [CENTRAL: CN‐00550607] KreisH , JohnsonR , MayerG , BrattstromC , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine‐free immunosuppression in renal transplantation resulting in lower blood pressure and improved renal function [abstract no: A3662]. Journal of the American Society of Nephrology2000;11(Sept):696A‐7A. [CENTRAL: CN‐00550424] KreisH , OberbauerR , CampistolJM , MathewT , DalozeP , SchenaFP , et al. Long‐term benefits with sirolimus‐based therapy after early cyclosporine withdrawal. Journal of the American Society of Nephrology2004;15(3):809‐17. [MEDLINE: 14978184] KreisH , OberbauerR , ClaessonK , MotaA , AriasM , DurandD , et al. Quality‐of‐life assessments in sirolimus‐treated renal transplant patients after cyclosporine elimination [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00446200] KreisH , OberbauerR , MotaA , ClaessonK , RiadH , CampistolJM , et al. Sirolimus‐based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a continuous combination of sirolimus and cyclosporine [abstract]. American Journal of Transplantation2003;3(Suppl 5):460. [CENTRAL: CN‐00446201] LegendreC , BraultY , MoralesJM , OberbauerR , AltieriP , RiadH , et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years. Clinical Transplantation2007;21(3):330‐6. [MEDLINE: 17488381] LegendreC , DalozeP , ColonJ , ChapmanJ , PenaJ , MartinezJ , et al. Sirolimus (Rapamune) used with or without cyclosporine for long term therapy: a comparison of cardiovascular risk factors. [abstract no: 1015]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00416111] LegendreC , MotaA , FriendP , SegoloniG , GrinyoJM , HutchisonB , et al. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 3 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):466. [CENTRAL: CN‐00446313] MathewT , KreisH , DoyenK . Malignancy in renal transplant recipients receiving sirolimus (rapamune) maintenance therapy: 2‐year follow up from 5 multicenter studies [abstract no: 58]. American Journal of Transplantation2002;2(Suppl 3):152. [CENTRAL: CN‐00416243] MathewT , KreisH , DoyenK . Two‐year incidence of malignancy in sirolimus (Rapamune)‐treated renal transplant recipients: follow‐up results from 5 multicenter studies [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416244] MathewT , KreisH , FriendP . Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation2004;18(4):446‐9. [MEDLINE: 15233824] MoralesJM , HartmannA , WalkerR , ArnsW , SenatorskiG , GrinyoJM , et al. Similar lipid profile but improved long‐term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplantation Proceedings2009;41(6):2339‐44. [MEDLINE: 19715914] MoralesJM , KreisH , OberbauerR , CampistolJM , MotaA , HenriquesAC , et al. 48‐month results of sirolimus‐based therapy following early cyclosporine withdrawal demonstrate superior renal allograft survival [abstract no: MO05]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:214. [CENTRAL: CN‐00509360] MoralesJM , OberbauerR , LegendreC , RuizJC , MotaA , ChapmanJ , et al. Analysis of risk factors for reduced renal function in renal transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal: 5‐year results from the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC156]. Journal of the American Society of Nephrology2005;16:72A. [CENTRAL: CN‐00644316] MotaA , AriasM , TaskinenEI , PaavonenT , BraultY , LegendreC , et al. Sirolimus‐based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. American Journal of Transplantation2004;4(6):953‐61. [MEDLINE: 15147430] MotaA , AriasM , TaskinenEI , PaavonenT , LegendreC , ClaessonK , et al. Sirolimus‐based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years following kidney transplantation [abstract no: 1486]. American Journal of Transplantation2004;4(Suppl 8):566. [CENTRAL: CN‐00509364] MotaA , SegoloniG , LegendreC , PratsD , HutchisonB , MoralesJM , et al. Patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy irrespective of baseline renal function [abstract no: 395]. American Journal of Transplantation2002;2(Suppl 3):237. [CENTRAL: CN‐00420843] OberbauerR , AriasM , ClaessonK , MotaA , ErisJM , HutchisonB , et al. Two‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 0257]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416378] OberbauerR , HutchisonB , ErisJ , AriasM , ClaessonK , MotaA , et al. Health‐related quality‐of‐life outcomes of sirolimus‐treated kidney transplant patients after elimination of cyclosporine A: results of a 2‐year randomized clinical trial. Transplantation2003;75(8):1277‐85. [MEDLINE: 12717216] OberbauerR , HutchisonB , ErisJ , AriasM , MotaA , the Rapamune Maintenance Regimen Study Group. Health‐related quality‐of‐life assessment in kidney transplant patients receiving sirolimus maintenance therapy with early elimination of cyclosporine: 3‐year results [abstract no: W758]. Nephrology Dialysis Transplantation2003;18(Suppl 4):243. [CENTRAL: CN‐00446999] OberbauerR , HutchisonB , ErisJ , RiadH , ClaessonK , LawenJ , et al. Three‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 249]. American Journal of Transplantation2003;3(Suppl 5):215. [CENTRAL: CN‐00447000] OberbauerR , KreisH , CampistolJM , MotaA , DalozeP , RuizJC , et al. Renal function improves significantly after early cyclosporine withdrawal in sirolimus‐treated renal transplant recipients: 3‐year results of the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC041]. Journal of the American Society of Nephrology2003;14(Nov):10A. [CENTRAL: CN‐00550606] OberbauerR , KreisH , JohnsonRW , MotaA , ClaessonK , RuizJC , et al. Long‐term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2‐year results of the Rapamune Maintenance Regimen Study. Transplantation2003;76(2):364‐70. [MEDLINE: 12883194] OberbauerR , KreisH , JohnsonRWG , MotaA , ClaessonK , AriasM , et al. Long‐term improvement in renal function is shown in patients treated with sirolimus (Rapamune) and cyclosporine withdrawal: 2‐year results of the Rapamune Maintenance Regimen trial [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416379] OberbauerR , MotaA , PratsD , MathewT , MoralesJM , DalozeP , et al. Renal transplant patients with risk factors for reduced renal function benefit from cyclosporine withdrawal and sirolimus maintenance therapy [abstract no: W742]. Nephrology Dialysis Transplantation2003;18(Suppl 4):786‐7. [CENTRAL: CN‐00447001] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation [abstract no: O80]. Transplantation2004;78(2 Suppl):30. [CENTRAL: CN‐00653813] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation.[erratum appears in Transpl Int. 2005 Mar;18(3):369]. Transplant International2005;18(1):22‐8. [MEDLINE: 15612979] PaczekL , MotaA , SchenaFP , JohnsonRW , PratsD , MathewT , et al. Renal function benefit from sirolimus maintenance therapy after early cyclosporine withdrawal in the presence of risk factors [abstract no: 180]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00447075] RuizJC , CampistolJM , GrinyoJM , MotaA , PratsD , GutierrezJA , et al. Early cyclosporine a withdrawal in kidney‐transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation2004;78(9):1312‐8. [MEDLINE: 15548969] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions [abstract no: SU‐FC0235]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):48A. [CENTRAL: CN‐00447509] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Proceedings2003;35(5):1669‐70. [MEDLINE: 12962750] RuizJC , CampistolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplantation Proceedings2007;39(7):2151‐2. [MEDLINE: 17889121] RuizJC , CampstolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. The early use of sirolimus with CsA elimination is not associated with progressive proteinuria [abstract no: P113]. Transplant International2007;20(Suppl 2):122. [CENTRAL: CN‐00740556] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Anaemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function [abstract no: 2504]. Nephrology2006;11(Suppl 2):A37. [CENTRAL: CN‐00644362] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus (SRL) maintenance therapy after early cyclosporine (CsA) withdrawal benefits renal transplant recipients with risk factors for reduced renal function: 5‐year results [abstract no: 103]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:90. [CENTRAL: CN‐00644320] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus‐based therapy following early cyclosporine withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract no: P150]. Nephrology2004;9(Suppl 1):A38. [CENTRAL: CN‐00509449] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 159]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN‐00644317] RussG , JamiesonN , OberbauerR , AriasM , MurgiaMG , BlanchoG , et al. Three‐year health‐related quality‐of‐life outcomes for sirolimus‐treated kidney transplant patients after elimination of cyclosporine. Transplant International2007;20(10):875‐83. [MEDLINE: 17854445] RussG , OberbauerR , FriendP , CampistolJM , BurkeJT . The impact of renal function on the incidence of anemia in sirolimus‐treated renal transplant recipients [abstract no: TH‐PO563]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. [CENTRAL: CN‐00615898] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Long‐term impact of baseline renal function in kidney transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal [abstract no: FC‐50004]. Nephrology2005;10(Suppl 1):A2. [CENTRAL: CN‐00644319] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 1009]. American Journal of Transplantation2005;5(Suppl 11):413. RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation2005;80(9):1204‐11. [MEDLINE: 16314787] SchenaFP , JamiesonN , ColonJ , ShokerA , PenaJ , MartinezM , et al. Favorable cardiovascular risk profile when sirolimus is used without cyclosporine compared to combination therapy: 3‐year results of the Rapamune Maintenance Regimen trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):479. [CENTRAL: CN‐00447616] VanrenterghemY , KreisH , OberbauerR , MotaA , JohnsonWG , Sirolimus Tri‐contienental Renal Transplant Study Group. Improved renal function in renal allograft recipients with sirolimus (Rapamune) maintenance therapy and early cyclosporine withdrawal: 12‐month results [abstract]. Nephrology Dialysis Transplantation2001;16(6):A209. [CENTRAL: CN‐00448163] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] WalkerR , RussG , ErisJ , HutchinsonB , ChapmanJ , PussellB , et al. Treatment of hyperlipidemia in sirolimus (SRL)‐treated renal transplant recipients: long‐term findings from the Rapamune Maintenance Regimen (RMR) Trial [abstract no 27]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:49. [CENTRAL: CN‐00644318] ">RMR Study 2001</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0074" title="StalloneG , DiPaolaS , SchenaA , InfanteB , GrandalianoG , BattagliaM , et al. Early withdrawal of cyclosporine A improves 1‐year kidney graft structure and function in sirolimus‐treated patients. Transplantation2003;75(7):998‐1003. [MEDLINE: 12698087] StalloneG , SchenaA , InfanteB , GrandalianoG , GesualdoL , SchenaPF , et al. Early withdrawal of cyclosporine (CSA) ameliorates 1‐year kidney graft function and structure in sirolimus (SRL)‐treated patients. [abstract no: 1014]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00527169] ">Stallone 2003</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>) </p> </li> <li> <p>TAC or CsA (seven studies: <a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0067" title="RossiniM , LoverreA , StalloneG , InfanteB , SchenaA , MaioranoA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 1149]. American Journal of Transplantation2007;7(Suppl 2):442. [CENTRAL: CN‐00725010] RossiniM , StalloneG , InfanteB , CapobiancoC , LoverreA , SchenaA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 548]. Transplant International2007;20(Suppl 2):226. ">Rossini 2007</a>; <a href="./references#CD006750-bbs2-0075" title="StalloneG , DiPaoloS , SchenaA , InfanteB , BattagliaM , DitonnoP , et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1‐year graft function. Journal of the American Society of Nephrology2004;15(1):228‐33. [MEDLINE: 14694177] StalloneG , InfanteB , SchenaA , DiPaoloS , GesualdoL , DitonnoP , et al. Sirolimus prolongs delayed graft function in recipients of sub‐optimal cadaveric kidney donors [abstract]. American Journal of Transplantation2003;3(Suppl 5):563. [CENTRAL: CN‐00447829] ">Stallone 2004</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>). </p> </li> </ul> </p> </section> <section id="CD006750-sec-0065"> <h5 class="title">Standard dose CNI versus low dose CNI and mTOR‐I</h5> <p>We identified 14 studies (80 reports, 3110 participants) that compared standard dose CNI with combination of low dose CNI and mTOR‐I; (<a href="./references#CD006750-bbs2-0010" title="BechsteinW , PaczekL . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. American Journal of Transplantation2002;2(Suppl 3):471. [CENTRAL: CN‐00415252] BechsteinWO , PaczekL , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus + steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00444369] BechsteinWO , PaczekL , WramnerL , SquiffletJP , ZygmuntAJ , European Rapamune Tacrolimus Study Group. A comparative, randomized trial of concentration‐controlled sirolimus combined with reduced‐dose tacrolimus or standard‐dose tacrolimus in renal allograft recipients. Transplantation Proceedings2013;45(6):2133‐40. [MEDLINE: 23953523] PaczekL , BechsteinW , WramnerL , SquiffletJP . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. PaczekL , BechsteinWO , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus +steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Bechstein‐193 2013</a>; <a href="./references#CD006750-bbs2-0011" title="BertoniE , BecherelliP , SalvadoriM . Triple therapy with neoral, steroids and enteric‐coated mycophenolate acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: F‐PO614]. Journal of the American Society of Nephrology2007;18(Abstracts):234A. [CENTRAL: CN‐00716078] RosatiA , BertoniE , RossoG , LartiA , MehmetajA , SalvadoriM . Triple therapy with Neoral, steroids and enteric coated mycophenolic acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: SaP477]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi396. [CENTRAL: CN‐00725011] ">Bertoni 2007</a>; <a href="./references#CD006750-bbs2-0012" title="BertoniE , LartiA , FarsettiS , RossoG , DiMariaL , ZanazziM . Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC‐MPS (M) [abstract]. Transplant International2009;22(Suppl 2):91. BertoniE , LartiA , RossoG , ZanazziM , DiMariaL , SalvadoriM . Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. Journal of Nephrology2011;24(5):613‐8. [MEDLINE: 21240873] ">Bertoni 2011</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a>; <a href="./references#CD006750-bbs2-0051" title="MuehlbacherF , NeumayerHH , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 1224]. American Journal of Transplantation2003;3(Suppl 5):465. [CENTRAL: CN‐00446852] MuhlbacherF , NeumayerHH , delCastilloD , StefoniS , ZygmuntAJ , BuddeK , et al. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study. Transplant International2014;27(2):176‐86. [MEDLINE: 24266855] MuhlbacherF , PaczekL . An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 399]. American Journal of Transplantation2002;2(Suppl 3):238. NeumayerH , MuhlbacherF , StefoniS , DelCastilloD , Myfortic Maintenance Renal Transplantation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416320] NeumayerHH , MuehlbacherF , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: W738]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00446926] ">Muhlbacher 2014</a>; <a href="./references#CD006750-bbs2-0053" title="CurtisJ , NashanB , PoniicelliC , MouradG , BogerR , RAD 156 Study Group. One year result of a multicenter, open‐label trial on safety and efficacy of certican (RAD) used in combination with simulect, corticosteroids, and full or reduced dose neoral in renal transplant [abstract no: 1335]. American Journal of Transplantation2001;1(Suppl 1):474. [CENTRAL: CN‐00444958] CurtisJ , NashanB , PonticelliC , MouradG , BogerR , RAD 156 Study Group. Everolimus (RAD) in combination with reduced dose with reduced dose neoral® maintains effective immunosuppression with improved tolerability compared to full dose neoral [abstract no: A4625]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):884A. [CENTRAL: CN‐00550720] MouradG , BogerR , CurtisJ , NashanB , PonticelliC , RAD B 156 Study Group. CERTICAN (TM) (RAD; EVEROLIMUS), the proliferation signal inhibitor, is complementary with a reduced dose NEORAL® based quadruple immunosuppressive regimen [abstract no: 1622]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487738] NashanB , CurtisJ , PonticelliC , MouradG , BogerR , RAD B156 Study Group. Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose neoral based quadruple immunosuppressive regimen [abstract no: 398]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487741] NashanB , MouradG , BogerR , CurtisJ , PonticelliC , HaasT . Everolimus and reduced‐exposure cyclosporine in de novo renal‐transplant recipients: a three‐year phase II, randomized, multicenter, open‐label study. Transplantation2004;78(9):1332‐40. [MEDLINE: 15548972] PonticelliC , CurtisJ , KovarikJM , NashanB , MouradG , FigueiredoJ , et al. Everolimus pharmacokinetics are unaltered with full‐dose versus reduced‐dose cyclosporine [abstract no: 318]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487748] RADB156 Study Group, BogerR , FreiU , GlotzD , KahanB , PonticelliC , et al. CERTICAN(TM) with reduced dose NEORAL® results in a significantly higher GFR in de novo renal transplant recipients over the first 12 Months compared to CERTICAN(TM)‐full dose NEORAL® as Assessed by Iohexol Clearance [abstract no:1623]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487751] ">Nashan 2004</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0058" title="PaolettiE , MarsanoL , BellinoD , CassottanaP , CannellaG . Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation2012;93(5):503‐8. [MEDLINE: 22318246] ">Paoletti 2012</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0068" title="RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Comparison of reduced‐and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra, ACT. 2003:64. [CENTRAL: CN‐00447521] RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. The safety and efficacy of reduced‐ and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results from Australia [abstract no: SA‐PO496]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):364A. [CENTRAL: CN‐00447522] RussGR , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplantation Proceedings2003;35(3 Suppl):115S‐7S. [MEDLINE: 12742480] WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Russ 2003</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>; <a href="./references#CD006750-bbs2-0081" title="CampistolJM , AlverangaD , HricikDE , VelosaJ , GrinyoJM , MouradG , et al. Sirolimus‐treated renal transplant recipients experience improved renal function with cyclosporine elimination: one‐year results from a phase II trial [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00487674] GonwaT , AlverangaD , AnconaG , BrinkerK , CambiV , CampistolJ , et al. Sirolimus (Rapamune) permits early elimination of cyclosporine in recipients of cadaveric renal allografts [abstract]. Transplantation2000;69(8 Suppl):S360. [CENTRAL: CN‐00445514] GonwaTA . Sirolimus (SRL) treated patients demonstrate improved renal function after withdrawal of cyclosporine (CSA) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):891A. [CENTRAL: CN‐00550647] GonwaTA , HricikDE , BrinkerK , GrinyoJM , SchenaFP , Sirolimus Renal Function Study Group. Improved renal function in sirolimus‐treated renal transplant patients after early cyclosporine elimination. Transplantation2002;74(11):1560‐7. [MEDLINE: 12490789] HricikDE , Rapamune Renal Function Study Group. Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal transplant patients [abstract no: 0430]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00583304] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] ">Velosa‐212 Study 2001</a>). Interventions were administered immediately post‐transplant in all studies. </p> <p>There were nine studies that investigated everolimus as the mTOR‐I (<a href="./references#CD006750-bbs2-0011" title="BertoniE , BecherelliP , SalvadoriM . Triple therapy with neoral, steroids and enteric‐coated mycophenolate acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: F‐PO614]. Journal of the American Society of Nephrology2007;18(Abstracts):234A. [CENTRAL: CN‐00716078] RosatiA , BertoniE , RossoG , LartiA , MehmetajA , SalvadoriM . Triple therapy with Neoral, steroids and enteric coated mycophenolic acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: SaP477]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi396. [CENTRAL: CN‐00725011] ">Bertoni 2007</a>; <a href="./references#CD006750-bbs2-0012" title="BertoniE , LartiA , FarsettiS , RossoG , DiMariaL , ZanazziM . Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC‐MPS (M) [abstract]. Transplant International2009;22(Suppl 2):91. BertoniE , LartiA , RossoG , ZanazziM , DiMariaL , SalvadoriM . Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. Journal of Nephrology2011;24(5):613‐8. [MEDLINE: 21240873] ">Bertoni 2011</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0053" title="CurtisJ , NashanB , PoniicelliC , MouradG , BogerR , RAD 156 Study Group. One year result of a multicenter, open‐label trial on safety and efficacy of certican (RAD) used in combination with simulect, corticosteroids, and full or reduced dose neoral in renal transplant [abstract no: 1335]. American Journal of Transplantation2001;1(Suppl 1):474. [CENTRAL: CN‐00444958] CurtisJ , NashanB , PonticelliC , MouradG , BogerR , RAD 156 Study Group. Everolimus (RAD) in combination with reduced dose with reduced dose neoral® maintains effective immunosuppression with improved tolerability compared to full dose neoral [abstract no: A4625]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):884A. [CENTRAL: CN‐00550720] MouradG , BogerR , CurtisJ , NashanB , PonticelliC , RAD B 156 Study Group. CERTICAN (TM) (RAD; EVEROLIMUS), the proliferation signal inhibitor, is complementary with a reduced dose NEORAL® based quadruple immunosuppressive regimen [abstract no: 1622]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487738] NashanB , CurtisJ , PonticelliC , MouradG , BogerR , RAD B156 Study Group. Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose neoral based quadruple immunosuppressive regimen [abstract no: 398]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487741] NashanB , MouradG , BogerR , CurtisJ , PonticelliC , HaasT . Everolimus and reduced‐exposure cyclosporine in de novo renal‐transplant recipients: a three‐year phase II, randomized, multicenter, open‐label study. Transplantation2004;78(9):1332‐40. [MEDLINE: 15548972] PonticelliC , CurtisJ , KovarikJM , NashanB , MouradG , FigueiredoJ , et al. Everolimus pharmacokinetics are unaltered with full‐dose versus reduced‐dose cyclosporine [abstract no: 318]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487748] RADB156 Study Group, BogerR , FreiU , GlotzD , KahanB , PonticelliC , et al. CERTICAN(TM) with reduced dose NEORAL® results in a significantly higher GFR in de novo renal transplant recipients over the first 12 Months compared to CERTICAN(TM)‐full dose NEORAL® as Assessed by Iohexol Clearance [abstract no:1623]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487751] ">Nashan 2004</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0058" title="PaolettiE , MarsanoL , BellinoD , CassottanaP , CannellaG . Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation2012;93(5):503‐8. [MEDLINE: 22318246] ">Paoletti 2012</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>); the remainder looked at sirolimus. TAC (CNI) was studied in five studies (<a href="./references#CD006750-bbs2-0010" title="BechsteinW , PaczekL . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. American Journal of Transplantation2002;2(Suppl 3):471. [CENTRAL: CN‐00415252] BechsteinWO , PaczekL , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus + steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00444369] BechsteinWO , PaczekL , WramnerL , SquiffletJP , ZygmuntAJ , European Rapamune Tacrolimus Study Group. A comparative, randomized trial of concentration‐controlled sirolimus combined with reduced‐dose tacrolimus or standard‐dose tacrolimus in renal allograft recipients. Transplantation Proceedings2013;45(6):2133‐40. [MEDLINE: 23953523] PaczekL , BechsteinW , WramnerL , SquiffletJP . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. PaczekL , BechsteinWO , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus +steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Bechstein‐193 2013</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0068" title="RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Comparison of reduced‐and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra, ACT. 2003:64. [CENTRAL: CN‐00447521] RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. The safety and efficacy of reduced‐ and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results from Australia [abstract no: SA‐PO496]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):364A. [CENTRAL: CN‐00447522] RussGR , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplantation Proceedings2003;35(3 Suppl):115S‐7S. [MEDLINE: 12742480] WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Russ 2003</a>) and the rest of the studies used CsA. </p> </section> <section id="CD006750-sec-0066"> <h5 class="title">Low versus normal dose CNI with or without mTOR‐I (mixed studies)</h5> <p>Five studies (83 reports, 3191 participants) had more than two arms and compared low dose versus normal dose CNI with or without mTOR‐I (<a href="./references#CD006750-bbs2-0006" title="HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagarajanCM , FassettR , et al. Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P‐309]. Transplant International2009;22(Suppl 2):172. HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagrajanC , FassettR , et al. Assessment of everolimus in maintenance renal transplant recipients: the Ascertain Study [abstract no: 1646]. Transplantation2008;86(Suppl 2):546. [CENTRAL: CN‐00740482] HoldaasH , RostaingL , MidtvedtK , SeronD , ColeE , ChapmanJ , FellstromB , et al. Conversion of long‐term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24‐month study.[Erratum appears in Transplantation. 2011 Nov 27;92(10):e61 Note: multiple investigator names added.]. Transplantation2011;92(4):410‐8. [MEDLINE: 21697773] O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Long‐term post transplantation switch to an everolimus‐based therapy with CNI elimination/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:42. O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Post‐hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7]. Transplantation Society of Australia &amp; New Zealand (TSANZ).29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:41. ">ASCERTAIN Study 2011</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0041" title="ArnsW , BuddeK , SommererC , WitzkeO , GubaM , JacobiJ , et al. Month 48 follow‐up results of HERAKLES trial on three different treatment regimen and switching off behaviour in de novo renal transplant patients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953873] ArnsW , NeumayerH , LehnerF , WitzkeO , SommererC , KliemV , et al. HERAKLES at month 24: follow‐up results on efficacy and safety of three different treatment regimens in de novo renal transplant patients demonstrate options for individualized immunosuppression [abstract no: BO148]. Transplant International2013;26(Suppl 2):21. [EMBASE: 71356261] ArnsW , SommererC , WitzkeO , LehnerF , ZeierM , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES trial [abstract no: 1722]. Transplantation2012;94(10):995. [EMBASE: 71251769] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/ mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: 716]. Transplantation2014;98(Suppl 1):81. [EMBASE: 71543792] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 24 [abstract no: B932]. American Journal of Transplantation2013;13(Suppl 5):310‐1. [EMBASE: 71057508] BuddeK , SommererC , WeithoferP , WitzkeO , GubaM , JacobiJ , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 48 [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954274] BuddeK , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES Study [abstract no: 50]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745997] GubaM , BuddeK , SommererC , NeumayerHH , LehnerF , ReinkeP , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: V62]. Transplant International2014;27(Suppl 3):22. [EMBASE: 71664029] GubaM , WitzkeO , LehnerF , ArnsW , SommererC , NeumayerH , et al. The HERAKLES study at 24 month: Superior renal function in an everolimus‐based CNI free regimen [abstract no: O219]. Transplant International2013;26(Suppl 2):110. [EMBASE: 71359365] HauserIA , WitzkeO , ArnsW , ReinkeP , SommererC , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novorenal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: P132]. Transplant International2014;27(Suppl 3):51. [EMBASE: 71664135] HoerningA , KohlerS , JunC , LuJ , FuJ , TebbeB , et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clinical &amp; Experimental Immunology2012;168(2):251‐9. [MEDLINE: 22471287] LehnerF , GubaM , ArnsW , SommererC , NeumayerHH , JacobiJ , et al. Follow‐up data from HERAKLES study at month 24: maintained superior renal function in patients on an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus [abstract no: P04]. Transplant International2013;26(Suppl 1):28. [EMBASE: 71356287] LehnerF , SommererC , WitzkeO , ArnsW , KliemV , NeumayerHH , et al. HERAKLES at month 24: efficacy and safety of 3 different regimens in de novo renal transplant patients [abstract no: BO148]. Transplant International2013;26(Suppl 2):82. [EMBASE: 71359263] SommererC , BuddeK , KliemV , WitzkeO , GubaM , JacobiJ , et al. Efficacy and safety of three different treatment regimen in de novo renal transplant patients: month 48 follow‐up results of the HERAKLES trial [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953341] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post HOC analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: 2921]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] SommererC , LehnerF , BuddeK , ArnsW , HauserIA , SuwelackB , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: P127]. Transplant International2014;27(Suppl 3):50. [EMBASE: 71664131] SommererC , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES Trial [abstract no: 51]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745998] WitzkeO , BuddeK , LehnerF , ZeierM , NeumayerHH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES study [abstract no: 1675]. Transplantation2012;94(Suppl):993. [EMBASE: 71251766] ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: follow‐up results of the HERAKLES trial at month 24 [abstract no: 495]. American Journal of Transplantation2013;13(Suppl S5):183. ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: 718]. Transplantation2014;98(Suppl 1):81‐2. [EMBASE: 71543794] ">HERAKLES Study 2012</a>; <a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>). Each were split to form two studies comparing low dose or withdrawal with or without mTOR‐I. </p> <p>Reporting of outcomes was variable, and definitions of outcomes were unclear in most studies. Acute rejection episodes were reported as biopsy proven (56 studies) or unspecified/mixed (19 studies). Most reported graft loss or failure (68 studies) and GFR (52 studies). Methods used to determine GFR varied: 15 studies applied the Nankivell formula; 17 used Cockcroft‐Gault; 12 used MDRD; six used nuclear GFR (iothalamate or Cr EDTA); and four did not state the method used. CMV infection rates were reported in 30 studies and malignancy rates were reported in 29 studies. </p> </section> </section> <section id="CD006750-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 72 studies following full text assessment: two studies included populations that did not match our inclusion criteria; 62 investigated interventions that were not relevant to this review; four measured outcomes not relevant to this review; two were incomplete studies that stopped early; one was only published as an abstract 35 years ago; and one study converted patients from TAC to sirolimus, however 40% we converted back to TAC. See <a href="./references#CD006750-sec-0122" title="">Characteristics of excluded studies</a>. </p> <p>This review excluded studies involving Belatacept as the intervention assessed efficacy of the new biologic agent rather than CNI withdrawal. The Belatacept studies has been analysed and published recently (<a href="./references#CD006750-bbs2-0169" title="MassonP , HendersonL , ChapmanJR , CraigJC , WebsterAC . Belatacept for kidney transplant recipients. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD010699.pub2] ">Mason 2014</a>). </p> </section> </section> <section id="CD006750-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>Study methodology reporting was incomplete in most studies. Randomisation methods and allocation concealment were clearly described in fewer than 50% of studies. Most were open‐label studies. Intention‐to‐treat (ITT) analysis was either not reported or did not contain adequate information in 20% of studies to assess reporting bias. Seven studies did not report all possible outcomes due to early termination. Details are summarised below and in <a href="#CD006750-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006750-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD006750-sec-0069"> <h4 class="title">Allocation</h4> <section id="CD006750-sec-0070"> <h5 class="title">Random sequence generation</h5> <p>Randomisation methods were reported in detail in 27 studies (<a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0006" title="HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagarajanCM , FassettR , et al. Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P‐309]. Transplant International2009;22(Suppl 2):172. HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagrajanC , FassettR , et al. Assessment of everolimus in maintenance renal transplant recipients: the Ascertain Study [abstract no: 1646]. Transplantation2008;86(Suppl 2):546. [CENTRAL: CN‐00740482] HoldaasH , RostaingL , MidtvedtK , SeronD , ColeE , ChapmanJ , FellstromB , et al. Conversion of long‐term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24‐month study.[Erratum appears in Transplantation. 2011 Nov 27;92(10):e61 Note: multiple investigator names added.]. Transplantation2011;92(4):410‐8. [MEDLINE: 21697773] O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Long‐term post transplantation switch to an everolimus‐based therapy with CNI elimination/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:42. O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Post‐hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7]. Transplantation Society of Australia &amp; New Zealand (TSANZ).29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:41. ">ASCERTAIN Study 2011</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0015" title="CaiL , ZengF , LiuB , WeiL , ChenZ , JiangJ . A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients. International Journal of Clinical Practice. Supplement2014;68(181):23‐30. [MEDLINE: 24673716] ">Cai 2014</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0021" title="AsderakisA , ChanL . Renal function with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month study in de novo renal transplant recipients [abstract no: O111]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ChanL , AndresA , BunnapradistS , GugliuzzaK , ParasuramanR , PeddiVR , et al. Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC‐MPS. Journal of Transplantation2012;2012:941640. [MEDLINE: 23227307] ChanL , HartM , AndresA , GugliuzzaK , BunnapradistS , ParasumaranR . Renal function and incidence of NODM with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month comparative study in de novo renal transplant recipients [abstract no: 718]. Transplantation2008;86(2S):251. NicholsonML , ChanL . Incidence of new onset diabetes mellitus in de novo renal transplant recipients treated with enteric‐coated mycophenolate sodium in combination with reduced or standard tacrolimus target levels: results of a 6‐month randomized study [abstract no: P266]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ">Chan 2012</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0030" title="DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , MarshallS , et al. MMF substitution for CSA in chronic allograft dysfunction: 2 year follow‐up of a multi‐center randomized controlled study [abstract no: 1513]. American Journal of Transplantation2005;5(Suppl 11):541. DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , SutterC , et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the &quot;creeping creatinine&quot; study. Transplantation2005;79(4):466‐75. [MEDLINE: 15729174] DudleyCR , MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi‐center randomized controlled study [abstract no: 41]. American Journal of Transplantation2002;2(Suppl 3):148. Tedesco de SilvaH . MMF replacing CSA reverses the &quot;creeping creatinine&quot; of renal transplant recipients of a multi‐center randomized controlled study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416751] ">Dudley 2005</a>; <a href="./references#CD006750-bbs2-0032" title="FangmannJ , ArnsW , MartiH , BuddeK , BeckurtsT , HaussJ . Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation ‐ impact on renal function and rejection episodes [abstract no: 113]. American Journal of Transplantation2005;5(Suppl 11):185. [CENTRAL: CN‐00644197] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]. American Journal of Transplantation2004;4(Suppl 8):353. [CENTRAL: CN‐00509182] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]. Transplantation2004;78(2 Suppl):280. FangmannJ , ArnsW , MartiHP , HaussJ , KettelerM , BeckurtsT , et al. Impact of daclizumab, low‐dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology Dialysis Transplantation2010;25(1):283‐92. [MEDLINE: 19773417] ">Fangmann 2010</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0047" title="JossN . Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. Scottish Medical Journal2005;50(2):82. [CENTRAL: CN‐00653805] JossN , Glasgow Transplant Group. Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:197. [CENTRAL: CN‐00636135] JossN , RodgerRS , McMillanMA , JunorBJ . Randomized study comparing cyclosporine with azathioprine one year after renal transplantation‐15‐year outcome data. Transplantation2007;83(5):582‐7. [MEDLINE: 17353778] MacPheeIA , BradleyJA , BriggsJD , JunorBJ , MacphersonSG , McMillanMA , et al. Long‐term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation1998;66(9):1186‐92. [MEDLINE: 9825816] MacPheeIA , BriggsJD , JunorBJ , McMillanMA , RodgerRS , WatsonMA . A prospective randomised controlled trial of long‐term outcome for renal transplant recipients converted from cyclosporin to azathioprine treatment one year after transplantation [abstract]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00602085] ">MacPhee 1998</a>; <a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0058" title="PaolettiE , MarsanoL , BellinoD , CassottanaP , CannellaG . Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation2012;93(5):503‐8. [MEDLINE: 22318246] ">Paoletti 2012</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>; <a href="./references#CD006750-bbs2-0065" title="RivelliRF , GoncalvesRT , LeiteMJr , SantosMA , DelgadoAG , CardosoLR , et al. Early withdrawal of calcineurin inhibitor from a sirolimus‐based immunosuppression stabilizes fibrosis and the transforming growth factor‐beta signalling pathway in kidney transplant. Nephrology2015;20(3):168‐76. [MEDLINE: 25404086] ">Rivelli 2015</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). Three studies were judged to be at high risk of bias; <a href="./references#CD006750-bbs2-0061" title="JensenJD , HansenHE , PedersenEB . Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron1994;67(3):297‐301. [MEDLINE: 7936019] PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation. A prospective, randomized study from 1 to 6 years after transplantation. Nephrology Dialysis Transplantation1993;8(3):250‐4. [MEDLINE: 8385294] PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporin to azathioprine 1 year after renal transplantation: a prospective randomized study from 1 to 6 years after transplantation [abstract]. Nephrology Dialysis Transplantation1993;8(9):1047. PedersenEB , HansenHE , KornerupHJ , MadsenS , SorensenAW . Long‐term graft survival after conversion from cyclosporine to azathioprine one year after renal transplantation. A prospective, randomized study from one to six years after transplantation [abstract]. 12th International Congress of Nephrology; 1993 June 13‐18; Jerusalem, Israel. 1993:194. [CENTRAL: CN‐00644352] PedersenEB , HansenHE , OlsenS . The effect of cyclosporine and azathioprine on GFR and renal histopathology 12 to 24 months after renal transplantation. Transplantation Proceedings1992;24(1):309‐10. [MEDLINE: 1539289] PedersenEB , HansenHE , OlsenS , DanielsenH , EiskjaerAW , JespersenB , et al. Comparison between the effect of cyclosporin and azathioprine on functional and morphological renal parameters in a randomised study from one to two years after renal transplantation [abstract]. Nephrology Dialysis Transplantation1991;6(10):832‐3. PedersenEB , HansenHE , OlsenS , DanielsenH , EiskjaerH , JespersenB , et al. Comparison between the effects of cyclosporine and azathioprine on functional and morphologic renal parameters in a randomized study from 12 to 24 months after renal transplantation. Clinical Transplantation1991;5(6 I):456‐66. [EMBASE: 22024462] ">Pedersen 1991</a> randomised alternate participants to intervention and control groups, and <a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a> and <a href="./references#CD006750-bbs2-0070" title="SchaeferHM , KizilisikAT , FeurerI , NylanderWA , LangoneAJ , HeldermanJH , et al. Short‐term results under three different immunosuppressive regimens at one center. Transplantation Proceedings2006;38(10):3466‐7. [MEDLINE: 17175305] ">Schaefer 2006</a> included a third non‐randomised arm to the studies. The remaining 53 studies did not report randomisation methods. </p> </section> <section id="CD006750-sec-0071"> <h5 class="title">Allocation concealment</h5> <p>Methods of allocation concealment were adequate in 25 studies (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>; <a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0028" title="Smak GregoorPJ , deSevauxRG , HeneRJ , HilbrandsLB , vanGelderT , HoitsmaAJ , et al. The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):699A. [CENTRAL: CN‐00447776] deSevauxRG , GregoorPJ , HeneRJ , HoitsmaAJ , VosP , WeimarW , et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. Journal of the American Society of Nephrology2001;12(8):1750‐7. [MEDLINE: 11461949] deSevauxRG , Smak GregoorPJ , HeneRJ , HoitsmaAJ , VosP , et al. Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00583239] deSévauxRG , Smak GregoorPJ , HenéRJ , WeimarW , HoitsmaAJ , VanGelderT , et al. A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]. Transplantation1998;65(12):S107. [CENTRAL: CN‐00583548] ">de Sevaux 2001</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0030" title="DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , MarshallS , et al. MMF substitution for CSA in chronic allograft dysfunction: 2 year follow‐up of a multi‐center randomized controlled study [abstract no: 1513]. American Journal of Transplantation2005;5(Suppl 11):541. DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , SutterC , et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the &quot;creeping creatinine&quot; study. Transplantation2005;79(4):466‐75. [MEDLINE: 15729174] DudleyCR , MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi‐center randomized controlled study [abstract no: 41]. American Journal of Transplantation2002;2(Suppl 3):148. Tedesco de SilvaH . MMF replacing CSA reverses the &quot;creeping creatinine&quot; of renal transplant recipients of a multi‐center randomized controlled study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416751] ">Dudley 2005</a>; <a href="./references#CD006750-bbs2-0032" title="FangmannJ , ArnsW , MartiH , BuddeK , BeckurtsT , HaussJ . Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation ‐ impact on renal function and rejection episodes [abstract no: 113]. American Journal of Transplantation2005;5(Suppl 11):185. [CENTRAL: CN‐00644197] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]. American Journal of Transplantation2004;4(Suppl 8):353. [CENTRAL: CN‐00509182] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]. Transplantation2004;78(2 Suppl):280. FangmannJ , ArnsW , MartiHP , HaussJ , KettelerM , BeckurtsT , et al. Impact of daclizumab, low‐dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology Dialysis Transplantation2010;25(1):283‐92. [MEDLINE: 19773417] ">Fangmann 2010</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0044" title="IsoniemiH . Renal allograft immunosuppression V: glucose intolerance occurring in different immunosuppressive treatments. Clinical Transplantation1991;5(3):268‐72. [EMBASE: 21188067] IsoniemiH . Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transplant International1991;4(1):31‐7. [MEDLINE: 2059298] IsoniemiH , AhonenJ , EklundB , HockerstedtK , SalmelaK , vonWillebrandE , et al. Renal allograft immunosuppression. II. A randomized trial of withdrawal of one drug in triple drug immunosuppression. Transplant International1990;3(3):121‐7. [MEDLINE: 2271083] IsoniemiH , AhonenJ , KrogerusL , EklundB , HockerstedtK , SalmelaK , et al. Chronic rejection of renal allografts with four immunosuppressive regimens. Transplantation Proceedings1992;24(6):2716‐7. [MEDLINE: 1465912] IsoniemiH , EklundB , HockerstedtK , KorsbackC , SalmelaK , vonWillebrandE , et al. Discontinuation of one drug in triple drug treatment of renal allograft patients: 1‐year results. Transplantation Proceedings1990;22(4):1365‐6. [MEDLINE: 2202111] IsoniemiH , KrogerusL , vonWillebrandE , TaskinenE , Gronhagen‐RiskaC , AhonenJ , et al. Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts. Transplant International1991;4(3):151‐6. [MEDLINE: 1958279] IsoniemiH , TikkanenM , HayryP , EklundB , HockerstedtK , SalmelaK , et al. Lipid profiles with triple drug immunosuppressive therapy and with double drug combinations after renal transplantation and stable graft function. Transplantation Proceedings1991;23(1 (Pt 2)):1029‐31. [MEDLINE: 1989148] IsoniemiH , TikkanenMJ , AhonenJ , HayryP . Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transplant International1991;4(3):130‐5. [MEDLINE: 1958276] IsoniemiH , vonWillebrandE , AhonenJ , EklundB , HockerstedtK , KrogerusL , et al. Late histopathological findings in renal allografts with four immunosuppressive regimens. Transplant International1992;5 Suppl 1:S6‐7. [MEDLINE: 14621718] IsoniemiHM , AhonenJ , TikkanenMJ , vonWillebrandEO , KrogerusL , EklundBH , et al. Long‐term consequences of different immunosuppressive regimens for renal allografts.[Erratum appears in Transplantation 1998 Sep 15;66(5):678]. Transplantation1993;55(3):494‐9. [MEDLINE: 8456467] IsoniemiHM , KrogerusL , vonWillebrandE , TaskinenE , AhonenJ , HayryP . Histopathological findings in well‐functioning, long‐term renal allografts. Kidney International1992;41(1):155‐60. [MEDLINE: 1593852] ">Isoniemi 1990</a>; <a href="./references#CD006750-bbs2-0047" title="JossN . Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. Scottish Medical Journal2005;50(2):82. [CENTRAL: CN‐00653805] JossN , Glasgow Transplant Group. Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:197. [CENTRAL: CN‐00636135] JossN , RodgerRS , McMillanMA , JunorBJ . Randomized study comparing cyclosporine with azathioprine one year after renal transplantation‐15‐year outcome data. Transplantation2007;83(5):582‐7. [MEDLINE: 17353778] MacPheeIA , BradleyJA , BriggsJD , JunorBJ , MacphersonSG , McMillanMA , et al. Long‐term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation1998;66(9):1186‐92. [MEDLINE: 9825816] MacPheeIA , BriggsJD , JunorBJ , McMillanMA , RodgerRS , WatsonMA . A prospective randomised controlled trial of long‐term outcome for renal transplant recipients converted from cyclosporin to azathioprine treatment one year after transplantation [abstract]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00602085] ">MacPhee 1998</a>; <a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0058" title="PaolettiE , MarsanoL , BellinoD , CassottanaP , CannellaG . Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation2012;93(5):503‐8. [MEDLINE: 22318246] ">Paoletti 2012</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>; <a href="./references#CD006750-bbs2-0071" title="RoodnatJ , HilbrandsLB , HeneRJ , deSevauxRG , GregoorPJ , Kal‐van GestelJA , et al. 15 year follow‐up of a multicentre, randomised, calcineurin inhibitor (CNI) withdrawal study in kidney transplantation [abstract no: BO156]. Transplant International2013;26(Suppl 2):83‐4. [EMBASE: 71359271] RoodnatJI , HilbrandsLB , HeneRJ , deSevauxRG , Smak GregoorPJ , Kal‐van GestelJA , et al. 15‐year follow‐up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation2014;98(1):47‐53. [MEDLINE: 24521775] Smak GregoorPJ , deSevauxRG , HeneRJ , HesseCJ , HilbrandsLB , VosP , et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation1999;68(10):1603‐6. [MEDLINE: 10589962] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow‐up data [abstract no: 441]. American Journal of Transplantation2001;1(Suppl 1):246. [CENTRAL: CN‐00763745] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Journal of the American Society of Nephrology2002;13(5):1365‐73. [MEDLINE: 11961025] Smak GregoorPJ , vanGelderT , IJzermansJN , WeimarW . Long‐term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00447777] VanGelderT , deSevauxR , HeneR , WeimarW , HoitsmaA , LigtenbergG , et al. Discontinuation of cyclosporine or prednisone 6 months after kidney transplantation: a randomized trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):920A. [CENTRAL: CN‐00583812] deSevauxRG , GregoorP , SmakJH , HeneRJ , WeimarW , HoitsmaAJ , et al. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomized study [abstract no: 935]. Transplantation1999;67(7):S240. [CENTRAL: CN‐00767038] ">Smak Gregoor 1999</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). Five studies were judged to be at high risk of bias (<a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0055" title="BloomR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]. Transplantation2008;86(2 Suppl):301. [CENTRAL: CN‐00740509] GastonR , BloomR , ShahT , CibrikD , AngelisM , MulgaonkarS , et al. 6‐month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH‐PO565]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00602020] GastonR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00653708] GastonRS , KaplanB , ShahT , CibrikD , ShawLM , AngelisM , et al. Fixed‐ or controlled‐dose mycophenolate mofetil with standard‐ or reduced‐dose calcineurin inhibitors: the OPTICEPT trial. American Journal of Transplantation2009;9(7):1607‐19. [MEDLINE: 19459794] KaplanB , GastonR , Meier‐KriescheH , BloomR , PatelD , ShawL . Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]. American Journal of Transplantation2009;9(Suppl 2):419. [CENTRAL: CN‐00794654] KaplanB , GastonRS , Meier‐KriescheHU , BloomRD , ShawLM . Mycophenolic acid exposure in high‐ and low‐weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Therapeutic Drug Monitoring2010;32(2):224‐7. [MEDLINE: 20216117] ShawL , KaplanB , AngelisM , BloomR , GastonR , Meier‐KriescheH , et al. Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU‐FC128]. Journal of the American Society of Nephrology2007;18(Abstracts):96A‐7A. [CENTRAL: CN‐00724911] ">OPTICEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0070" title="SchaeferHM , KizilisikAT , FeurerI , NylanderWA , LangoneAJ , HeldermanJH , et al. Short‐term results under three different immunosuppressive regimens at one center. Transplantation Proceedings2006;38(10):3466‐7. [MEDLINE: 17175305] ">Schaefer 2006</a>) and the method of allocation concealment was not reported or unclear in 53 studies. </p> </section> </section> <section id="CD006750-sec-0072"> <h4 class="title">Blinding</h4> <p>Almost all studies were open‐label. <a href="./references#CD006750-bbs2-0033" title="FergusonR , MulgaonkarS , Tedesco SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced‐exposure (R‐E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra (ACT). 2003:63. [CENTRAL: CN‐00445317] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorU , et al. FTY720 with reduced‐exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415638] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , RussG , et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12‐month preliminary results [abstract no: 624]. American Journal of Transplantation2003;3(Suppl 5):311. [CENTRAL: CN‐00445316] MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorfU , RussG , et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1‐year dose‐finding study.[Erratum appears in Am J Transplant. 2006 Dec;6(12):3044]. American Journal of Transplantation2006;6(8):1848‐57. [MEDLINE: 16771816] RussG , FergusonRM , MulgaonkarS , Tedesco‐SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced dose Neoral (RDN) may offer a safety/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]. American Journal of Transplantation2004;4(Suppl 8):432. [CENTRAL: CN‐00509451] ">Ferguson 2006</a> reported blinding of investigators and participants in one part of the study, and four studies (<a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0065" title="RivelliRF , GoncalvesRT , LeiteMJr , SantosMA , DelgadoAG , CardosoLR , et al. Early withdrawal of calcineurin inhibitor from a sirolimus‐based immunosuppression stabilizes fibrosis and the transforming growth factor‐beta signalling pathway in kidney transplant. Nephrology2015;20(3):168‐76. [MEDLINE: 25404086] ">Rivelli 2015</a>) reported blinding of outcome investigators. </p> </section> <section id="CD006750-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Outcome data was reported or analysed as Intention‐ to‐treat in (ITT) in 55 studies (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>; <a href="./references#CD006750-bbs2-0003" title="AndresA , MarcenR , SanchezJ , ValdesF , ErrastiP , SolaR , et al. Comparative study of three different patterns of immunosuppression based on induction with basiliximab and low initial doses or delayed initiation of neoral in kidney transplant recipients at high risk of delayed graft function [abstract no: 1629]. American Journal of Transplantation2005;5(Suppl 11):570. [CENTRAL: CN‐00644164] AndresA , MarcenR , ValdesF , PlumedJS , SolaR , ErrastiP , et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clinical Transplantation2009;23(1):23‐32. [MEDLINE: 18798851] MarcenR , AndresA , Sanchez‐PlumedJ , ValdesF , ErrastiP , SolaR , et al. A randomized study to compare immunosuppression based on basiliximab induction and low initial doses or delayed neoral in kidney transplant recipients at high risk for delayed graft function [abstract no: PO‐266]. Transplant International2005;18(Suppl 1):114. ">Andres 2009</a>; <a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0006" title="HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagarajanCM , FassettR , et al. Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P‐309]. Transplant International2009;22(Suppl 2):172. HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagrajanC , FassettR , et al. Assessment of everolimus in maintenance renal transplant recipients: the Ascertain Study [abstract no: 1646]. Transplantation2008;86(Suppl 2):546. [CENTRAL: CN‐00740482] HoldaasH , RostaingL , MidtvedtK , SeronD , ColeE , ChapmanJ , FellstromB , et al. Conversion of long‐term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24‐month study.[Erratum appears in Transplantation. 2011 Nov 27;92(10):e61 Note: multiple investigator names added.]. Transplantation2011;92(4):410‐8. [MEDLINE: 21697773] O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Long‐term post transplantation switch to an everolimus‐based therapy with CNI elimination/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:42. O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Post‐hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7]. Transplantation Society of Australia &amp; New Zealand (TSANZ).29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:41. ">ASCERTAIN Study 2011</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0012" title="BertoniE , LartiA , FarsettiS , RossoG , DiMariaL , ZanazziM . Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC‐MPS (M) [abstract]. Transplant International2009;22(Suppl 2):91. BertoniE , LartiA , RossoG , ZanazziM , DiMariaL , SalvadoriM . Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. Journal of Nephrology2011;24(5):613‐8. [MEDLINE: 21240873] ">Bertoni 2011</a>; <a href="./references#CD006750-bbs2-0013" title="BuddeK , BosmansJ , ZeierM , SennesaelJ , HoptU , FischerWH , et al. Safety and efficacy of reduced or full dose of cyclosporine (neoral®) in combination with mycophenolate sodium (Myfortic®), basiliximab (Simulect®), and steroids in de novo kidney transplant recipients [abstract]. Transplantation2004;78(2 Suppl):83. [CENTRAL: CN‐00527096] BuddeK , BosmansJL , SennesaelJ , ZeierM , HoptU , FischerW , et al. Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric‐coated mycophenolate‐sodium, and steroids [abstract no: 1195]. American Journal of Transplantation2005;5(Suppl 11):461. [CENTRAL: CN‐00644165] BuddeK , BosmansJL , SennesaelJ , ZeierM , PisarskiP , SchutzM , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab. Clinical Nephrology2007;67(3):164‐75. [MEDLINE: 17390741] BuddeK , ZeierM , BosmansJL , SennesaelJ , GlanderP , FischerW , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab [abstract no: F‐PO1088]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00644166] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Budde 2007</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0015" title="CaiL , ZengF , LiuB , WeiL , ChenZ , JiangJ . A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients. International Journal of Clinical Practice. Supplement2014;68(181):23‐30. [MEDLINE: 24673716] ">Cai 2014</a>; <a href="./references#CD006750-bbs2-0016" title="FranzS , RegeniterA , HopferH , MihatschM , DickenmannM . Tubular toxicity in sirolimus‐ and cyclosporine‐based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. American Journal of Kidney Diseases2010;55(2):335‐43. [MEDLINE: 19926370] GianniniO , DickenmannM , KimMJ , FranzS , MayrM , MihatschMJ , et al. The CALFREE Study ‐ an open, prospective, randomized single center study to investigate calcineurin free immunosuppression in 100 de novo, normal risk renal transplant recipients: preliminary results [abstract no: P04.02]. Kidney &amp; Blood Pressure Research2004;27(5‐6):329. [CENTRAL: CN‐00615861] ">CALFREE Study 2010</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0019" title="ChadbanS , CampbellS , RussG , WalkerR , ChapmanJ , PussellB , et al. A one‐year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric‐coated mycophenolate sodium (EC‐MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA‐ME), basiliximab and steroids in de novo kidney transplantation [abstract no: 32]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:51. [CENTRAL: CN‐00583470] ChadbanS , ErisJ , RussG , CampbellS , ChapmanJ , PussellB , et al. Enteric‐coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology2013;18(1):63‐70. [MEDLINE: 23110508] ">Chadban 2013</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0022" title="AlvaradoA , ChhabraD , WangE , NajafianN , FriedewaldJ , HoB , et al. Prospective randomized study to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone‐free immunosuppressive regimen [abstract no: 53]. American Journal of Transplantation2012;12(Suppl S3):42. [EMBASE: 70746000] AlvaradoA , ShettyA , TraitanonO , LeventhalJ , MasV , ChhabraD , et al. Calcineurin‐inhibitor conversion to mTOR inhibitor in renal transplant recipients leads to worse long term clinical outcomes [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953109] ChhabraD , AlvaradoA , DalalP , LeventhalJ , WangC , Sustento‐ReodicaN , et al. Impact of calcineurin‐inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone‐free regimen. American Journal of Transplantation2013;13(11):2902‐11. [MEDLINE: 24007570] GallonL , TraitanonO , Sustento‐ReodicaN , LeventhalJ , AnsariMJ , GehrauRC , et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International2014;87(4):828‐38. [MEDLINE: 25354238] ShahG , XuL , DalalP , ChhabranD , FriedewaldJ , HoB , et al. Conversion from CNI to SRL in a pred‐free immunosuppressive regimen: interim report of a prospective randomized study [abstract no: 1641]. American Journal of Transplantation2010;10(Suppl 4):504. ">Chhabra 2013</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0027" title="FormicaR , NickersonP , PoggioE , TinckamK , RushD , GibsonI , et al. Immune monitoring and tacrolimus (TAC) withdrawal in low risk recipients of kidney transplants‐results of CTOT09 [abstract]. Transplantation2014;98(Suppl 1):225. [EMBASE: 71544207] HricikDE , FormicaRN , NickersonP , RushD , FairchildRL , PoggioED , et al. Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients. Journal of the American Society of Nephrology2015;26(12):3114‐22. [MEDLINE: 25925687] NickersonP , WiebeC , FormicaR , TinckamK , PoggioE , BunnapradistS , et al. Epitope mismatch predicts de novo DSA after CNI withdrawal in low‐risk kidney transplant recipients [abstract]. Transplantation2014;98(Suppl 1):137. [EMBASE: 71543963] ">CTOT‐09 Study 2015</a>; <a href="./references#CD006750-bbs2-0028" title="Smak GregoorPJ , deSevauxRG , HeneRJ , HilbrandsLB , vanGelderT , HoitsmaAJ , et al. The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):699A. [CENTRAL: CN‐00447776] deSevauxRG , GregoorPJ , HeneRJ , HoitsmaAJ , VosP , WeimarW , et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. Journal of the American Society of Nephrology2001;12(8):1750‐7. [MEDLINE: 11461949] deSevauxRG , Smak GregoorPJ , HeneRJ , HoitsmaAJ , VosP , et al. Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00583239] deSévauxRG , Smak GregoorPJ , HenéRJ , WeimarW , HoitsmaAJ , VanGelderT , et al. A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]. Transplantation1998;65(12):S107. [CENTRAL: CN‐00583548] ">de Sevaux 2001</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0031" title="El‐AgroudyA , AlarrayedS , GhareebS , FaridE , AlhellowH , AbdullaS . Long‐term outcome of a prospective randomized trial of conversion from tacrolimus to sirolimus treatment after renal transplantation [abstract no: B964]. Transplantation2014;98(Suppl 1):539. [EMBASE: 71545346] ">El‐Agroudy 2014</a>; <a href="./references#CD006750-bbs2-0032" title="FangmannJ , ArnsW , MartiH , BuddeK , BeckurtsT , HaussJ . Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation ‐ impact on renal function and rejection episodes [abstract no: 113]. American Journal of Transplantation2005;5(Suppl 11):185. [CENTRAL: CN‐00644197] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]. American Journal of Transplantation2004;4(Suppl 8):353. [CENTRAL: CN‐00509182] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]. Transplantation2004;78(2 Suppl):280. FangmannJ , ArnsW , MartiHP , HaussJ , KettelerM , BeckurtsT , et al. Impact of daclizumab, low‐dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology Dialysis Transplantation2010;25(1):283‐92. [MEDLINE: 19773417] ">Fangmann 2010</a>; <a href="./references#CD006750-bbs2-0033" title="FergusonR , MulgaonkarS , Tedesco SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced‐exposure (R‐E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra (ACT). 2003:63. [CENTRAL: CN‐00445317] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorU , et al. FTY720 with reduced‐exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415638] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , RussG , et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12‐month preliminary results [abstract no: 624]. American Journal of Transplantation2003;3(Suppl 5):311. [CENTRAL: CN‐00445316] MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorfU , RussG , et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1‐year dose‐finding study.[Erratum appears in Am J Transplant. 2006 Dec;6(12):3044]. American Journal of Transplantation2006;6(8):1848‐57. [MEDLINE: 16771816] RussG , FergusonRM , MulgaonkarS , Tedesco‐SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced dose Neoral (RDN) may offer a safety/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]. American Journal of Transplantation2004;4(Suppl 8):432. [CENTRAL: CN‐00509451] ">Ferguson 2006</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a>; <a href="./references#CD006750-bbs2-0036" title="GrimbertP , BaronC , FruchaudG , HemeryF , DesvauxD , BuissonC , et al. Long‐term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low‐risk renal transplant recipients. Transplant International2002;15(11):550‐5. [MEDLINE: 12461659] ">Grimbert 2002</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0039" title="HazzanM , BuobD , LabaletteM , ProvotF , GlowackiF , HoffmannM , et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation2006;82(5):657‐62. [MEDLINE: 16969289] HazzanM , CopinMC , LabaletteM , GlowackiF , ProvotF , RoumilhacD , et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients receiving mycophenolate mofetil: results from a prospective, randomized trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00445673] HazzanM , HertigA , BuobD , NoelC , CopinM , RondeauE , et al. Cyclosporin induces epithelial to mesenchymal transition in renal grafts [abstract no: 131]. American Journal of Transplantation2008;8(Suppl 2):214. HazzanM , LabaletteM , CopinMC , GlowackiF , ProvotF , PruvFR , et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Journal of the American Society of Nephrology2005;16(8):2509‐16. [MEDLINE: 15987748] ">Hazzan 2005</a>; <a href="./references#CD006750-bbs2-0041" title="ArnsW , BuddeK , SommererC , WitzkeO , GubaM , JacobiJ , et al. Month 48 follow‐up results of HERAKLES trial on three different treatment regimen and switching off behaviour in de novo renal transplant patients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953873] ArnsW , NeumayerH , LehnerF , WitzkeO , SommererC , KliemV , et al. HERAKLES at month 24: follow‐up results on efficacy and safety of three different treatment regimens in de novo renal transplant patients demonstrate options for individualized immunosuppression [abstract no: BO148]. Transplant International2013;26(Suppl 2):21. [EMBASE: 71356261] ArnsW , SommererC , WitzkeO , LehnerF , ZeierM , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES trial [abstract no: 1722]. Transplantation2012;94(10):995. [EMBASE: 71251769] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/ mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: 716]. Transplantation2014;98(Suppl 1):81. [EMBASE: 71543792] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 24 [abstract no: B932]. American Journal of Transplantation2013;13(Suppl 5):310‐1. [EMBASE: 71057508] BuddeK , SommererC , WeithoferP , WitzkeO , GubaM , JacobiJ , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 48 [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954274] BuddeK , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES Study [abstract no: 50]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745997] GubaM , BuddeK , SommererC , NeumayerHH , LehnerF , ReinkeP , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: V62]. Transplant International2014;27(Suppl 3):22. [EMBASE: 71664029] GubaM , WitzkeO , LehnerF , ArnsW , SommererC , NeumayerH , et al. The HERAKLES study at 24 month: Superior renal function in an everolimus‐based CNI free regimen [abstract no: O219]. Transplant International2013;26(Suppl 2):110. [EMBASE: 71359365] HauserIA , WitzkeO , ArnsW , ReinkeP , SommererC , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novorenal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: P132]. Transplant International2014;27(Suppl 3):51. [EMBASE: 71664135] HoerningA , KohlerS , JunC , LuJ , FuJ , TebbeB , et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clinical &amp; Experimental Immunology2012;168(2):251‐9. [MEDLINE: 22471287] LehnerF , GubaM , ArnsW , SommererC , NeumayerHH , JacobiJ , et al. Follow‐up data from HERAKLES study at month 24: maintained superior renal function in patients on an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus [abstract no: P04]. Transplant International2013;26(Suppl 1):28. [EMBASE: 71356287] LehnerF , SommererC , WitzkeO , ArnsW , KliemV , NeumayerHH , et al. HERAKLES at month 24: efficacy and safety of 3 different regimens in de novo renal transplant patients [abstract no: BO148]. Transplant International2013;26(Suppl 2):82. [EMBASE: 71359263] SommererC , BuddeK , KliemV , WitzkeO , GubaM , JacobiJ , et al. Efficacy and safety of three different treatment regimen in de novo renal transplant patients: month 48 follow‐up results of the HERAKLES trial [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953341] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post HOC analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: 2921]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] SommererC , LehnerF , BuddeK , ArnsW , HauserIA , SuwelackB , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: P127]. Transplant International2014;27(Suppl 3):50. [EMBASE: 71664131] SommererC , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES Trial [abstract no: 51]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745998] WitzkeO , BuddeK , LehnerF , ZeierM , NeumayerHH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES study [abstract no: 1675]. Transplantation2012;94(Suppl):993. [EMBASE: 71251766] ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: follow‐up results of the HERAKLES trial at month 24 [abstract no: 495]. American Journal of Transplantation2013;13(Suppl S5):183. ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: 718]. Transplantation2014;98(Suppl 1):81‐2. [EMBASE: 71543794] ">HERAKLES Study 2012</a>; <a href="./references#CD006750-bbs2-0042" title="BakkerRC , HollanderAA , MallatMJ , BruijnJA , PaulLC , deFijterJW . Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney International2003;64(3):1027‐34. [MEDLINE: 12911553] HollanderAA , vanSaaseJL , KootteAM , vanDorpWT , vanBockelHJ , vanEsLA , et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet1995;345(8950):610‐4. [MEDLINE: 7898178] ">Hollander 1995</a>; <a href="./references#CD006750-bbs2-0044" title="IsoniemiH . Renal allograft immunosuppression V: glucose intolerance occurring in different immunosuppressive treatments. Clinical Transplantation1991;5(3):268‐72. [EMBASE: 21188067] IsoniemiH . Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transplant International1991;4(1):31‐7. [MEDLINE: 2059298] IsoniemiH , AhonenJ , EklundB , HockerstedtK , SalmelaK , vonWillebrandE , et al. Renal allograft immunosuppression. II. A randomized trial of withdrawal of one drug in triple drug immunosuppression. Transplant International1990;3(3):121‐7. [MEDLINE: 2271083] IsoniemiH , AhonenJ , KrogerusL , EklundB , HockerstedtK , SalmelaK , et al. Chronic rejection of renal allografts with four immunosuppressive regimens. Transplantation Proceedings1992;24(6):2716‐7. [MEDLINE: 1465912] IsoniemiH , EklundB , HockerstedtK , KorsbackC , SalmelaK , vonWillebrandE , et al. Discontinuation of one drug in triple drug treatment of renal allograft patients: 1‐year results. Transplantation Proceedings1990;22(4):1365‐6. [MEDLINE: 2202111] IsoniemiH , KrogerusL , vonWillebrandE , TaskinenE , Gronhagen‐RiskaC , AhonenJ , et al. Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts. Transplant International1991;4(3):151‐6. [MEDLINE: 1958279] IsoniemiH , TikkanenM , HayryP , EklundB , HockerstedtK , SalmelaK , et al. Lipid profiles with triple drug immunosuppressive therapy and with double drug combinations after renal transplantation and stable graft function. Transplantation Proceedings1991;23(1 (Pt 2)):1029‐31. [MEDLINE: 1989148] IsoniemiH , TikkanenMJ , AhonenJ , HayryP . Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transplant International1991;4(3):130‐5. [MEDLINE: 1958276] IsoniemiH , vonWillebrandE , AhonenJ , EklundB , HockerstedtK , KrogerusL , et al. Late histopathological findings in renal allografts with four immunosuppressive regimens. Transplant International1992;5 Suppl 1:S6‐7. [MEDLINE: 14621718] IsoniemiHM , AhonenJ , TikkanenMJ , vonWillebrandEO , KrogerusL , EklundBH , et al. Long‐term consequences of different immunosuppressive regimens for renal allografts.[Erratum appears in Transplantation 1998 Sep 15;66(5):678]. Transplantation1993;55(3):494‐9. [MEDLINE: 8456467] IsoniemiHM , KrogerusL , vonWillebrandE , TaskinenE , AhonenJ , HayryP . Histopathological findings in well‐functioning, long‐term renal allografts. Kidney International1992;41(1):155‐60. [MEDLINE: 1593852] ">Isoniemi 1990</a>; <a href="./references#CD006750-bbs2-0045" title="HausbergM , LangD , LeversA , SuwelackB , KistersK , TokmakF , et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. Journal of Hypertension2006;24(5):957‐64. [MEDLINE: 16612259] HausbergM , SuwelackB , KoschM , BarenbrockM , GerhardtU , HohageH , et al. Effects of calcineurin‐inhibitor withdrawal on sympathetic nerve activity and blood pressure in renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift2001;126:S193. [CENTRAL: CN‐00383083] KoschM , HausbergM , SuwelackB . Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation2003;76(10):1516‐9. [MEDLINE: 14657697] KoschM , SuwelackB , BarenbrockM , KobeltV , HohageH , RahnKH , et al. Studies on effects of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Deutsche Medizinische Wochenschrift2001;126:S185. [CENTRAL: CN‐00383367] ">Kosch 2003a</a>; <a href="./references#CD006750-bbs2-0047" title="JossN . Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. Scottish Medical Journal2005;50(2):82. [CENTRAL: CN‐00653805] JossN , Glasgow Transplant Group. Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:197. [CENTRAL: CN‐00636135] JossN , RodgerRS , McMillanMA , JunorBJ . Randomized study comparing cyclosporine with azathioprine one year after renal transplantation‐15‐year outcome data. Transplantation2007;83(5):582‐7. [MEDLINE: 17353778] MacPheeIA , BradleyJA , BriggsJD , JunorBJ , MacphersonSG , McMillanMA , et al. Long‐term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation1998;66(9):1186‐92. [MEDLINE: 9825816] MacPheeIA , BriggsJD , JunorBJ , McMillanMA , RodgerRS , WatsonMA . A prospective randomised controlled trial of long‐term outcome for renal transplant recipients converted from cyclosporin to azathioprine treatment one year after transplantation [abstract]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00602085] ">MacPhee 1998</a>; <a href="./references#CD006750-bbs2-0048" title="Martinez‐MierG , Mendez‐LopezMT , Budar‐FernandezLF , Estrada‐OrosJ , Franco‐AbaroaR , George‐MicelliE , et al. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation2006;82(11):1533‐6. [MEDLINE: 17164728] ">Martinez‐Mier 2006</a>; <a href="./references#CD006750-bbs2-0050" title="David‐NetoE , LemosF , AntonopoulosI , SouzaP , PiovesanA , VenturaC , KanashiroH , et al. Five‐year follow‐up of the MoDIFY study (modification of doses to improve function through the years) shows benefit of low tacrolimus and regular MMF doses [abstract]. Journal of Urology2011;185(4 Suppl 1):e828. [EMBASE: 70378695] David‐NetoE , LemosFC , deSouzaPS , VenturaCG , deCastroMCR\ , AgenaF , et al. Five‐year follow‐up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]. American Journal of Transplantation2010;10(Suppl 4):508. [EMBASE: 70465030] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Interim analysis of the MODIFY study in renal transplantation [abstract]. Transplantation2004;78(2 Suppl):278‐9. [CENTRAL: CN‐00509408] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. Transplantation2004;78(2 Suppl):278. David‐NetoE , PereiraLM , deCastroCR , MattosRM , SumitaNM , MendesME , et al. Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract]. American Journal of Transplantation2004;4(Suppl 8):234‐5. [CENTRAL: CN‐00509150] David‐NetoE , PereiraLM , deCastroMC , MattosRM , VenturaCG , SumitaNM , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):255. [CENTRAL: CN‐00509409] David‐NetoE , SouzaPS , PanajotopoulosN , RodriguesH , VenturaCG , DavidDS , et al. The impact of pretransplant donor‐specific antibodies on graft outcome in renal transplantation: a six‐year follow‐up study. Clinics2012;67(4):355‐61. [MEDLINE: 22522761] PereiraLM , deCastroMC , VenturaCG , ReisFS , SumitaNM , SaitoMI , et al. The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract]. American Journal of Transplantation2005;5(Suppl 11):466. PereiraLM , deCastroMC , VenturaCG , SoaresPS , FerreiraGF , SaldanhaLB , et al. A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1‐year result of the MODIFY study [abstract no: 53]. American Journal of Transplantation2006;6(Suppl 2):84. [CENTRAL: CN‐00671794] ">MODIFY Study 2012</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0058" title="PaolettiE , MarsanoL , BellinoD , CassottanaP , CannellaG . Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation2012;93(5):503‐8. [MEDLINE: 22318246] ">Paoletti 2012</a>; <a href="./references#CD006750-bbs2-0059" title="PascualM , CurtisJ , DelmonicoFL , FarrellML , WilliamsWW , KalilR , et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation2003;75(9):1501‐5. [MEDLINE: 12792504] WongW , Tolkoff‐RubinN , DelmonicoFL , CardarelliF , SaidmanSL , FarrellML , et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplantation2004;18(4):341‐8. [MEDLINE: 15233807] WongW , Tolkoff‐RubinN , DelmonicoFL , FarellML , ShihV , WilliamsW , et al. Analysis of the cardiovascular risk profile in stable renal transplant recipients after 50% cyclosporine reduction [abstract]. American Journal of Transplantation2003;3(Suppl 5):213. [CENTRAL: CN‐00448411] WongW , Tolkoff‐RubinN , DelmonicoFL , FarrellML , ShihV , CosimiAB , et al. A randomized clinical trial to analyze the effect of 50% cyclosporine reduction on the cardiovascular risk profile in stable kidney transplant recipients [abstract]. Journal of the American Society of Nephrology2003;14(Nov):186A. [CENTRAL: CN‐00550675] ">Pascual 2003</a>; <a href="./references#CD006750-bbs2-0062" title="PontrelliP , RossiniM , InfanteB , StalloneG , SchenaA , LoverreA , et al. Rapamycin inhibits PAI‐1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation2008;85(1):125‐34. [MEDLINE: 18192922] RossiniM , PontrelliP , StalloneG , InfanteB , SchenaA , LoverreA , et al. Regression of glomerulosclerosis in chronic allograft nephropathy (CAN) following calcineurin inhibitors (CNI) withdrawal and conversion to sirolimus (SRL) [abstract no: TH‐PO554]. Journal of the American Society of Nephrology2006;17(Abstracts):225A. [CENTRAL: CN‐00725009] StalloneG , PontrelliP , InfanteB , SchenaA , UrsiM , RanieriE , et al. Rapamycin (RAPA) inhibits PAI‐1 expression and reduce interstitial fibrosis in chronic allograft nephropathy (CAN) [abstract no: SO04]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v4. [CENTRAL: CN‐00716118] ">Pontrelli 2008</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>; <a href="./references#CD006750-bbs2-0065" title="RivelliRF , GoncalvesRT , LeiteMJr , SantosMA , DelgadoAG , CardosoLR , et al. Early withdrawal of calcineurin inhibitor from a sirolimus‐based immunosuppression stabilizes fibrosis and the transforming growth factor‐beta signalling pathway in kidney transplant. Nephrology2015;20(3):168‐76. [MEDLINE: 25404086] ">Rivelli 2015</a>; <a href="./references#CD006750-bbs2-0066" title="BalshawR , MarraC , NashanB , HagenmeyerEG , KeownP . First year cost‐implications of early cyclosporine withdrawal in renal transplantation [abstract no: 2378]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415221] CampistolJM , ErisJ , OberbauerR , FriendP , HutchisonB , MoralesJM , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology2006;17(2):581‐9. [MEDLINE: 16434506] CampistolJM , KreisH , OberbauerR , MotaA , RiadH , ChapmanJ , et al. Sirolimus‐based therapy following early cyclosporin withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract]. American Journal of Transplantation2004;4(Suppl 8):344. [CENTRAL: CN‐00509115] CampistolJM , LegendreC , FriendP , RiadH , CastagnetoM . Evaluating cardiovascular risk factors associated with long‐term sirolimus (Rapamune®) immunotherapy used with or without cyclosporine [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):311. [CENTRAL: CN‐00550754] CampistolJM , OberbauerR , HartmannA , KreisH , MotaA , AriasM , et al. Long‐term graft survival is significantly better in patients receiving sirolimus‐based therapy after early cyclosporine withdrawal [abstract no: W736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):784. [CENTRAL: CN‐00444661] CampistolJM , OberbauerR , KreisH , BraultY , BurkeJT , Rapamune Maintenance Regimen Study Group. Predicting 10‐year graft survival with sirolimus used either as base therapy or in association with cyclosporine [abstract no: 1458]. American Journal of Transplantation2003;3(Suppl 5):474. [CENTRAL: CN‐00444662] CampistolJM , OberbauerR , KreisH , LawenJ , MoralesJM , ChapmanJ , et al. Elimination of cyclosporine with sirolimus‐based immunotherapy: 2‐year results confirm improved renal function [abstract no: SA‐P0489]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00444663] ChapmanJ , JohnsonRW , KreisH , OberbauerR , VanrenterghemY , ClaessonK , et al. Improved renal function using sirolimus (Rapamune®) maintenance therapy and cyclosporine elimination in renal allograft recipients: 12‐month results of the tri‐continental trial [abstract no: A4615]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):882A. [CENTRAL: CN‐00550709] ChapmanJ , OberbauerR , CampistolJM , GrinyoJM , MoralesJM , MotaA , et al. Renal transplant patients receiving sirolimus‐based therapy after early cyclosporine withdrawal demonstrate superior renal allograft survival and improved renal function at 48 months after transplantation [abstract no: SU‐FC103]. Journal of the American Society of Nephrology2004;15(Oct):66A. [CENTRAL: CN‐00583160] ErisJ , GrinyoJM , BraultY , HutchisonB . Sirolimus therapy after early cyclosporine withdrawal in renal transplantation significantly reduces the rate of skin cancer compared with continuous combined therapy with cyclosporine [abstract no: OR‐040]. Transplant International2005;18(Suppl):10. ErisJ , RussG , HutchinsonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation [abstract no: 105]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644323] ErisJ , RussG , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Conversion to sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation [abstract no: 1581]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00644325] FriendP , MotaA , KreisH , SegoloniG , LegendreC , PratsD , et al. Cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy is beneficial to patients regardless of baseline renal function [abstract no: 0553]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415680] FriendP , RussG , OberbauerR , MurgiaMG , TufvesonG , ChapmanJ , et al. Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function. Transplant International2007;20(9):754‐60. [MEDLINE: 17565578] GrinyoJM , VanrentergheimY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. Sirolimus (Rapamune) in patients receiving kidney from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 534]. American Journal of Transplantation2002;2(Suppl 3):272. [CENTRAL: CN‐00415776] GrinyoJM , VanrenterghemY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. The effects of sirolimus (Rapamune) in patients receiving kidneys from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 0435]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00420830] HartmannA , ColonJ , PenaJ , MartinezJ , WalkerR , ArnsW , et al. Favourable cardiovascular risk profile in renal transplant patients receiving sirolimus maintenance therapy following cyclosporine withdrawal: 3 year results of the Rapamune Maintenance Regimen trial [abstract no: W756]. Nephrology Dialysis Transplantation2003;18(Suppl 4):791‐2. [CENTRAL: CN‐00445657] HartmannA , MotaA , LegendreC , SegoloniG , GrinyoJM , HutchisonB , et al. Patients receiving sirolimus maintenance therapy have better renal function after early cyclosporine withdrawal irrespective of baseline renal function: intent‐to‐treat results at 3 years [abstract no: W743]. Nephrology Dialysis Transplantation2003;18(Suppl 4):787. [CENTRAL: CN‐00445658] HartmannA , OberbauerR , KreisH , JohnsonRW , MotaA , SchenaFP , et al. Long‐term results of cyclosporine elimination with sirolimus‐based therapy show improved renal function [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):19. [CENTRAL: CN‐00550651] HutchisonB , ClaessonK , MotaA , ErisJM , KreisH , OberbauerR , et al. Quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination: 2‐year results [abstract no: 499]. American Journal of Transplantation2002;2(Suppl 3):263. [CENTRAL: CN‐00415909] JohnsonR , OberbauerR , KreisH , BrattstromB , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation [abstract no: 0429]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00445947] JohnsonRW , KreisH , OberbauerR , BrattstromC , ClaessonK , ErisJ . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation2001;72(5):777‐86. [MEDLINE: 11571437] KeownP , ChenJ , KreisH , OberbauerR , ClaessonK , MotaA , et al. Improved quality of life after cyclosporine elimination in sirolimus‐treated renal transplant patients [abstract no: A4711]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):901A. [CENTRAL: CN‐00550607] KreisH , JohnsonR , MayerG , BrattstromC , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine‐free immunosuppression in renal transplantation resulting in lower blood pressure and improved renal function [abstract no: A3662]. Journal of the American Society of Nephrology2000;11(Sept):696A‐7A. [CENTRAL: CN‐00550424] KreisH , OberbauerR , CampistolJM , MathewT , DalozeP , SchenaFP , et al. Long‐term benefits with sirolimus‐based therapy after early cyclosporine withdrawal. Journal of the American Society of Nephrology2004;15(3):809‐17. [MEDLINE: 14978184] KreisH , OberbauerR , ClaessonK , MotaA , AriasM , DurandD , et al. Quality‐of‐life assessments in sirolimus‐treated renal transplant patients after cyclosporine elimination [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00446200] KreisH , OberbauerR , MotaA , ClaessonK , RiadH , CampistolJM , et al. Sirolimus‐based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a continuous combination of sirolimus and cyclosporine [abstract]. American Journal of Transplantation2003;3(Suppl 5):460. [CENTRAL: CN‐00446201] LegendreC , BraultY , MoralesJM , OberbauerR , AltieriP , RiadH , et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years. Clinical Transplantation2007;21(3):330‐6. [MEDLINE: 17488381] LegendreC , DalozeP , ColonJ , ChapmanJ , PenaJ , MartinezJ , et al. Sirolimus (Rapamune) used with or without cyclosporine for long term therapy: a comparison of cardiovascular risk factors. [abstract no: 1015]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00416111] LegendreC , MotaA , FriendP , SegoloniG , GrinyoJM , HutchisonB , et al. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 3 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):466. [CENTRAL: CN‐00446313] MathewT , KreisH , DoyenK . Malignancy in renal transplant recipients receiving sirolimus (rapamune) maintenance therapy: 2‐year follow up from 5 multicenter studies [abstract no: 58]. American Journal of Transplantation2002;2(Suppl 3):152. [CENTRAL: CN‐00416243] MathewT , KreisH , DoyenK . Two‐year incidence of malignancy in sirolimus (Rapamune)‐treated renal transplant recipients: follow‐up results from 5 multicenter studies [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416244] MathewT , KreisH , FriendP . Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation2004;18(4):446‐9. [MEDLINE: 15233824] MoralesJM , HartmannA , WalkerR , ArnsW , SenatorskiG , GrinyoJM , et al. Similar lipid profile but improved long‐term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplantation Proceedings2009;41(6):2339‐44. [MEDLINE: 19715914] MoralesJM , KreisH , OberbauerR , CampistolJM , MotaA , HenriquesAC , et al. 48‐month results of sirolimus‐based therapy following early cyclosporine withdrawal demonstrate superior renal allograft survival [abstract no: MO05]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:214. [CENTRAL: CN‐00509360] MoralesJM , OberbauerR , LegendreC , RuizJC , MotaA , ChapmanJ , et al. Analysis of risk factors for reduced renal function in renal transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal: 5‐year results from the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC156]. Journal of the American Society of Nephrology2005;16:72A. [CENTRAL: CN‐00644316] MotaA , AriasM , TaskinenEI , PaavonenT , BraultY , LegendreC , et al. Sirolimus‐based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. American Journal of Transplantation2004;4(6):953‐61. [MEDLINE: 15147430] MotaA , AriasM , TaskinenEI , PaavonenT , LegendreC , ClaessonK , et al. Sirolimus‐based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years following kidney transplantation [abstract no: 1486]. American Journal of Transplantation2004;4(Suppl 8):566. [CENTRAL: CN‐00509364] MotaA , SegoloniG , LegendreC , PratsD , HutchisonB , MoralesJM , et al. Patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy irrespective of baseline renal function [abstract no: 395]. American Journal of Transplantation2002;2(Suppl 3):237. [CENTRAL: CN‐00420843] OberbauerR , AriasM , ClaessonK , MotaA , ErisJM , HutchisonB , et al. Two‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 0257]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416378] OberbauerR , HutchisonB , ErisJ , AriasM , ClaessonK , MotaA , et al. Health‐related quality‐of‐life outcomes of sirolimus‐treated kidney transplant patients after elimination of cyclosporine A: results of a 2‐year randomized clinical trial. Transplantation2003;75(8):1277‐85. [MEDLINE: 12717216] OberbauerR , HutchisonB , ErisJ , AriasM , MotaA , the Rapamune Maintenance Regimen Study Group. Health‐related quality‐of‐life assessment in kidney transplant patients receiving sirolimus maintenance therapy with early elimination of cyclosporine: 3‐year results [abstract no: W758]. Nephrology Dialysis Transplantation2003;18(Suppl 4):243. [CENTRAL: CN‐00446999] OberbauerR , HutchisonB , ErisJ , RiadH , ClaessonK , LawenJ , et al. Three‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 249]. American Journal of Transplantation2003;3(Suppl 5):215. [CENTRAL: CN‐00447000] OberbauerR , KreisH , CampistolJM , MotaA , DalozeP , RuizJC , et al. Renal function improves significantly after early cyclosporine withdrawal in sirolimus‐treated renal transplant recipients: 3‐year results of the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC041]. Journal of the American Society of Nephrology2003;14(Nov):10A. [CENTRAL: CN‐00550606] OberbauerR , KreisH , JohnsonRW , MotaA , ClaessonK , RuizJC , et al. Long‐term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2‐year results of the Rapamune Maintenance Regimen Study. Transplantation2003;76(2):364‐70. [MEDLINE: 12883194] OberbauerR , KreisH , JohnsonRWG , MotaA , ClaessonK , AriasM , et al. Long‐term improvement in renal function is shown in patients treated with sirolimus (Rapamune) and cyclosporine withdrawal: 2‐year results of the Rapamune Maintenance Regimen trial [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416379] OberbauerR , MotaA , PratsD , MathewT , MoralesJM , DalozeP , et al. Renal transplant patients with risk factors for reduced renal function benefit from cyclosporine withdrawal and sirolimus maintenance therapy [abstract no: W742]. Nephrology Dialysis Transplantation2003;18(Suppl 4):786‐7. [CENTRAL: CN‐00447001] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation [abstract no: O80]. Transplantation2004;78(2 Suppl):30. [CENTRAL: CN‐00653813] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation.[erratum appears in Transpl Int. 2005 Mar;18(3):369]. Transplant International2005;18(1):22‐8. [MEDLINE: 15612979] PaczekL , MotaA , SchenaFP , JohnsonRW , PratsD , MathewT , et al. Renal function benefit from sirolimus maintenance therapy after early cyclosporine withdrawal in the presence of risk factors [abstract no: 180]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00447075] RuizJC , CampistolJM , GrinyoJM , MotaA , PratsD , GutierrezJA , et al. Early cyclosporine a withdrawal in kidney‐transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation2004;78(9):1312‐8. [MEDLINE: 15548969] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions [abstract no: SU‐FC0235]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):48A. [CENTRAL: CN‐00447509] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Proceedings2003;35(5):1669‐70. [MEDLINE: 12962750] RuizJC , CampistolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplantation Proceedings2007;39(7):2151‐2. [MEDLINE: 17889121] RuizJC , CampstolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. The early use of sirolimus with CsA elimination is not associated with progressive proteinuria [abstract no: P113]. Transplant International2007;20(Suppl 2):122. [CENTRAL: CN‐00740556] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Anaemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function [abstract no: 2504]. Nephrology2006;11(Suppl 2):A37. [CENTRAL: CN‐00644362] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus (SRL) maintenance therapy after early cyclosporine (CsA) withdrawal benefits renal transplant recipients with risk factors for reduced renal function: 5‐year results [abstract no: 103]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:90. [CENTRAL: CN‐00644320] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus‐based therapy following early cyclosporine withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract no: P150]. Nephrology2004;9(Suppl 1):A38. [CENTRAL: CN‐00509449] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 159]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN‐00644317] RussG , JamiesonN , OberbauerR , AriasM , MurgiaMG , BlanchoG , et al. Three‐year health‐related quality‐of‐life outcomes for sirolimus‐treated kidney transplant patients after elimination of cyclosporine. Transplant International2007;20(10):875‐83. [MEDLINE: 17854445] RussG , OberbauerR , FriendP , CampistolJM , BurkeJT . The impact of renal function on the incidence of anemia in sirolimus‐treated renal transplant recipients [abstract no: TH‐PO563]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. [CENTRAL: CN‐00615898] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Long‐term impact of baseline renal function in kidney transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal [abstract no: FC‐50004]. Nephrology2005;10(Suppl 1):A2. [CENTRAL: CN‐00644319] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 1009]. American Journal of Transplantation2005;5(Suppl 11):413. RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation2005;80(9):1204‐11. [MEDLINE: 16314787] SchenaFP , JamiesonN , ColonJ , ShokerA , PenaJ , MartinezM , et al. Favorable cardiovascular risk profile when sirolimus is used without cyclosporine compared to combination therapy: 3‐year results of the Rapamune Maintenance Regimen trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):479. [CENTRAL: CN‐00447616] VanrenterghemY , KreisH , OberbauerR , MotaA , JohnsonWG , Sirolimus Tri‐contienental Renal Transplant Study Group. Improved renal function in renal allograft recipients with sirolimus (Rapamune) maintenance therapy and early cyclosporine withdrawal: 12‐month results [abstract]. Nephrology Dialysis Transplantation2001;16(6):A209. [CENTRAL: CN‐00448163] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] WalkerR , RussG , ErisJ , HutchinsonB , ChapmanJ , PussellB , et al. Treatment of hyperlipidemia in sirolimus (SRL)‐treated renal transplant recipients: long‐term findings from the Rapamune Maintenance Regimen (RMR) Trial [abstract no 27]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:49. [CENTRAL: CN‐00644318] ">RMR Study 2001</a>; <a href="./references#CD006750-bbs2-0069" title="SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]. Transplant International2007;20(Suppl 2):20. SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]. Transplantation2008;86(2 Suppl):39. [CENTRAL: CN‐00679020] ">Salvadori 2007</a>; <a href="./references#CD006750-bbs2-0071" title="RoodnatJ , HilbrandsLB , HeneRJ , deSevauxRG , GregoorPJ , Kal‐van GestelJA , et al. 15 year follow‐up of a multicentre, randomised, calcineurin inhibitor (CNI) withdrawal study in kidney transplantation [abstract no: BO156]. Transplant International2013;26(Suppl 2):83‐4. [EMBASE: 71359271] RoodnatJI , HilbrandsLB , HeneRJ , deSevauxRG , Smak GregoorPJ , Kal‐van GestelJA , et al. 15‐year follow‐up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation2014;98(1):47‐53. [MEDLINE: 24521775] Smak GregoorPJ , deSevauxRG , HeneRJ , HesseCJ , HilbrandsLB , VosP , et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation1999;68(10):1603‐6. [MEDLINE: 10589962] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow‐up data [abstract no: 441]. American Journal of Transplantation2001;1(Suppl 1):246. [CENTRAL: CN‐00763745] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Journal of the American Society of Nephrology2002;13(5):1365‐73. [MEDLINE: 11961025] Smak GregoorPJ , vanGelderT , IJzermansJN , WeimarW . Long‐term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00447777] VanGelderT , deSevauxR , HeneR , WeimarW , HoitsmaA , LigtenbergG , et al. Discontinuation of cyclosporine or prednisone 6 months after kidney transplantation: a randomized trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):920A. [CENTRAL: CN‐00583812] deSevauxRG , GregoorP , SmakJH , HeneRJ , WeimarW , HoitsmaAJ , et al. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomized study [abstract no: 935]. Transplantation1999;67(7):S240. [CENTRAL: CN‐00767038] ">Smak Gregoor 1999</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0074" title="StalloneG , DiPaolaS , SchenaA , InfanteB , GrandalianoG , BattagliaM , et al. Early withdrawal of cyclosporine A improves 1‐year kidney graft structure and function in sirolimus‐treated patients. Transplantation2003;75(7):998‐1003. [MEDLINE: 12698087] StalloneG , SchenaA , InfanteB , GrandalianoG , GesualdoL , SchenaPF , et al. Early withdrawal of cyclosporine (CSA) ameliorates 1‐year kidney graft function and structure in sirolimus (SRL)‐treated patients. [abstract no: 1014]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00527169] ">Stallone 2003</a>; <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>; <a href="./references#CD006750-bbs2-0077" title="HillebrandU , SuwelackB , GerhardtU , KobeltV , KraemerJ , HohageH . Impact of calcineurin inhibitor withdrawal and mycophenolate mofetil substitution on hematologic toxicity [abstract no: 0014]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415864] SuwelackB , DietKH , KobeltV , HohageH , GerhardtU . Impact of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in chronic allograft nephropathy [abstract no: 1048]. American Journal of Transplantation2002;2(Suppl 3):402. [CENTRAL: CN‐00416722] SuwelackB , GerhardtU , HohageH . Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. American Journal of Transplantation2004;4(4):655‐62. [MEDLINE: 15023160] SuwelackB , GerhardtU , KobeltV , HillebrandU , MatzkiesF , HohageH . Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels. Transplantation Proceedings2002;34(5):1803‐5. [MEDLINE: 12176583] SuwelackB , HausbergM , HillebrandU , RahnKH , HohageH . Study on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients [abstract no: 0637]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416723] SuwelackB , KobeltV , GerhardtU , VolmerS , HohageH . Course of intima thickness in long term renal transplant recipients treated with or without calcineurin‐inhibitors [abstract no: P04.21]. Kidney &amp; Blood Pressure Research2004;27(5‐6):335. [CENTRAL: CN‐00615862] SuwelackB , KobeltV , HillebrandU , GerhardtU , MatzkiesF , HohageH . Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. Transplantation Proceedings2002;34(5):1808‐9. [MEDLINE: 12176585] SuwelackB , KobeltV , HohageH , GerhardtU . Studies on effects of calcineurin‐inhibitor withdrawal on arterial wall structure and intima media thickness in longterm transplant recipients [abstract no: P290]. Transplantation2004;78(2 Suppl):295. [CENTRAL: CN‐00509495] SuwelackB , MalyarV , WaldschmidtG , HohageH . 5 year follow‐up of a randomized study on calcineurin‐inhibitor‐withdrawal with addition of MMF in chronic allograft nephropathy [abstract no: F‐PO600]. Journal of the American Society of Nephrology2007;18(Abstracts):231A. SuwelackBM , GerhardtUW , HohageH . Influence of calcineurin‐inhibitor free immunosuppression on carotid intima media thickness in chronic allograft nephropathy [abstract no: 659]. American Journal of Transplantation2003;3(Suppl 5):320. [CENTRAL: CN‐00447914] ">Suwelack 2002</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>; <a href="./references#CD006750-bbs2-0081" title="CampistolJM , AlverangaD , HricikDE , VelosaJ , GrinyoJM , MouradG , et al. Sirolimus‐treated renal transplant recipients experience improved renal function with cyclosporine elimination: one‐year results from a phase II trial [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00487674] GonwaT , AlverangaD , AnconaG , BrinkerK , CambiV , CampistolJ , et al. Sirolimus (Rapamune) permits early elimination of cyclosporine in recipients of cadaveric renal allografts [abstract]. Transplantation2000;69(8 Suppl):S360. [CENTRAL: CN‐00445514] GonwaTA . Sirolimus (SRL) treated patients demonstrate improved renal function after withdrawal of cyclosporine (CSA) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):891A. [CENTRAL: CN‐00550647] GonwaTA , HricikDE , BrinkerK , GrinyoJM , SchenaFP , Sirolimus Renal Function Study Group. Improved renal function in sirolimus‐treated renal transplant patients after early cyclosporine elimination. Transplantation2002;74(11):1560‐7. [MEDLINE: 12490789] HricikDE , Rapamune Renal Function Study Group. Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal transplant patients [abstract no: 0430]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00583304] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] ">Velosa‐212 Study 2001</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). </p> <p>There was missing outcome data in seven studies (<a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a>; <a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0040" title="HeeringP , WesthoffA , IvensK K , GrabenseeB . Comparison between the effects of CSA and azathioprine on functional renal parameters in randomized study after renal transplantation [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):940. [CENTRAL: CN‐00484304] HeeringP , WesthoffA , IvensK , HelmchenU , GrabenseeB . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine: a randomized controlled study [abstract]. 12th International Congress of Nephrology; 1993 Jun 13‐18; Jerusalem, Israel. 1993:194. HeeringP , WesthoffK , IvensB , KutkuhnB , GrabenseeH . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine [abstract]. Nephrology Dialysis Transplantation1993;8(9):1041. [CENTRAL: CN‐00260889] IvensK , HeeringP , WitholdW , KochM , ReinauerH , GrabenseeB . Withdrawal of cyclosporine improves the cardio‐vascular risk profile in renal graft recipients [abstract]. Journal of the American Society of Nephrology1994;5(3):1013. ">Heering 1993</a>; <a href="./references#CD006750-bbs2-0051" title="MuehlbacherF , NeumayerHH , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 1224]. American Journal of Transplantation2003;3(Suppl 5):465. [CENTRAL: CN‐00446852] MuhlbacherF , NeumayerHH , delCastilloD , StefoniS , ZygmuntAJ , BuddeK , et al. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study. Transplant International2014;27(2):176‐86. [MEDLINE: 24266855] MuhlbacherF , PaczekL . An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 399]. American Journal of Transplantation2002;2(Suppl 3):238. NeumayerH , MuhlbacherF , StefoniS , DelCastilloD , Myfortic Maintenance Renal Transplantation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416320] NeumayerHH , MuehlbacherF , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: W738]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00446926] ">Muhlbacher 2014</a>; <a href="./references#CD006750-bbs2-0055" title="BloomR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]. Transplantation2008;86(2 Suppl):301. [CENTRAL: CN‐00740509] GastonR , BloomR , ShahT , CibrikD , AngelisM , MulgaonkarS , et al. 6‐month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH‐PO565]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00602020] GastonR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00653708] GastonRS , KaplanB , ShahT , CibrikD , ShawLM , AngelisM , et al. Fixed‐ or controlled‐dose mycophenolate mofetil with standard‐ or reduced‐dose calcineurin inhibitors: the OPTICEPT trial. American Journal of Transplantation2009;9(7):1607‐19. [MEDLINE: 19459794] KaplanB , GastonR , Meier‐KriescheH , BloomR , PatelD , ShawL . Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]. American Journal of Transplantation2009;9(Suppl 2):419. [CENTRAL: CN‐00794654] KaplanB , GastonRS , Meier‐KriescheHU , BloomRD , ShawLM . Mycophenolic acid exposure in high‐ and low‐weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Therapeutic Drug Monitoring2010;32(2):224‐7. [MEDLINE: 20216117] ShawL , KaplanB , AngelisM , BloomR , GastonR , Meier‐KriescheH , et al. Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU‐FC128]. Journal of the American Society of Nephrology2007;18(Abstracts):96A‐7A. [CENTRAL: CN‐00724911] ">OPTICEPT Study 2009</a>). </p> <p>Attrition bias was judged to be unclear for the remaining 21 studies.</p> </section> <section id="CD006750-sec-0074"> <h4 class="title">Selective reporting</h4> <p>There were 54 studies that reported prespecified outcomes (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>; <a href="./references#CD006750-bbs2-0003" title="AndresA , MarcenR , SanchezJ , ValdesF , ErrastiP , SolaR , et al. Comparative study of three different patterns of immunosuppression based on induction with basiliximab and low initial doses or delayed initiation of neoral in kidney transplant recipients at high risk of delayed graft function [abstract no: 1629]. American Journal of Transplantation2005;5(Suppl 11):570. [CENTRAL: CN‐00644164] AndresA , MarcenR , ValdesF , PlumedJS , SolaR , ErrastiP , et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clinical Transplantation2009;23(1):23‐32. [MEDLINE: 18798851] MarcenR , AndresA , Sanchez‐PlumedJ , ValdesF , ErrastiP , SolaR , et al. A randomized study to compare immunosuppression based on basiliximab induction and low initial doses or delayed neoral in kidney transplant recipients at high risk for delayed graft function [abstract no: PO‐266]. Transplant International2005;18(Suppl 1):114. ">Andres 2009</a>; <a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0006" title="HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagarajanCM , FassettR , et al. Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P‐309]. Transplant International2009;22(Suppl 2):172. HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagrajanC , FassettR , et al. Assessment of everolimus in maintenance renal transplant recipients: the Ascertain Study [abstract no: 1646]. Transplantation2008;86(Suppl 2):546. [CENTRAL: CN‐00740482] HoldaasH , RostaingL , MidtvedtK , SeronD , ColeE , ChapmanJ , FellstromB , et al. Conversion of long‐term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24‐month study.[Erratum appears in Transplantation. 2011 Nov 27;92(10):e61 Note: multiple investigator names added.]. Transplantation2011;92(4):410‐8. [MEDLINE: 21697773] O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Long‐term post transplantation switch to an everolimus‐based therapy with CNI elimination/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:42. O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Post‐hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7]. Transplantation Society of Australia &amp; New Zealand (TSANZ).29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:41. ">ASCERTAIN Study 2011</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0009" title="BarsoumRS , MorseyAA , IskanderIR , MorganMM , FayadTM , AtallaNT , et al. The Cairo Kidney Center protocol for rapamycin‐based sequential immunosuppression in kidney transplant recipients: 2‐year outcomes. Experimental &amp; Clinical Transplantation2007;5(2):649‐57. [MEDLINE: 18194116] ">Barsoum 2007</a>; <a href="./references#CD006750-bbs2-0011" title="BertoniE , BecherelliP , SalvadoriM . Triple therapy with neoral, steroids and enteric‐coated mycophenolate acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: F‐PO614]. Journal of the American Society of Nephrology2007;18(Abstracts):234A. [CENTRAL: CN‐00716078] RosatiA , BertoniE , RossoG , LartiA , MehmetajA , SalvadoriM . Triple therapy with Neoral, steroids and enteric coated mycophenolic acid vs everolimus: efficacy, side effects and pharmaco‐economic aspects. A monocentric experience [abstract no: SaP477]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi396. [CENTRAL: CN‐00725011] ">Bertoni 2007</a>; <a href="./references#CD006750-bbs2-0012" title="BertoniE , LartiA , FarsettiS , RossoG , DiMariaL , ZanazziM . Cyclosporine (CyA) very low dose with everolimus (E) high dose is associated with better outcomes in renal transplant patients with respect to standard treatment with EC‐MPS (M) [abstract]. Transplant International2009;22(Suppl 2):91. BertoniE , LartiA , RossoG , ZanazziM , DiMariaL , SalvadoriM . Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. Journal of Nephrology2011;24(5):613‐8. [MEDLINE: 21240873] ">Bertoni 2011</a>; <a href="./references#CD006750-bbs2-0013" title="BuddeK , BosmansJ , ZeierM , SennesaelJ , HoptU , FischerWH , et al. Safety and efficacy of reduced or full dose of cyclosporine (neoral®) in combination with mycophenolate sodium (Myfortic®), basiliximab (Simulect®), and steroids in de novo kidney transplant recipients [abstract]. Transplantation2004;78(2 Suppl):83. [CENTRAL: CN‐00527096] BuddeK , BosmansJL , SennesaelJ , ZeierM , HoptU , FischerW , et al. Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric‐coated mycophenolate‐sodium, and steroids [abstract no: 1195]. American Journal of Transplantation2005;5(Suppl 11):461. [CENTRAL: CN‐00644165] BuddeK , BosmansJL , SennesaelJ , ZeierM , PisarskiP , SchutzM , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab. Clinical Nephrology2007;67(3):164‐75. [MEDLINE: 17390741] BuddeK , ZeierM , BosmansJL , SennesaelJ , GlanderP , FischerW , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab [abstract no: F‐PO1088]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00644166] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Budde 2007</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0015" title="CaiL , ZengF , LiuB , WeiL , ChenZ , JiangJ . A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients. International Journal of Clinical Practice. Supplement2014;68(181):23‐30. [MEDLINE: 24673716] ">Cai 2014</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0019" title="ChadbanS , CampbellS , RussG , WalkerR , ChapmanJ , PussellB , et al. A one‐year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric‐coated mycophenolate sodium (EC‐MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA‐ME), basiliximab and steroids in de novo kidney transplantation [abstract no: 32]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:51. [CENTRAL: CN‐00583470] ChadbanS , ErisJ , RussG , CampbellS , ChapmanJ , PussellB , et al. Enteric‐coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology2013;18(1):63‐70. [MEDLINE: 23110508] ">Chadban 2013</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0021" title="AsderakisA , ChanL . Renal function with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month study in de novo renal transplant recipients [abstract no: O111]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ChanL , AndresA , BunnapradistS , GugliuzzaK , ParasuramanR , PeddiVR , et al. Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC‐MPS. Journal of Transplantation2012;2012:941640. [MEDLINE: 23227307] ChanL , HartM , AndresA , GugliuzzaK , BunnapradistS , ParasumaranR . Renal function and incidence of NODM with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month comparative study in de novo renal transplant recipients [abstract no: 718]. Transplantation2008;86(2S):251. NicholsonML , ChanL . Incidence of new onset diabetes mellitus in de novo renal transplant recipients treated with enteric‐coated mycophenolate sodium in combination with reduced or standard tacrolimus target levels: results of a 6‐month randomized study [abstract no: P266]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ">Chan 2012</a>; <a href="./references#CD006750-bbs2-0022" title="AlvaradoA , ChhabraD , WangE , NajafianN , FriedewaldJ , HoB , et al. Prospective randomized study to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone‐free immunosuppressive regimen [abstract no: 53]. American Journal of Transplantation2012;12(Suppl S3):42. [EMBASE: 70746000] AlvaradoA , ShettyA , TraitanonO , LeventhalJ , MasV , ChhabraD , et al. Calcineurin‐inhibitor conversion to mTOR inhibitor in renal transplant recipients leads to worse long term clinical outcomes [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953109] ChhabraD , AlvaradoA , DalalP , LeventhalJ , WangC , Sustento‐ReodicaN , et al. Impact of calcineurin‐inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone‐free regimen. American Journal of Transplantation2013;13(11):2902‐11. [MEDLINE: 24007570] GallonL , TraitanonO , Sustento‐ReodicaN , LeventhalJ , AnsariMJ , GehrauRC , et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International2014;87(4):828‐38. [MEDLINE: 25354238] ShahG , XuL , DalalP , ChhabranD , FriedewaldJ , HoB , et al. Conversion from CNI to SRL in a pred‐free immunosuppressive regimen: interim report of a prospective randomized study [abstract no: 1641]. American Journal of Transplantation2010;10(Suppl 4):504. ">Chhabra 2013</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0028" title="Smak GregoorPJ , deSevauxRG , HeneRJ , HilbrandsLB , vanGelderT , HoitsmaAJ , et al. The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):699A. [CENTRAL: CN‐00447776] deSevauxRG , GregoorPJ , HeneRJ , HoitsmaAJ , VosP , WeimarW , et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. Journal of the American Society of Nephrology2001;12(8):1750‐7. [MEDLINE: 11461949] deSevauxRG , Smak GregoorPJ , HeneRJ , HoitsmaAJ , VosP , et al. Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00583239] deSévauxRG , Smak GregoorPJ , HenéRJ , WeimarW , HoitsmaAJ , VanGelderT , et al. A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]. Transplantation1998;65(12):S107. [CENTRAL: CN‐00583548] ">de Sevaux 2001</a>; <a href="./references#CD006750-bbs2-0029" title="EtienneI , ToupanceO , BenichouJ , ThierryA , Al NajjarA , HuraultdL , et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Nephrology Dialysis Transplantation2010;25(9):3096‐106. [MEDLINE: 20299336] ">DICAM Study 2010</a>; <a href="./references#CD006750-bbs2-0030" title="DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , MarshallS , et al. MMF substitution for CSA in chronic allograft dysfunction: 2 year follow‐up of a multi‐center randomized controlled study [abstract no: 1513]. American Journal of Transplantation2005;5(Suppl 11):541. DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , SutterC , et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the &quot;creeping creatinine&quot; study. Transplantation2005;79(4):466‐75. [MEDLINE: 15729174] DudleyCR , MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi‐center randomized controlled study [abstract no: 41]. American Journal of Transplantation2002;2(Suppl 3):148. Tedesco de SilvaH . MMF replacing CSA reverses the &quot;creeping creatinine&quot; of renal transplant recipients of a multi‐center randomized controlled study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416751] ">Dudley 2005</a>; <a href="./references#CD006750-bbs2-0032" title="FangmannJ , ArnsW , MartiH , BuddeK , BeckurtsT , HaussJ . Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation ‐ impact on renal function and rejection episodes [abstract no: 113]. American Journal of Transplantation2005;5(Suppl 11):185. [CENTRAL: CN‐00644197] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: 715]. American Journal of Transplantation2004;4(Suppl 8):353. [CENTRAL: CN‐00509182] FangmannJ , ArnsW , MartiH , BuddeK , NeumayerH , BeckurtsT , et al. Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract no: P249]. Transplantation2004;78(2 Suppl):280. FangmannJ , ArnsW , MartiHP , HaussJ , KettelerM , BeckurtsT , et al. Impact of daclizumab, low‐dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology Dialysis Transplantation2010;25(1):283‐92. [MEDLINE: 19773417] ">Fangmann 2010</a>; <a href="./references#CD006750-bbs2-0033" title="FergusonR , MulgaonkarS , Tedesco SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced‐exposure (R‐E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra (ACT). 2003:63. [CENTRAL: CN‐00445317] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorU , et al. FTY720 with reduced‐exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415638] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , RussG , et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12‐month preliminary results [abstract no: 624]. American Journal of Transplantation2003;3(Suppl 5):311. [CENTRAL: CN‐00445316] MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorfU , RussG , et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1‐year dose‐finding study.[Erratum appears in Am J Transplant. 2006 Dec;6(12):3044]. American Journal of Transplantation2006;6(8):1848‐57. [MEDLINE: 16771816] RussG , FergusonRM , MulgaonkarS , Tedesco‐SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced dose Neoral (RDN) may offer a safety/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]. American Journal of Transplantation2004;4(Suppl 8):432. [CENTRAL: CN‐00509451] ">Ferguson 2006</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0041" title="ArnsW , BuddeK , SommererC , WitzkeO , GubaM , JacobiJ , et al. Month 48 follow‐up results of HERAKLES trial on three different treatment regimen and switching off behaviour in de novo renal transplant patients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953873] ArnsW , NeumayerH , LehnerF , WitzkeO , SommererC , KliemV , et al. HERAKLES at month 24: follow‐up results on efficacy and safety of three different treatment regimens in de novo renal transplant patients demonstrate options for individualized immunosuppression [abstract no: BO148]. Transplant International2013;26(Suppl 2):21. [EMBASE: 71356261] ArnsW , SommererC , WitzkeO , LehnerF , ZeierM , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES trial [abstract no: 1722]. Transplantation2012;94(10):995. [EMBASE: 71251769] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/ mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: 716]. Transplantation2014;98(Suppl 1):81. [EMBASE: 71543792] BuddeK , ArnsW , SommererC , LehnerF , ZeierM , NeumayerH , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 24 [abstract no: B932]. American Journal of Transplantation2013;13(Suppl 5):310‐1. [EMBASE: 71057508] BuddeK , SommererC , WeithoferP , WitzkeO , GubaM , JacobiJ , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 48 [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954274] BuddeK , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES Study [abstract no: 50]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745997] GubaM , BuddeK , SommererC , NeumayerHH , LehnerF , ReinkeP , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: follow‐up of the HERAKLES study at month 36 [abstract no: V62]. Transplant International2014;27(Suppl 3):22. [EMBASE: 71664029] GubaM , WitzkeO , LehnerF , ArnsW , SommererC , NeumayerH , et al. The HERAKLES study at 24 month: Superior renal function in an everolimus‐based CNI free regimen [abstract no: O219]. Transplant International2013;26(Suppl 2):110. [EMBASE: 71359365] HauserIA , WitzkeO , ArnsW , ReinkeP , SommererC , NeumayerHH , et al. Efficacy and safety of three different treatment regimens in de novorenal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: P132]. Transplant International2014;27(Suppl 3):51. [EMBASE: 71664135] HoerningA , KohlerS , JunC , LuJ , FuJ , TebbeB , et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clinical &amp; Experimental Immunology2012;168(2):251‐9. [MEDLINE: 22471287] LehnerF , GubaM , ArnsW , SommererC , NeumayerHH , JacobiJ , et al. Follow‐up data from HERAKLES study at month 24: maintained superior renal function in patients on an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus [abstract no: P04]. Transplant International2013;26(Suppl 1):28. [EMBASE: 71356287] LehnerF , SommererC , WitzkeO , ArnsW , KliemV , NeumayerHH , et al. HERAKLES at month 24: efficacy and safety of 3 different regimens in de novo renal transplant patients [abstract no: BO148]. Transplant International2013;26(Suppl 2):82. [EMBASE: 71359263] SommererC , BuddeK , KliemV , WitzkeO , GubaM , JacobiJ , et al. Efficacy and safety of three different treatment regimen in de novo renal transplant patients: month 48 follow‐up results of the HERAKLES trial [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953341] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post HOC analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: 2921]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] SommererC , LehnerF , BuddeK , ArnsW , HauserIA , SuwelackB , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract no: P127]. Transplant International2014;27(Suppl 3):50. [EMBASE: 71664131] SommererC , WitzkeO , LehnerF , ZeierM , NeumayerH , StanglM , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: results of the HERAKLES Trial [abstract no: 51]. American Journal of Transplantation2012;12(Suppl S3):41. [EMBASE: 70745998] WitzkeO , BuddeK , LehnerF , ZeierM , NeumayerHH , StanglM , et al. Superior renal function in an everolimus‐based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: the HERAKLES study [abstract no: 1675]. Transplantation2012;94(Suppl):993. [EMBASE: 71251766] ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: follow‐up results of the HERAKLES trial at month 24 [abstract no: 495]. American Journal of Transplantation2013;13(Suppl S5):183. ZeierM , BuddeK , ArnsW , GubaM , SommererC , NeumayerH , et al. Efficacy and safety of three different treatment regimens in de novo renal transplant patients: month 36 follow‐up results of HERAKLES trial [abstract no: 718]. Transplantation2014;98(Suppl 1):81‐2. [EMBASE: 71543794] ">HERAKLES Study 2012</a>; <a href="./references#CD006750-bbs2-0044" title="IsoniemiH . Renal allograft immunosuppression V: glucose intolerance occurring in different immunosuppressive treatments. Clinical Transplantation1991;5(3):268‐72. [EMBASE: 21188067] IsoniemiH . Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transplant International1991;4(1):31‐7. [MEDLINE: 2059298] IsoniemiH , AhonenJ , EklundB , HockerstedtK , SalmelaK , vonWillebrandE , et al. Renal allograft immunosuppression. II. A randomized trial of withdrawal of one drug in triple drug immunosuppression. Transplant International1990;3(3):121‐7. [MEDLINE: 2271083] IsoniemiH , AhonenJ , KrogerusL , EklundB , HockerstedtK , SalmelaK , et al. Chronic rejection of renal allografts with four immunosuppressive regimens. Transplantation Proceedings1992;24(6):2716‐7. [MEDLINE: 1465912] IsoniemiH , EklundB , HockerstedtK , KorsbackC , SalmelaK , vonWillebrandE , et al. Discontinuation of one drug in triple drug treatment of renal allograft patients: 1‐year results. Transplantation Proceedings1990;22(4):1365‐6. [MEDLINE: 2202111] IsoniemiH , KrogerusL , vonWillebrandE , TaskinenE , Gronhagen‐RiskaC , AhonenJ , et al. Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts. Transplant International1991;4(3):151‐6. [MEDLINE: 1958279] IsoniemiH , TikkanenM , HayryP , EklundB , HockerstedtK , SalmelaK , et al. Lipid profiles with triple drug immunosuppressive therapy and with double drug combinations after renal transplantation and stable graft function. Transplantation Proceedings1991;23(1 (Pt 2)):1029‐31. [MEDLINE: 1989148] IsoniemiH , TikkanenMJ , AhonenJ , HayryP . Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transplant International1991;4(3):130‐5. [MEDLINE: 1958276] IsoniemiH , vonWillebrandE , AhonenJ , EklundB , HockerstedtK , KrogerusL , et al. Late histopathological findings in renal allografts with four immunosuppressive regimens. Transplant International1992;5 Suppl 1:S6‐7. [MEDLINE: 14621718] IsoniemiHM , AhonenJ , TikkanenMJ , vonWillebrandEO , KrogerusL , EklundBH , et al. Long‐term consequences of different immunosuppressive regimens for renal allografts.[Erratum appears in Transplantation 1998 Sep 15;66(5):678]. Transplantation1993;55(3):494‐9. [MEDLINE: 8456467] IsoniemiHM , KrogerusL , vonWillebrandE , TaskinenE , AhonenJ , HayryP . Histopathological findings in well‐functioning, long‐term renal allografts. Kidney International1992;41(1):155‐60. [MEDLINE: 1593852] ">Isoniemi 1990</a>; <a href="./references#CD006750-bbs2-0045" title="HausbergM , LangD , LeversA , SuwelackB , KistersK , TokmakF , et al. Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. Journal of Hypertension2006;24(5):957‐64. [MEDLINE: 16612259] HausbergM , SuwelackB , KoschM , BarenbrockM , GerhardtU , HohageH , et al. Effects of calcineurin‐inhibitor withdrawal on sympathetic nerve activity and blood pressure in renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift2001;126:S193. [CENTRAL: CN‐00383083] KoschM , HausbergM , SuwelackB . Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation2003;76(10):1516‐9. [MEDLINE: 14657697] KoschM , SuwelackB , BarenbrockM , KobeltV , HohageH , RahnKH , et al. Studies on effects of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Deutsche Medizinische Wochenschrift2001;126:S185. [CENTRAL: CN‐00383367] ">Kosch 2003a</a>; <a href="./references#CD006750-bbs2-0047" title="JossN . Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. Scottish Medical Journal2005;50(2):82. [CENTRAL: CN‐00653805] JossN , Glasgow Transplant Group. Randomised study comparing cyclosporin with azathioprine one year after renal transplantation ‐ 15 year outcome [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:197. [CENTRAL: CN‐00636135] JossN , RodgerRS , McMillanMA , JunorBJ . Randomized study comparing cyclosporine with azathioprine one year after renal transplantation‐15‐year outcome data. Transplantation2007;83(5):582‐7. [MEDLINE: 17353778] MacPheeIA , BradleyJA , BriggsJD , JunorBJ , MacphersonSG , McMillanMA , et al. Long‐term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation1998;66(9):1186‐92. [MEDLINE: 9825816] MacPheeIA , BriggsJD , JunorBJ , McMillanMA , RodgerRS , WatsonMA . A prospective randomised controlled trial of long‐term outcome for renal transplant recipients converted from cyclosporin to azathioprine treatment one year after transplantation [abstract]. Journal of the American Society of Nephrology1996;7(9):1915. [CENTRAL: CN‐00602085] ">MacPhee 1998</a>; <a href="./references#CD006750-bbs2-0050" title="David‐NetoE , LemosF , AntonopoulosI , SouzaP , PiovesanA , VenturaC , KanashiroH , et al. Five‐year follow‐up of the MoDIFY study (modification of doses to improve function through the years) shows benefit of low tacrolimus and regular MMF doses [abstract]. Journal of Urology2011;185(4 Suppl 1):e828. [EMBASE: 70378695] David‐NetoE , LemosFC , deSouzaPS , VenturaCG , deCastroMCR\ , AgenaF , et al. Five‐year follow‐up of the MoDIFY Study (Modification of Doses to Improve Function through the Years) shows benefit of low tacrolimus and regular MMF doses [abstract no: 1655]. American Journal of Transplantation2010;10(Suppl 4):508. [EMBASE: 70465030] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Interim analysis of the MODIFY study in renal transplantation [abstract]. Transplantation2004;78(2 Suppl):278‐9. [CENTRAL: CN‐00509408] David‐NetoE , PereiraLM , CastroMC , MattosRM , SumitaNM , MendesE , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. Transplantation2004;78(2 Suppl):278. David‐NetoE , PereiraLM , deCastroCR , MattosRM , SumitaNM , MendesME , et al. Interim analysis of the MODIFY study in renal transplantation (Modification of Doses to Improve Function through the Years) [abstract]. American Journal of Transplantation2004;4(Suppl 8):234‐5. [CENTRAL: CN‐00509150] David‐NetoE , PereiraLM , deCastroMC , MattosRM , VenturaCG , SumitaNM , et al. Therapeutic levels of mycophenolic acid under fixed doses of MMF on the first two months after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):255. [CENTRAL: CN‐00509409] David‐NetoE , SouzaPS , PanajotopoulosN , RodriguesH , VenturaCG , DavidDS , et al. The impact of pretransplant donor‐specific antibodies on graft outcome in renal transplantation: a six‐year follow‐up study. Clinics2012;67(4):355‐61. [MEDLINE: 22522761] PereiraLM , deCastroMC , VenturaCG , ReisFS , SumitaNM , SaitoMI , et al. The MODIFY Study in renal transplantation (Modification of Doses to Improve Function Through the Years) [abstract]. American Journal of Transplantation2005;5(Suppl 11):466. PereiraLM , deCastroMC , VenturaCG , SoaresPS , FerreiraGF , SaldanhaLB , et al. A prospective, randomized and controlled trial of tacrolimus minimization in renal transplantation: 1‐year result of the MODIFY study [abstract no: 53]. American Journal of Transplantation2006;6(Suppl 2):84. [CENTRAL: CN‐00671794] ">MODIFY Study 2012</a>; <a href="./references#CD006750-bbs2-0053" title="CurtisJ , NashanB , PoniicelliC , MouradG , BogerR , RAD 156 Study Group. One year result of a multicenter, open‐label trial on safety and efficacy of certican (RAD) used in combination with simulect, corticosteroids, and full or reduced dose neoral in renal transplant [abstract no: 1335]. American Journal of Transplantation2001;1(Suppl 1):474. [CENTRAL: CN‐00444958] CurtisJ , NashanB , PonticelliC , MouradG , BogerR , RAD 156 Study Group. Everolimus (RAD) in combination with reduced dose with reduced dose neoral® maintains effective immunosuppression with improved tolerability compared to full dose neoral [abstract no: A4625]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):884A. [CENTRAL: CN‐00550720] MouradG , BogerR , CurtisJ , NashanB , PonticelliC , RAD B 156 Study Group. CERTICAN (TM) (RAD; EVEROLIMUS), the proliferation signal inhibitor, is complementary with a reduced dose NEORAL® based quadruple immunosuppressive regimen [abstract no: 1622]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487738] NashanB , CurtisJ , PonticelliC , MouradG , BogerR , RAD B156 Study Group. Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose neoral based quadruple immunosuppressive regimen [abstract no: 398]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487741] NashanB , MouradG , BogerR , CurtisJ , PonticelliC , HaasT . Everolimus and reduced‐exposure cyclosporine in de novo renal‐transplant recipients: a three‐year phase II, randomized, multicenter, open‐label study. Transplantation2004;78(9):1332‐40. [MEDLINE: 15548972] PonticelliC , CurtisJ , KovarikJM , NashanB , MouradG , FigueiredoJ , et al. Everolimus pharmacokinetics are unaltered with full‐dose versus reduced‐dose cyclosporine [abstract no: 318]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487748] RADB156 Study Group, BogerR , FreiU , GlotzD , KahanB , PonticelliC , et al. CERTICAN(TM) with reduced dose NEORAL® results in a significantly higher GFR in de novo renal transplant recipients over the first 12 Months compared to CERTICAN(TM)‐full dose NEORAL® as Assessed by Iohexol Clearance [abstract no:1623]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487751] ">Nashan 2004</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0057" title="Pacheco‐SilvaA , TonatoE , DuraoMJr , Requiao‐MouraL , ArrudaE , ChinenR , et al. A randomized clinical trial of early conversion from tacrolimus to everolimus in deceased donor kidney transplantation [abstract no: P460]. Transplant International2013;26(Suppl 2):277‐8. [EMBASE: 71360073] ">Pacheco‐Silva 2013</a>; <a href="./references#CD006750-bbs2-0059" title="PascualM , CurtisJ , DelmonicoFL , FarrellML , WilliamsWW , KalilR , et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation2003;75(9):1501‐5. [MEDLINE: 12792504] WongW , Tolkoff‐RubinN , DelmonicoFL , CardarelliF , SaidmanSL , FarrellML , et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplantation2004;18(4):341‐8. [MEDLINE: 15233807] WongW , Tolkoff‐RubinN , DelmonicoFL , FarellML , ShihV , WilliamsW , et al. Analysis of the cardiovascular risk profile in stable renal transplant recipients after 50% cyclosporine reduction [abstract]. American Journal of Transplantation2003;3(Suppl 5):213. [CENTRAL: CN‐00448411] WongW , Tolkoff‐RubinN , DelmonicoFL , FarrellML , ShihV , CosimiAB , et al. A randomized clinical trial to analyze the effect of 50% cyclosporine reduction on the cardiovascular risk profile in stable kidney transplant recipients [abstract]. Journal of the American Society of Nephrology2003;14(Nov):186A. [CENTRAL: CN‐00550675] ">Pascual 2003</a>; <a href="./references#CD006750-bbs2-0060" title="PascualJ , BloomD , TorrealbaJ , BrahmbhattR , ChangZ , SollingerHW , et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T‐regulatory cells. American Journal of Transplantation2008;8(7):1529‐36. [MEDLINE: 18510645] ">Pascual 2008</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0062" title="PontrelliP , RossiniM , InfanteB , StalloneG , SchenaA , LoverreA , et al. Rapamycin inhibits PAI‐1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation2008;85(1):125‐34. [MEDLINE: 18192922] RossiniM , PontrelliP , StalloneG , InfanteB , SchenaA , LoverreA , et al. Regression of glomerulosclerosis in chronic allograft nephropathy (CAN) following calcineurin inhibitors (CNI) withdrawal and conversion to sirolimus (SRL) [abstract no: TH‐PO554]. Journal of the American Society of Nephrology2006;17(Abstracts):225A. [CENTRAL: CN‐00725009] StalloneG , PontrelliP , InfanteB , SchenaA , UrsiM , RanieriE , et al. Rapamycin (RAPA) inhibits PAI‐1 expression and reduce interstitial fibrosis in chronic allograft nephropathy (CAN) [abstract no: SO04]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v4. [CENTRAL: CN‐00716118] ">Pontrelli 2008</a>; <a href="./references#CD006750-bbs2-0066" title="BalshawR , MarraC , NashanB , HagenmeyerEG , KeownP . First year cost‐implications of early cyclosporine withdrawal in renal transplantation [abstract no: 2378]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415221] CampistolJM , ErisJ , OberbauerR , FriendP , HutchisonB , MoralesJM , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology2006;17(2):581‐9. [MEDLINE: 16434506] CampistolJM , KreisH , OberbauerR , MotaA , RiadH , ChapmanJ , et al. Sirolimus‐based therapy following early cyclosporin withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract]. American Journal of Transplantation2004;4(Suppl 8):344. [CENTRAL: CN‐00509115] CampistolJM , LegendreC , FriendP , RiadH , CastagnetoM . Evaluating cardiovascular risk factors associated with long‐term sirolimus (Rapamune®) immunotherapy used with or without cyclosporine [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):311. [CENTRAL: CN‐00550754] CampistolJM , OberbauerR , HartmannA , KreisH , MotaA , AriasM , et al. Long‐term graft survival is significantly better in patients receiving sirolimus‐based therapy after early cyclosporine withdrawal [abstract no: W736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):784. [CENTRAL: CN‐00444661] CampistolJM , OberbauerR , KreisH , BraultY , BurkeJT , Rapamune Maintenance Regimen Study Group. Predicting 10‐year graft survival with sirolimus used either as base therapy or in association with cyclosporine [abstract no: 1458]. American Journal of Transplantation2003;3(Suppl 5):474. [CENTRAL: CN‐00444662] CampistolJM , OberbauerR , KreisH , LawenJ , MoralesJM , ChapmanJ , et al. Elimination of cyclosporine with sirolimus‐based immunotherapy: 2‐year results confirm improved renal function [abstract no: SA‐P0489]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00444663] ChapmanJ , JohnsonRW , KreisH , OberbauerR , VanrenterghemY , ClaessonK , et al. Improved renal function using sirolimus (Rapamune®) maintenance therapy and cyclosporine elimination in renal allograft recipients: 12‐month results of the tri‐continental trial [abstract no: A4615]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):882A. [CENTRAL: CN‐00550709] ChapmanJ , OberbauerR , CampistolJM , GrinyoJM , MoralesJM , MotaA , et al. Renal transplant patients receiving sirolimus‐based therapy after early cyclosporine withdrawal demonstrate superior renal allograft survival and improved renal function at 48 months after transplantation [abstract no: SU‐FC103]. Journal of the American Society of Nephrology2004;15(Oct):66A. [CENTRAL: CN‐00583160] ErisJ , GrinyoJM , BraultY , HutchisonB . Sirolimus therapy after early cyclosporine withdrawal in renal transplantation significantly reduces the rate of skin cancer compared with continuous combined therapy with cyclosporine [abstract no: OR‐040]. Transplant International2005;18(Suppl):10. ErisJ , RussG , HutchinsonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation [abstract no: 105]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644323] ErisJ , RussG , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Conversion to sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation [abstract no: 1581]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00644325] FriendP , MotaA , KreisH , SegoloniG , LegendreC , PratsD , et al. Cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy is beneficial to patients regardless of baseline renal function [abstract no: 0553]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415680] FriendP , RussG , OberbauerR , MurgiaMG , TufvesonG , ChapmanJ , et al. Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function. Transplant International2007;20(9):754‐60. [MEDLINE: 17565578] GrinyoJM , VanrentergheimY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. Sirolimus (Rapamune) in patients receiving kidney from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 534]. American Journal of Transplantation2002;2(Suppl 3):272. [CENTRAL: CN‐00415776] GrinyoJM , VanrenterghemY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. The effects of sirolimus (Rapamune) in patients receiving kidneys from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 0435]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00420830] HartmannA , ColonJ , PenaJ , MartinezJ , WalkerR , ArnsW , et al. Favourable cardiovascular risk profile in renal transplant patients receiving sirolimus maintenance therapy following cyclosporine withdrawal: 3 year results of the Rapamune Maintenance Regimen trial [abstract no: W756]. Nephrology Dialysis Transplantation2003;18(Suppl 4):791‐2. [CENTRAL: CN‐00445657] HartmannA , MotaA , LegendreC , SegoloniG , GrinyoJM , HutchisonB , et al. Patients receiving sirolimus maintenance therapy have better renal function after early cyclosporine withdrawal irrespective of baseline renal function: intent‐to‐treat results at 3 years [abstract no: W743]. Nephrology Dialysis Transplantation2003;18(Suppl 4):787. [CENTRAL: CN‐00445658] HartmannA , OberbauerR , KreisH , JohnsonRW , MotaA , SchenaFP , et al. Long‐term results of cyclosporine elimination with sirolimus‐based therapy show improved renal function [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):19. [CENTRAL: CN‐00550651] HutchisonB , ClaessonK , MotaA , ErisJM , KreisH , OberbauerR , et al. Quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination: 2‐year results [abstract no: 499]. American Journal of Transplantation2002;2(Suppl 3):263. [CENTRAL: CN‐00415909] JohnsonR , OberbauerR , KreisH , BrattstromB , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation [abstract no: 0429]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00445947] JohnsonRW , KreisH , OberbauerR , BrattstromC , ClaessonK , ErisJ . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation2001;72(5):777‐86. [MEDLINE: 11571437] KeownP , ChenJ , KreisH , OberbauerR , ClaessonK , MotaA , et al. Improved quality of life after cyclosporine elimination in sirolimus‐treated renal transplant patients [abstract no: A4711]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):901A. [CENTRAL: CN‐00550607] KreisH , JohnsonR , MayerG , BrattstromC , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine‐free immunosuppression in renal transplantation resulting in lower blood pressure and improved renal function [abstract no: A3662]. Journal of the American Society of Nephrology2000;11(Sept):696A‐7A. [CENTRAL: CN‐00550424] KreisH , OberbauerR , CampistolJM , MathewT , DalozeP , SchenaFP , et al. Long‐term benefits with sirolimus‐based therapy after early cyclosporine withdrawal. Journal of the American Society of Nephrology2004;15(3):809‐17. [MEDLINE: 14978184] KreisH , OberbauerR , ClaessonK , MotaA , AriasM , DurandD , et al. Quality‐of‐life assessments in sirolimus‐treated renal transplant patients after cyclosporine elimination [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00446200] KreisH , OberbauerR , MotaA , ClaessonK , RiadH , CampistolJM , et al. Sirolimus‐based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a continuous combination of sirolimus and cyclosporine [abstract]. American Journal of Transplantation2003;3(Suppl 5):460. [CENTRAL: CN‐00446201] LegendreC , BraultY , MoralesJM , OberbauerR , AltieriP , RiadH , et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years. Clinical Transplantation2007;21(3):330‐6. [MEDLINE: 17488381] LegendreC , DalozeP , ColonJ , ChapmanJ , PenaJ , MartinezJ , et al. Sirolimus (Rapamune) used with or without cyclosporine for long term therapy: a comparison of cardiovascular risk factors. [abstract no: 1015]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00416111] LegendreC , MotaA , FriendP , SegoloniG , GrinyoJM , HutchisonB , et al. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 3 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):466. [CENTRAL: CN‐00446313] MathewT , KreisH , DoyenK . Malignancy in renal transplant recipients receiving sirolimus (rapamune) maintenance therapy: 2‐year follow up from 5 multicenter studies [abstract no: 58]. American Journal of Transplantation2002;2(Suppl 3):152. [CENTRAL: CN‐00416243] MathewT , KreisH , DoyenK . Two‐year incidence of malignancy in sirolimus (Rapamune)‐treated renal transplant recipients: follow‐up results from 5 multicenter studies [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416244] MathewT , KreisH , FriendP . Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation2004;18(4):446‐9. [MEDLINE: 15233824] MoralesJM , HartmannA , WalkerR , ArnsW , SenatorskiG , GrinyoJM , et al. Similar lipid profile but improved long‐term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplantation Proceedings2009;41(6):2339‐44. [MEDLINE: 19715914] MoralesJM , KreisH , OberbauerR , CampistolJM , MotaA , HenriquesAC , et al. 48‐month results of sirolimus‐based therapy following early cyclosporine withdrawal demonstrate superior renal allograft survival [abstract no: MO05]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:214. [CENTRAL: CN‐00509360] MoralesJM , OberbauerR , LegendreC , RuizJC , MotaA , ChapmanJ , et al. Analysis of risk factors for reduced renal function in renal transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal: 5‐year results from the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC156]. Journal of the American Society of Nephrology2005;16:72A. [CENTRAL: CN‐00644316] MotaA , AriasM , TaskinenEI , PaavonenT , BraultY , LegendreC , et al. Sirolimus‐based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. American Journal of Transplantation2004;4(6):953‐61. [MEDLINE: 15147430] MotaA , AriasM , TaskinenEI , PaavonenT , LegendreC , ClaessonK , et al. Sirolimus‐based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years following kidney transplantation [abstract no: 1486]. American Journal of Transplantation2004;4(Suppl 8):566. [CENTRAL: CN‐00509364] MotaA , SegoloniG , LegendreC , PratsD , HutchisonB , MoralesJM , et al. Patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy irrespective of baseline renal function [abstract no: 395]. American Journal of Transplantation2002;2(Suppl 3):237. [CENTRAL: CN‐00420843] OberbauerR , AriasM , ClaessonK , MotaA , ErisJM , HutchisonB , et al. Two‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 0257]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416378] OberbauerR , HutchisonB , ErisJ , AriasM , ClaessonK , MotaA , et al. Health‐related quality‐of‐life outcomes of sirolimus‐treated kidney transplant patients after elimination of cyclosporine A: results of a 2‐year randomized clinical trial. Transplantation2003;75(8):1277‐85. [MEDLINE: 12717216] OberbauerR , HutchisonB , ErisJ , AriasM , MotaA , the Rapamune Maintenance Regimen Study Group. Health‐related quality‐of‐life assessment in kidney transplant patients receiving sirolimus maintenance therapy with early elimination of cyclosporine: 3‐year results [abstract no: W758]. Nephrology Dialysis Transplantation2003;18(Suppl 4):243. [CENTRAL: CN‐00446999] OberbauerR , HutchisonB , ErisJ , RiadH , ClaessonK , LawenJ , et al. Three‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 249]. American Journal of Transplantation2003;3(Suppl 5):215. [CENTRAL: CN‐00447000] OberbauerR , KreisH , CampistolJM , MotaA , DalozeP , RuizJC , et al. Renal function improves significantly after early cyclosporine withdrawal in sirolimus‐treated renal transplant recipients: 3‐year results of the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC041]. Journal of the American Society of Nephrology2003;14(Nov):10A. [CENTRAL: CN‐00550606] OberbauerR , KreisH , JohnsonRW , MotaA , ClaessonK , RuizJC , et al. Long‐term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2‐year results of the Rapamune Maintenance Regimen Study. Transplantation2003;76(2):364‐70. [MEDLINE: 12883194] OberbauerR , KreisH , JohnsonRWG , MotaA , ClaessonK , AriasM , et al. Long‐term improvement in renal function is shown in patients treated with sirolimus (Rapamune) and cyclosporine withdrawal: 2‐year results of the Rapamune Maintenance Regimen trial [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416379] OberbauerR , MotaA , PratsD , MathewT , MoralesJM , DalozeP , et al. Renal transplant patients with risk factors for reduced renal function benefit from cyclosporine withdrawal and sirolimus maintenance therapy [abstract no: W742]. Nephrology Dialysis Transplantation2003;18(Suppl 4):786‐7. [CENTRAL: CN‐00447001] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation [abstract no: O80]. Transplantation2004;78(2 Suppl):30. [CENTRAL: CN‐00653813] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation.[erratum appears in Transpl Int. 2005 Mar;18(3):369]. Transplant International2005;18(1):22‐8. [MEDLINE: 15612979] PaczekL , MotaA , SchenaFP , JohnsonRW , PratsD , MathewT , et al. Renal function benefit from sirolimus maintenance therapy after early cyclosporine withdrawal in the presence of risk factors [abstract no: 180]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00447075] RuizJC , CampistolJM , GrinyoJM , MotaA , PratsD , GutierrezJA , et al. Early cyclosporine a withdrawal in kidney‐transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation2004;78(9):1312‐8. [MEDLINE: 15548969] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions [abstract no: SU‐FC0235]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):48A. [CENTRAL: CN‐00447509] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Proceedings2003;35(5):1669‐70. [MEDLINE: 12962750] RuizJC , CampistolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplantation Proceedings2007;39(7):2151‐2. [MEDLINE: 17889121] RuizJC , CampstolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. The early use of sirolimus with CsA elimination is not associated with progressive proteinuria [abstract no: P113]. Transplant International2007;20(Suppl 2):122. [CENTRAL: CN‐00740556] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Anaemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function [abstract no: 2504]. Nephrology2006;11(Suppl 2):A37. [CENTRAL: CN‐00644362] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus (SRL) maintenance therapy after early cyclosporine (CsA) withdrawal benefits renal transplant recipients with risk factors for reduced renal function: 5‐year results [abstract no: 103]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:90. [CENTRAL: CN‐00644320] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus‐based therapy following early cyclosporine withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract no: P150]. Nephrology2004;9(Suppl 1):A38. [CENTRAL: CN‐00509449] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 159]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN‐00644317] RussG , JamiesonN , OberbauerR , AriasM , MurgiaMG , BlanchoG , et al. Three‐year health‐related quality‐of‐life outcomes for sirolimus‐treated kidney transplant patients after elimination of cyclosporine. Transplant International2007;20(10):875‐83. [MEDLINE: 17854445] RussG , OberbauerR , FriendP , CampistolJM , BurkeJT . The impact of renal function on the incidence of anemia in sirolimus‐treated renal transplant recipients [abstract no: TH‐PO563]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. [CENTRAL: CN‐00615898] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Long‐term impact of baseline renal function in kidney transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal [abstract no: FC‐50004]. Nephrology2005;10(Suppl 1):A2. [CENTRAL: CN‐00644319] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 1009]. American Journal of Transplantation2005;5(Suppl 11):413. RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation2005;80(9):1204‐11. [MEDLINE: 16314787] SchenaFP , JamiesonN , ColonJ , ShokerA , PenaJ , MartinezM , et al. Favorable cardiovascular risk profile when sirolimus is used without cyclosporine compared to combination therapy: 3‐year results of the Rapamune Maintenance Regimen trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):479. [CENTRAL: CN‐00447616] VanrenterghemY , KreisH , OberbauerR , MotaA , JohnsonWG , Sirolimus Tri‐contienental Renal Transplant Study Group. Improved renal function in renal allograft recipients with sirolimus (Rapamune) maintenance therapy and early cyclosporine withdrawal: 12‐month results [abstract]. Nephrology Dialysis Transplantation2001;16(6):A209. [CENTRAL: CN‐00448163] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] WalkerR , RussG , ErisJ , HutchinsonB , ChapmanJ , PussellB , et al. Treatment of hyperlipidemia in sirolimus (SRL)‐treated renal transplant recipients: long‐term findings from the Rapamune Maintenance Regimen (RMR) Trial [abstract no 27]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:49. [CENTRAL: CN‐00644318] ">RMR Study 2001</a>; <a href="./references#CD006750-bbs2-0068" title="RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Comparison of reduced‐and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra, ACT. 2003:64. [CENTRAL: CN‐00447521] RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. The safety and efficacy of reduced‐ and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results from Australia [abstract no: SA‐PO496]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):364A. [CENTRAL: CN‐00447522] RussGR , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplantation Proceedings2003;35(3 Suppl):115S‐7S. [MEDLINE: 12742480] WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Russ 2003</a>; <a href="./references#CD006750-bbs2-0069" title="SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]. Transplant International2007;20(Suppl 2):20. SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]. Transplantation2008;86(2 Suppl):39. [CENTRAL: CN‐00679020] ">Salvadori 2007</a>; <a href="./references#CD006750-bbs2-0071" title="RoodnatJ , HilbrandsLB , HeneRJ , deSevauxRG , GregoorPJ , Kal‐van GestelJA , et al. 15 year follow‐up of a multicentre, randomised, calcineurin inhibitor (CNI) withdrawal study in kidney transplantation [abstract no: BO156]. Transplant International2013;26(Suppl 2):83‐4. [EMBASE: 71359271] RoodnatJI , HilbrandsLB , HeneRJ , deSevauxRG , Smak GregoorPJ , Kal‐van GestelJA , et al. 15‐year follow‐up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation2014;98(1):47‐53. [MEDLINE: 24521775] Smak GregoorPJ , deSevauxRG , HeneRJ , HesseCJ , HilbrandsLB , VosP , et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation1999;68(10):1603‐6. [MEDLINE: 10589962] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow‐up data [abstract no: 441]. American Journal of Transplantation2001;1(Suppl 1):246. [CENTRAL: CN‐00763745] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Journal of the American Society of Nephrology2002;13(5):1365‐73. [MEDLINE: 11961025] Smak GregoorPJ , vanGelderT , IJzermansJN , WeimarW . Long‐term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00447777] VanGelderT , deSevauxR , HeneR , WeimarW , HoitsmaA , LigtenbergG , et al. Discontinuation of cyclosporine or prednisone 6 months after kidney transplantation: a randomized trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):920A. [CENTRAL: CN‐00583812] deSevauxRG , GregoorP , SmakJH , HeneRJ , WeimarW , HoitsmaAJ , et al. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomized study [abstract no: 935]. Transplantation1999;67(7):S240. [CENTRAL: CN‐00767038] ">Smak Gregoor 1999</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0074" title="StalloneG , DiPaolaS , SchenaA , InfanteB , GrandalianoG , BattagliaM , et al. Early withdrawal of cyclosporine A improves 1‐year kidney graft structure and function in sirolimus‐treated patients. Transplantation2003;75(7):998‐1003. [MEDLINE: 12698087] StalloneG , SchenaA , InfanteB , GrandalianoG , GesualdoL , SchenaPF , et al. Early withdrawal of cyclosporine (CSA) ameliorates 1‐year kidney graft function and structure in sirolimus (SRL)‐treated patients. [abstract no: 1014]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00527169] ">Stallone 2003</a>; <a href="./references#CD006750-bbs2-0075" title="StalloneG , DiPaoloS , SchenaA , InfanteB , BattagliaM , DitonnoP , et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1‐year graft function. Journal of the American Society of Nephrology2004;15(1):228‐33. [MEDLINE: 14694177] StalloneG , InfanteB , SchenaA , DiPaoloS , GesualdoL , DitonnoP , et al. Sirolimus prolongs delayed graft function in recipients of sub‐optimal cadaveric kidney donors [abstract]. American Journal of Transplantation2003;3(Suppl 5):563. [CENTRAL: CN‐00447829] ">Stallone 2004</a>; <a href="./references#CD006750-bbs2-0062" title="PontrelliP , RossiniM , InfanteB , StalloneG , SchenaA , LoverreA , et al. Rapamycin inhibits PAI‐1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation2008;85(1):125‐34. [MEDLINE: 18192922] RossiniM , PontrelliP , StalloneG , InfanteB , SchenaA , LoverreA , et al. Regression of glomerulosclerosis in chronic allograft nephropathy (CAN) following calcineurin inhibitors (CNI) withdrawal and conversion to sirolimus (SRL) [abstract no: TH‐PO554]. Journal of the American Society of Nephrology2006;17(Abstracts):225A. [CENTRAL: CN‐00725009] StalloneG , PontrelliP , InfanteB , SchenaA , UrsiM , RanieriE , et al. Rapamycin (RAPA) inhibits PAI‐1 expression and reduce interstitial fibrosis in chronic allograft nephropathy (CAN) [abstract no: SO04]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v4. [CENTRAL: CN‐00716118] ">Pontrelli 2008</a>; <a href="./references#CD006750-bbs2-0077" title="HillebrandU , SuwelackB , GerhardtU , KobeltV , KraemerJ , HohageH . Impact of calcineurin inhibitor withdrawal and mycophenolate mofetil substitution on hematologic toxicity [abstract no: 0014]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415864] SuwelackB , DietKH , KobeltV , HohageH , GerhardtU . Impact of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in chronic allograft nephropathy [abstract no: 1048]. American Journal of Transplantation2002;2(Suppl 3):402. [CENTRAL: CN‐00416722] SuwelackB , GerhardtU , HohageH . Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. American Journal of Transplantation2004;4(4):655‐62. [MEDLINE: 15023160] SuwelackB , GerhardtU , KobeltV , HillebrandU , MatzkiesF , HohageH . Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels. Transplantation Proceedings2002;34(5):1803‐5. [MEDLINE: 12176583] SuwelackB , HausbergM , HillebrandU , RahnKH , HohageH . Study on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients [abstract no: 0637]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416723] SuwelackB , KobeltV , GerhardtU , VolmerS , HohageH . Course of intima thickness in long term renal transplant recipients treated with or without calcineurin‐inhibitors [abstract no: P04.21]. Kidney &amp; Blood Pressure Research2004;27(5‐6):335. [CENTRAL: CN‐00615862] SuwelackB , KobeltV , HillebrandU , GerhardtU , MatzkiesF , HohageH . Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. Transplantation Proceedings2002;34(5):1808‐9. [MEDLINE: 12176585] SuwelackB , KobeltV , HohageH , GerhardtU . Studies on effects of calcineurin‐inhibitor withdrawal on arterial wall structure and intima media thickness in longterm transplant recipients [abstract no: P290]. Transplantation2004;78(2 Suppl):295. [CENTRAL: CN‐00509495] SuwelackB , MalyarV , WaldschmidtG , HohageH . 5 year follow‐up of a randomized study on calcineurin‐inhibitor‐withdrawal with addition of MMF in chronic allograft nephropathy [abstract no: F‐PO600]. Journal of the American Society of Nephrology2007;18(Abstracts):231A. SuwelackBM , GerhardtUW , HohageH . Influence of calcineurin‐inhibitor free immunosuppression on carotid intima media thickness in chronic allograft nephropathy [abstract no: 659]. American Journal of Transplantation2003;3(Suppl 5):320. [CENTRAL: CN‐00447914] ">Suwelack 2002</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). </p> <p>Eight studies were judged to be at high risk of reporting bias. Three studies did not report all possible outcomes due to early termination (<a href="./references#CD006750-bbs2-0027" title="FormicaR , NickersonP , PoggioE , TinckamK , RushD , GibsonI , et al. Immune monitoring and tacrolimus (TAC) withdrawal in low risk recipients of kidney transplants‐results of CTOT09 [abstract]. Transplantation2014;98(Suppl 1):225. [EMBASE: 71544207] HricikDE , FormicaRN , NickersonP , RushD , FairchildRL , PoggioED , et al. Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients. Journal of the American Society of Nephrology2015;26(12):3114‐22. [MEDLINE: 25925687] NickersonP , WiebeC , FormicaR , TinckamK , PoggioE , BunnapradistS , et al. Epitope mismatch predicts de novo DSA after CNI withdrawal in low‐risk kidney transplant recipients [abstract]. Transplantation2014;98(Suppl 1):137. [EMBASE: 71543963] ">CTOT‐09 Study 2015</a>; <a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0056" title="FlechnerS , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)+ mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year safety results from the Orion Trial [abstract no: 444]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no: 1141]. American Journal of Transplantation2007;7(Suppl 2):440. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no: 52]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653711] FlechnerS , GlydaM , SteinbergS , HarlerMB , ORION Trial Investigators. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from The ORION Study [abstract no: P477]. Transplant International2007;20(Suppl 2):209. FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year efficacy results from the ORION trial [abstract no: 287]. American Journal of Transplantation2008;8(Suppl 2):254. [CENTRAL: CN‐00653710] FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. Preliminary two‐year efficacy results from a randomized, open‐label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + mycophenolate regimen (MMF) in de novo renal allograft recipients [abstract no: 531]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740478] FlechnerSM , GlydaM , CockfieldS , GrinyoJ , LegendreC , RussG , et al. The ORION Study: comparison of two sirolimus‐based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.[Erratum appears in Am J Transplant. 2012 Jan;12(1):268]. American Journal of Transplantation2011;11(8):1633‐44. [MEDLINE: 21668635] FlechnerSM , GlydaM , See TaiS , ORION Trial Investigators. Delayed graft function (DGF) in two sirolimus (SRL)‐based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients [abstract no: 299]. American Journal of Transplantation2009;9(Suppl 2):277. [CENTRAL: CN‐00774294] FlechnerSM , GlydaM , SteinbergS , CopleyJB , ORION Trial Investigators. The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: interim results from the Orion Study [abstract no: SU‐FC124]. Journal of the American Society of Nephrology2007;18(Abstracts):95A. [CENTRAL: CN‐00716077] RussG , FlechnerSM , CockfieldS , GrinyoJ , WissingKM , LegendreC , et al. Cardiovascular risk profile of renal transplant recipients enrolled in an open‐label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC)+ mycophenolate regimen (MMF): preliminary results from the Orion Trial [abstract no: 445]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] ">ORION Study 2011</a>). <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a> and <a href="./references#CD006750-bbs2-0018" title="HertigA , KamarN , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract]. Transplantation2014;98:81. [EMBASE: 71543793] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , Hurault De LignyB , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: O5]. Transplant International2013;26(Suppl 3):2. [EMBASE: 71356080] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , LignyBH , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: P081]. Transplant International2013;26(Suppl 2):201. [EMBASE: 71359712] RostaingL , HertigA , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Fibrosis progression according to epithelial‐mesenchymal transition profile: a randomized trial of everolimus versus CsA. American Journal of Transplantation2015;15(5):1303‐12. [MEDLINE: 25808994] ">CERTITEM Study 2015</a> did not report all prespecified outcomes. Full‐text publications had not been identified for three studies 10 years after the abstracts were first published (<a href="./references#CD006750-bbs2-0043" title="HolmA , HernandezM , CamarenaA , PerezL , SantosM , PorrasMA . Efficacy, tolerability and safety of mycophenolate mofetil (Cellcept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD, adults and pediatric renal transplant recipients (experience with 405 patients) [abstract no: 627]. Transplantation2008;86(Suppl 2):220. [CENTRAL: CN‐00740576] ">Holm 2008</a>; <a href="./references#CD006750-bbs2-0067" title="RossiniM , LoverreA , StalloneG , InfanteB , SchenaA , MaioranoA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 1149]. American Journal of Transplantation2007;7(Suppl 2):442. [CENTRAL: CN‐00725010] RossiniM , StalloneG , InfanteB , CapobiancoC , LoverreA , SchenaA , et al. Proteinuria and vascular endothelial growth factor (VEGF) expression following calcineurin inhibitors (CNI) withdrawal and conversion to rapamycin [abstract no: 548]. Transplant International2007;20(Suppl 2):226. ">Rossini 2007</a>; <a href="./references#CD006750-bbs2-0069" title="SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate (MPS) and basiliximab in combination with reduced or standard cyclosporine (CsA) in old recipients of kidney transplant (KTx) [abstract no: O069]. Transplant International2007;20(Suppl 2):20. SalvadoriM , ScolariMP , StefoniS , BertoniE , SandriniS , RigottiP , et al. Randomized trial of sodium mycophenolate and basiliximab in combination with reduced or standard cyclosporine exposure in old recipients of kidney transplants from deceased donors [abstract no: 108]. Transplantation2008;86(2 Suppl):39. [CENTRAL: CN‐00679020] ">Salvadori 2007</a>). </p> <p>Twenty four studies had insufficient information to ascertain reporting bias.</p> </section> <section id="CD006750-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>Of the 83 included studies, 49 received pharmaceutical industry funding, which is a potential source for bias (<a href="./references#CD006750-bbs2-0001" title="AbramowiczD , DelCarmen RialM , VitkoS , delCastilloD , ManasD , LaoM , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen: results of a five‐year, prospective, randomized study. Journal of the American Society of Nephrology2005;16(7):2234‐40. [MEDLINE: 15917338] AbramowiczD , ManasD , LaoM , VanrenterghemY , DelCastilloD , WijngaardP , et al. Cyclosporine withdrawal from a mycophenolate mofetil‐containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation2002;74(12):1725‐34. [MEDLINE: 12499889] delCastilloD , AbramowiczD , ManasD , LaoM , VanrenterghemY , BarkerD , et al. Benefits of cyclosporine (CsA) withdrawal in stable renal transplant recipients, receiving mycophenolate mofetil (MMF) and steroids (S): a multicenter, randomised, controlled study [abstract no: A3674]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):726A. [CENTRAL: CN‐00550730] ">Abramowicz 2002</a>; <a href="./references#CD006750-bbs2-0003" title="AndresA , MarcenR , SanchezJ , ValdesF , ErrastiP , SolaR , et al. Comparative study of three different patterns of immunosuppression based on induction with basiliximab and low initial doses or delayed initiation of neoral in kidney transplant recipients at high risk of delayed graft function [abstract no: 1629]. American Journal of Transplantation2005;5(Suppl 11):570. [CENTRAL: CN‐00644164] AndresA , MarcenR , ValdesF , PlumedJS , SolaR , ErrastiP , et al. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clinical Transplantation2009;23(1):23‐32. [MEDLINE: 18798851] MarcenR , AndresA , Sanchez‐PlumedJ , ValdesF , ErrastiP , SolaR , et al. A randomized study to compare immunosuppression based on basiliximab induction and low initial doses or delayed neoral in kidney transplant recipients at high risk for delayed graft function [abstract no: PO‐266]. Transplant International2005;18(Suppl 1):114. ">Andres 2009</a>; <a href="./references#CD006750-bbs2-0004" title="ArnsW , RathT , SommererC , ReinkeP , HallerH , SuwelackB , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation2014;98(Suppl 1):145. [EMBASE: 71543988] BuddeK , RathT , SommererC , HallerH , ReinkeP , WitzkeO , et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology2015;83(1):11‐21. [MEDLINE: 25512099] BuddeK , SommererC , HallerH , SuwelackB , MayC , PaulusE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 928]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746881] BuddeK , SommererC , RathT , ReinkeP , HallerH , WitzkeO , et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology2015;28(1):115‐23. [MEDLINE: 25192833] BuddeK , SommererC , ReinkeP , HallerH , ArnsW , WitzkeO , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 4 year data of the APOLLO Trial [abstract no: B396]. American Journal of Transplantation2013;13(Suppl S5):311‐2. [EMBASE: 71057512] BuddeK , ZeierM , HallerH , ArnsW , KramerS , VogelEM , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: 1639]. American Journal of Transplantation2010;10(Suppl 4):504. [EMBASE: 70465014] HallerH , RathT , ZeierM , ArnsW , KramerS , VogelE , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: Sa645]. NDT Plus2010;3(Suppl 3):iii259. [EMBASE: 70484111] RathT , BuddeK , SommererC , HallerH , SuwelackB , MayC , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 3 year data of the APOLLO trial [abstract no: 1684]. Transplantation2012;94:994. [EMBASE: 71251767] RathT , SommererC , SuwelackB , ArnsW , HallerH , ReinkeP , et al. Outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 5 year data of the APOLLO trial [abstract]. Transplantation International2014;98:50. [EMBASE: 71664130] ReinkeP , HallerH , RathT , ArnsW , PaulusE , ScheidfS , et al. Two year data of the APOLLO trial: Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: P141]. Transplant International2011;24:50. [EMBASE: 70537441] RhatT , SommererC , HallerH , ReinkeP , WitzkeO , SuwelackB , et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years APOLLO trial [abstract no: P271]. Transplant International2013;26(Suppl 2):240. [EMBASE: 71359891] SommererC , RathT , BuddeK , HallerH , ArnsW , ScheidlS , et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 year follow‐up data of the APOLLO trial [abstract no: RO‐185]. Transplant International2011;24(Suppl 2):180. [EMBASE: 70527714] SommererC , RathT , HallerH , ArnsW , SuwelackB , ReinkeP , et al. 4 year data of the APOLLO trial: outcome on renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients [abstract no: V79]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356263] ">APOLLO Study 2015</a>; <a href="./references#CD006750-bbs2-0005" title="AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR‐matched de novo kidney transplant recipients. Transplantation2006;82(1):62‐8. [MEDLINE: 16861943] AsbergA , MidtvedtK , LinePD , NarverudJ , HoldaasH , JenssenT , et al. Calcineurin inhibitor‐avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients [abstract no: SP737]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv264. AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clinical Transplantation2009;23(4):511‐8. [MEDLINE: 19210527] AsbergA , MidtvedtK , VoytovichMH , LinePD , NarverudJ , ReisaeterAV , et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation [abstract no: 529]. American Journal of Transplantation2008;8(Suppl 2):319. ">Asberg 2006</a>; <a href="./references#CD006750-bbs2-0006" title="HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagarajanCM , FassettR , et al. Everolimus in maintenance renal transplant recipients: the ASCERTAIN Study [abstract no: P‐309]. Transplant International2009;22(Suppl 2):172. HoldaasH , MidtvedtK , SeronD , O'ConnellP , ThiagrajanC , FassettR , et al. Assessment of everolimus in maintenance renal transplant recipients: the Ascertain Study [abstract no: 1646]. Transplantation2008;86(Suppl 2):546. [CENTRAL: CN‐00740482] HoldaasH , RostaingL , MidtvedtK , SeronD , ColeE , ChapmanJ , FellstromB , et al. Conversion of long‐term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24‐month study.[Erratum appears in Transplantation. 2011 Nov 27;92(10):e61 Note: multiple investigator names added.]. Transplantation2011;92(4):410‐8. [MEDLINE: 21697773] O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Long‐term post transplantation switch to an everolimus‐based therapy with CNI elimination/minimization does not overall impact graft function: the ASCERTAIN study [abstract no: 8]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:42. O'ConnellP , FassettR , PilmoreH , ChapmanJ , HutchisonB , RussG , et al. Post‐hoc analysis of the ASCERTAIN trial: everolimus based therapy with CNI elimination improves renal function in select populations [abstract no: 7]. Transplantation Society of Australia &amp; New Zealand (TSANZ).29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:41. ">ASCERTAIN Study 2011</a>; <a href="./references#CD006750-bbs2-0008" title="BansalD , YadavAK , KumarV , MinzM , SakhujaV , JhaV . Deferred pre‐emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of t‐regulatory cell population: a randomized, controlled trial. PLoS ONE [Electronic Resource]2013;8(10):e75591. [MEDLINE: 24146762] ">Bansal 2013</a>; <a href="./references#CD006750-bbs2-0010" title="BechsteinW , PaczekL . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. American Journal of Transplantation2002;2(Suppl 3):471. [CENTRAL: CN‐00415252] BechsteinWO , PaczekL , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus + steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00444369] BechsteinWO , PaczekL , WramnerL , SquiffletJP , ZygmuntAJ , European Rapamune Tacrolimus Study Group. A comparative, randomized trial of concentration‐controlled sirolimus combined with reduced‐dose tacrolimus or standard‐dose tacrolimus in renal allograft recipients. Transplantation Proceedings2013;45(6):2133‐40. [MEDLINE: 23953523] PaczekL , BechsteinW , WramnerL , SquiffletJP . A phase II, open‐label, concentration‐controlled, randomized 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. PaczekL , BechsteinWO , WramnerL , SquiffletJP , European Sirolimus‐Tacrolimus Study Group. An open‐label, concentration‐controlled, randomised 6‐month study of standard‐dose tacrolimus + sirolimus +steroids compared to reduced‐dose tacrolimus + sirolimus + steroids in renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Bechstein‐193 2013</a>; <a href="./references#CD006750-bbs2-0013" title="BuddeK , BosmansJ , ZeierM , SennesaelJ , HoptU , FischerWH , et al. Safety and efficacy of reduced or full dose of cyclosporine (neoral®) in combination with mycophenolate sodium (Myfortic®), basiliximab (Simulect®), and steroids in de novo kidney transplant recipients [abstract]. Transplantation2004;78(2 Suppl):83. [CENTRAL: CN‐00527096] BuddeK , BosmansJL , SennesaelJ , ZeierM , HoptU , FischerW , et al. Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric‐coated mycophenolate‐sodium, and steroids [abstract no: 1195]. American Journal of Transplantation2005;5(Suppl 11):461. [CENTRAL: CN‐00644165] BuddeK , BosmansJL , SennesaelJ , ZeierM , PisarskiP , SchutzM , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab. Clinical Nephrology2007;67(3):164‐75. [MEDLINE: 17390741] BuddeK , ZeierM , BosmansJL , SennesaelJ , GlanderP , FischerW , et al. Reduced‐exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric‐coated mycophenolic acid and basiliximab [abstract no: F‐PO1088]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00644166] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Budde 2007</a>; <a href="./references#CD006750-bbs2-0014" title="EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CAESAR Study Group. Low‐dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]. 3rd International Congress on Immunosuppression; 2004 Dec 8‐11; San Diego (CA). 2004. [CENTRAL: CN‐00550672] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , CallejaE , et al. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]. Transplantation2004;78(2 Suppl):458. [CENTRAL: CN‐00509171] EkbergH , GrinyoJ , NashanB , VanrenterghemY , VincentiF , VoulgariA , et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. American Journal of Transplantation2007;7(3):560‐70. [MEDLINE: 17229079] GrinyoJ , VanrenterghemY , NashanB , VincentiF , EkbergH , SpleissO , et al. Association of three polymorphisms with acute rejection after kidney transplantation: an exploratory pharmacogenetic analysis of a randomized multicenter clinical trial (the CAESAR study) [abstract no: 1020]. American Journal of Transplantation2006;6(Suppl 2):410. [CENTRAL: CN‐00678972] KuypersDR , EkbergH , GrinyoJ , NashanB , VincentiF , SnellP , et al. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clinical Pharmacokinetics2009;48(5):329‐41. [MEDLINE: 19566116] VincentiF , VanrenterghemY , NashanB , GrinyoJ , EkbergH , Nasmyth‐MillerC , et al. The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose/withdrawal and standard dose) to optimize renal function in renal allograft recipients ‐ 18 month results [abstract no: 1507]. American Journal of Transplantation2005;5(Suppl 11):539. [CENTRAL: CN‐00644286] ">CAESAR Study 2007</a>; <a href="./references#CD006750-bbs2-0015" title="CaiL , ZengF , LiuB , WeiL , ChenZ , JiangJ . A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients. International Journal of Clinical Practice. Supplement2014;68(181):23‐30. [MEDLINE: 24673716] ">Cai 2014</a>; <a href="./references#CD006750-bbs2-0016" title="FranzS , RegeniterA , HopferH , MihatschM , DickenmannM . Tubular toxicity in sirolimus‐ and cyclosporine‐based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. American Journal of Kidney Diseases2010;55(2):335‐43. [MEDLINE: 19926370] GianniniO , DickenmannM , KimMJ , FranzS , MayrM , MihatschMJ , et al. The CALFREE Study ‐ an open, prospective, randomized single center study to investigate calcineurin free immunosuppression in 100 de novo, normal risk renal transplant recipients: preliminary results [abstract no: P04.02]. Kidney &amp; Blood Pressure Research2004;27(5‐6):329. [CENTRAL: CN‐00615861] ">CALFREE Study 2010</a>; <a href="./references#CD006750-bbs2-0017" title="MjornstedtL , Schwartz SorensenS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant International2015;28(1):42‐51. [MEDLINE: 25176389] MjornstedtL , SorensenSS , vonZur MuhlenB , JespersenB , HansenJM , BistrupC , et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. American Journal of Transplantation2012;12(10):2744‐53. [MEDLINE: 22812414] MurbraechK , HoldaasH , MasseyR , UndsetLH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: An echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation2014;97(2):184‐7. [MEDLINE: 24092385] MurbraechK , MasseyR , UndsetLH , MidtvedtK , HoldaasH , AakhusS . Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients ‐ a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Clinical Transplantation2015;29(8):678‐84. [MEDLINE: 25982053] ">CENTRAL Study 2012</a>; <a href="./references#CD006750-bbs2-0018" title="HertigA , KamarN , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract]. Transplantation2014;98:81. [EMBASE: 71543793] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , Hurault De LignyB , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: O5]. Transplant International2013;26(Suppl 3):2. [EMBASE: 71356080] HertigA , KamarN , AnglicheauD , MoulinB , HazzanM , LignyBH , et al. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM trial [abstract no: P081]. Transplant International2013;26(Suppl 2):201. [EMBASE: 71359712] RostaingL , HertigA , AlbanoL , AnglicheauD , DurrbachA , VuibletV , et al. Fibrosis progression according to epithelial‐mesenchymal transition profile: a randomized trial of everolimus versus CsA. American Journal of Transplantation2015;15(5):1303‐12. [MEDLINE: 25808994] ">CERTITEM Study 2015</a>; <a href="./references#CD006750-bbs2-0019" title="ChadbanS , CampbellS , RussG , WalkerR , ChapmanJ , PussellB , et al. A one‐year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric‐coated mycophenolate sodium (EC‐MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA‐ME), basiliximab and steroids in de novo kidney transplantation [abstract no: 32]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:51. [CENTRAL: CN‐00583470] ChadbanS , ErisJ , RussG , CampbellS , ChapmanJ , PussellB , et al. Enteric‐coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology2013;18(1):63‐70. [MEDLINE: 23110508] ">Chadban 2013</a>; <a href="./references#CD006750-bbs2-0020" title="ChanL , GreensteinS , HardyMA , HartmannE , BunnapradistS , CibrikD , et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation2008;85(6):821‐6. [MEDLINE: 18360262] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA‐PO2529]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):678A. [CENTRAL: CN‐00716072] ChanL , HartmannE , CibrikD , CooperM , ShawLM . Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation2010;90(1):31‐7. [MEDLINE: 20517177] ">Chan 2008</a>; <a href="./references#CD006750-bbs2-0021" title="AsderakisA , ChanL . Renal function with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month study in de novo renal transplant recipients [abstract no: O111]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ChanL , AndresA , BunnapradistS , GugliuzzaK , ParasuramanR , PeddiVR , et al. Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC‐MPS. Journal of Transplantation2012;2012:941640. [MEDLINE: 23227307] ChanL , HartM , AndresA , GugliuzzaK , BunnapradistS , ParasumaranR . Renal function and incidence of NODM with enteric‐coated mycophenolate sodium in combination with reduced and standard tacrolimus levels: results of a 6‐month comparative study in de novo renal transplant recipients [abstract no: 718]. Transplantation2008;86(2S):251. NicholsonML , ChanL . Incidence of new onset diabetes mellitus in de novo renal transplant recipients treated with enteric‐coated mycophenolate sodium in combination with reduced or standard tacrolimus target levels: results of a 6‐month randomized study [abstract no: P266]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ">Chan 2012</a>; <a href="./references#CD006750-bbs2-0022" title="AlvaradoA , ChhabraD , WangE , NajafianN , FriedewaldJ , HoB , et al. Prospective randomized study to evaluate the feasability of CNI elimination with conversion to sirolimus in prednisone‐free immunosuppressive regimen [abstract no: 53]. American Journal of Transplantation2012;12(Suppl S3):42. [EMBASE: 70746000] AlvaradoA , ShettyA , TraitanonO , LeventhalJ , MasV , ChhabraD , et al. Calcineurin‐inhibitor conversion to mTOR inhibitor in renal transplant recipients leads to worse long term clinical outcomes [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953109] ChhabraD , AlvaradoA , DalalP , LeventhalJ , WangC , Sustento‐ReodicaN , et al. Impact of calcineurin‐inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone‐free regimen. American Journal of Transplantation2013;13(11):2902‐11. [MEDLINE: 24007570] GallonL , TraitanonO , Sustento‐ReodicaN , LeventhalJ , AnsariMJ , GehrauRC , et al. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney International2014;87(4):828‐38. [MEDLINE: 25354238] ShahG , XuL , DalalP , ChhabranD , FriedewaldJ , HoB , et al. Conversion from CNI to SRL in a pred‐free immunosuppressive regimen: interim report of a prospective randomized study [abstract no: 1641]. American Journal of Transplantation2010;10(Suppl 4):504. ">Chhabra 2013</a>; <a href="./references#CD006750-bbs2-0023" title="BresnahanB , CibrikD , JensikS , WhelchelJ , KlintmalmG , CohenD , et al. Treatment of high‐risk renal transplant recipients with EC‐MPS (Myfortic®) is safe and efficacious [abstract no: PUB216]. Journal of the American Society of Nephrology2005;16:829A. [CENTRAL: CN‐00644277] BuddeK , ZeierM , CohenD , KirchherrB , MyProms Study Group. How much exposure is needed in the first week in patients receiving induction with basiliximab and enteric coated mycophenolate sodium? [abstract no: 1206]. American Journal of Transplantation2005;5(Suppl 11):464. [CENTRAL: CN‐00602063] CibrikD , JensikS , BresnahanB , WhelchelJ , KlintmalmG , ERL2405‐US01 Study Group. Safety and efficacy of EC‐MPS in combination with simulect and neoral in de novo renal transplant high‐risk recipients [abstract no: 135]. American Journal of Transplantation2005;5(Suppl 11):190. [CENTRAL: CN‐00644170] CibrikD , JensikS , Meier‐KriescheH , BresnahanB , LiebermanB , Myfortic US01 Renal Transplant Group. Enteric‐coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no: 220]. American Journal of Transplantation2004;4(Suppl 8):218. [CENTRAL: CN‐00644278] CibrikD , Meier‐KriescheHU , BresnahanB , WuYM , KlintmalmG , KewCE , et al. Renal function with cyclosporine C2 monitoring, enteric‐coated mycophenolate sodium and basiliximab: a 12‐month randomized trial in renal transplant recipients. Clinical Transplantation2007;21(2):192‐201. [MEDLINE: 17425744] LegendreC , CohenD , ZeierM , RostaingL , BuddeK . Efficacy and safety of enteric‐coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12‐month multicenter, open‐label, prospective studies. Transplantation Proceedings2007;39(5):1386‐91. [MEDLINE: 17580145] LegendreCH , RostaingL , KirchherrB , MyProms Study Group. Tolerability of enteric coated mycophenolate sodium (EC‐MPS) in combination with neoral and steroids in de novo kidney transplant recipients: a 12 months prospective trial [abstract no: 1209]. American Journal of Transplantation2005;5(Suppl 11):464‐5. [CENTRAL: CN‐00602066] Meier‐KriescheH , CibrikD , BresnahanB , CohenD , LiebermanB . Optimized Neoral C2 monitoring in combination with enteric‐coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12‐month results of a multicenter, randomized, prospective trial [abstract no: F‐PO1068]. Journal of the American Society of Nephrology2004;15(Oct):299A. [CENTRAL: CN‐00583408] PietruckF , BuddeK , SalvadoriM , SollingerH , BourbigotB , GentilMA , et al. Efficacy and safety of enteric‐coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clinical Transplantation2007;21(1):117‐25. [MEDLINE: 17302600] RostaingL , LegendreCH , CohenD , BuddeK , ZeierM , KirchherrB , et al. Safety and tolerability of enteric coated mycophenolate sodium in combination with neoral and steroids in de novo kidney transplant recipients: 12 months analysis of a prospective trial [abstract no: T‐PO50030]. Nephrology2005;10(Suppl 1):A215. [CENTRAL: CN‐00644301] ">Cibrik 2007</a>; <a href="./references#CD006750-bbs2-0025" title='ChunDX , AlexandreH , SandrineGS , OlivierT , IsabelleE , ChristopheL , et al. The phenotype of tubular epithelial cells does not recover after a conversion from cyclosporine A to siroliumus [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii517. [EMBASE: 70766851] JoannidesR , MonteilC , DeLignyBH , WesteelPF , IacobM , ThervetE , et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. American Journal of Transplantation2011;11(11):2414‐22. [MEDLINE: 21929645] LebranchuY , EtienneI , TouchardG , ThervetE , WestellP , ToupanceO , et al. Comparison of efficacy and safety of cyclosporine (CsA) discontinuation with introduction of sirolimus (SRL) at week 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF) [abstract no: 53]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00724873] LebranchuY , ThierryA , ThervetE , BuchlerM , EtienneI , WesteelPF , et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF‐four‐year results of the Postconcept study. American Journal of Transplantation2011;11(8):1665‐75. [MEDLINE: 21797975] LebranchuY , ThierryA , ToupanceO , WesteelPF , EtienneI , ThervetE , et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. American Journal of Transplantation2009;9(5):1115‐23. [MEDLINE: 19422337] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30 months follow up of a multicenter randomized controlled trial: The CONCEPT Study [abstract no: Sa706]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00765353] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , MazouzH , et al. Impact on renal function of early conversion at 3 months from cyclosporine (CsA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) in kidney transplantation: 30‐months follow up of a multicenter randomized controlled trial: the Concept Study [abstract no: 241]. American Journal of Transplantation2009;9(Suppl 2):260. [EMBASE: 70010114] LebranchuY , ToupanceO , TouchardG , ThervetE , EtienneI , WesteelPF , et al. Impact of early conversion at 3 months from cyclosporine (CSA) to sirolimus (SRL) in association with mycophenolate mofetil (MMF) on renal function ‐ "results at 48 months of follow up of a multicenter randomized controlled trial: The Concept Study" [abstract no: 376]. American Journal of Transplantation2010;10(Suppl 4):151. [EMBASE: 70463737] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , LegendreC , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: 527]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00716068] ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , WesteelPF , et al. Comparison of interstitial fibrosis (IF) by automatic quantification at one year in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction [abstract no: TH‐FC040]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716074] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , ThierryA , MoulinB , et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. American Journal of Transplantation2009;9(11):2552‐60. [MEDLINE: 19843033] ServaisA , Meas‐YedidV , ToupanceO , LebranchuY , TouchardG , WesteelPF , et al. Impact of interstitial fibrosis (IF) by automatic quantification at one year on the evolution of renal function in transplant recipients with cyclosporine discontinuation and sirolimus introduction [abstract no: 1103]. American Journal of Transplantation2009;9(Suppl 2):502. [CENTRAL: CN‐00775138] ThervetE , ServaisA , Meas‐YedidV , LebranchuY , EtienneI , TouchardG , et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients (RTR) with cyclosporine (CSA) discontinuation and sirolimus (SRL) introduction [abstract no: 450]. Transplantation2008;86(Suppl 2):159. [CENTRAL: CN‐00740483] ThierryA , LebranchuY , ToupanceO , WesteelPF , EtienneE , ThervetE , et al. Impact of inflammatory subclinical lesions (ISCL) at M12 on renal function at M48: results from Post‐Concept Study [abstract no: 1648]. American Journal of Transplantation2010;10(Suppl 4):506. ThierryA , ThervetE , VuibletV , GoujonJM , MachetMC , NoelLH , et al. Long‐term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. American Journal of Transplantation2011;11(10):2153‐61. [MEDLINE: 21883902] VuibletV , BirembautP , FrancoisA , CordonnierC , NoelLH , GoujonJM , et al. Sirolimus‐based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrology Dialysis Transplantation2012;27(1):411‐6. [MEDLINE: 21617191] VuibletV , BirembautP , FrancoisA , JaureguyM , ThierryA , ThervetE , et al. Sirolimus‐based regimen is associated with decreased expression of vascular endothelial growth factor in kidneys: ancillary study of the CONCEPT Study [abstract no: 1652]. American Journal of Transplantation2010;10(Suppl 4):507. Xu‐DuboisYC , HertigA , LebranchuY , Hurault de LignyB , ThervetE , JaureguyM , et al. Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial. Transplant International2014;27(4):344‐52. [MEDLINE: 24279707] Xu‐DuboisYC , LebranchuY , Hurault de LignyB , ThervetE , MazouzH , LepogampP , et al. Conversion from cyclosporine to sirolimus at M3 after renal transplantation does not reduce the score of epithelial to mesenchymal transition at M12: ancillary study of the CONCEPT Study [abstract no: 1664]. American Journal of Transplantation2010;10(Suppl 4):510. '>CONCEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0026" title="AlberuJ , PascoeMD , CampistolJM , SchenaFP , Rial MdelC , PolinskyM , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24‐month results from the CONVERT trial. Transplantation2011;92(3):303‐10. [MEDLINE: 21792049] AlberuJ , SchenaFP , WaliR , PascoeM , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus (SRL)‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT trial [abstract no: TH‐FC082]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601954] BrennanD , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract no: TH‐FC083]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601955] ChapmanJ , CampistolJM , GrinyoJM , MoralesJM , MotaA , SchenaFP . Results from a long‐term extension study in renal allograft recipients show that sirolimus‐based therapy without cyclosporine is a safe alternative to sirolimus plus cyclosporine therapy. [abstract no: F‐PO1050]. Journal of the American Society of Nephrology2004;15(Oct):295A. [CENTRAL: CN‐00583164] OberbauerR , SchenaFP , WaliR , PascoeM , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial [abstract no: F‐FC154]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00601952] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , BrownF , et al. A randomised, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PS71]. Nephrology2005;10(Suppl 3):A397. [CENTRAL: CN‐00644366] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24‐month safety and efficacy results from the CONVERT trial study group [abstract]. Immunology &amp; Cell Biology2007;85(4):A27‐8. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 18‐month efficacy and safety results from a large, randomized, open‐label, comparative trial [abstract no: 106]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644368] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: results of the CONVERT trial [abstract no: 2006]. Nephrology2006;11(Suppl 2):A35. [CENTRAL: CN‐00583835] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Factors contributing to the development of urinary protein excretion after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A21. PussellB , RussG , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Reduced incidence of malignancy in renal transplant recipients converted from calcineurin inhibitors (CNIS) to sirolimus (SRL) compared with those who continued CNI therapy [abstract no: 1582]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00583837] PussellB , RussG , WalkerR , CampbellS , O'ConnellP , et al. Lower malignancy rates in renal allograft recipients converted to sirolimus‐based, calcineurin inhibitor‐free immunotherapy: 24 month results from the CONVERT Trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. PussellB , RussG , WalkerR , O'ConnellP , KanellisJ . Determinants of proteinuria after conversion from a calcineurin inhibitor to sirolimus‐based immunosuppressive regimen: results from the CONVERT Trial [abstract no: 1572]. Nephrology2006;11(Suppl 2):A21. [CENTRAL: CN‐00583834] RussG , PussellB , WalkerR , CampbellS , O'ConnellP , KanellisJ , et al. Analysis of the incidence of anaemia and its treatment after sirolimus conversion versus calcineurin inhibitor continuation in renal allograft recipients: 2‐year results from the ongoing CONVERT trial [abstract]. Immunology &amp; Cell Biology2007;85(4):A20. RussG , SchenaFP , OberbauerR , The Sirolimus CONVERT Trial Study Group. Incidence and treatment of anemia after conversion to sirolimus vs. continuation of calcineurin inhibitors in renal allograft recipients: 2‐year results from the CONVERT Trial [abstract no: TH‐FC081]. Journal of the American Society of Nephrology2006;17(Abstracts):18A. [CENTRAL: CN‐00601953] SchenaFP , PascoeMD , AlberuJ , delCarmen RialM , OberbauerR , BrennanDC , et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24‐month efficacy and safety results from the CONVERT trial. Transplantation2009;87(2):233‐42. [MEDLINE: 19155978] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM . A randomized, open‐label, comparative evaluation of the safety and efficacy of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: PO‐456]. Transplant International2005;18(Suppl 1). SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus CONVERT Trial Study Group. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12‐month results from a large, randomized, open‐label, comparative trial [abstract no: TH‐FC155]. Journal of the American Society of Nephrology2005;16:33A. [CENTRAL: CN‐00601956] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. A randomized, open‐label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients [abstract no: 1008]. American Journal of Transplantation2005;5(Suppl 11):413. [CENTRAL: CN‐00689212] SchenaFP , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , The Sirolimus Renal Conversion Trial Study Group. Conversion to sirolimus in kidney transplant patients receiving maintenance calcineurin inhibitor immunosuppression: a randomized, open‐label, comparative clinical trial [abstract no: SP440]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v165. [CENTRAL: CN‐00689740] SteinbergS , SchenaFP , WaliR , The Sirolimus CONVERT Trial Study Group. Multivariate and univariate analyses of factors influencing renal allograft function after conversion to sirolimus (SRL)‐based immunotherapy from calcineurin inhibitors (CI) [abstract no: TH‐PO582]. Journal of the American Society of Nephrology2006;17(Abstracts):231A. [CENTRAL: CN‐00601958] VathsalaA , SchenaF , WaliRK , PascoeMD , AlberuJ , DelCarmen RialM , et al. Conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: a randomized, open‐label, comparative trial [abstract no: T‐PO50036]. Nephrology2005;10(Suppl 1):A217. [CENTRAL: CN‐00601967] ">CONVERT Trial 2009</a>; <a href="./references#CD006750-bbs2-0028" title="Smak GregoorPJ , deSevauxRG , HeneRJ , HilbrandsLB , vanGelderT , HoitsmaAJ , et al. The cyclosporine sparing effect of mycophenolate mofetil, a randomized study [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):699A. [CENTRAL: CN‐00447776] deSevauxRG , GregoorPJ , HeneRJ , HoitsmaAJ , VosP , WeimarW , et al. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. Journal of the American Society of Nephrology2001;12(8):1750‐7. [MEDLINE: 11461949] deSevauxRG , Smak GregoorPJ , HeneRJ , HoitsmaAJ , VosP , et al. Addition of mycophenolate mofetil to cyclosporine and prednisone allows for a lower dose of cyclosporine after renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00583239] deSévauxRG , Smak GregoorPJ , HenéRJ , WeimarW , HoitsmaAJ , VanGelderT , et al. A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone [abstract no: 418]. Transplantation1998;65(12):S107. [CENTRAL: CN‐00583548] ">de Sevaux 2001</a>; <a href="./references#CD006750-bbs2-0030" title="DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , MarshallS , et al. MMF substitution for CSA in chronic allograft dysfunction: 2 year follow‐up of a multi‐center randomized controlled study [abstract no: 1513]. American Journal of Transplantation2005;5(Suppl 11):541. DudleyC , PohankaE , RiadH , DedochovaJ , WijngaardP , SutterC , et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the &quot;creeping creatinine&quot; study. Transplantation2005;79(4):466‐75. [MEDLINE: 15729174] DudleyCR , MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi‐center randomized controlled study [abstract no: 41]. American Journal of Transplantation2002;2(Suppl 3):148. Tedesco de SilvaH . MMF replacing CSA reverses the &quot;creeping creatinine&quot; of renal transplant recipients of a multi‐center randomized controlled study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416751] ">Dudley 2005</a>; <a href="./references#CD006750-bbs2-0033" title="FergusonR , MulgaonkarS , Tedesco SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced‐exposure (R‐E) cyclosporine [neoral] (CsA): acute rejection prophylaxis in de novo renal transplant (Tx) recipients [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra (ACT). 2003:63. [CENTRAL: CN‐00445317] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorU , et al. FTY720 with reduced‐exposure neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Interim results [abstract no: 0049]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415638] FergusonRM , MulgaonkarS , TedescoH , OppenheimerF , WalkerR , RussG , et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12‐month preliminary results [abstract no: 624]. American Journal of Transplantation2003;3(Suppl 5):311. [CENTRAL: CN‐00445316] MulgaonkarS , TedescoH , OppenheimerF , WalkerR , KunzendorfU , RussG , et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1‐year dose‐finding study.[Erratum appears in Am J Transplant. 2006 Dec;6(12):3044]. American Journal of Transplantation2006;6(8):1848‐57. [MEDLINE: 16771816] RussG , FergusonRM , MulgaonkarS , Tedesco‐SilvaH , OppenheimerF , WalkerR , et al. FTY720 with reduced dose Neoral (RDN) may offer a safety/tolerability profile advantage over conventional immunosuppressive therapies [abstract no: 1000]. American Journal of Transplantation2004;4(Suppl 8):432. [CENTRAL: CN‐00509451] ">Ferguson 2006</a>; <a href="./references#CD006750-bbs2-0034" title="FlechnerSM , BurkeJT , CookDJ , MastroianniB , SavasK , GoldfarbD , et al. A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]. American Journal of Transplantation2003;3(Suppl 5):450. [CENTRAL: CN‐00445351] FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract no: 1317]. American Journal of Transplantation2002;2(Suppl 3):470. FlechnerSM , CookDJ , GoldfarbD , ModlinC , MastroianniB , SavasK , et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415657] FlechnerSM , GoldfarbD , ModlinC , FengJ , KrishnamurthiV , MastroianniB , et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation2002;74(8):1070‐6. [MEDLINE: 12438948] FlechnerSM , GoldfarbD , SolezK , ModlinCS , MastroianniB , SavasK , et al. Kidney transplantation with sirolimus and mycophenolate mofetil‐based immunosuppression: 5‐year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation2007;83(7):883‐92. [MEDLINE: 17460558] FlechnerSM , KurianS , SolezK , CookDJ , BurkeJT , RollinH , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs [abstract no: O361]. Transplantation2004;78(2 Suppl):141. [CENTRAL: CN‐00509193] FlechnerSM , KurianSM , SolezK , CookDJ , BurkeJT , RollinH , et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. American Journal of Transplantation2004;4(11):1776‐85. [MEDLINE: 15476476] FlechnerSM , SolezK , CookDJ , BurkeJT , RollinH , MastoianniB , et al. Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (CNI) drugs [abstract]. American Journal of Transplantation2004;4(Suppl 8):296. [CENTRAL: CN‐00509194] ">Flechner‐318 Study 2002</a>; <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0038" title="GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract no: 1075]. Nephrology2007;12(Suppl 2):A19. [CENTRAL: CN‐00653709] GallagherM , JardineM , CassA , PerkovicV , PetrieJ , McDonaldS , et al. 20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation [abstract]. Immunology &amp; Cell Biology2007;85(4):A19. GallagherM , JardineM , PerkovicV , CassA , McDonaldS , PetrieJ , et al. Cyclosporine withdrawal improves long‐term graft survival in renal transplantation. Transplantation2009;87(12):1877‐83. [MEDLINE: 19543068] GallagherM , WebsterA , JardineM , PerkovicV , CassA , ErisJ . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 078]. Nephrology2008;13(Suppl 3):A119. [CENTRAL: CN‐00758532] GallagherMP , ErisJM , TillerDJ , HallBM . Long term outcome of Australian multicentre trial of cyclosporin withdrawal in cadaveric renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415694] GallagherMP , HallB , CraigJ , BerryG , TillerDJ , ErisJ , et al. A randomized controlled trial of cyclosporine withdrawal in renal‐transplant recipients: 15‐year results. Transplantation2004;78(11):1653‐60. [MEDLINE: 15591955] GallagherMP , KellyPJ , JardineM , PerkovicV , CassA , CraigJC , et al. Long‐term cancer risk of immunosuppressive regimens after kidney transplantation. Journal of the American Society of Nephrology2010;21(5):852‐8. [MEDLINE: 20431040] GallagherMP , WebsterAC , JardineMJ , PerkovicV , CassA , ErisJM . Twenty year cancer outcomes of a randomized trial of immunosuppression in kidney transplant recipients: results of the Australian multicentre trial of cyclosporine withdrawal [abstract no: 288]. Transplantation2008;86(2 Suppl):102. HallBM , TillerDJ , HardieI , MahonyJ , MathewT , ThatcherG , et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long‐term cyclosporine, short‐term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. New England Journal of Medicine1988;318(23):1499‐507. [MEDLINE: 3285215] ">Hall 1988</a>; <a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0051" title="MuehlbacherF , NeumayerHH , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 1224]. American Journal of Transplantation2003;3(Suppl 5):465. [CENTRAL: CN‐00446852] MuhlbacherF , NeumayerHH , delCastilloD , StefoniS , ZygmuntAJ , BuddeK , et al. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study. Transplant International2014;27(2):176‐86. [MEDLINE: 24266855] MuhlbacherF , PaczekL . An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 399]. American Journal of Transplantation2002;2(Suppl 3):238. NeumayerH , MuhlbacherF , StefoniS , DelCastilloD , Myfortic Maintenance Renal Transplantation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416320] NeumayerHH , MuehlbacherF , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: W738]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00446926] ">Muhlbacher 2014</a>; <a href="./references#CD006750-bbs2-0053" title="CurtisJ , NashanB , PoniicelliC , MouradG , BogerR , RAD 156 Study Group. One year result of a multicenter, open‐label trial on safety and efficacy of certican (RAD) used in combination with simulect, corticosteroids, and full or reduced dose neoral in renal transplant [abstract no: 1335]. American Journal of Transplantation2001;1(Suppl 1):474. [CENTRAL: CN‐00444958] CurtisJ , NashanB , PonticelliC , MouradG , BogerR , RAD 156 Study Group. Everolimus (RAD) in combination with reduced dose with reduced dose neoral® maintains effective immunosuppression with improved tolerability compared to full dose neoral [abstract no: A4625]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):884A. [CENTRAL: CN‐00550720] MouradG , BogerR , CurtisJ , NashanB , PonticelliC , RAD B 156 Study Group. CERTICAN (TM) (RAD; EVEROLIMUS), the proliferation signal inhibitor, is complementary with a reduced dose NEORAL® based quadruple immunosuppressive regimen [abstract no: 1622]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487738] NashanB , CurtisJ , PonticelliC , MouradG , BogerR , RAD B156 Study Group. Certican (RAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose neoral based quadruple immunosuppressive regimen [abstract no: 398]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487741] NashanB , MouradG , BogerR , CurtisJ , PonticelliC , HaasT . Everolimus and reduced‐exposure cyclosporine in de novo renal‐transplant recipients: a three‐year phase II, randomized, multicenter, open‐label study. Transplantation2004;78(9):1332‐40. [MEDLINE: 15548972] PonticelliC , CurtisJ , KovarikJM , NashanB , MouradG , FigueiredoJ , et al. Everolimus pharmacokinetics are unaltered with full‐dose versus reduced‐dose cyclosporine [abstract no: 318]. 10th ESOT &amp; 12th ETCO Congress. Bridging the Future; 2001 Oct 6‐11; Lisboa, Portugal. 2001. [CENTRAL: CN‐00487748] RADB156 Study Group, BogerR , FreiU , GlotzD , KahanB , PonticelliC , et al. CERTICAN(TM) with reduced dose NEORAL® results in a significantly higher GFR in de novo renal transplant recipients over the first 12 Months compared to CERTICAN(TM)‐full dose NEORAL® as Assessed by Iohexol Clearance [abstract no:1623]. A Transplant Odyssey; 2001 Aug 20‐23; Istanbul, Turkey. 2001. [CENTRAL: CN‐00487751] ">Nashan 2004</a>; <a href="./references#CD006750-bbs2-0054" title="OhCK , HaJW , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus (Certican) with low dose of cyclosporine in de novo kidney recipients after 1 month of transplantation (Preliminary results). Journal of the Korean Society for Transplantation2012;26(2):83‐91. [DOI: 10.4285/jkstn.2012.26.2.83] OhCK , HuhKH , HaJ , KimYH , KimYL , KimYS . Safety and efficacy of the early introduction of everolimus with reduced‐exposure cyclosporine a in de novo kidney recipients. Transplantation2015;99(1):180‐6. [MEDLINE: 24983307] ">Oh 2012</a>; <a href="./references#CD006750-bbs2-0055" title="BloomR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]. Transplantation2008;86(2 Suppl):301. [CENTRAL: CN‐00740509] GastonR , BloomR , ShahT , CibrikD , AngelisM , MulgaonkarS , et al. 6‐month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH‐PO565]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00602020] GastonR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00653708] GastonRS , KaplanB , ShahT , CibrikD , ShawLM , AngelisM , et al. Fixed‐ or controlled‐dose mycophenolate mofetil with standard‐ or reduced‐dose calcineurin inhibitors: the OPTICEPT trial. American Journal of Transplantation2009;9(7):1607‐19. [MEDLINE: 19459794] KaplanB , GastonR , Meier‐KriescheH , BloomR , PatelD , ShawL . Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]. American Journal of Transplantation2009;9(Suppl 2):419. [CENTRAL: CN‐00794654] KaplanB , GastonRS , Meier‐KriescheHU , BloomRD , ShawLM . Mycophenolic acid exposure in high‐ and low‐weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Therapeutic Drug Monitoring2010;32(2):224‐7. [MEDLINE: 20216117] ShawL , KaplanB , AngelisM , BloomR , GastonR , Meier‐KriescheH , et al. Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU‐FC128]. Journal of the American Society of Nephrology2007;18(Abstracts):96A‐7A. [CENTRAL: CN‐00724911] ">OPTICEPT Study 2009</a>; <a href="./references#CD006750-bbs2-0056" title="FlechnerS , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)+ mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year safety results from the Orion Trial [abstract no: 444]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no: 1141]. American Journal of Transplantation2007;7(Suppl 2):440. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no: 52]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653711] FlechnerS , GlydaM , SteinbergS , HarlerMB , ORION Trial Investigators. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from The ORION Study [abstract no: P477]. Transplant International2007;20(Suppl 2):209. FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year efficacy results from the ORION trial [abstract no: 287]. American Journal of Transplantation2008;8(Suppl 2):254. [CENTRAL: CN‐00653710] FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. Preliminary two‐year efficacy results from a randomized, open‐label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + mycophenolate regimen (MMF) in de novo renal allograft recipients [abstract no: 531]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740478] FlechnerSM , GlydaM , CockfieldS , GrinyoJ , LegendreC , RussG , et al. The ORION Study: comparison of two sirolimus‐based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.[Erratum appears in Am J Transplant. 2012 Jan;12(1):268]. American Journal of Transplantation2011;11(8):1633‐44. [MEDLINE: 21668635] FlechnerSM , GlydaM , See TaiS , ORION Trial Investigators. Delayed graft function (DGF) in two sirolimus (SRL)‐based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients [abstract no: 299]. American Journal of Transplantation2009;9(Suppl 2):277. [CENTRAL: CN‐00774294] FlechnerSM , GlydaM , SteinbergS , CopleyJB , ORION Trial Investigators. The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: interim results from the Orion Study [abstract no: SU‐FC124]. Journal of the American Society of Nephrology2007;18(Abstracts):95A. [CENTRAL: CN‐00716077] RussG , FlechnerSM , CockfieldS , GrinyoJ , WissingKM , LegendreC , et al. Cardiovascular risk profile of renal transplant recipients enrolled in an open‐label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC)+ mycophenolate regimen (MMF): preliminary results from the Orion Trial [abstract no: 445]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] ">ORION Study 2011</a>; <a href="./references#CD006750-bbs2-0059" title="PascualM , CurtisJ , DelmonicoFL , FarrellML , WilliamsWW , KalilR , et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation2003;75(9):1501‐5. [MEDLINE: 12792504] WongW , Tolkoff‐RubinN , DelmonicoFL , CardarelliF , SaidmanSL , FarrellML , et al. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplantation2004;18(4):341‐8. [MEDLINE: 15233807] WongW , Tolkoff‐RubinN , DelmonicoFL , FarellML , ShihV , WilliamsW , et al. Analysis of the cardiovascular risk profile in stable renal transplant recipients after 50% cyclosporine reduction [abstract]. American Journal of Transplantation2003;3(Suppl 5):213. [CENTRAL: CN‐00448411] WongW , Tolkoff‐RubinN , DelmonicoFL , FarrellML , ShihV , CosimiAB , et al. A randomized clinical trial to analyze the effect of 50% cyclosporine reduction on the cardiovascular risk profile in stable kidney transplant recipients [abstract]. Journal of the American Society of Nephrology2003;14(Nov):186A. [CENTRAL: CN‐00550675] ">Pascual 2003</a>; <a href="./references#CD006750-bbs2-0060" title="PascualJ , BloomD , TorrealbaJ , BrahmbhattR , ChangZ , SollingerHW , et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T‐regulatory cells. American Journal of Transplantation2008;8(7):1529‐36. [MEDLINE: 18510645] ">Pascual 2008</a>; <a href="./references#CD006750-bbs2-0063" title="PeddiV , QaziY , ShafferD , LuanF , ShihabF , TomlanovichS , et al. Effect of everolimus with low dose tacrolimus vs mycophenolate with standard tacrolimus regimen in African‐American de novo renal transplant recipients [abstract no: B955]. Transplantation2014;98(Suppl 1):536. [EMBASE: 71545337] QaziY , ShafferD , KaplanB , KimD , LuanF , PeddiV , et al. Efficacy and safety of everolimus with low‐dose tacrolimus in de novo renal transplant recipients: 12‐month randomized study [abstract no: 713]. Transplantation2014;98(Suppl 1):80. [EMBASE: 71543789] ShihabF , QaziY , KaplanB , KimD , MulgaonkarS , PeddiV , et al. Everolimus‐facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients [abstract no: B962]. Transplantation2014;98(Suppl 1):538‐9. [EMBASE: 71545344] ">Qazi 2014</a>; <a href="./references#CD006750-bbs2-0064" title="FrimatL , Cassuto‐ViguierE , CharpentierB , NoelC , ProvotF , RostaingL , et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'REFERENCE' study. American Journal of Transplantation2006;6(11):2725‐34. [MEDLINE: 17049060] KesslerM . Renal function evaluation after half dose reduction of Neoral in combination with Cellcept in renal transplant patients with altered renal function: preliminary 12 months results: randomized, open, multicentric, prospective, controlled study [abstract no: 773]. American Journal of Transplantation2003;3(Suppl 5):350. [CENTRAL: CN‐00446065] KesslerM , FrimatL . Renal function evaluation after half dose reduction of neoral® in combination with Cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF‐REFERENCE study: a randomised [abstract no: 013]. Transplantation2004;78(2 Suppl):5. [CENTRAL: CN‐00509272] KesslerM , FrimatL , Cassuto‐ViguierE , CharpentierB , DjeffalR , NoelC , et al. Impact of cyclosporine reduction with MMF in chronic allograft dysfunction: 4‐year results of a multicenter randomized controlled study. The &quot;Reference&quot; study [abstract no: 850]. American Journal of Transplantation2006;6(Suppl 2):353. [CENTRAL: CN‐00765336] KesslerM , FrimatL , CharpentierB , DurrbachA , NoelC , PruvotF , et al. Renal function evaluation after half dose reduction of neoral® in combination with cellcept® in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF ‐ REFERENCE study: a randomised, open, multicentre, prospective, controlled study [abstract no: 462]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00602100] ">REFERENCE Study 2006</a>; <a href="./references#CD006750-bbs2-0066" title="BalshawR , MarraC , NashanB , HagenmeyerEG , KeownP . First year cost‐implications of early cyclosporine withdrawal in renal transplantation [abstract no: 2378]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415221] CampistolJM , ErisJ , OberbauerR , FriendP , HutchisonB , MoralesJM , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology2006;17(2):581‐9. [MEDLINE: 16434506] CampistolJM , KreisH , OberbauerR , MotaA , RiadH , ChapmanJ , et al. Sirolimus‐based therapy following early cyclosporin withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract]. American Journal of Transplantation2004;4(Suppl 8):344. [CENTRAL: CN‐00509115] CampistolJM , LegendreC , FriendP , RiadH , CastagnetoM . Evaluating cardiovascular risk factors associated with long‐term sirolimus (Rapamune®) immunotherapy used with or without cyclosporine [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):311. [CENTRAL: CN‐00550754] CampistolJM , OberbauerR , HartmannA , KreisH , MotaA , AriasM , et al. Long‐term graft survival is significantly better in patients receiving sirolimus‐based therapy after early cyclosporine withdrawal [abstract no: W736]. Nephrology Dialysis Transplantation2003;18(Suppl 4):784. [CENTRAL: CN‐00444661] CampistolJM , OberbauerR , KreisH , BraultY , BurkeJT , Rapamune Maintenance Regimen Study Group. Predicting 10‐year graft survival with sirolimus used either as base therapy or in association with cyclosporine [abstract no: 1458]. American Journal of Transplantation2003;3(Suppl 5):474. [CENTRAL: CN‐00444662] CampistolJM , OberbauerR , KreisH , LawenJ , MoralesJM , ChapmanJ , et al. Elimination of cyclosporine with sirolimus‐based immunotherapy: 2‐year results confirm improved renal function [abstract no: SA‐P0489]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00444663] ChapmanJ , JohnsonRW , KreisH , OberbauerR , VanrenterghemY , ClaessonK , et al. Improved renal function using sirolimus (Rapamune®) maintenance therapy and cyclosporine elimination in renal allograft recipients: 12‐month results of the tri‐continental trial [abstract no: A4615]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):882A. [CENTRAL: CN‐00550709] ChapmanJ , OberbauerR , CampistolJM , GrinyoJM , MoralesJM , MotaA , et al. Renal transplant patients receiving sirolimus‐based therapy after early cyclosporine withdrawal demonstrate superior renal allograft survival and improved renal function at 48 months after transplantation [abstract no: SU‐FC103]. Journal of the American Society of Nephrology2004;15(Oct):66A. [CENTRAL: CN‐00583160] ErisJ , GrinyoJM , BraultY , HutchisonB . Sirolimus therapy after early cyclosporine withdrawal in renal transplantation significantly reduces the rate of skin cancer compared with continuous combined therapy with cyclosporine [abstract no: OR‐040]. Transplant International2005;18(Suppl):10. ErisJ , RussG , HutchinsonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation [abstract no: 105]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:91. [CENTRAL: CN‐00644323] ErisJ , RussG , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Conversion to sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation [abstract no: 1581]. Nephrology2006;11(Suppl 2):A24. [CENTRAL: CN‐00644325] FriendP , MotaA , KreisH , SegoloniG , LegendreC , PratsD , et al. Cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy is beneficial to patients regardless of baseline renal function [abstract no: 0553]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415680] FriendP , RussG , OberbauerR , MurgiaMG , TufvesonG , ChapmanJ , et al. Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function. Transplant International2007;20(9):754‐60. [MEDLINE: 17565578] GrinyoJM , VanrentergheimY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. Sirolimus (Rapamune) in patients receiving kidney from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 534]. American Journal of Transplantation2002;2(Suppl 3):272. [CENTRAL: CN‐00415776] GrinyoJM , VanrenterghemY , HutchisonB , SegoloniG , DurandD , SorbaG , et al. The effects of sirolimus (Rapamune) in patients receiving kidneys from older donors: 2‐year results from the Rapamune Maintenance Regimen trial [abstract no: 0435]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00420830] HartmannA , ColonJ , PenaJ , MartinezJ , WalkerR , ArnsW , et al. Favourable cardiovascular risk profile in renal transplant patients receiving sirolimus maintenance therapy following cyclosporine withdrawal: 3 year results of the Rapamune Maintenance Regimen trial [abstract no: W756]. Nephrology Dialysis Transplantation2003;18(Suppl 4):791‐2. [CENTRAL: CN‐00445657] HartmannA , MotaA , LegendreC , SegoloniG , GrinyoJM , HutchisonB , et al. Patients receiving sirolimus maintenance therapy have better renal function after early cyclosporine withdrawal irrespective of baseline renal function: intent‐to‐treat results at 3 years [abstract no: W743]. Nephrology Dialysis Transplantation2003;18(Suppl 4):787. [CENTRAL: CN‐00445658] HartmannA , OberbauerR , KreisH , JohnsonRW , MotaA , SchenaFP , et al. Long‐term results of cyclosporine elimination with sirolimus‐based therapy show improved renal function [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):19. [CENTRAL: CN‐00550651] HutchisonB , ClaessonK , MotaA , ErisJM , KreisH , OberbauerR , et al. Quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination: 2‐year results [abstract no: 499]. American Journal of Transplantation2002;2(Suppl 3):263. [CENTRAL: CN‐00415909] JohnsonR , OberbauerR , KreisH , BrattstromB , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine free immunosuppression in renal transplantation: an international trial with the tablet formulation [abstract no: 0429]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00445947] JohnsonRW , KreisH , OberbauerR , BrattstromC , ClaessonK , ErisJ . Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation2001;72(5):777‐86. [MEDLINE: 11571437] KeownP , ChenJ , KreisH , OberbauerR , ClaessonK , MotaA , et al. Improved quality of life after cyclosporine elimination in sirolimus‐treated renal transplant patients [abstract no: A4711]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):901A. [CENTRAL: CN‐00550607] KreisH , JohnsonR , MayerG , BrattstromC , ClaessonK , ErisJ , et al. Sirolimus allows early cyclosporine‐free immunosuppression in renal transplantation resulting in lower blood pressure and improved renal function [abstract no: A3662]. Journal of the American Society of Nephrology2000;11(Sept):696A‐7A. [CENTRAL: CN‐00550424] KreisH , OberbauerR , CampistolJM , MathewT , DalozeP , SchenaFP , et al. Long‐term benefits with sirolimus‐based therapy after early cyclosporine withdrawal. Journal of the American Society of Nephrology2004;15(3):809‐17. [MEDLINE: 14978184] KreisH , OberbauerR , ClaessonK , MotaA , AriasM , DurandD , et al. Quality‐of‐life assessments in sirolimus‐treated renal transplant patients after cyclosporine elimination [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00446200] KreisH , OberbauerR , MotaA , ClaessonK , RiadH , CampistolJM , et al. Sirolimus‐based therapy following early cyclosporine withdrawal results in superior renal allograft survival compared with a continuous combination of sirolimus and cyclosporine [abstract]. American Journal of Transplantation2003;3(Suppl 5):460. [CENTRAL: CN‐00446201] LegendreC , BraultY , MoralesJM , OberbauerR , AltieriP , RiadH , et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus‐based therapy: a multivariate analysis of results at five years. Clinical Transplantation2007;21(3):330‐6. [MEDLINE: 17488381] LegendreC , DalozeP , ColonJ , ChapmanJ , PenaJ , MartinezJ , et al. Sirolimus (Rapamune) used with or without cyclosporine for long term therapy: a comparison of cardiovascular risk factors. [abstract no: 1015]. American Journal of Transplantation2002;2(Suppl 3):393. [CENTRAL: CN‐00416111] LegendreC , MotaA , FriendP , SegoloniG , GrinyoJM , HutchisonB , et al. Superior renal function after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 3 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):466. [CENTRAL: CN‐00446313] MathewT , KreisH , DoyenK . Malignancy in renal transplant recipients receiving sirolimus (rapamune) maintenance therapy: 2‐year follow up from 5 multicenter studies [abstract no: 58]. American Journal of Transplantation2002;2(Suppl 3):152. [CENTRAL: CN‐00416243] MathewT , KreisH , DoyenK . Two‐year incidence of malignancy in sirolimus (Rapamune)‐treated renal transplant recipients: follow‐up results from 5 multicenter studies [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416244] MathewT , KreisH , FriendP . Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies. Clinical Transplantation2004;18(4):446‐9. [MEDLINE: 15233824] MoralesJM , HartmannA , WalkerR , ArnsW , SenatorskiG , GrinyoJM , et al. Similar lipid profile but improved long‐term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. Transplantation Proceedings2009;41(6):2339‐44. [MEDLINE: 19715914] MoralesJM , KreisH , OberbauerR , CampistolJM , MotaA , HenriquesAC , et al. 48‐month results of sirolimus‐based therapy following early cyclosporine withdrawal demonstrate superior renal allograft survival [abstract no: MO05]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:214. [CENTRAL: CN‐00509360] MoralesJM , OberbauerR , LegendreC , RuizJC , MotaA , ChapmanJ , et al. Analysis of risk factors for reduced renal function in renal transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal: 5‐year results from the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC156]. Journal of the American Society of Nephrology2005;16:72A. [CENTRAL: CN‐00644316] MotaA , AriasM , TaskinenEI , PaavonenT , BraultY , LegendreC , et al. Sirolimus‐based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. American Journal of Transplantation2004;4(6):953‐61. [MEDLINE: 15147430] MotaA , AriasM , TaskinenEI , PaavonenT , LegendreC , ClaessonK , et al. Sirolimus‐based therapy after early cyclosporine withdrawal results in significantly better renal histology and function at 3 years following kidney transplantation [abstract no: 1486]. American Journal of Transplantation2004;4(Suppl 8):566. [CENTRAL: CN‐00509364] MotaA , SegoloniG , LegendreC , PratsD , HutchisonB , MoralesJM , et al. Patients benefit from cyclosporine withdrawal followed by sirolimus (Rapamune) maintenance therapy irrespective of baseline renal function [abstract no: 395]. American Journal of Transplantation2002;2(Suppl 3):237. [CENTRAL: CN‐00420843] OberbauerR , AriasM , ClaessonK , MotaA , ErisJM , HutchisonB , et al. Two‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 0257]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416378] OberbauerR , HutchisonB , ErisJ , AriasM , ClaessonK , MotaA , et al. Health‐related quality‐of‐life outcomes of sirolimus‐treated kidney transplant patients after elimination of cyclosporine A: results of a 2‐year randomized clinical trial. Transplantation2003;75(8):1277‐85. [MEDLINE: 12717216] OberbauerR , HutchisonB , ErisJ , AriasM , MotaA , the Rapamune Maintenance Regimen Study Group. Health‐related quality‐of‐life assessment in kidney transplant patients receiving sirolimus maintenance therapy with early elimination of cyclosporine: 3‐year results [abstract no: W758]. Nephrology Dialysis Transplantation2003;18(Suppl 4):243. [CENTRAL: CN‐00446999] OberbauerR , HutchisonB , ErisJ , RiadH , ClaessonK , LawenJ , et al. Three‐year assessment of health‐related quality of life in sirolimus‐treated kidney transplant patients after cyclosporine elimination [abstract no: 249]. American Journal of Transplantation2003;3(Suppl 5):215. [CENTRAL: CN‐00447000] OberbauerR , KreisH , CampistolJM , MotaA , DalozeP , RuizJC , et al. Renal function improves significantly after early cyclosporine withdrawal in sirolimus‐treated renal transplant recipients: 3‐year results of the Rapamune Maintenance Regimen (RMR) trial [abstract no: F‐FC041]. Journal of the American Society of Nephrology2003;14(Nov):10A. [CENTRAL: CN‐00550606] OberbauerR , KreisH , JohnsonRW , MotaA , ClaessonK , RuizJC , et al. Long‐term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2‐year results of the Rapamune Maintenance Regimen Study. Transplantation2003;76(2):364‐70. [MEDLINE: 12883194] OberbauerR , KreisH , JohnsonRWG , MotaA , ClaessonK , AriasM , et al. Long‐term improvement in renal function is shown in patients treated with sirolimus (Rapamune) and cyclosporine withdrawal: 2‐year results of the Rapamune Maintenance Regimen trial [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416379] OberbauerR , MotaA , PratsD , MathewT , MoralesJM , DalozeP , et al. Renal transplant patients with risk factors for reduced renal function benefit from cyclosporine withdrawal and sirolimus maintenance therapy [abstract no: W742]. Nephrology Dialysis Transplantation2003;18(Suppl 4):786‐7. [CENTRAL: CN‐00447001] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation [abstract no: O80]. Transplantation2004;78(2 Suppl):30. [CENTRAL: CN‐00653813] OberbauerR , SegoloniG , CampistolJM , KreisH , MotaA , LawenJ , et al. Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation.[erratum appears in Transpl Int. 2005 Mar;18(3):369]. Transplant International2005;18(1):22‐8. [MEDLINE: 15612979] PaczekL , MotaA , SchenaFP , JohnsonRW , PratsD , MathewT , et al. Renal function benefit from sirolimus maintenance therapy after early cyclosporine withdrawal in the presence of risk factors [abstract no: 180]. American Journal of Transplantation2003;3(Suppl 5):197. [CENTRAL: CN‐00447075] RuizJC , CampistolJM , GrinyoJM , MotaA , PratsD , GutierrezJA , et al. Early cyclosporine a withdrawal in kidney‐transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation2004;78(9):1312‐8. [MEDLINE: 15548969] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions [abstract no: SU‐FC0235]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):48A. [CENTRAL: CN‐00447509] RuizJC , CampistolJM , MotaA , PratsD , GutierrezJA , CastroA , et al. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Proceedings2003;35(5):1669‐70. [MEDLINE: 12962750] RuizJC , CampistolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplantation Proceedings2007;39(7):2151‐2. [MEDLINE: 17889121] RuizJC , CampstolJM , Sanchez‐FructuosoA , MotaA , GrinyoJM , PaulJ , et al. The early use of sirolimus with CsA elimination is not associated with progressive proteinuria [abstract no: P113]. Transplant International2007;20(Suppl 2):122. [CENTRAL: CN‐00740556] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Anaemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function [abstract no: 2504]. Nephrology2006;11(Suppl 2):A37. [CENTRAL: CN‐00644362] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus (SRL) maintenance therapy after early cyclosporine (CsA) withdrawal benefits renal transplant recipients with risk factors for reduced renal function: 5‐year results [abstract no: 103]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand (TSANZ); 2006 Mar 29‐31; Canberra, Australia. 2006:90. [CENTRAL: CN‐00644320] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Sirolimus‐based therapy following early cyclosporine withdrawal resulted in superior renal allograft survival at 48 months compared with continuous combined sirolimus and cyclosporine [abstract no: P150]. Nephrology2004;9(Suppl 1):A38. [CENTRAL: CN‐00509449] RussG , ErisJ , HutchisonB , WalkerR , ChapmanJ , PussellB , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 159]. Nephrology2005;10(Suppl 3):A422. [CENTRAL: CN‐00644317] RussG , JamiesonN , OberbauerR , AriasM , MurgiaMG , BlanchoG , et al. Three‐year health‐related quality‐of‐life outcomes for sirolimus‐treated kidney transplant patients after elimination of cyclosporine. Transplant International2007;20(10):875‐83. [MEDLINE: 17854445] RussG , OberbauerR , FriendP , CampistolJM , BurkeJT . The impact of renal function on the incidence of anemia in sirolimus‐treated renal transplant recipients [abstract no: TH‐PO563]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. [CENTRAL: CN‐00615898] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Long‐term impact of baseline renal function in kidney transplant patients receiving sirolimus maintenance therapy after early cyclosporine withdrawal [abstract no: FC‐50004]. Nephrology2005;10(Suppl 1):A2. [CENTRAL: CN‐00644319] RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function: intent‐to‐treat results at 4 years [abstract no: 1009]. American Journal of Transplantation2005;5(Suppl 11):413. RussG , SegoloniG , OberbauerR , LegendreC , MotaA , ErisJ , et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation2005;80(9):1204‐11. [MEDLINE: 16314787] SchenaFP , JamiesonN , ColonJ , ShokerA , PenaJ , MartinezM , et al. Favorable cardiovascular risk profile when sirolimus is used without cyclosporine compared to combination therapy: 3‐year results of the Rapamune Maintenance Regimen trial [abstract]. American Journal of Transplantation2003;3(Suppl 5):479. [CENTRAL: CN‐00447616] VanrenterghemY , KreisH , OberbauerR , MotaA , JohnsonWG , Sirolimus Tri‐contienental Renal Transplant Study Group. Improved renal function in renal allograft recipients with sirolimus (Rapamune) maintenance therapy and early cyclosporine withdrawal: 12‐month results [abstract]. Nephrology Dialysis Transplantation2001;16(6):A209. [CENTRAL: CN‐00448163] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] WalkerR , RussG , ErisJ , HutchinsonB , ChapmanJ , PussellB , et al. Treatment of hyperlipidemia in sirolimus (SRL)‐treated renal transplant recipients: long‐term findings from the Rapamune Maintenance Regimen (RMR) Trial [abstract no 27]. 24th Annual Scientific Meeting. Transplantation Society of Australia &amp; New Zealand [TSANZ]; 2006 Mar 29‐31; Canberra, Australia. 2006:49. [CENTRAL: CN‐00644318] ">RMR Study 2001</a>; <a href="./references#CD006750-bbs2-0068" title="RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Comparison of reduced‐and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results [abstract]. Transplantation Society of Australia and New Zealand. 21st Annual Meeting; 2003 Apr 9‐11; Canberra, ACT. 2003:64. [CENTRAL: CN‐00447521] RussG , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. The safety and efficacy of reduced‐ and standard‐target concentration tacrolimus plus sirolimus in renal allograft recipients: preliminary 6‐month results from Australia [abstract no: SA‐PO496]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):364A. [CENTRAL: CN‐00447522] RussGR , CampbellS , ChadbanS , ErisJ , O'ConnellP , PussellB , et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplantation Proceedings2003;35(3 Suppl):115S‐7S. [MEDLINE: 12742480] WhelchelJ , PaczekL , BechsteinWO , RussG . A regimen of sirolimus and reduced‐dose tacrolimus results in improved renal allograft function: combined analysis of the North American target, European and Australian sirolimus‐tacrolimus trials [abstract]. American Journal of Transplantation2003;3(Suppl 5):464. [CENTRAL: CN‐00448351] ">Russ 2003</a>; <a href="./references#CD006750-bbs2-0071" title="RoodnatJ , HilbrandsLB , HeneRJ , deSevauxRG , GregoorPJ , Kal‐van GestelJA , et al. 15 year follow‐up of a multicentre, randomised, calcineurin inhibitor (CNI) withdrawal study in kidney transplantation [abstract no: BO156]. Transplant International2013;26(Suppl 2):83‐4. [EMBASE: 71359271] RoodnatJI , HilbrandsLB , HeneRJ , deSevauxRG , Smak GregoorPJ , Kal‐van GestelJA , et al. 15‐year follow‐up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation2014;98(1):47‐53. [MEDLINE: 24521775] Smak GregoorPJ , deSevauxRG , HeneRJ , HesseCJ , HilbrandsLB , VosP , et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation1999;68(10):1603‐6. [MEDLINE: 10589962] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow‐up data [abstract no: 441]. American Journal of Transplantation2001;1(Suppl 1):246. [CENTRAL: CN‐00763745] Smak GregoorPJ , deSevauxRG , LigtenbergG , HoitsmaAJ , HeneRJ , WeimarW , et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Journal of the American Society of Nephrology2002;13(5):1365‐73. [MEDLINE: 11961025] Smak GregoorPJ , vanGelderT , IJzermansJN , WeimarW . Long‐term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00447777] VanGelderT , deSevauxR , HeneR , WeimarW , HoitsmaA , LigtenbergG , et al. Discontinuation of cyclosporine or prednisone 6 months after kidney transplantation: a randomized trial [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):920A. [CENTRAL: CN‐00583812] deSevauxRG , GregoorP , SmakJH , HeneRJ , WeimarW , HoitsmaAJ , et al. Withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: a randomized study [abstract no: 935]. Transplantation1999;67(7):S240. [CENTRAL: CN‐00767038] ">Smak Gregoor 1999</a>; <a href="./references#CD006750-bbs2-0072" title="GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. A randomized multicenter trial of early conversion to sirolimus/mycophenolate/steroids versus cyclosporine/mycophenolate/steroids in renal transplantation: one‐year analysis (SMART‐Study) [abstract no: 1088]. American Journal of Transplantation2009;9(Suppl 2):497. [CENTRAL: CN‐00763842] GubaM , PratschkeJ , HugoC , KraemerB , BurmeisterD , BrockmannJ , et al. Comparison of a delayed low‐dose sirolimus (Siro)/mycophenolate mofetil (MMF)‐based therapy with standard cyclosporine (CsA/MMF‐based immunosuppression in patients after kidney transplantation (SMART study) [abstract no: P188]. Transplant International2007;20(Suppl 2):141. [CENTRAL: CN‐00724890] GubaM , PratschkeJ , HugoC , KramerB , Nohr‐WestphalC , BrockmannJ . Renal function, efficacy and safety of sirolimus and mycophenolate mofetil therapy after early calcineurin‐inhibitor withdrawal in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial [abstract no: O‐296]. Transplant International2009;22(Suppl 2):78. GubaM , PratschkeJ , HugoC , KramerBK , PascherA , PressmarK , et al. Early conversion to a sirolimus‐based, calcineurin‐inhibitor‐free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant International2012;25(4):416‐23. [MEDLINE: 22320241] GubaM , PratschkeJ , HugoC , KrämerBK , Nohr‐WestphalC , BrockmannJ , et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short‐term calcineurin inhibitor‐based quadruple therapy in de novo renal transplant patients: one‐year analysis of a randomized multicenter trial. Transplantation2010;90(2):175‐83. [MEDLINE: 20463641] JauchKW , PratschkeJ , HugoC , KramerB , HakenbergO , BrockmannJ , et al. Delayed introduction of a calcineurin‐inhibitor (CNI)‐free, sirolimus (SRL)‐based immunosuppression in renal transplantation is safe. Preliminary results of the randomised, multicenter SMART Trial [abstract no: 535]. Transplantation2008;86(Suppl 2):187. [CENTRAL: CN‐00740484] ">SMART TX Study 2010</a>; <a href="./references#CD006750-bbs2-0073" title="KalilR , PearsonTC , MulgaonkarS , PatelA , ShidbanH , WeirM , et al. Final 1‐year outcomes of the spare‐the‐nephron (STN) trial: mycophenolate mofetil (MMF) ‐ based regimen combined with sirolimus (SRL) to preserve renal function in renal transplantation [abstract no: TH‐FC042]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716075] MulgaonkarS , PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Final renal function outcomes from the Spare‐the‐Nephron (STN) trial: mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy and CNI withdrawal in renal transplant recipients [abstract no: 530]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00690361] PatelA , WeirMR , WaliR , PearsonT , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 1138]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615833] PearsonT , MulgaonkarS , KalilR , PatelA , ScandlingJ , PatelD , et al. CNI withdrawal in African Americans ‐ 1 year outcomes of African American renal transplant recipients in the Spare‐the‐Nephron (STN) trial [abstract no: 1083]. American Journal of Transplantation2009;9(Suppl 2):496. PearsonTC , MulgaonkarS , PatelA , ScandlingJ , ShidbanH , WeirM , et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare‐the‐Nephron (STN) trial [abstract no: 129]. American Journal of Transplantation2008;8(Suppl 2):213. [CENTRAL: CN‐00690150] PearsonTC , PatelA , ScandlingJ , ShidbanH , WeirM , PatelD , et al. Final results of the Spare the Nephron trial (CNI withdrawal trial) [abstract no: 629]. Transplantation2008;86(2 Suppl):220‐1. ScandlingJ , MulgaonkarS , ShidbanH , WaidT , PeddiVR , PatelD . Effect of conversion from a calcineurin inhibitor (CNI)‐based regimen to sirolimus on proteinuria: 1‐year results of the spare‐the‐nephron trial in renal transplant recipients [abstract no: F‐PO594]. Journal of the American Society of Nephrology2007;18(Abstracts):230A. [CENTRAL: CN‐00716076] WaliR , PearsonTC , ShidbanH , PatelA , ChanL , PatelD . The Spare‐the‐Nephron Trial: Evaluating mycophenolate mofetil (MMF)/Sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal, 1 year interim results [abstract no: F‐PO1087]. Journal of the American Society of Nephrology2006;17(Abstracts):565A. [CENTRAL: CN‐00615895] WeirM , MulgaonkarS , PearsonT , PatelA , PatelD , ShidbanH , et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2‐year outcomes of the SPARE‐THE‐NEPHRON (STN) trial [abstract no: 33]. American Journal of Transplantation2009;9(Suppl 2):200‐1. WeirMR , MulgaonkarS , ChanL , ShidbanH , WaidTH , PrestonD , et al. Mycophenolate mofetil‐based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare‐the‐Nephron trial. Kidney International2011;79(8):897‐907. [MEDLINE: 21191361] WeirMR , PearsonTC , PatelA , PeddiVR , KalilR , ScandlingJ , et al. Long‐term follow‐up of kidney transplant recipients in the Spare‐the‐Nephron‐Trial. Transplantation2016;101(1):157‐65. [MEDLINE: 26950714] WeirMR , WaliR , PearsonTC , PatelA , MulgaonkarS , ShidbanH , et al. Spare‐the‐Nephron (STN) Trial: Updated 1 year efficacy and safety of mycophenolate mofetil/Sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients [abstract no: 51]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615832] ">Spare‐the‐Nephron Study 2011</a>; <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>; <a href="./references#CD006750-bbs2-0077" title="HillebrandU , SuwelackB , GerhardtU , KobeltV , KraemerJ , HohageH . Impact of calcineurin inhibitor withdrawal and mycophenolate mofetil substitution on hematologic toxicity [abstract no: 0014]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415864] SuwelackB , DietKH , KobeltV , HohageH , GerhardtU . Impact of calcineurin‐inhibitor withdrawal on arterial distensibility and endothelial function in chronic allograft nephropathy [abstract no: 1048]. American Journal of Transplantation2002;2(Suppl 3):402. [CENTRAL: CN‐00416722] SuwelackB , GerhardtU , HohageH . Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. American Journal of Transplantation2004;4(4):655‐62. [MEDLINE: 15023160] SuwelackB , GerhardtU , KobeltV , HillebrandU , MatzkiesF , HohageH . Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels. Transplantation Proceedings2002;34(5):1803‐5. [MEDLINE: 12176583] SuwelackB , HausbergM , HillebrandU , RahnKH , HohageH . Study on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients [abstract no: 0637]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416723] SuwelackB , KobeltV , GerhardtU , VolmerS , HohageH . Course of intima thickness in long term renal transplant recipients treated with or without calcineurin‐inhibitors [abstract no: P04.21]. Kidney &amp; Blood Pressure Research2004;27(5‐6):335. [CENTRAL: CN‐00615862] SuwelackB , KobeltV , HillebrandU , GerhardtU , MatzkiesF , HohageH . Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels. Transplantation Proceedings2002;34(5):1808‐9. [MEDLINE: 12176585] SuwelackB , KobeltV , HohageH , GerhardtU . Studies on effects of calcineurin‐inhibitor withdrawal on arterial wall structure and intima media thickness in longterm transplant recipients [abstract no: P290]. Transplantation2004;78(2 Suppl):295. [CENTRAL: CN‐00509495] SuwelackB , MalyarV , WaldschmidtG , HohageH . 5 year follow‐up of a randomized study on calcineurin‐inhibitor‐withdrawal with addition of MMF in chronic allograft nephropathy [abstract no: F‐PO600]. Journal of the American Society of Nephrology2007;18(Abstracts):231A. SuwelackBM , GerhardtUW , HohageH . Influence of calcineurin‐inhibitor free immunosuppression on carotid intima media thickness in chronic allograft nephropathy [abstract no: 659]. American Journal of Transplantation2003;3(Suppl 5):320. [CENTRAL: CN‐00447914] ">Suwelack 2002</a>; <a href="./references#CD006750-bbs2-0078" title="BagulA , NicholsonM , ChavezR , GrinyoJ , FreiU , VanrenterghemY , et al. Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the SYMPHONY study [abstract no: P23]. British Transplantation Society (BTS).10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ChavezR , NicholsonM , GrinyoJ , FreiU , VanrenterghemY , DalozeP , et al. SYMPHONY ‐ comparing efficacy of standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Sub analysis of GFR in cases that completed one year within an intended regime [abstract no: O06]. British Transplantation Society (BTS). 10th Annual Congress; 2007 Mar 28‐30; Manchester, UK. 2007. ClaesK , Meier‐KriescheHU , ScholdJD , VanrenterghemY , HalloranPF , EkbergH . Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrology Dialysis Transplantation2012;27(2):850‐7. [MEDLINE: 21617197] ColomH , Fernandez De TroconizI , CaldesA , OppenheimerF , Sanchez PlumedJ , GentilMA , et al. Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]. Transplantation2008;86(2 Suppl):37. [CENTRAL: CN‐00678981] DalozeP , EkbergH , VincentiF , Tedesco‐SilvaH , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F‐PO1078]. Journal of the American Society of Nephrology2006;17(Abstracts):563A. DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. Transplant International2009;22(12):1172‐81. [MEDLINE: 19891046] DemirbasA , HugoC , GrinyoJ , FreiU , GurkanA , MarcenR , et al. Results of the Symphony Study are applicable across transplant populations; experience from Spain, Turkey and Germany [abstract no: P581]. Transplant International2007;20(Suppl 2):234. EkbergH , BernasconiC , HalloranP . CNI minimisation with 2 G mycophenolate mofetil ‐ what have we learned from the Symphony Study [abstract no: 964]. Transplantation2008;86(2 Suppl):334. [CENTRAL: CN‐00671785] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrology Dialysis Transplantation2010;25(6):2004‐10. [MEDLINE: 20106825] EkbergH , BernasconiC , NoldekeJ , YussimA , MjornstedtL , ErkenU , et al. Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653721] EkbergH , HalloranP , VanrenterghemY , ScholdJ , Meier‐KriescheH . Renal function progression following DGF and early AR is not impaired if function is restored: evidence from the Symphony Study [abstract no: P583]. Transplant International2007;20(Suppl 2):235. EkbergH , MamelokR , BernasconiC , VincentiF , Tedesco‐SilvaH , DalozeP , et al. The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no: 58]. American Journal of Transplantation2007;7(Suppl 2):161. [CENTRAL: CN‐00615834] EkbergH , Tedesco‐SilvaH , DemirbasA , BitkoS , KlempnauerJ , GurkanA , et al. Improved outcomes after de novo renal transplantation: 2‐year results from the Symphony Study [abstract no: 531]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653754] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: LB04]. American Journal of Transplantation2008;8(Suppl 2):336. [CENTRAL: CN‐00653755] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , KlempnauerJ , GurkanA , et al. CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3‐year results from the Symphony Study [abstract no: 623]. Transplantation2008;86(2 Suppl):218. [CENTRAL: CN‐00676055] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine2007;357(25):2562‐75. [MEDLINE: 18094377] EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , GurkanA , et al. Symphony ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]. American Journal of Transplantation2006;6(Suppl 2):83. EkbergH , VincentiF , Tedesco da SilvaH , DalozeP , PearsonT . Low‐dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]. American Journal of Transplantation2006;6(Suppl 2):300. [CENTRAL: CN‐00602015] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study. Clinical Transplantation2010;24(4):500‐9. [MEDLINE: 19758267] FreiU , DalozeP , VitkoS , KlempnauerJ , Reyes‐AcevedoR , TitizI , et al. Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00653713] FreiU , EkbergH , Tedesco‐SilvaH , DemirbasA , VitkoS , NashanB , et al. SYMPHONY ‐ comparing standard immunosuppression to low‐dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F‐FC152]. Journal of the American Society of Nephrology2006;17(Abstracts):69A. [CENTRAL: CN‐00602018] GrinyoJ , EkbergH , OppenheimerF , GentilMA , HernandezD , PlumedJS , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: P342]. Transplant International2007;20(Suppl 2):177. [CENTRAL: CN‐00653737] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]. American Journal of Transplantation2006;6(Suppl 2):345. [CENTRAL: CN‐00602016] GrinyoJ , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard‐dose cyclosporine, low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony PK sub‐study [abstract no: 1151]. American Journal of Transplantation2007;7(Suppl 2):443. GrinyoJM , EkbergH , MamelokRD , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard‐dose or low‐dose cyclosporine, low‐dose tacrolimus or low‐dose sirolimus: the Symphony pharmacokinetic substudy. Nephrology Dialysis Transplantation2009;24(7):2269‐76. [MEDLINE: 19357111] HalloranP , Meier‐KriescheHU , ScholdJ , VanrenterghemY . Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no: 1137]. American Journal of Transplantation2007;7(Suppl 2):439. [CENTRAL: CN‐00615835] HugoC , FreiU , MargreiterR , PeetersP , OkE , ViebahnR , et al. Elderly kidney transplant recipients are a high‐risk group for death, infections and PTx diabetes: evidence from the Symphony study [abstract no: 154]. American Journal of Transplantation2007;7(Suppl 2):186. [CENTRAL: CN‐00724927] HugoC , FreiU , MargreiterR , PeetersP , TozH , ViebahnR , et al. Marginal donor quality transmits a high risk profile in elderly but not young renal transplant patients ‐ a subgroup analysis of the Symphony Study [abstract no: F‐PO1471]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):436A. [CENTRAL: CN‐00724891] KuypersD , EkbergH , OppenheimerF , PlumedJ , RodriguezG , HernandezD , et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low‐dose tacrolimus, low‐dose cyclosporine, low‐dose sirolimus or standard‐dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH‐PO564]. Journal of the American Society of Nephrology2006;17(Abstracts):227A. LlaudoI , ColomH , Gimenez‐BonafeP , TorrasJ , CaldesA , SarriasM , et al. Do drug transporter (ABCB1) SNPs and P‐glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the SYMPHONY study. Transplant International2013;26(2):177‐86. [MEDLINE: 23216707] LloberasN , BrunetM , TorrasJ , CruzadoJM , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony Study [abstract no: TH‐PO508]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724892] LloberasN , BrunetM , TorrasJ , OppenheimerF , Sanchez‐PlumedJ , GentilMA , et al. Influence of MRP2 and UGT1A9 polymorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]. Transplantation2008;86(2 Suppl):733. [CENTRAL: CN‐00671787] LloberasN , LlaudoI , TorrasJ , CaldesA , CruzadoJM . Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]. Transplantation2008;86(2 Suppl):734. [CENTRAL: CN‐00671786] LloberasN , LlaudoI , TorrasJ , CruzadoJM , CaldesA , OppenheimerF , et al. Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenomic substudy (Symphony Study) [abstract no: TH‐PO507]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):220A. [CENTRAL: CN‐00724893] LloberasN , TorrasJ , CruzadoJM , AndreuF , OppenheimerF , Sanchez‐PlumedJ , et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients‐results of the pharmacogenomic substudy within the Symphony Study. Nephrology Dialysis Transplantation2011;26(11):3784‐93. [MEDLINE: 21427078] Meier‐KriescheH , HalloranP , VanrenterghemY , ScholdJ . Early immunosuppression exposure and incidence of acute rejection and renal function progression: evidence from the Symphony Study [abstract no: 244]. American Journal of Transplantation2007;7(Suppl 2):210. [CENTRAL: CN‐00724894] Meier‐KriescheH , ScholdJ , VanrenterghemY , HalloranP , EkbergH . Factors associated with BMI increases early after renal transplantation: evidence from the Symphony Study [abstract no: P582]. Transplant International2007;20(Suppl 2):234. O'ConnellPJ , WalkerRG , IerinoF , ErisJ , RussG , GrinyoJ , et al. Results of the SYMPHONY trial in renal transplantation ‐ comparing standard immunosuppression to low dose cyclosporine (low‐CSA), tacrolimus (low‐TAC) or sirolimus (low‐SRL with MMF, daclizumab and corticosteroids [abstract]. Immunology and Cell Biology2007;85(4):A33. OppenheimerF , RebelloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low toxicity immunosuppressive regimens. Preliminary results of the quality of life substudy of the Elite Symphony Study [abstract no: TH‐PO566]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00747305] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , SanchezJ , GonzalezM , et al. Health care resource consumption (HCRC) of patients receiving low toxicity immunosuppressive regimens. One year follow up results of the quality of life substudy within the Symphony study [abstract no: P108]. Transplant International2007;20(Suppl 2):121. [CENTRAL: CN‐00724895] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Cost‐effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]. Transplantation2008;86(2 Suppl):38. [CENTRAL: CN‐00677744] OppenheimerF , RebolloP , GrinyoJM , OrtegaF , Sanchez‐PlumedJ , Gonzalez‐MolinaM , et al. Health‐related quality of life of patients receiving low‐toxicity immunosuppressive regimens: a substudy of the Symphony study. Transplantation2009;87(8):1210‐3. [MEDLINE: 19384168] VanrenterghemY , Meier‐KriescheH , ScholdJ , HalloranP , EkbergH . Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: evidence from the Symphony Study [abstract no: P580]. Transplant International2007;20(Suppl 2):234. ">SYMPHONY Study 2007</a>; <a href="./references#CD006750-bbs2-0079" title="SaitoK , UchidaK , TakaharaS , YoshimuraN , TeraokaS , Cornu‐ArtisC , et al. Efficacy of everolimus with reduced cyclosporine in Japanese de novo renal transplant recipients: 24‐month, randomized, multicenter study [abstract no: B944]. American Journal of Transplantation2013;13(Suppl S5):314. [EMBASE: 71057520] TakaharaS , UchidaK , YoshimuraN , TeraokaS , KobayashiE , TeshimaR , et al. Efficacy and safety of concentration controlled everolimus with reduced dose cyclosporine in Japanese adult de‐novo renal transplant patients: 12 month results [abstract no: 935]. American Journal of Transplantation2012;12(Suppl S3):300. [EMBASE: 70746888] TakahashiK , UchidaK , YoshimuraN , TakaharaS , TeraokaS , TeshimaR , et al. Efficacy and safety of concentration‐controlled everolimus with reduced‐dose cyclosporine in Japanese de novo renal transplant patients: 12‐month results. Transplantation Research2013;2(1):14. [MEDLINE: 23866828] UchidaK , HoshinagaK , WataraiY , GotoN , KusakaM , SasakiH , et al. Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. Transplantation Proceedings2014;46(5):1314‐8. [MEDLINE: 24935294] WataraiY , AkutsuN , SaitoK , NakagawaY , KamisawaO , KenmochiT . Everolimus plus reduced‐exposure calcineurin inhibitor versus mycophenolate mofetil plus standard‐exposure calcineurin inhibitor: 2‐year results in living donor kidney transplant recipients [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953410] ">Takahashi 2013a</a>; <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>; <a href="./references#CD006750-bbs2-0081" title="CampistolJM , AlverangaD , HricikDE , VelosaJ , GrinyoJM , MouradG , et al. Sirolimus‐treated renal transplant recipients experience improved renal function with cyclosporine elimination: one‐year results from a phase II trial [abstract]. Nephrology Dialysis Transplantation2001;16(6):A208. [CENTRAL: CN‐00487674] GonwaT , AlverangaD , AnconaG , BrinkerK , CambiV , CampistolJ , et al. Sirolimus (Rapamune) permits early elimination of cyclosporine in recipients of cadaveric renal allografts [abstract]. Transplantation2000;69(8 Suppl):S360. [CENTRAL: CN‐00445514] GonwaTA . Sirolimus (SRL) treated patients demonstrate improved renal function after withdrawal of cyclosporine (CSA) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):891A. [CENTRAL: CN‐00550647] GonwaTA , HricikDE , BrinkerK , GrinyoJM , SchenaFP , Sirolimus Renal Function Study Group. Improved renal function in sirolimus‐treated renal transplant patients after early cyclosporine elimination. Transplantation2002;74(11):1560‐7. [MEDLINE: 12490789] HricikDE , Rapamune Renal Function Study Group. Sirolimus improves renal function without increasing acute rejection after cyclosporine elimination in renal transplant patients [abstract no: 0430]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sep 1; Rome, Italy. 2000. [CENTRAL: CN‐00583304] VelosaJA , LarsonTS , GloorJM , StegallMD . Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. American Journal of Kidney Diseases2001;38(4 Suppl 2):S3‐S10. [MEDLINE: 11583938] ">Velosa‐212 Study 2001</a>; <a href="./references#CD006750-bbs2-0082" title="ClatworthyM , BradleyV , WallinE , CamilleriB , WilliamsP , BradleyJA , et al. Sirolimus conversion post‐renal transplantation. 5 year follow up data [abstract no: P246]. British Transplantation Society (BTS).12th Annual Congress; 2009 Apr 21‐24; Liverpool, UK. 2009. ClatworthyMR , BradleyV , BradleyJA , WatsonCJ . Sirolimus conversion post‐renal transplantation ‐ 5 year follow‐up data [abstract no: 1096]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00766450] WatsonCJ , FirthJ , BradleyJ , WilliamsPF , SmithJC , PalmerCR , et al. Superior renal function following conversion to sirolimus after renal transplantation ‐ preliminary results from a randomised trial [abstract]. American Journal of Transplantation2004;4(Suppl 8):220‐1. [CENTRAL: CN‐00509555] WatsonCJ , FirthJ , WilliamsPF , BradleyJR , PritchardN , ChaudhryA , et al. A randomized controlled trial of late conversion from CNI‐based to sirolimus‐based immunosuppression following renal transplantation. American Journal of Transplantation2005;5(10):2496‐503. [MEDLINE: 16162200] WillcocksLC , ChaudhryAN , SmithJC , OjhaS , DoffingerR , WatsonCJ , et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. American Journal of Transplantation2007;7(8):2006‐11. [MEDLINE: 17578505] ">Watson 2005</a>; <a href="./references#CD006750-bbs2-0083" title="ArnsW , BeckerT , BuddeK , EisenbergerU , FischerW , KramerS , et al. Conversion to an everolimus/enteric‐coated mycophenolate sodium regimen in de novo renal transplant improves 2 year renal function [abstract no: 15]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. ArnsW , BuddeK , BeckerT , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: The ZEUS Study [abstract no: SU656]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00763609] BeckerT , ArnsW , BuddeK , EisenbergerU , FischerW , KramerS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study [abstract no: O‐297]. Transplant International2009;22(Suppl 2):78‐9. BeckerT , ArnsW , BuddeK , PietruckF , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1757]. Transplantation2010;90(Suppl 2S):109. [EMBASE: 71531312] BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the ZEUS trial [abstract no: 1638]. American Journal of Transplantation2010;10(Suppl 4):503. BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Analysis of renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS Study [abstract no: 237]. American Journal of Transplantation2009;9(Suppl 2):259. [EMBASE: 70010110] BuddeK , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus‐based, calcineurin‐inhibitor‐free regimen in recipients of de‐novo kidney transplants: an open‐label, randomised, controlled trial.[Erratum appears in Lancet. 2012 Dec 8;380(9858):1994], [Erratum appears in Lancet. 2011 Jun 11;377(9782):2006 Note: Wuthrich, Rudolf P [added]]. Lancet2011;377(9768):837‐47. [MEDLINE: 21334736] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Multi‐center, open‐label, prospective, randomized, parallel group study investigating an everolimus‐based CNI‐free regimen in comparison to a cyclosporine‐based standard therapy in de novo renal transplant patients (Zeus Study) [abstract no: 1640]. Transplantation2008;86(Suppl 2):544. [CENTRAL: CN‐00740480] BuddeK , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Renal function, efficacy and safety of everolimus (RAD)/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the Zeus Study [abstract no: 264]. Transplantation2008;86(Suppl 2):93. [CENTRAL: CN‐00740481] BuddeK , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusEM , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 927]. American Journal of Transplantation2012;12(Suppl S3):298. [EMBASE: 70746880] BuddeK , LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3‐year results from the randomized ZEUS study. [Erratum appears in Am J Transplant. 2012 Nov;12(11):3165]. American Journal of Transplantation2012;12(6):1528‐40. [MEDLINE: 22642473] BuddeK , LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , et al. Five‐year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. American Journal of Transplantation2015;15(1):119‐28. [MEDLINE: 25521535] BuddeK , WitzkeO , SommererC , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 5 years follow‐up of the ZEUS trial [abstract no: 18]. American Journal of Transplantation2013;13(Suppl S5):35‐6. [EMBASE: 71056595] EisenbergerU , BuddeK , WitzkeO , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: Histological assessment from biopsy analyses [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71953380] EisenbergerU , PietruckF , BeckerT , ArnsW , ReinkeP , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS Study [abstract no: SU667]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. [CENTRAL: CN‐00774728] EisenbergerU , PietruckF , KlempnauerJ , ArnsW , FehrT , SommererC , et al. Everolimus (RAD)/enteric‐coated mycophenolate sodium (ECMPS) therapy after calcineurin inhibitor (CNI) withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: 3.1]. Swiss Medical Weekly2008;138(Suppl 167):5S. EisenbergerU , WitzkeO , HauserI , LehnerF , SommererC , WuethrichR , et al. Explorative analysis of ZEUS after 5 years: histological assessment from biopsy analyses [abstract no: O220]. Transplant International2015;28(Suppl 4):83. [EMBASE: 72111464] LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , ScheidlS , et al. Renal function in everolimus/enteric‐coated mycophenolate sodium treated de novo living renal transplant recipients after calcineurin inhibitor withdrawal: subgroup analysis of the ZEUS study [abstract no: P142]. Transplant International2011;24(Suppl 3):50‐1. [EMBASE: 70537442] LehnerF , BuddeK , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 3 year follow‐up of the ZEUS trial [abstract no: O‐199]. Transplant International2011;24(Suppl 3):57. [EMBASE: 70527276] LehnerF , BuddeK , WuethrichR , ReinkeP , ArnsW , MuehlfeldA , et al. Post Hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen: 5 year follow‐up data [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954049] LehnerF , BuddeK , ZeierM , WuthrichRP , ReinkeP , EisenbergerU , et al. Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International2014;27(11):1192‐204. [MEDLINE: 25070687] LehnerF , SommererC , ArnsW , BuddeK , WuethrichR , ReinkeP , et al. Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from CNI to everolimus‐based regimen: 5 year data post hoc analysis from the ZEUS study [abstract no: BO333]. Transplant International2015;28(Suppl 4):242‐3. [EMBASE: 72111925] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichR , et al. Post hoc subgroup analysis of ZEUS: Outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract]. Transplantation2014;98(Suppl 1):613. [EMBASE: 71545612] LehnerF , SommererC , ArnsW , ReinkeP , EisenbergerU , WuthrichRP , et al. Post Hoc subgroup analysis from ZEUS: outcome on renal function, efficacy and safety in living‐donor kidney transplant recipients after conversion from a calcineurin inhibitor to an everolimus based regimen [abstract no: V22]. Transplant International2013;26(Suppl 1):8. [EMBASE: 71356217] LehnerF , SommererC , ReinkeP , ArnsW , EisenbergerU , PaulusE , et al. 5‐year follow‐up on the ZEUS KTX trial: everolimus conversion after CNI withdrawal [abstract no: BO142]. Transplant International2013;26(Suppl 2):81. [EMBASE: 71359257] PietruckF , BeckerT , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: 1093]. American Journal of Transplantation2009;9(Suppl 2):499. [CENTRAL: CN‐00774729] PietruckF , BuddeK , ArnsW , ReinkeP , EisenbergerU , FischerW , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 2 years follow‐up of the Zeus‐trial [abstract no: OM007]. NDT Plus2010;3(Suppl 3):iii553. [EMBASE: 70484927] PietruckF , KlempnauerJ , ArnsW , SommererC , ReinkeP , EisenbergerU , et al. Everolimus/enteric‐coated mycophenolate sodium (EC‐MPS) therapy after calcineurin inhibitor withdrawal in de novo renal transplant patients: final outcomes of the ZEUS study [abstract no: TH‐FC041]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. [CENTRAL: CN‐00716070] ReinkeP , ArnsW , BeckerT , EisenbergerU , FischerW , KramerS , et al. Efficacy and safety of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract no: O‐202]. Transplant International2009;22(Suppl 2):53. ReinkeP , LehnerF , WitzkeO , SommererC , EisenbergerU , ArnsW , et al. 5 Years follow‐up on renal function ‐ ZEUS trial: Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients [abstract no: V76]. Transplant International2013;26(Suppl 1):21. [EMBASE: 71356260] SommererC , LehnerF , ArnsW , ReinkeP , EisenbergerU , HellerK , et al. Post hoc analysis of ZEUS and HERAKLES, two prospective, open‐label, multicenter, randomized trials: Onset and progression of diabetes in kidney transplant recipients on cyclosporine standard or converted to CNI‐free or CNI‐low everolimus regimen [abstract]. Transplantation2014;98(Suppl 1):145‐6. [EMBASE: 71543989] WitzkeO , LehnerF , ArnsW , ReinkeP , EisenbergerU , PaulusE , et al. Improved renal function of an everolimus/enteric‐coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: 4 years follow‐up of the ZEUS trial [abstract no: 1671]. Transplantation2012;94(Suppl 10S):993. [EMBASE: 71251765] van derGietM , BrakemeierS , LiefeldtL , GlanderP , DiekmannF , HohneM , et al. The impact of everolimus versus CNI‐based immunosuppression on cardiovascular function and stiffness after renal transplantation [abstract no: 1646]. American Journal of Transplantation2010;10(Suppl 4):506. ">ZEUS Study 2011</a>). </p> <p>In two studies, one study arm was terminated due to increased rates of acute rejection (<a href="./references#CD006750-bbs2-0049" title="BaasMC , GerdesVE , tenBergeIJ , HeutinckKM , FlorquinS , MeijersJC , et al. Treatment with everolimus is associated with a procoagulant state. Thrombosis Research2013;132(2):307‐11. [MEDLINE: 23906938] BaasMC , KersJ , FlorquinS , deFijterJW , van derHeideJJ , van denBergh WeermanMA , et al. Cyclosporine versus everolimus: effects on the glomerulus. Clinical Transplantation2013;27(4):535‐40. [MEDLINE: 23795805] BaasMC , StruijkGH , MoesDJ , van denBerkIA , JonkersRE , deFijterJW , et al. Interstitial pneumonitis caused by everolimus: a case‐cohort study in renal transplant recipients. Transplant International2014;27(5):428‐36. [MEDLINE: 24484452] BemelmanFJ , deMaarEF , PressRR , vanKanHJ , tenBergeIJ , Homan van der HeideJJ , et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation2009;88(3):421‐8. [MEDLINE: 19667948] HavenithSH , YongSL , vanDonselaar‐van der PantKA , vanLierRA , tenBergeIJ , BemelmanFJ . Everolimus‐treated renal transplant recipients have a more robust CMV‐specific CD8+ T‐cell response compared with cyclosporine‐ or mycophenolate‐treated patients. Transplantation2013;95(1):184‐91. [MEDLINE: 23222818] StruijkGH , MinneeRC , KochSD , ZwindermanAH , vanDonselaar‐van der PantKA , IduMM , et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney International2010;78(9):934‐40. [MEDLINE: 20703211] VanDijkM , VanRoonA , SandersJS . Intima media thickness (IMT) and major adverse cardiac events (MACE) in patients after kidney transplantation [abstract no: P226]. Transplant International2015;28(Suppl 4):431. [EMBASE: 72112220] tenBergeIJ , DeMaarE , PressR , van derHeideJH , deFijterH , BemelmanFJ . Minimization of immunosuppressive drug therapy at 6 months after renal transplantation: everolimus or cyclosporin superior to mycophenolate sodium [abstract no: 532]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740475] van derHeideJJ , deFijterJW , deMaarEF , tenBergeI , BemelmanFJ . Low acute rejection rate and superior renal function 2 years after early CsA withdrawal and overnight switch to everolimus [abstract no: 1654]. American Journal of Transplantation2010;10(Suppl 4):508. ">MECANO Study 2009</a>; <a href="./references#CD006750-bbs2-0056" title="FlechnerS , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC)+ mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year safety results from the Orion Trial [abstract no: 444]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study [abstract no: 1141]. American Journal of Transplantation2007;7(Suppl 2):440. [CENTRAL: CN‐00740477] FlechnerS , GlydaM , SteinbergS , HarlerMB . A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from the ORION study [abstract no: 52]. American Journal of Transplantation2007;7(Suppl 2):160. [CENTRAL: CN‐00653711] FlechnerS , GlydaM , SteinbergS , HarlerMB , ORION Trial Investigators. A randomized, open‐label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: acute rejection and graft survival results from The ORION Study [abstract no: P477]. Transplant International2007;20(Suppl 2):209. FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. A randomized, open‐label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2‐year efficacy results from the ORION trial [abstract no: 287]. American Journal of Transplantation2008;8(Suppl 2):254. [CENTRAL: CN‐00653710] FlechnerSM , CockfieldS , GrinyoJ , RussG , WissingKM , LegendreC , et al. Preliminary two‐year efficacy results from a randomized, open‐label, comparative study of two different sirolimus (SRL) regimens versus a tacrolimus (TAC) + mycophenolate regimen (MMF) in de novo renal allograft recipients [abstract no: 531]. Transplantation2008;86(Suppl 2):186. [CENTRAL: CN‐00740478] FlechnerSM , GlydaM , CockfieldS , GrinyoJ , LegendreC , RussG , et al. The ORION Study: comparison of two sirolimus‐based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.[Erratum appears in Am J Transplant. 2012 Jan;12(1):268]. American Journal of Transplantation2011;11(8):1633‐44. [MEDLINE: 21668635] FlechnerSM , GlydaM , See TaiS , ORION Trial Investigators. Delayed graft function (DGF) in two sirolimus (SRL)‐based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients [abstract no: 299]. American Journal of Transplantation2009;9(Suppl 2):277. [CENTRAL: CN‐00774294] FlechnerSM , GlydaM , SteinbergS , CopleyJB , ORION Trial Investigators. The efficacy of sirolimus (SRL) and tacrolimus (TAC) withdrawal versus SRL and mycophenolate mofetil (MMF) compared with TAC and MMF in de novo renal allograft recipients: interim results from the Orion Study [abstract no: SU‐FC124]. Journal of the American Society of Nephrology2007;18(Abstracts):95A. [CENTRAL: CN‐00716077] RussG , FlechnerSM , CockfieldS , GrinyoJ , WissingKM , LegendreC , et al. Cardiovascular risk profile of renal transplant recipients enrolled in an open‐label, randomized study comparing 2 sirolimus (SRL) regimens with a tacrolimus (TAC)+ mycophenolate regimen (MMF): preliminary results from the Orion Trial [abstract no: 445]. Transplantation2008;86(Suppl 2):156. [CENTRAL: CN‐00740477] ">ORION Study 2011</a>) and in <a href="./references#CD006750-bbs2-0040" title="HeeringP , WesthoffA , IvensK K , GrabenseeB . Comparison between the effects of CSA and azathioprine on functional renal parameters in randomized study after renal transplantation [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):940. [CENTRAL: CN‐00484304] HeeringP , WesthoffA , IvensK , HelmchenU , GrabenseeB . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine: a randomized controlled study [abstract]. 12th International Congress of Nephrology; 1993 Jun 13‐18; Jerusalem, Israel. 1993:194. HeeringP , WesthoffK , IvensB , KutkuhnB , GrabenseeH . Increased risk in conversion of stable renal allografts from cyclosporin to azathioprine [abstract]. Nephrology Dialysis Transplantation1993;8(9):1041. [CENTRAL: CN‐00260889] IvensK , HeeringP , WitholdW , KochM , ReinauerH , GrabenseeB . Withdrawal of cyclosporine improves the cardio‐vascular risk profile in renal graft recipients [abstract]. Journal of the American Society of Nephrology1994;5(3):1013. ">Heering 1993</a> and <a href="./references#CD006750-bbs2-0027" title="FormicaR , NickersonP , PoggioE , TinckamK , RushD , GibsonI , et al. Immune monitoring and tacrolimus (TAC) withdrawal in low risk recipients of kidney transplants‐results of CTOT09 [abstract]. Transplantation2014;98(Suppl 1):225. [EMBASE: 71544207] HricikDE , FormicaRN , NickersonP , RushD , FairchildRL , PoggioED , et al. Adverse outcomes of tacrolimus withdrawal in immune‐quiescent kidney transplant recipients. Journal of the American Society of Nephrology2015;26(12):3114‐22. [MEDLINE: 25925687] NickersonP , WiebeC , FormicaR , TinckamK , PoggioE , BunnapradistS , et al. Epitope mismatch predicts de novo DSA after CNI withdrawal in low‐risk kidney transplant recipients [abstract]. Transplantation2014;98(Suppl 1):137. [EMBASE: 71543963] ">CTOT‐09 Study 2015</a> the studies were stopped due to increased acute rejections in the CNI withdrawal group. </p> <p><a href="./references#CD006750-bbs2-0035" title="GarciaR , HanzawaNM , MachadoPG , MoreiraSR , PrismichG , FelipeCR , et al. A calcineurin inhibitor‐free regimen for low risk kidney transplant recipients [abstract no: 2379]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00520337] GarciaR , MachadoPG , FelipeCR , ParkSI , SpinelliGA , FrancoMF , et al. Exploratory calcineurin inhibitor‐free regimens in living‐related kidney transplant recipients. Brazilian Journal of Medical &amp; Biological Research2007;40(4):457‐65. [MEDLINE: 17401488] ">Garcia 2007</a> included a third group of non‐randomised patients after the interim analysis of randomised patients. </p> <p>Only preliminary data were reported in <a href="./references#CD006750-bbs2-0024" title="CockfieldS , WhelchelJ , MacDonaldA . An open‐label, concentration‐controlled, randomized, 6‐month study of standard‐dose tacrolimus + sirolimus + corticosteroids compared to reduced‐dose tacrolimus + sirolimus + corticosteroids in renal allograft recipients [abstract no: 1021]. American Journal of Transplantation2002;2(Suppl 3):395. [MEDLINE: CN‐00420821] DalozeP , WhelchelJ , CockfieldS , MacDonaldA . A 6‐month multicenter randomized concentration‐controlled study of reduced‐dose tacrolimus (TAC)+sirolimus(SRL)+corticosteroids(CS) compared to standard‐dose TAC+SRL+CS in clinical kidney transplantation [abstract no: 0555]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00415490] ">Cockfield 2002</a> and <a href="./references#CD006750-bbs2-0051" title="MuehlbacherF , NeumayerHH , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 1224]. American Journal of Transplantation2003;3(Suppl 5):465. [CENTRAL: CN‐00446852] MuhlbacherF , NeumayerHH , delCastilloD , StefoniS , ZygmuntAJ , BuddeK , et al. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open‐label comparative study. Transplant International2014;27(2):176‐86. [MEDLINE: 24266855] MuhlbacherF , PaczekL . An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: 399]. American Journal of Transplantation2002;2(Suppl 3):238. NeumayerH , MuhlbacherF , StefoniS , DelCastilloD , Myfortic Maintenance Renal Transplantation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416320] NeumayerHH , MuehlbacherF , delCastilloD , StefoniS , European Sirolimus CsA Minimisation Study Group. An open‐label study to evaluate the efficacy &amp; safety of cyclosporine reduction in de novo renal allograft recipients receiving sirolimus: a dose comparative study [abstract no: W738]. Nephrology Dialysis Transplantation2003;18(Suppl 4):785. [CENTRAL: CN‐00446926] ">Muhlbacher 2014</a>. </p> <p>There was a high drop‐out rate in four studies (<a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>; <a href="./references#CD006750-bbs2-0055" title="BloomR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: Efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 1 and 2 years [abstract no: 862]. Transplantation2008;86(2 Suppl):301. [CENTRAL: CN‐00740509] GastonR , BloomR , ShahT , CibrikD , AngelisM , MulgaonkarS , et al. 6‐month outcomes of monitored mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) in renal allograft recipients: an interim analysis of the OPTICEPT trial [abstract no: TH‐PO565]. Journal of the American Society of Nephrology2006;17(Abstracts):228A. [CENTRAL: CN‐00602020] GastonR , KaplanB , Meier‐KriescheH , ShawL , ShahT , PatelD , et al. Opticept Trial: efficacy and safety of monitored MMF in combination with CNI in renal transplantation at 12 months [abstract no: 526]. American Journal of Transplantation2008;8(Suppl 2):319. [CENTRAL: CN‐00653708] GastonRS , KaplanB , ShahT , CibrikD , ShawLM , AngelisM , et al. Fixed‐ or controlled‐dose mycophenolate mofetil with standard‐ or reduced‐dose calcineurin inhibitors: the OPTICEPT trial. American Journal of Transplantation2009;9(7):1607‐19. [MEDLINE: 19459794] KaplanB , GastonR , Meier‐KriescheH , BloomR , PatelD , ShawL . Mycophenolate mofetil may require dose modification based on weight: an analysis of MPA exposure in the OptiCept Trial [abstract no: 787]. American Journal of Transplantation2009;9(Suppl 2):419. [CENTRAL: CN‐00794654] KaplanB , GastonRS , Meier‐KriescheHU , BloomRD , ShawLM . Mycophenolic acid exposure in high‐ and low‐weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial. Therapeutic Drug Monitoring2010;32(2):224‐7. [MEDLINE: 20216117] ShawL , KaplanB , AngelisM , BloomR , GastonR , Meier‐KriescheH , et al. Correlation between mycophenolic acid (MPA) trough and abbreviated AUC levels in renal allograft recipients in the Opticept Trial [abstract no: SU‐FC128]. Journal of the American Society of Nephrology2007;18(Abstracts):96A‐7A. [CENTRAL: CN‐00724911] ">OPTICEPT Study 2009</a>, <a href="./references#CD006750-bbs2-0076" title="DeanPG , GrandeJP , SethiS , ParkWD , GriffinMD , CosioFG , et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation2008;85(8):1212‐5. [MEDLINE: 18431244] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effect of immunosuppression on renal function and graft histology: a comparison of tacrolimus and sirolimus [abstract no: 379]. American Journal of Transplantation2005;5(Suppl 11):252. [CENTRAL: CN‐00725015] DeanPG , LarsonTS , ReaDJ , GriffinMD , TextorSC , SchwabTR , et al. The effects of calcineurin inhibitor avoidance on renal function and graft histology after kidney transplantation: a prospective, randomized comparison of tacrolimus and sirolimus [abstract no: 259]. Transplantation2004;78(2 Suppl):89. [CENTRAL: CN‐00509154] DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus [abstract]. American Journal of Transplantation2004;4(Suppl 8):229. DeanPG , LundWJ , LarsonTS , PrietoM , NybergSL , IshitaniMB , et al. Wound‐healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation2004;77(10):1555‐61. [MEDLINE: 15239621] HamadA , BuehrigCK , KrepsMA , LagerDJ , FidlerME , GloorJM , et al. Frequency of polyomavirus‐associated nephropathy in a randomized controlled trial of tacrolimus versus sirolimus‐based immunosuppression [abstract no: 147]. American Journal of Transplantation2003;3(Suppl 5):189. [CENTRAL: CN‐00445626] KudvaYC , BasuA , LarsonTS , StegallMD . Metabolic complications after renal transplantation: a comparison of sirolimus vs tacrolimus‐based immunosuppression [abstract no: 256]. American Journal of Transplantation2003;3(Suppl 5):217. [CENTRAL: CN‐00446214] LarsonTS , DeanPG , GriffinMD , PrietoM , SchwabTR , CosioFG , et al. Preserving renal function by avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs. tacrolimus [abstract no: 461]. American Journal of Transplantation2004;4(Suppl 8):285. [CENTRAL: CN‐00509307] LarsonTS , DeanPG , StegallMD , GriffinMD , TextorSC , SchwabTR , et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. American Journal of Transplantation2006;6(3):514‐22. [MEDLINE: 16468960] LarsonTS , GriffinMD , PrietoM , SchwabTR , LundWJ , NybergSL , et al. Avoiding calcineurin‐inhibitors in renal transplantation: a randomized trial of sirolimus vs tacrolimus [abstract no: 1261]. American Journal of Transplantation2003;3(Suppl 5):475. [CENTRAL: CN‐00446279] LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: 396]. American Journal of Transplantation2002;2(Suppl 3):237. LarsonTS , VelosaJA , PrietoM , LundWJ , GriffinMD , GloorJM , et al. Kidney transplantation without calcineurin‐inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract no: O552]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. [CENTRAL: CN‐00416102] LundWJ , LarsonTS , StegallMD , PrietoM , KremersWK . Obesity increases wound complications in sirolimus‐treated renal allograft recipients [abstract]. American Journal of Transplantation2003;3(Suppl 5):214. [CENTRAL: CN‐00446497] QianQ , DuH , KingBF , KumarS , CosioFG , TorresVE . Sirolimus reduces polycystic liver volume in ADPKD patients after renal transplantation [abstract no: SA‐PO094]. Journal of the American Society of Nephrology2007;18(Abstracts):365A. [CENTRAL: CN‐00716079] QianQ , DuH , KingBF , KumarS , DeanPG , CosioFG , et al. Sirolimus reduces polycystic liver volume in ADPKD patients. Journal of the American Society of Nephrology2008;19(3):631‐8. [MEDLINE: 18199797] StegallMD , LarsonTS , PrietoM , GloorJ , TextorS , NybergS , et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplantation Proceedings2003;35(3 Suppl):125S‐7S. [MEDLINE: 12742483] ">Stegall 2003</a>, <a href="./references#CD006750-bbs2-0080" title="CampbellS , WalkerR , PilmoreH , KanellisJ , RussG , HutchisonB , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 43]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:64. CarmelliniM , GarciaV , WangZ , VergaraM , RussG . Efficacy of everolimus with reduced‐exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology2015;28(5):633‐9. [MEDLINE: 25708913] CarmelliniM , GarciaV , WongZ , VergaraM , EscrigC , RussG . Treatment with everolimus and reduced‐exposure cyclosporine is efficacious in de novo renal transplant recipients at increased risk for efficacy failure: Post‐Hoc analysis from the A2309 study [abstract]. American Journal of Transplantation2015;15(Suppl 3). [EMBASE: 71954404] ChadbanS , PilmoreH , RussG , KanellisJ , CampbellS , O'ConnellP , et al. Everolimus plus reduced‐exposure cyclosporin versus mycophenolic acid plus cyclosporin: seven year follow‐up of ANZ patients from a randomised controlled trial [abstract no: 079]. Nephrology2015;30(Suppl 3):39. [EMBASE: 71995868] CibrikD , JohnstonT , KimYS , WalkerR , ZibariG , MangeK , et al. Everolimus allows for around 60% reduction in CsA exposure over 12 months: results from a multicenter, prospective study in renal transplantation [abstract no: 1667]. American Journal of Transplantation2010;10(Suppl 4):511. [EMBASE: 70465042] CibrikD , JohnstonT , KimYS , WalkerRG , ZibariG , Cornu‐ArtisC , et al. Everolimus exposure and relationship to efficacy and safety: results from a multicenter study in renal transplantation using reduced CsA exposure [abstract no: LB25]. American Journal of Transplantation2010;10(S4):567‐8. [EMBASE: 70465240] CibrikD , KimYS , JohnstonT , WalkerR , ZibariG , et al. Benefits of everolimus with reduced CsA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 378]. American Journal of Transplantation2010;10(Suppl 4):151‐2. [EMBASE: 70463739] CibrikD , SilvaHT , VathsalaA , LackovaE , Cornu‐ArtisC , WalkerRG , et al. Randomized trial of everolimus‐facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation2013;95(7):933‐42. [MEDLINE: 23422495] ColussiG , VergaraM , WangZ , RolandR . Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology2015;83(6):338‐44. [MEDLINE: 25816807] KanellisJ , WalkerR , PilmoreH , RussG , HutchisonB , ChadbanS , et al. Benefits of everolimus with reduced CSA exposure on renal function: a multicenter, prospective study in renal transplantation [abstract no: 6]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 Jun 29‐Jul 1; Canberra (ACT). 2011:40. KimYS , Tedesco‐SilvaH , JohnstonT , LeeP , ZibariG , WalkerR , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 1615]. Transplantation2010;90(Suppl):256. [EMBASE: 71531587] PattisonJ , RiadH , YaqoobM , ChanL . Correlation of everolimus exposure with reduced CsA exposure to efficacy and safety outcomes: results from a multicentre study in renal transplantation [abstract no: 19]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Preserved efficacy and renal function from 12 to 24 months with everolimus facilitated CsA reduction [abstract no: 47]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. PattisonJ , RiadH , YaqoobM , Tedesco‐SilvaH . Renal function in de novo kidney transplant patients receiving everolimus with reduced dose cyclosporin or enteric‐coated mycophenolic acid with standard‐dose cyclosporin: results from a large‐scale, randomised, international trial [abstract no: O36]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RiadH , PattisonJ , YaqoobM , ChanL . 12 month analysis of effects of graft type, donor criteria and gender on improved renal allograft function with everolimus facilitated CNI reduction [abstract no: 21]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , KimYS . Lower incidence of CMV and BK virus with everolimus vs. mycophenolate in de novo renal transplant patients at 12 months [abstract no: 20]. British Transplantation Society (BTS). 14th Annual Congress; 2011 Mar 9‐11; Bournemouth, UK. 2011. RiadH , PattisonJ , YaqoobM , Tedesco‐SilvaH . Everolimus with reduced‐dose cyclosporin as a strategy to optimise long‐term renal function: results from a randomised study in 833 de novo kidney transplant recipients [abstract no: P43]. British Transplantation Society (BTS). 13th Annual Congress; 2010 Mar 17‐19; Kensington, UK. 2010. RussG , ChadbanS , CampbellS , HutchisonB , KanellisJ , O'ConnellP , et al. Everolimus plus reduced‐dose cyclosporine: results from a randomized, phase III study in 833 de‐novo renal transplant recipients [abstract no: 70]. Immunology &amp; Cell Biology2010;88(6):A22. [EMBASE: 70313681] RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Everolimus plus reduced CSA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 1]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:36. RussG , WalkerR , PilmoreH , KanellisJ , HutchisonB , ChadbanS , et al. Lower incidence of cytomegalovirus and BK virus with everolimus versus mycophenolate in de novo renal transplant patients: results from a multicenter, prospective study [abstract no: 70]. Transplantation Society of Australia &amp; New Zealand (TSANZ). 29th Annual Scientific Meeting; 2011 June 29‐Jul 1; Canberra, ACT. 2011:82. ShihabF , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Exposure‐response analysis of everolimus with reduced cyclosporine in renal transplant recipients at 24 months in a randomized trial [abstract no: 929]. American Journal of Transplantation2012;12(Suppl S3):298‐9. [EMBASE: 70746882] ShihabF , CibrikD , KimYS , JohnstonT , WalkerR , RolandR , et al. De novo everolimus combined with reduced cyclosporine exposure ‐ analysis of renal function at 12 months in renal transplant recipients [abstract no: 2023]. Transplantation2010;90(Suppl 2S):110. ShihabFS , CibrikD , ChanL , KimYS , CarmelliniM , WalkerR , et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation2013;27(2):217‐26. [MEDLINE: 23230975] Tedesco SilvaHJr , CibrikD , JohnstonT , LackovaE , MangeK , PanisC , et al. Everolimus plus reduced‐exposure CsA versus mycophenolic acid plus standard‐exposure CsA in renal‐transplant recipients. American Journal of Transplantation2010;10(6):1401‐13. [MEDLINE: 20455882] Tedesco‐SilvaH , JohnstonTS , KimY , ZibariG , WalkerR , MangeK , et al. Everolimus‐treated renal transplant patients have a lower incidence of CMV and BKV: results from a multicenter, prospective study [abstract: 1659]. American Journal of Transplantation2010;10(Suppl 4):509. [EMBASE: 70465034] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , TufvetsonG , ZibariG , et al. Everolimus with reduced exposure of cyclosporine: efficacy results from a randomized prospective study in 833 de novo renal transplant recipients [abstract no: 427]. Transplantation2010;90(Suppl):110. [EMBASE: 71531315] Tedesco‐SilvaH , KimYS , JohnstonT , WalkerR , ZibariG , MangeK , et al. Everolimus plus reduced CsA exposure: efficacy results from a multicenter, randomized prospective study in renal transplantation [abstract no: 374]. American Journal of Transplantation2010;10(Suppl 4):150. [EMBASE: 70463735] Tedesco‐SilvaH , KimYS , LackovaE , JohnstonT , ZibariG , PanisC , et al. Everolimus with reduced‐dose cyclosporine as a strategy for optimizing long‐term renal function: results from a randomized study in 833 de‐novo renal‐transplant recipients [abstract no: P‐371]. Transplant International2009;22(Suppl 2):186‐7. VathsalaA , ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , et al. Dose related incidences of wound healing events in renal transplant recipients treated with everolimus and cyclosporine [abstract no: 2060]. Transplantation2012;90(Suppl):615. [EMBASE: 71532274] WalkerR , CibrikD , Tedesco‐SilvaH , JohnstonT , KimYS , ZibariG , et al. Everolimus allows for a 60% reduction in cyclosporine exposure in subject cohorts defined by geography [abstract no: 1616]. Transplantation2010;90(Suppl 2S):610. [EMBASE: 71532265] WisemanAC , McCagueK , KimY , GeisslerF , CooperM . The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. American Journal of Transplantation2013;13(2):442‐9. [MEDLINE: 23205690] ZibariG , KimYS , CibrikD , JohnstonT , WalkerR , MangeK , et al. Wound healing events are dose related: a multicenter, prospective study on everolimus in renal transplantation [abstract no: 1661]. American Journal of Transplantation2010;10(Suppl 4):510. [EMBASE: 70465036] ">Tedesco‐Silva 2010</a>) which resulted in protocol amendment in <a href="./references#CD006750-bbs2-0037" title="CampistolJM , GrinyoJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. Sirolimus, TAC and corticosteroids in the postoperative period. Preliminary results [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami (FL). 2002. GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open, multicenter, trial comparing tacrolimus (TAC) withdrawal with TAC dose reduction in de novo renal transplants, receiving sirolimus (SIR), TAC and steroids in the postoperative time. Initial results [abstract no: SA‐PO0491]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):363A. [CENTRAL: CN‐00445561] GrinyoJM , CampistolJM , PaulJ , GarciaJ , AriasM , MoralesJM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, tac and corticosteroids in the postoperative period. Preliminary results [abstract]. American Journal of Transplantation2002;2(Suppl 3):394. GrinyoJM , CampistolJM , PaulJ , Garcia‐MartinezJ , MoralesJM , PratsD , et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. American Journal of Transplantation2004;4(8):1308‐14. [MEDLINE: 15268733] MoralesJM , GrinyoJM , CampistolJM , GarciaJ , AriasM , PaulJ , et al. FK‐506 withdrawal from a regimen of sirolimus plus FK‐506 results at 2 years in an improvement in renal function, blood pressure and proteinuria in ongoing kidney recipients [abstract no: 1192]. American Journal of Transplantation2005;5(Suppl 11):460. [CENTRAL: CN‐00724880] MoralesJM , GrinyoJM , CampistolJM , Garcia‐MartinezJ , AriasM , PaulJ , et al. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation2008;86(4):620‐2. [MEDLINE: 18724234] PaulJ , GrinyoJM , CampistolJM , GarciaJ , MoralesJM , AriasM , et al. A randomised, open‐label, pilot study to compare the safety and efficacy of tacrolimus (TAC) elimination with tac dose reduction in de novo renal allograft recipients, receiving sirolimus, TAC and corticosteroids in the postoperative period: preliminary results [abstract]. Nephrology Dialysis Transplantation2002;17(Suppl 1):18‐9. [CENTRAL: CN‐00550490] ">Grinyo 2004</a>. </p> </section> </section> <section id="CD006750-sec-0076"> <h3 class="title" id="CD006750-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD006750-tbl-0001"><b>Summary of findings for the main comparison</b> Calcineurin inhibitor (CNI) withdrawal versus standard dose CNI for kidney transplant recipients</a>; <a href="./full#CD006750-tbl-0002"><b>Summary of findings 2</b> Low dose calcineurin inhibitors (CNI) versus to standard dose CNI for kidney transplant recipients</a>; <a href="./full#CD006750-tbl-0003"><b>Summary of findings 3</b> Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</a>; <a href="./full#CD006750-tbl-0004"><b>Summary of findings 4</b> Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</a>; <a href="./full#CD006750-tbl-0005"><b>Summary of findings 5</b> Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal versus standard dose CNI</a>; <a href="./full#CD006750-tbl-0006"><b>Summary of findings 6</b> Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI</a> </p> <section id="CD006750-sec-0077"> <h4 class="title">CNI withdrawal (avoidance or late withdrawal) versus standard dose CNI</h4> <p>There was little or no difference in patient death between CNI withdrawal and standard dose CNI regimens (<a href="./references#CD006750-fig-0003" title="">Analysis 1.1</a> (14 studies 2010 participants): RR 1.09, 95% CI 0.96 to 1.24; I<sup>2</sup> = 0%; moderate certainty evidence). </p> <p>Acute rejection episodes were higher with CNI withdrawal whether diagnosed by biopsy or clinically (<a href="./references#CD006750-fig-0004" title="">Analysis 1.2</a> (15 studies, 1666 participants): RR 2.54, 95% CI 1.56 to 4.12; I<sup>2</sup> = 70%; moderate certainty). However GFR increased (<a href="./references#CD006750-fig-0005" title="">Analysis 1.3</a> (8 studies, 910 participants): MD 3.56 mL/min, 95% CI ‐1.25 to 8.25; I<sup>2</sup> = 66%; low certainty) and graft loss decreased (<a href="./references#CD006750-fig-0006" title="">Analysis 1.4</a> (16 studies, 2090 participants): RR 0.85, 95% CI 0.74 to 0.98; I<sup>2</sup> = 0%; low certainty) with CNI withdrawal. </p> <p>There was 18% reduction in hypertension noted with CNI withdrawal (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.1 (5 studies, 950 participants): RR 0.82, 95% CI 0.71 to 0.95; I<sup>2</sup> = 36%; low certainty). There was no differences in incidences of hyperlipidaemia (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.2 (3 studies, 562 participants): RR 0.88, 95% CI 0.63 to 1.21; I<sup>2</sup> = 2%), CMV infection (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.3 (7 studies, 608 participants): RR 0.87, 95% CI 0.52 to 1.45; I<sup>2</sup> = 0%; low certainty), diabetes mellitus (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.4 (6 studies, 810 participants): RR 0.85, 95% CI 0.94 to 1.42; I<sup>2</sup> = 0%), malignancy (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.5 (6 studies, 1079 participants): RR 1.10, 95% CI 0.936 to 1.30; I<sup>2</sup> = 0%; low certainty), or total infections (<a href="./references#CD006750-fig-0008" title="">Analysis 1.6</a>.6 (6 studies, 724 participants): RR 0.96, 95% CI 0.61 to 1.51; I<sup>2</sup> = 46%) between the groups. </p> <section id="CD006750-sec-0078"> <h5 class="title">Subgroup analyses</h5> <section id="CD006750-sec-0079"> <h6 class="title">CNI avoidance versus standard dose CNI</h6> <p>There was more acute rejection episodes in CNI avoidance compared with standard dose CNI (<a href="./references#CD006750-fig-0009" title="">Analysis 1.7</a>.1 (3 studies, 238 participants): RR 2.16, 95% CI 0.85 to 5.49; I<sup>2</sup> = 84%, low certainity). However, there was no difference in death (<a href="./references#CD006750-fig-0003" title="">Analysis 1.1</a>.1 (4 studies, 566 participants): RR 1.11, 95% CI 0.94 to 1.32; I<sup>2</sup> = 0%), GFR (<a href="./references#CD006750-fig-0010" title="">Analysis 1.8</a>.1 (3 studies, 242 participant): MD ‐2.22 mL/min, 95% CI ‐14.84 to 10.40; I<sup>2</sup> = 84%, very low certainity), and graft loss (<a href="./references#CD006750-fig-0011" title="">Analysis 1.9</a>.1 (4 studies, 566 participants): RR 0.96, 95% CI 0.79 to 1.16; I<sup>2</sup> = 0%, low certainity). </p> </section> <section id="CD006750-sec-0080"> <h6 class="title">Late withdrawal versus standard dose CNI</h6> <p>Analysis of late withdrawal studies indicated that there was no difference in death (<a href="./references#CD006750-fig-0003" title="">Analysis 1.1</a>.2 (10 studies, 1444 participants): RR 1.06, 95% CI 0.88 to 1.29; I<sup>2</sup> = 0%), however acute rejection episodes were higher in CNI withdrawal group (<a href="./references#CD006750-fig-0009" title="">Analysis 1.7</a>.2 (12 studies, 1428 participants): RR 3.21, 95% CI 1.59 to 6.48; I<sup>2</sup> = 66%, moderate certainity). GFR was higher (<a href="./references#CD006750-fig-0010" title="">Analysis 1.8</a>.2 (5 studies, 668 participants): MD 5.54 mL/min, 95% CI 1.66 to 9.43; I<sup>2</sup> = 29%, low certainity) and there was less graft loss (<a href="./references#CD006750-fig-0011" title="">Analysis 1.9</a>.2 (13 studies, 1848 participants): RR 0.84, 95% CI 0.72 to 0.97; I<sup>2</sup> = 0%, low certainity) in the CNI withdrawal group. </p> </section> <section id="CD006750-sec-0081"> <h6 class="title">Type of antimetabolite (MMF/MPA or AZA)</h6> <p>Subgroup analysis on antimetabolites found a higher acute rejection episodes associated with CNI withdrawal compared with standard dose CNI in the MMF/MPA studies (<a href="./references#CD006750-fig-0012" title="">Analysis 2.1</a>.1 (10 studies, 1110 participants): RR 3.51, 95% CI 1.79 to 6.88; I<sup>2</sup> = 65%) but not in AZA studies (<a href="./references#CD006750-fig-0012" title="">Analysis 2.1</a>.2 (5 studies, 556 participants): RR 1.81, 95% CI 0.78 to 4.19; I<sup>2</sup> = 72%). </p> </section> <section id="CD006750-sec-0082"> <h6 class="title">Type of CNI (CsA or TAC)</h6> <p>When classified by CNI type, acute rejection episodes increased in the withdrawal arm of CsA studies (<a href="./references#CD006750-fig-0013" title="">Analysis 3.1</a>.1 (11 studies, 1500 participants): RR 2.13, 95% CI 1.31 to 3.48; I<sup>2</sup> = 71%), TAC (<a href="./references#CD006750-fig-0013" title="">Analysis 3.1</a>.2 (2 studies, 88 participants): RR 5.65, 95% CI 1.96 to 16.27; I<sup>2</sup> = 0%), and in studies that investigated either CsA or TAC (<a href="./references#CD006750-fig-0013" title="">Analysis 3.1</a>.3 (2 studies, 78 participants): RR 9.00, 95% CI 0.52 to 156.9) compared with standard dose CNI. </p> </section> </section> <section id="CD006750-sec-0083"> <h5 class="title">Sensitivity analyses</h5> <p>On sensitivity analyses stratified for steroid‐free regimens the effects were not different from steroid regimens for death, acute rejection and GFR. When stratified for time of follow‐up, the reduction in graft loss observed in the CNI withdrawal group was not significant when the long‐term studies were excluded in the analysis (RR 1.07, 95% CI 0.72 to 1.57; forest plot not shown). </p> </section> </section> <section id="CD006750-sec-0084"> <h4 class="title">Low dose CNI versus standard dose CNI</h4> <p>There was little or no difference in patient death between low dose and standard dose CNI regimens (<a href="./references#CD006750-fig-0014" title="">Analysis 4.1</a> (15 studies, 3462 participants): RR 0.79, 95% CI 0.50 to 1.27; I<sup>2</sup> = 0%; moderate certainty). </p> <p>There was a lower incidence of acute rejection (<a href="./references#CD006750-fig-0015" title="">Analysis 4.2</a> (19 studies, 3757 participants): RR 0.87, 95% CI 0.76 to 1.00; I<sup>2</sup> = 0%; moderate certainty) and graft loss (<a href="./references#CD006750-fig-0017" title="">Analysis 4.4</a> (15 studies, 3286 participants): RR 0.75, 95% CI 0.55 to 1.02; I<sup>2</sup> = 0%; moderate certainty) in the low dose CNI group. </p> <p>Patients treated with low dose CNI had higher GFR (<a href="./references#CD006750-fig-0016" title="">Analysis 4.3</a> (13 studies, 2623 participants): MD 4.10, 95% CI 2.07 to 6.12; I<sup>2</sup> = 16%; moderate certainty). Low dose CNI regimen probably slightly lowers SCr (<a href="./references#CD006750-fig-0018" title="">Analysis 4.5</a> (6 studies, 742 participants): MD ‐4.28 µmol/L, 95% CI ‐14.65 to 6.10; I<sup>2</sup> = 37%; low certainty). </p> <p>Hypertension was probably reduced (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.1 (5 studies, 1877 participants): RR 0.84, 95% CI 0.70 to 1.00; I<sup>2</sup> = 0%; low certainty) in the low dose CNI group. There was no difference in hyperlipidaemia (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.2 (3 studies, 1443 participants): RR 1.04, 95% CI 0.90 to 1.19; I<sup>2</sup> = 12%), CMV infection (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.3 (6 studies, 1948 participants): RR 1.23, 95% CI 0.94 to 1.62; I<sup>2</sup> = 10%; moderate certainty), diabetes mellitus (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.4 (5 studies, 1292 participants): RR 0.82, 95% CI 0.50 to 1.34; I<sup>2</sup> = 53%), malignancy (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.5 (5 studies, 1637 participants): RR 0.90, 95% CI 0.41 to 1.97; I<sup>2</sup> = 0%; low certainty), and total infections (<a href="./references#CD006750-fig-0020" title="">Analysis 4.7</a>.6 (9 studies, 1437 participants): RR 0.95, 95% CI 0.84 to 1.07; I<sup>2</sup> = 0%). </p> <section id="CD006750-sec-0085"> <h5 class="title">Subgroup analyses</h5> <section id="CD006750-sec-0086"> <h6 class="title">Low dose CNI immediately post‐transplant versus standard dose CNI</h6> <p>For studies which compared low dose CNI immediately post‐transplant with standard dose CNI regimens, there were less acute rejection episodes (<a href="./references#CD006750-fig-0021" title="">Analysis 4.8</a>.1 (12 studies, 2209 participants): RR 0.82, 95% CI 0.67 to 1.00; I<sup>2</sup> = 0%) and graft loss (<a href="./references#CD006750-fig-0023" title="">Analysis 4.10</a>.1 (11 studies, 2800 participants): RR 0.75, 95% CI 0.55 to 1.03; I<sup>2</sup> = 0%), and GFR improved (<a href="./references#CD006750-fig-0022" title="">Analysis 4.9</a>.1 (9 studies, 2200 participants): MD 3.09 mL/min, 95% CI 0.95 to 5.23; I<sup>2</sup> = 4%) with the low dose regimen. </p> </section> <section id="CD006750-sec-0087"> <h6 class="title">Late intervention with low dose CNI versus standard dose CNI</h6> <p>For studies which compared late intervention with low dose CNI, there was no difference acute rejection (<a href="./references#CD006750-fig-0021" title="">Analysis 4.8</a>.2 (6 studies, 759 participants): RR 1.05, 95% CI 0.61 to 1.81; I<sup>2</sup> = 21%) or graft loss (<a href="./references#CD006750-fig-0023" title="">Analysis 4.10</a>.2 (3 studies, 306 participants): RR 0.95, 95% CI 0.12 to 7.56; I<sup>2</sup> = 0%) however GFR was higher (<a href="./references#CD006750-fig-0022" title="">Analysis 4.9</a>.2 (3 studies, 243 participants): MD 8.81 mL/min, 95% CI 3.79 to 13.83; I<sup>2</sup> = 0%). </p> </section> <section id="CD006750-sec-0088"> <h6 class="title">Type of CNI (CsA or TAC)</h6> <p>When studies were classified on the type of CNI, there was less acute rejection in the low dose CsA (<a href="./references#CD006750-fig-0024" title="">Analysis 5.1</a>.1 (16 studies, 2906 participants): RR 0.87, 95% CI 0.76 to 1.01; I<sup>2</sup> = 0%) compared to standard dose CsA but the results were not significant for low dose TAC (<a href="./references#CD006750-fig-0024" title="">Analysis 5.1</a>.2 (2 studies, 371 participants): RR 1.53, 95% CI 0.61 to 3.83; I<sup>2</sup> = 0%) and for studies which used either CsA or TAC (<a href="./references#CD006750-fig-0024" title="">Analysis 5.1</a>.3 (1 study, 480 participants): RR 0.64, 95% CI 0.34 to 1.19). </p> </section> </section> <section id="CD006750-sec-0089"> <h5 class="title">Sensitivity analysis</h5> <p>When stratified for steroid‐free regimens, the reduction in graft loss was significant when the study using a steroid‐free regimen was excluded from the analysis (RR 0.72, 95% CI 0.52 to 0.98; forest plot not shown). </p> <p>When stratified for induction treatment with IL2RA or anti‐lymphocyte serum or globulin, the incidence of acute rejection was similar between the groups (12 studies: RR 0.84, 95% CI 0.66 to 1.07; forest plot not shown). </p> </section> </section> <section id="CD006750-sec-0090"> <h4 class="title">CNI withdrawal (avoidance or withdrawal) with mTOR‐I substitution versus standard dose CNI </h4> <p>There was little or no difference in death (<a href="./references#CD006750-fig-0025" title="">Analysis 6.1</a> (23 studies, 5427 participants): RR 0.96, 95% CI 0.68 to 1.36; I<sup>2</sup> = 0%; moderate certainty) and graft loss (<a href="./references#CD006750-fig-0028" title="">Analysis 6.4</a> (25 studies, 5446 participants): RR 0.94, 95% CI 0.75 to 1.19; I<sup>2</sup> = 0%; low certainty) between the CNI withdrawal with mTOR‐I and standard dose CNI regimens. </p> <p>There was an increase in acute rejection episodes (<a href="./references#CD006750-fig-0026" title="">Analysis 6.2</a> (30 studies, 5903 participants): RR 1.43, 95% CI 1.15 to 1.78; I<sup>2</sup> = 52%; moderate certainty) in the mTOR‐I group. Patients in the CNI withdrawal with mTOR‐I group had a higher GFR compared to standard dose CNI regimen (<a href="./references#CD006750-fig-0027" title="">Analysis 6.3</a> (23 studies, 4427 participants): MD 5.29, 95% CI 2.08 to 8.51; I<sup>2</sup> = 90%). SCr was lower at one year in the CNI withdrawal with mTOR‐I group (<a href="./references#CD006750-fig-0029" title="">Analysis 6.5</a> (12 studies, 1702 participants): MD ‐17.10 µmol/L, 95% CI ‐26.95 to ‐7.25; I<sup>2</sup> = 76%). </p> <p>CNI withdrawal with mTOR‐I group had a higher incidence of hyperlipidaemia (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.2 (13 studies 3494 participants): RR 1.76, 95% CI 1.40 to 2.20; I<sup>2</sup> = 49%). There was little or no difference in hypertension <a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.1 (7 studies, 2207 participants): RR 0.86, 95% CI 0.64 to 1.15; I<sup>2</sup> = 79%), diabetes mellitus (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.4 (11 studies, 2833 participants): RR 1.27, 95% CI 0.97 to 1.66; I<sup>2</sup> = 0%), and infections (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.6 (9 studies, 1624 participants): RR 0.99, 95% CI 0.92 to 1.07; I<sup>2</sup> = 0%) between the two groups. There was a reduction in malignancy (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.5 (14 studies, 3699 participants): RR 0.69, 95% CI 0.47 to 1.00; I<sup>2</sup> = 19%; low certainty) and CMV infection (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.3 (13 studies, 2503 participants): RR 0.60, 95% CI 0.44 to 0.82; I<sup>2</sup> = 43%; moderate certainty) in the mTOR‐I group compared to those treated with standard dose CNI regimen. There was an increase in lymphoceles in the CNI withdrawal, mTOR‐I group (<a href="./references#CD006750-fig-0031" title="">Analysis 6.7</a>.7 (8 studies, 1926 participants): RR 1.45, 95% CI 0.95, 2.21; I<sup>2</sup> = 56%; low certainty). </p> <section id="CD006750-sec-0091"> <h5 class="title">Subgroup analysis</h5> <section id="CD006750-sec-0092"> <h6 class="title">CNI avoidance with mTOR‐I substitution versus standard dose CNI</h6> <p>There was an increase acute rejection episodes (<a href="./references#CD006750-fig-0032" title="">Analysis 6.8</a>.1 (11 studies, 1844 participants): RR 1.27, 95% CI 0.98 to 1.65; I<sup>2</sup> = 31%), while GFR was better (<a href="./references#CD006750-fig-0033" title="">Analysis 6.9</a>.1 (9 studies, 1748 participants): MD 6.45 mL/min, 95% CI 1.33 to 11.58; I<sup>2</sup> = 86%) in the CNI avoidance with mTOR‐I regimen. Graft loss (<a href="./references#CD006750-fig-0034" title="">Analysis 6.10</a>.1 (8 studies, 1420 participants): RR 1.03, 95% CI 0.72 to 1.48; I<sup>2</sup> = 0%) was similar in the two groups. </p> </section> <section id="CD006750-sec-0093"> <h6 class="title">Late CNI withdrawal with mTOR‐I substitution versus standard dose CNI</h6> <p>Acute rejection episodes were higher in the late CNI withdrawal with mTOR‐I substitution group (<a href="./references#CD006750-fig-0032" title="">Analysis 6.8</a>.2 (17 studies, 3636 participants): RR 1.90, 95% CI 1.44 to 2.51; I<sup>2</sup> = 23%). GFR was not significantly higher (<a href="./references#CD006750-fig-0033" title="">Analysis 6.9</a>.2 (14 studies, 2679 participants): MD 4.55 mL/min, 95% CI 0.26 to 8.85; I<sup>2</sup> = 92%) and there was no difference in graft loss (<a href="./references#CD006750-fig-0034" title="">Analysis 6.10</a>.2 (17 studies, 4026 participants): RR 0.92, 95% CI 0.65 to 1.30; I<sup>2</sup> = 13%) in the late CNI withdrawal with mTOR‐I group. </p> </section> <section id="CD006750-sec-0094"> <h6 class="title">Type of CNI (CsA or TAC)</h6> <p>There were more acute rejection episodes in the late CNI withdrawal with mTOR‐I group compared to standard dose CsA (<a href="./references#CD006750-fig-0035" title="">Analysis 7.1</a>.1 (18 studies, 5903 participants): RR 1.42, 95% CI 1.15 to 1.76; I<sup>2</sup> = 37%) and standard dose TAC (<a href="./references#CD006750-fig-0035" title="">Analysis 7.1</a>.2 (7 studies, 753 participants): RR 2.23, 95% CI 1.43 to 3.49; I<sup>2</sup> = 15%), however in studies which used either CsA or TAC (<a href="./references#CD006750-fig-0035" title="">Analysis 7.1</a>.3 (5 studies, 1687 participants): RR 0.97, 95% CI 0.40 to 2.33; I<sup>2</sup> = 64%) there were no differences in acute rejection episodes. </p> </section> </section> <section id="CD006750-sec-0095"> <h5 class="title">Sensitivity analyses</h5> <p>On sensitivity analyses stratified for steroid‐free regimens the effects were not different from steroid regimens for death, acute rejection, and GFR. </p> </section> </section> <section id="CD006750-sec-0096"> <h4 class="title">Low dose CNI with mTOR‐I versus standard dose CNI</h4> <p>There was little or no difference in patient deaths (<a href="./references#CD006750-fig-0036" title="">Analysis 8.1</a> (11 studies, 2750 participants): RR 1.16, 95% CI 0.71 to 1.90; I<sup>2</sup> = 0%; moderate certainty), acute rejection episodes (<a href="./references#CD006750-fig-0037" title="">Analysis 8.2</a> (16 studies, 3300 participants): RR 1.13, 95% CI 0.91 to 1.40; I<sup>2</sup> = 22%; moderate certainty), and graft loss (<a href="./references#CD006750-fig-0039" title="">Analysis 8.4</a> (16 studies, 3304 participants): RR 0.67, 95% CI 0.45 to 1.01; I<sup>2</sup> = 0%; moderate certainty) when low dose CNI with mTOR‐I was compared to standard dose CNI. </p> <p>Patients treated with low dose CNI in combination with mTOR‐I had a higher GFR compared with standard dose CNI regimens (<a href="./references#CD006750-fig-0038" title="">Analysis 8.3</a> (11 studies, 1749 participants): MD 6.24 mL/min, 95% CI 3.28 to 9.19; I<sup>2</sup> = 56%; moderate certainty), and a lower SCr at one year (<a href="./references#CD006750-fig-0040" title="">Analysis 8.5</a> (6 studies, 1320 participants): MD ‐14.14 µmol/L, 95% CI ‐22.55 to ‐5.72; I<sup>2</sup> = 17%). </p> <p>Hypertension (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.1 (5 studies, 1421 participants): RR 0.98, 95% CI 0.80 to 1.20; I<sup>2</sup> = 0%, low certainity), hyperlipidaemia (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.2 (8 studies, 1793 participants): RR 1.07, 95% CI 0.89 to 1.28; I<sup>2</sup> = 30%), and diabetes mellitus (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.4 (5 studies, 686 participants): RR 1.36, 95% CI 0.81 to 2.27; I<sup>2</sup> = 0%) were noted to be similar in patients treated with either low dose CNI in combination with mTOR‐I or standard dose CNI regimens. There was no reduction in malignancy in the low CNI in combination with mTOR‐I group compared to those treated with standard dose CNI regimens (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.5 (5 studies, 1074 participants): RR 1.22, 95% CI 0.42 to 3.52; I<sup>2</sup> = 0%, low certainity). There was little or no difference in total Infections (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.6 (5 studies, 1271 participants): RR 0.95, 95% CI 0.83 to 1.08; I<sup>2</sup> = 28%) and CMV infection (<a href="./references#CD006750-fig-0042" title="">Analysis 8.7</a>.3 (5 studies, 1250 participants): RR 0.41, 95% CI 0.16 to 1.06; I<sup>2</sup> = 74%; low certainty) between the two groups. </p> <section id="CD006750-sec-0097"> <h5 class="title">Subgroup analysis</h5> <section id="CD006750-sec-0098"> <h6 class="title">CNI and mTOR‐I combination with standard dose CNI regimen in the immediate post‐transplant period </h6> <p>GFR was higher in the low dose CNI with mTOR‐I group (<a href="./references#CD006750-fig-0044" title="">Analysis 8.9</a>.1 (10 studies, 1537 participants): MD 6.91 mL/min, 95% CI 3.86 to 9.96; I<sup>2</sup> = 53%), however acute rejection (<a href="./references#CD006750-fig-0045" title="">Analysis 8.10</a>.1 (14 studies, 2736 participants): RR 1.09, 95% CI 0.86 to 1.39; I<sup>2</sup> = 27%) and graft loss (<a href="./references#CD006750-fig-0043" title="">Analysis 8.8</a>.1 (14 studies, 2736 participants): RR 0.75, 95% CI 0.48 to 1.18; I<sup>2</sup> = 0%) were similar in the two groups. </p> </section> <section id="CD006750-sec-0099"> <h6 class="title">Late introduction of low dose CNI regimen with mTOR‐I substitution</h6> <p>Incidence of acute rejection was higher in the low dose CNI with mTOR‐I group (<a href="./references#CD006750-fig-0045" title="">Analysis 8.10</a>.2 (2 studies, 564 participants): RR 1.38, 95% CI 0.82 to 2.31; I<sup>2</sup> = 0%), there was no difference in graft loss (<a href="./references#CD006750-fig-0043" title="">Analysis 8.8</a>.2 (2 studies, 568 participants): RR 0.40, 95% CI 0.15 to 1.04; I<sup>2</sup> = 0%) and one study reported no difference in GFR in the late withdrawal group (<a href="./references#CD006750-fig-0044" title="">Analysis 8.9</a>.2 (1 study, 212 participants): MD 0.58 mL/min, 95% CI ‐5.00 to 6.16). </p> </section> <section id="CD006750-sec-0100"> <h6 class="title">Type of CNI (CsA or TAC)</h6> <p>There was no difference in acute rejection in the low dose CsA with mTOR‐I compared to standard dose CsA (<a href="./references#CD006750-fig-0046" title="">Analysis 9.1</a>.1 (11 studies, 2232 participants): RR 0.97, 95% CI 0.78 to 1.22; I<sup>2</sup> = 7%), however acute rejection was higher when low dose TAC with mTOR‐I was compared to standard dose TAC (<a href="./references#CD006750-fig-0046" title="">Analysis 9.1</a>.2 (5 studies, 1068 participants): RR 1.58, 95% CI 1.16 to 2.13; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD006750-sec-0101"> <h5 class="title">Sensitivity analysis</h5> <p>On sensitivity analyses stratified for steroid free regimens the effects were not different from steroid regimens for death, acute rejection, or GFR. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006750-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006750-sec-0102"></div> <section id="CD006750-sec-0103"> <h3 class="title" id="CD006750-sec-0103">Summary of main results</h3> <p>This review describes CNI withdrawal or tapering classified according to: CNI withdrawal, low dose CNI, CNI withdrawal with mTOR‐I substitution and low dose CNI with mTOR‐I compared to standard dose CNI regimens. The four groups were further stratified into CNI avoidance and withdrawal studies for major outcomes. </p> <p>In the CNI withdrawal comparison with standard regimens, there was an increase in both clinical acute rejection and BPAR. GFR was higher in the withdrawal group especially over longer time periods. Death, diabetes mellitus, hyperlipidaemia, total and CMV infections were not significantly different between the groups. Standard dose CNI regimens were more likely to be associated with hypertension when compared to CNI withdrawal patients. Graft loss was lower in the CNI withdrawal group; however, when stratified for avoidance studies, there was no difference in graft loss between the groups. These protocols (late withdrawal or avoidance) resulted in an increase in acute rejection with no clear benefit in terms of reduced graft loss. There was also no difference in the type of CNI (TAC or CsA) used or steroid‐free regimens in causing acute rejection. The beneficial effects of CNI withdrawal in reducing graft loss were lost when studies with long‐term outcomes were excluded. </p> <p>In the low dose CNI comparison with standard dose regimens, there was a reduction in acute rejection, however when studies which administered induction treatment (IL2RA or anti‐lymphocyte serum or globulin) were excluded from the analysis, acute rejection was similar in the low dose CNI and standard dose CNI regimens, both in the immediate and late introduction groups. GFR was higher in the low dose CNI group at both one and five years. There were no significant differences in death, diabetes mellitus, hyperlipidaemia, and CMV infection between the groups. Low dose CNI regimens had a marginal reduction in hypertension and total infections. Graft loss was reduced in the low dose CNI regimen, however when stratified for early and late intervention (taper), the effect was limited to the early intervention studies. </p> <p>In the CNI avoidance or tapering with mTOR‐I substitution compared to standard dose CNI regimens, there was no difference in death between the two groups. The mTOR‐I substitution regimen however had more acute rejections (clinical and biopsy‐proven) and had more hyperlipidaemia. CMV infection and malignancy were significantly lower in the mTOR‐I substitution group. GFR was higher in the CNI avoidance with mTOR‐I subgroup but not in the late intervention subgroup. There was no difference in other outcomes when stratified for early or late intervention. Overall these protocols (avoidance or tapering) showed no major change compared to CNI alone except for the increase in acute rejection when compared with either CNI (CsA or TAC). The major benefit of mTOR‐I substitution is seen in the reduction in malignancies and CMV infections over time. </p> <p>When low dose CNI was combined with mTOR‐I and compared to standard dose CNI regimens, there were no differences in death, graft loss or acute rejection. Adverse events including malignancy were not significantly different between the groups. GFR and SCr at one year favoured the low dose CNI with mTOR‐I regimen. However when stratified for early and late intervention there was increased acute rejection in the low dose CNI with mTOR‐I regimens. </p> <p>This review investigated a large number of studies comparing different CNI regimens. Many studies and reports were published in multiple journals at various time points and were presented as abstracts at scientific meetings without acknowledging previous publications. The same studies were also published under different authors and this review combined these reports under a single study and reported outcomes systematically. The methodology was robust and the studies were also assessed for study quality and heterogeneity explored by subgroup and stratified analysis. The review classified interventions into four groups which reduced multiple comparisons due to several different regimens. </p> </section> <section id="CD006750-sec-0104"> <h3 class="title" id="CD006750-sec-0104">Overall completeness and applicability of evidence</h3> <p>Short time scales of most studies restrict the external validity of this review. Moving away from CNI may have multiple adverse long‐term effects that will not be measured by these studies. The studies also do not mention of antibody‐mediated rejection and pretransplant donor specific antibodies which could impact on short‐ and long‐term graft survival. Removal of CNI may remove one long‐term problem (CNI toxicity) but potentially cause worsening of other immunological issues which may in turn limit the duration of the graft. Low dose CNI seem the best option and mTOR‐I benefits appear to be limited to a reduction in the risks of malignancy and CMV infection, though these benefits are uncertain and are not the case when combined with CNI. </p> </section> <section id="CD006750-sec-0105"> <h3 class="title" id="CD006750-sec-0105">Quality of the evidence</h3> <p>The overall quality of the evidence was poor, with unclear risks of bias due to poor reporting (<a href="#CD006750-fig-0002">Figure 2</a>); only 30% reported randomisation method and allocation concealment. Almost all studies were open‐label however for study outcomes such as death and graft loss they were not downgraded on GRADE assessment. Studies were analysed as intent to treat in 60% and all pre specified outcomes were reported in 54 studies. Almost half the studies received pharmaceutical funding which were classified as a high risk of bias. </p> <p>The studies also used variable outcome measures and induction immunosuppression regimens. There is also variability in dosing, drug monitoring and time intervals of reporting outcomes. Most studies did not indicate baseline SCr or GFR to assess for changes due to the intervention. The follow‐up duration in majority of the included studies was between six months and three years which is a major limitation for concluding long‐term outcomes such as patient and graft survival. </p> </section> <section id="CD006750-sec-0106"> <h3 class="title" id="CD006750-sec-0106">Potential biases in the review process</h3> <p>There are multiple limitations of this review. The quality of data reporting was variable in terms of outcome and adverse effects. Most studies did not indicate the baseline creatinine or GFR to assess for changes due to the intervention. The standard deviation or confidence intervals were not noted when recording outcomes such as GFR and creatinine. Adverse effects were prevalent rather than incident cases which may affect outcomes such as diabetes mellitus, hyperlipidaemia and hypertension. The number of patients affected by individual outcomes were not indicated but mentioned as being significant with or without P values. Outcome reporting was not defined in cases of CMV, hypertension, hyperlipidaemia (total or low‐density lipoprotein) or diabetes mellitus. Different studies used different targets for CNI monitoring and also used either trough (C0) or two hour (C2) levels; some studies based the dose on mg/kg body weight and this review used the study author definitions to classify low dose and standard dose regimens. This may have some limitation in external validity of these recommendations. However we have tried to minimise this by subclassification into four groups and analyse them further into early and late interventions. Most studies were short‐term and did not capture long‐term hard outcomes such as graft survival, patient survival or adverse effects (such as cardiovascular outcomes) and malignancy. The duration of the majority of studies was between six months and three years with only three studies of up to five years duration. This raises the concern of how outcomes might be different after that time, particularly with regards to antibody‐mediated rejection which can be a complication of reduced immune suppression. The only studies that included more than 10 years of follow‐up tended to be much older studies, and compared immunosuppression such as azathioprine which is now largely obsolete or in very little use. The data from these studies is therefore limited by era effect. Studies with longer follow‐up are required to confirm the potential benefits of CNI reduction or risks of long‐term antibody‐mediated rejection, most studies also do not differentiate between patients with high versus low immunological risk. </p> </section> <section id="CD006750-sec-0107"> <h3 class="title" id="CD006750-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>This is the first review which sub classified studies into four different intervention groups and analysed them as low dose calcineurin inhibitor or CNI withdrawal with or without mTOR‐I substitution. The classification analysed the possible advantages noted in various studies with additional immunosuppressive agent such as mTOR‐I or continuation of CNI at a low dose. </p> <p><a href="./references#CD006750-bbs2-0174" title="SharifA , ShabirS , ChandS , CockwellP , BallS , BorrowsR . Meta‐analysis of calcineurin inhibitor sparing regimens in kidney transplantation. Journal of the American Society of Nephrology2011;22(11):2107‐18. [MEDLINE: 21949096] ">Sharif 2011</a> (56 studies, 11,337 participants) showed a similar increase in acute rejection without affecting graft survival, infection, and patient survival, it also concluded an increase in graft failure when mTOR‐I was used. The review however did not classify studies into low dose or withdrawal as in our review but performed a pooled analysis which resulted in significant heterogeneity. In contrast to the conclusions of this review, <a href="./references#CD006750-bbs2-0174" title="SharifA , ShabirS , ChandS , CockwellP , BallS , BorrowsR . Meta‐analysis of calcineurin inhibitor sparing regimens in kidney transplantation. Journal of the American Society of Nephrology2011;22(11):2107‐18. [MEDLINE: 21949096] ">Sharif 2011</a> reported lower NODAT in the CNI‐sparing group. <a href="./references#CD006750-bbs2-0171" title="MooreJ , MiddletonL , CockwellP , AduD , BallS , LittleMA , et al. Calcineurin Inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta‐analysis. Transplantation2009;87(4):591‐605. [MEDLINE: 19307799] ">Moore 2009</a> included only CNI‐sparing with MMF. The results were not stratified for mTOR‐I; however the studies were classified into those who had de novo CNI minimisation and elective minimisation or elimination of CNI. The results in the withdrawal group were similar to our review but the lower dose of CNI was not beneficial in reduction of acute rejection as we report. A systematic review by <a href="./references#CD006750-bbs2-0168" title="LimW.H , ErisJ , KannellisJ , PussellB , WildZ , WitcombeD , et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. American Journal of Transplantation2014;14(9):2106‐19. [MEDLINE: 25088685] ">Lim 2014</a> (29 studies, 2350 participants) analysed conversion to an mTOR‐I based immunosuppression from CNI based therapy. They review reported short‐term improvements in GFR with mTOR‐I but increased acute rejections; there were no differences in graft loss or death. The conclusions of <a href="./references#CD006750-bbs2-0168" title="LimW.H , ErisJ , KannellisJ , PussellB , WildZ , WitcombeD , et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. American Journal of Transplantation2014;14(9):2106‐19. [MEDLINE: 25088685] ">Lim 2014</a> are similar to our analysis of CNI withdrawal with mTOR‐I, however our review also analysed low dose CNI and mTOR‐I substitution. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006750-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow chart showing number of studies identified" data-id="CD006750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart showing number of studies identified</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 1 Death." data-id="CD006750-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 2 Acute rejection." data-id="CD006750-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 2 Acute rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 3 GFR." data-id="CD006750-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 3 GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 4 Graft loss." data-id="CD006750-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 4 Graft loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 5 Serum creatinine." data-id="CD006750-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 5 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 6 Adverse events." data-id="CD006750-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 7 Subgroup analysis: acute rejection." data-id="CD006750-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 7 Subgroup analysis: acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 8 Subgroup analysis: GFR." data-id="CD006750-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 8 Subgroup analysis: GFR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 9 Subgroup analysis: graft loss." data-id="CD006750-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 CNI withdrawal versus standard dose CNI, Outcome 9 Subgroup analysis: graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (antimetabolite): CNI withdrawal versus standard dose CNI, Outcome 1 Acute rejection." data-id="CD006750-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (antimetabolite): CNI withdrawal versus standard dose CNI, Outcome 1 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Subgroup analysis (CNI type): CNI withdrawal versus standard dose CNI, Outcome 1 Acute rejection." data-id="CD006750-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Subgroup analysis (CNI type): CNI withdrawal versus standard dose CNI, Outcome 1 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 1 Death." data-id="CD006750-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 2 Acute rejection." data-id="CD006750-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 2 Acute rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 3 GFR." data-id="CD006750-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 3 GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 4 Graft loss." data-id="CD006750-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 4 Graft loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 5 Serum creatinine." data-id="CD006750-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 5 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 6 Change in GFR at 12 months." data-id="CD006750-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 6 Change in GFR at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 7 Adverse events." data-id="CD006750-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 8 Subgroup analysis: acute rejection." data-id="CD006750-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 8 Subgroup analysis: acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 9 Subgroup analysis: GFR." data-id="CD006750-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 9 Subgroup analysis: GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Low dose CNI versus standard dose CNI, Outcome 10 Subgroup analysis: graft loss." data-id="CD006750-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Low dose CNI versus standard dose CNI, Outcome 10 Subgroup analysis: graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Subgroup analysis (CNI type): low dose CNI versus standard dose CNI, Outcome 1 Acute rejection." data-id="CD006750-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Subgroup analysis (CNI type): low dose CNI versus standard dose CNI, Outcome 1 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 1 Death." data-id="CD006750-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 1 Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 2 Acute rejection." data-id="CD006750-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 2 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 3 GFR." data-id="CD006750-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 3 GFR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 4 Graft loss." data-id="CD006750-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 4 Graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 5 Serum creatinine at 1 year." data-id="CD006750-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 5 Serum creatinine at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 6 Change in GFR." data-id="CD006750-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 6 Change in GFR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 7 Adverse events." data-id="CD006750-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 7 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 8 Subgroup analysis: acute rejection." data-id="CD006750-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 8 Subgroup analysis: acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 9 Subgroup analysis: GFR." data-id="CD006750-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 9 Subgroup analysis: GFR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 10 Subgroup analysis: graft loss." data-id="CD006750-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI, Outcome 10 Subgroup analysis: graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Subgroup analysis (CNI type): CNI withdrawal + mTOR‐I versus standard dose CNI, Outcome 1 Acute rejection." data-id="CD006750-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Subgroup analysis (CNI type): CNI withdrawal + mTOR‐I versus standard dose CNI, Outcome 1 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 1 Death." data-id="CD006750-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 2 Acute rejection." data-id="CD006750-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 2 Acute rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 3 GFR." data-id="CD006750-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 3 GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 4 Graft loss." data-id="CD006750-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 4 Graft loss.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 5 Serum creatinine at 1 year." data-id="CD006750-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 5 Serum creatinine at 1 year.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 6 Change in GFR at 2 years." data-id="CD006750-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 6 Change in GFR at 2 years.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 7 Adverse events." data-id="CD006750-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 8 Subgroup analysis: graft loss." data-id="CD006750-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 8 Subgroup analysis: graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 9 Subgroup analysis: GFR." data-id="CD006750-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 9 Subgroup analysis: GFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 10 Subgroup analysis: acute rejection." data-id="CD006750-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Low dose CNI + mTOR‐I versus CNI, Outcome 10 Subgroup analysis: acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006750-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/urn:x-wiley:14651858:media:CD006750:CD006750-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_t/tCD006750-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Subgroup analysis (CNI type): low dose CNI + mTOR‐I versus standard dose CNI, Outcome 1 Acute rejection." data-id="CD006750-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Subgroup analysis (CNI type): low dose CNI + mTOR‐I versus standard dose CNI, Outcome 1 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/media/CDSR/CD006750/image_n/nCD006750-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CNI withdrawal versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI withdrawal<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 9 months to 20 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.09<br/> (0.96 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010 (14 )</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 1,000<br/> (216 to 279) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 9 months to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.54<br/> (1.56 to 4.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1666 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4 5 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1,000<br/> (214 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 3.56 mL/min more (1.13 less to 8.25</p> <p>more) than the control group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>910 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 9 months to 20 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.74 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2090 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 9 10 11 12</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1,000<br/> (175 to 231) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/> (0.71 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>950 (5 )</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>555 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1,000<br/> (394 to 527) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 9 months to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.52 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>608 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1,000<br/> (51 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 1 to 15 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/> (0.93 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1079 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2 4 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1,000<br/> (239 to 334) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> despite different follow up times, heterogeneity not noted on analysis </p> <p><sup>2</sup> Most studies were ITT analysis, some small studies did not specify randomisation and allocation concealment </p> <p><sup>3</sup> Larger studies closer to pooled estimate on funnel plot </p> <p><sup>4</sup> Some studies were small with large confidence intervals, CI fails to exclude benefit or harm </p> <p><sup>5</sup> Heterogeneity low when biopsy‐proven rejections were analysed in subgroup </p> <p><sup>6</sup> Smaller studies not distributed around point estimate </p> <p><sup>7</sup> Significant heterogeneity noted despite separating time periods of reporting GFR </p> <p><sup>8</sup> Only few studies reported GFR with possible attrition bias </p> <p><sup>9</sup> 2 large studies had more than 2 comparison groups </p> <p><sup>10</sup> Very few studies reported the outcome </p> <p><sup>11</sup> Symmetric distribution studies around estimate of effect </p> <p><sup>12</sup> 2 studies with high event rates skew the effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal versus standard dose CNI for kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose calcineurin inhibitors (CNI) versus to standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low dose CNI versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> low dose CNI<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose CNI</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/> (0.50 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3462 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1,000<br/> (12 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/> (0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3757 (19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1,000<br/> (139 to 183) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 4.1 mL/min more (2.07 more to 6.12 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2623 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/> (0.55 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3286 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Sensitivity analysis after excluding 1 study which also involved steroid withdrawal; significant reduction in graft loss in the low dose regimen </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1,000<br/> (32 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.70 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1877 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 7 8 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1,000<br/> (153 to 218) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.94 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1948 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 8 10</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000<br/> (95 to 163) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.41 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1637 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000<br/> (6 to 30) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most studies with ITT analysis, randomisation procedure and allocation concealment not clear from most publications </p> <p><sup>2</sup> Minimal heterogeneity noted on analysis </p> <p><sup>3</sup> Several small studies with wide confidence intervals </p> <p><sup>4</sup> Despite studies with or without induction, sensitivity analysis made no difference to outcome </p> <p><sup>5</sup> Heterogeneity noted only between subgroups </p> <p><sup>6</sup> Only 2/15 studies had more than 2 comparison groups </p> <p><sup>7</sup> Industry sponsored </p> <p><sup>8</sup> 1/6 studies did not report some outcomes due to high dropout </p> <p><sup>9</sup> Only 5 studies reported the outcome and had wide CI </p> <p><sup>10</sup> Few studies reported the outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Low dose calcineurin inhibitors (CNI) versus to standard dose CNI for kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CNI withdrawal + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI withdrawal + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI withdrawal + mTOR</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.69 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5427 (23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (18 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.43<br/> (1.15 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5903 (30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 3 4 5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1,000<br/> (154 to 238) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 1 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/> (0.75 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5446 (25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1,000<br/> (40 to 64) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/> (0.64 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2207 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>218 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1,000<br/> (139 to 250) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV Infection<br/> follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.60<br/> (0.44 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2503 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>9 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1,000<br/> (66 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.47 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000<br/> (26 to 54) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: lymphocele<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.95 to 2.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1926 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6 8 11</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1,000<br/> (95 to 220) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Randomisation method and allocation concealment performed in most studies </p> <p><sup>2</sup> No significant heterogeneity noted in analysis </p> <p><sup>3</sup> Only 2 studies had more than 2 comparison arms </p> <p><sup>4</sup> Many studies with small events and wide CI </p> <p><sup>5</sup> Significant heterogeneity in studies in biopsy‐proven acute rejection </p> <p><sup>6</sup> Funnel plot skewed </p> <p><sup>7</sup> Significant heterogeneity noted </p> <p><sup>8</sup> Few studies reported this outcome </p> <p><sup>9</sup> Moderate heterogeneity but follow‐up times are variable </p> <p><sup>10</sup> Not all studies reported the outcome </p> <p><sup>11</sup> Heterogeneity is not significant when 1 long‐term study was excluded </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Low dose CNI + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> low dose CNI + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low dose CNI + mTORi</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16<br/> (0.71 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2750 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1,000<br/> (16 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.91 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3300 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1,000<br/> (120 to 185) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR in the intervention group was 6.24 mL/min more (3.28 more to 9.19 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1749 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.45 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3304 (16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1,000<br/> (17 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: hypertension<br/> Follow‐up: range 6 months to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.80 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1421 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1,000<br/> (162 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: CMV infection<br/> Follow‐up: range 1 to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.41<br/> (0.16 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1250 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 7 9</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1,000<br/> (17 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events: malignancy<br/> Follow‐up: range 1 to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/> (0.42 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1074 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 4 7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1,000<br/> (5 to 40) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Randomisation and allocation process not clear in some studies </p> <p><sup>2</sup> No significant heterogeneity </p> <p><sup>3</sup> Only 2 of the studies had more than 2 comparisons </p> <p><sup>4</sup> Some small studies with wide CI </p> <p><sup>5</sup> Substantial heterogeneity noted due to recording at different time periods </p> <p><sup>6</sup> Small number of events and some small studies with wide CI </p> <p><sup>7</sup> Only few studies reported this outcome </p> <p><sup>8</sup> 95% CI fails to exclude benefit or harm </p> <p><sup>9</sup> Heterogeneity present but when abstract only studies are removed, heterogeneity is zero </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI for kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal versus standard dose CNI</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subgroup analysis: CNI avoidance and late withdrawal versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI avoidance and late withdrawal<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI avoidance and withdrawal</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: avoidance<br/> Follow‐up: range 1 to 12 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.16<br/> (0.85 to 5.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>238 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>744 per 1,000<br/> (293 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.21<br/> (1.59 to 6.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1428 (12)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1,000<br/> (162 to 661) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for avoidance studies in the intervention group was 2.22 mL/min lower (14.84 less to 10.4 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for late withdrawal studies in the intervention group was 5.54 mL/min more (1.66 more to 9.43 more) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>668 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5 6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.79 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>566 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>7 8</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>341 per 1,000<br/> (281 to 412) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.72 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1831 (13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3 9 10</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1,000<br/> (187 to 252) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> 3 small studies with one study including a non‐randomised arm </p> <p><sup>2</sup> Significant heterogeneity </p> <p><sup>3</sup> Several small studies with wide confidence intervals </p> <p><sup>4</sup> Small numbers to make a judgement of difference </p> <p><sup>5</sup> Skewed funnel plot </p> <p><sup>6</sup> Substantial heterogeneity </p> <p><sup>7</sup> 2/4 are small studies with wide CI </p> <p><sup>8</sup> 4 studies included with one study with high event rate </p> <p><sup>9</sup> No heterogeneity identified on analysis </p> <p><sup>10</sup> Larger studies are not industry sponsored </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006750-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Subgroup analysis: CNI avoidance and late withdrawal + mTORi versus standard dose CNI for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/> <b>Intervention:</b> CNI avoidance and late withdrawal + mTORi<br/> <b>Comparison:</b> standard dose CNI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard dose CNI</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CNI avoidance and withdrawal + mTORi</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: avoidance<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/> (0.98 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1844 (11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1,000<br/> (229 to 386) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Acute rejection: late withdrawal<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.90<br/> (1.44 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3636 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1,000<br/> (94 to 163) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: avoidance<br/> Follow‐up: range 6 months to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for avoidance studies in the intervention group was 6.45 mL/min higher (1.33 higher to 11.58 higher) than the control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1748 (9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GFR: late withdrawal<br/> Follow‐up: range 6 months to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean GFR for late withdrawal studies in the intervention group was MD 4.55 higher<br/> (0.26 higher to 8.85 higher) than for control group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2679 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: avoidance</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.72 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1420 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000<br/> (53 to 110) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Graft loss: late withdrawal</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.65 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4026 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1,000<br/> (30 to 59) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Several smaller studies with wide CI </p> <p><sup>2</sup> Significant heterogeneity </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/full#CD006750-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CNI withdrawal versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.93, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.85, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.83, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.56, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1066</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.08, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Biopsy‐proven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [2.10, 9.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [‐1.13, 8.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐5.38, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Two years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.90 [1.43, 14.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Over 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.09 [4.81, 17.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.17 [5.89, 32.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>31.78 [10.58, 52.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.04 [‐5.99, 28.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.52, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.62, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.93, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.61, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Subgroup analysis: acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.56, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.85, 5.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [1.59, 6.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [‐1.13, 8.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐14.84, 10.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.54 [1.66, 9.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.79, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CNI withdrawal versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (antimetabolite): CNI withdrawal versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.56, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 MMF/MPA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [1.79, 6.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 AZA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.78, 4.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (antimetabolite): CNI withdrawal versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis (CNI type): CNI withdrawal versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.56, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.31, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.65 [1.96, 16.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Either CSA or TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.52, 156.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis (CNI type): CNI withdrawal versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Low dose CNI versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.50, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Early intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Late intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.74, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Biopsy‐proven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.10 [2.07, 6.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [‐1.35, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [1.78, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Two years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.10 [4.14, 18.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.28 [‐14.65, 6.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.46 [‐11.25, 8.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.18 [‐46.12, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in GFR at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.94, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.50, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.41, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Immediate intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Late intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.61, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.21 [1.90, 6.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Immediate intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [0.95, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Late intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.81 [3.79, 13.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Immediate intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.55, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Late intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.12, 7.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Low dose CNI versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis (CNI type): low dose CNI versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CsA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.61, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Either CsA or TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.34, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis (CNI type): low dose CNI versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.68, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.54, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.59, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.15, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.12, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Biopsy‐proven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.10, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.29 [2.08, 8.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [‐0.02, 10.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.02 [0.59, 9.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Two years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.08 [‐0.85, 13.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Five years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.30 [2.43, 10.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum creatinine at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.10 [‐26.95, ‐7.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [0.01, 12.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Two years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐15.00, 15.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.40, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.97, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.47, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Lymphocele</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.95, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.27, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.98, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.44, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.29 [2.08, 8.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.45 [1.33, 11.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.26, 8.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Avoidance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.72, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Late withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.65, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">CNI withdrawal or avoidance + mTOR‐I versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis (CNI type): CNI withdrawal + mTOR‐I versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.15, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CsA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.15, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.43, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Either CsA or TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.40, 2.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis (CNI type): CNI withdrawal + mTOR‐I versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Low dose CNI + mTOR‐I versus CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.71, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low dose CNI + immediate mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.62, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 low dose CNI + late mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.52, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unspecified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.90, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Biopsy‐proven</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.83, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.24 [3.28, 9.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.79 [‐3.57, 15.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 One year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.63 [4.11, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Two years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐3.00, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum creatinine at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.14 [‐22.55, ‐5.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in GFR at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hyperlipidaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.89, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.16, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.81, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.42, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Immediate mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.48, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Late mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.15, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: GFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.24 [3.28, 9.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Immediate mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.91 [3.86, 9.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Late mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐3.00, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Immediate mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.86, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Late mTOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.82, 2.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Low dose CNI + mTOR‐I versus CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006750-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis (CNI type): low dose CNI + mTOR‐I versus standard dose CNI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.91, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CsA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.78, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 TAC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1068</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.16, 2.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis (CNI type): low dose CNI + mTOR‐I versus standard dose CNI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006750.pub2/references#CD006750-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006750.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006750-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006750-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD006750-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD006750-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006750-note-0014">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006750\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006750\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006750\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006750\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006750\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006750.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006750.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006750.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006750.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006750.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717043607"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006750.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717043611"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006750.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dae3d08aaf3f1',t:'MTc0MDcxNzA0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 